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Attention-deficit/hyperactivity disorder (ADHD) is characterised by clinically impairing levels of 
inattention and hyperactivity/impulsivity along with cognitive deficits and problems with 
emotional lability (EL). Stimulant medication, although the first line treatment, can be problematic 
due to for example, adverse effects and partial response. Patients often explore alternative 
treatments.   
 
In children, a small to moderate effect of Omega-3 polyunsaturated fatty acid supplementation (n-3 
PUFA) in reducing ADHD symptoms has been found. However effects on cognition and EL are 
unclear. Part one, consists of two meta-analyses examining the effects of n-3 PUFA supplementation 
on cognition and EL. In children with ADHD or with a related neurodevelopmental disorder, there 
was suggestive evidence for effects on EL with little evidence for effects on cognition. In the general 
population there was little evidence for effects on cognition. A randomised-controlled trial (RCT) of 
n-3 PUFA supplementation has not yet been conducted in adults with ADHD.   
 
Part two, was an RCT of n-3 PUFA supplementation in 81 adults with ADHD.  Baseline case/control 
comparisons showed the ADHD cases to have impaired cognitive performance and high levels of EL, 
with no difference in n-3 PUFA levels.  Supplementation with n-3 PUFA in the ADHD cases indicated 
no beneficial effect in the intent-to-treat analysis but some indication of an effect in the per-
protocol analysis.  
 
Self-medication with cannabis appears common in ADHD.  Part three was an RCT of the 
cannabinoid medication, Sativex in 30 adults with ADHD. Results indicated a beneficial effect on 
ADHD symptoms and potentially cognitive performance and EL.   
 
The cannabinoid medication, Sativex, could be a promising avenue for further research as an 
alternative treatment for adults with ADHD.  Although evidence for n-3 PUFA supplementation is 
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PSQI Pittsburgh Sleep Quality Index 
PUFA Polyunsaturated Fatty Acids 
QbTest Quantitative Behaviour Test 
RBC Red Blood Cell 
RCT Randomised Controlled Trial 
RDs Related Disorders 
RTV Reaction Time Variability 
SART Sustained Attention to Response Task 
SAS Statistical Analysis Software 
SCL-90 Symptom Checklist-90 
SD Standard Deviation 
SDRT Standard Deviation of Reaction Time 
SE Standard Error 
SES Socio-economic Status 
SGDP Social, Genetic and Developmental Psychiatry Centre 
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Chapter 1: Introduction 
1.1 Overview of Attention-deficit/hyperactivity disorder (ADHD) 
1.1.1 Historical background 
In 1798 one of the first known accounts of what we now call Attention Deficit Hyperactivity 
Disorder (ADHD) was recorded by Alexander Crichton, describing a state of ‘mental restlessness’ 
(Crichton, 2008). At the start of the twentieth century a series of case studies were reported by 
George Frederick Still (considered the father of British paediatrics) in the prestigious Goulstonian 
lectures (Still, 2006). Treatment attempts with amphetamines were described as early as 1937 by 
Bradley who later, in a seminal paper, described the effects of stimulant medication in groups of 
children including those who would be categorised as having ADHD  (Bradley, 1950). In the 1940s 
the brain was suggested to be the source of ADHD-like symptoms which were described as minimal 
brain damage in the wake of an encephalitis epidemic (Lange, Reichl, Lange, Tucha, & Tucha, 2010).  
ADHD in adulthood was first formally described in the 70s with the successful treatment of adult 
patients exhibiting symptoms of ADHD, with stimulant medication (Wood, Reimherr, Wender, & 
Johnson, 1976).   In 1980, the third edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-III) created the first reliable operational diagnostic criteria for the disorder. The 
establishment of criteria started numerous programmes of research which resulted in the scientific 
community viewing ADHD as an impairing, often persistent, developmental and neurobiologically-
based disorder of high prevalence caused by a complex interplay of genetic and environmental risk 
factors. 
 
1.1.2 Diagnostic classification 
ADHD is characterised by the core behavioural symptoms of impulsivity, hyperactivity and/or 
inattention. Classified as a neurodevelopmental condition, it emerges in childhood and persists into 
adulthood and has both biological and environmental underpinnings  (Biederman, Petty, Clarke, 
Lomedico, & Faraone, 2011; Bolea-Alamañac et al., 2014; Gittelman, Mannuzza, Shenker, & 
Bonagura, 1985; Greenfield, Hechtman, & Weiss, 1988; Ronald Kessler, Adler, Barkley, et al., 2005; 
Lara et al., 2009; Mannuzza et al., 1991; Wenwei, 1996).  
 
The recent publication of the fifth edition of the DSM (The DSM-5) acknowledges the continuation 
of ADHD into adulthood and provides several changes from the previous DSM-IV: the ADHD 
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diagnosis in adults can be made with five instead of the six symptoms required in childhood; 
concurrent diagnosis of ADHD and Autism Spectrum Disorder (ASD) can now be made; and 
childhood symptoms (without impairment) can be present before 12 years instead of 7.  The DSM-5 
criteria for ADHD is detailed below (American Psychiatric Association, 2013). 
 
DSM-5 criteria for ADHD 
People with ADHD show a persistent pattern of inattention and/or hyperactivity-impulsivity that 
interferes with functioning or development:  
Inattention: Six or more symptoms of inattention for children up to age 16, or five or more for 
adolescents 17 and older and adults; symptoms of inattention have been present for at least 6 
months, and they are inappropriate for developmental level:   
 Often fails to give close attention to details or makes careless mistakes in schoolwork, at 
work, or with other activities. 
 Often has trouble holding attention on tasks or play activities. 
 Often does not seem to listen when spoken to directly. 
 Often does not follow through on instructions and fails to finish schoolwork, chores, or 
duties in the workplace (e.g., loses focus, side-tracked). 
 Often has trouble organizing tasks and activities. 
 Often avoids, dislikes, or is reluctant to do tasks that require mental effort over a long 
period of time (such as schoolwork or homework). 
 Often loses things necessary for tasks and activities (e.g. school materials, pencils, books, 
tools, wallets, keys, paperwork, eyeglasses, mobile telephones). 
 Is often easily distracted 
 Is often forgetful in daily activities. 
 
Hyperactivity and Impulsivity: Six or more symptoms of hyperactivity-impulsivity for children up 
to age 16, or five or more for adolescents 17 and older and adults; symptoms of hyperactivity-
impulsivity have been present for at least 6 months to an extent that is disruptive and 
inappropriate for the person’s developmental level: 
 Often fidgets with or taps hands or feet, or squirms in seat. 
 Often leaves seat in situations when remaining seated is expected. 
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 Often runs about or climbs in situations where it is not appropriate (adolescents or adults 
may be limited to feeling restless). 
 Often unable to play or take part in leisure activities quietly. 
 Is often "on the go" acting as if "driven by a motor". 
 Often talks excessively. 
 Often blurts out an answer before a question has been completed. 
 Often has trouble waiting his/her turn. 
 Often interrupts or intrudes on others (e.g., butts into conversations or games). 
In addition, the following conditions must be met: 
 Several inattentive or hyperactive-impulsive symptoms were present before age 12 years. 
 Several symptoms are present in two or more settings, (e.g., at home, school or work; with 
friends or relatives; in other activities). 
 There is clear evidence that the symptoms interfere with, or reduce the quality of, social, 
school, or work functioning. 
 The symptoms do not happen only during the course of schizophrenia or another psychotic 
disorder. The symptoms are not better explained by another mental disorder (e.g. Mood 
Disorder, Anxiety Disorder, Dissociative Disorder, or a Personality Disorder). 
 
Based on the types of symptoms, three kinds (presentations) of ADHD can occur: 
Combined Presentation: if enough symptoms of both inattention and hyperactivity-impulsivity 
were present for the past 6 months. 
Predominantly Inattentive Presentation: if enough symptoms of inattention, but not 
hyperactivity-impulsivity, were present for the past six months. 
Predominantly Hyperactive-Impulsive Presentation: if enough symptoms of hyperactivity-
impulsivity but not inattention were present for the past six months. 
In partial remission: DSM-5 also classifies sub-threshold cases as ‘in partial remission’ cases when 






1.1.3 Emotional lability 
The recent DSM-5 lists emotional lability (EL), characterised by irritability, mood lability and low 
frustration tolerance, as a characteristic feature of ADHD that may be used to support the diagnosis 
(American Psychiatric Association, 2013).  EL is associated with persistence of ADHD into 
adulthood and is independently associated with a wide range of occupational, social and 
educational impairments (Anastopoulos et al., 2011; Barkley & Fischer, 2010; Skirrow & Asherson, 
2012). Therefore EL is associated with increased impairment in ADHD. 
 
Debate as to whether EL reflects a core domain of ADHD in adults is ongoing.  Arguments in favour 
point toward the common co-occurrence of EL in adults with ADHD (Barkley & Fischer, 2010; 
Barkley & Murphy, 2010) which remains in a non-comorbid sample (Skirrow & Asherson, 2012); 
evidence that treatment with ADHD medication (e.g. methylphenidate or atomoxetine) has a similar 
effect size on reducing the core symptoms of inattention or hyperactivity/impulsivity as it does on 
EL (Reimherr et al., 2005, 2007; Rosler et al., 2010; reviewed in Skirrow, McLoughlin, Kuntsi, & 
Asherson, 2009); that EL is present at an increased rate in family members of individuals with 
ADHD (Epstein et al., 2000; Surman et al., 2011) and shares genetic influences with ADHD 
(Merwood et al., 2014).  However, against the notion of EL as a core ADHD domain is that it is non-
specific, occurring across a range of other psychiatric and neurodevelopmental disorders. For 
example, irritability and temper problems are often included in the diagnostic criteria for 
borderline personality disorder and bipolar disorder (American Psychiatric Association, 2013;  
Asherson et al., 2014).   As will be discussed in section 1.1.5.  such comorbidities are frequent in 
ADHD with mood disorders as high as 38% in adults (Kessler et al., 2006) and around 60% of 
children may have oppositional defiant disorder (Kadesjö & Gillberg, 2001). Comorbidity has also 
been shown to be associated with severity of EL in ADHD children and adolescents (Anastopoulos 
et al., 2011; Sobanski et al., 2010). Therefore although the nature of the relationship of EL in ADHD 
is still debated, it is recommended that individuals with chronic problems with emotion regulation 
or mood instability should always be screened for ADHD (Asherson et al., 2014).   
 
1.1.4 Prevalence 
Meta-analyses of over 100 studies have estimated the worldwide prevalence of ADHD in children 
and adolescents to be around 5% (Polanczyk, de Lima, Horta, Biederman, & Rohde, 2007; 
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Polanczyk, Willcutt, Salum, Kieling, & Rohde, 2014).  This estimate was subject to significant 
variability due to the choice of diagnostic criteria, the source of information used, and the inclusion 
of the requirement for functional impairment, as well as symptoms, for diagnosis. Prevalence rates 
did not differ widely by geographical location. In addition there was no evidence worldwide to 
suggest an increased prevalence of ADHD over the past three decades (Polanczyk et al., 2014).  
 
Meta-analyses suggest the pooled prevalence of ADHD in adulthood is around 2.5% (Simon, Czobor, 
Bálint, Mészáros, & Bitter, 2009).  In older adults a similar prevalence rate (2.8%) has been found 
(Michielsen et al., 2012).  Longitudinal follow-up studies of children with ADHD find that 
approximately two-thirds of youths with ADHD retain impairing symptoms of the disorder (i.e. they 
meet partial diagnostic status with impairments)  by the age of 25 years (Faraone, Biederman, & 
Mick, 2006).  Interestingly, in a follow-up study (at a mean age of 11 and 18 years) of children with 
ADHD (in the UK) a much higher persistence rate of around 80% was found for the full diagnosis. 
This may have been due to the selection of DSM-IV combined subtype cases at baseline (Cheung et 
al., 2015).  Similar unpublished findings were found by the Dutch group led by Jan Buitelaar.   
 
In children and adolescents ADHD predominantly affects males with a male to female sex ratio in 
the order of 4:1 in clinical studies and 2.4:1 in population studies (Polanczyk et al., 2007).  However 
epidemiological and clinical studies indicate the sex discrepancy almost disappears in adulthood 
(Kooij et al., 2005; Kooij, Aeckerlin, & Buitelaar, 2001; Matte et al., 2015), potentially due to a 
referral bias amongst treatment-seeking patients, or potentially sex-specific effects of ADHD over 
the course of the disorder (Faraone et al., 2015). Although some studies have associated ethnicity 
with the ADHD diagnosis (Lingineni et al., 2012; Visser et al., 2014), this may be due to referral 
patterns and barriers to care that disproportionately affect particular ethnic groups. It has 
therefore been concluded that the true prevalence of ADHD does not vary with ethnicity (Faraone 
et al., 2015). 
 
1.1.5 Comorbidity  
ADHD in both childhood and adulthood shows high levels of comorbidity (Bolea-Alamañac et al., 
2014).  In childhood comorbidities include tic disorders, depression, anxiety, learning difficulties, 
ASD, dyslexia, obsessive compulsive disorder, bipolar disorder, conduct and substance use 
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disorders, obesity, personality disorders and difficulties with motor coordination (developmental 
coordination disorder (DCD)) (Bolea-Alamañac et al., 2014; Germanò, Gagliano, & Curatolo, 2010; 
Taurines et al., 2010).  In an analysis of the 2007 National Survey of Children's Health on 61,779 
children including 5028 with ADHD, 33% of those with ADHD had one comorbid disorder, 16% had 
2 and 18% had 3 or more.  Parent report showed a significantly higher level of comorbid problems 
compared to the non-ADHD children, for example, 46% vs 5% had a learning disability  and 18% vs 
2% had anxiety (Larson, Russ, Kahn, & Halfon, 2011).   Comorbidity was associated with a range of 
impairment including problems with school, socialising and family relations.  Children's functioning 
declined with increasing numbers of comorbid conditions, and use of health and educational 
services increased (Larson et al., 2011).    
 
Several studies have suggested that those whose ADHD persists into adulthood have more severe 
symptoms and are more impaired than those who remit. For example, higher ADHD symptom 
severity and the presence of comorbid disorders (particularly mood, anxiety and conduct 
disorders) are commonly found to predict persistence (Biederman et al., 1996, 2011; Kessler, Adler, 
Barkley, et al., 2005; Lara et al., 2009; Molina et al., 2009). Around 75% of adult cases are said to 
have at least one comorbid condition (Kooij et al., 2010).  Comorbidities in adulthood include 
substance abuse, ASD, dyslexia, learning difficulties, personality disorder, depression, anxiety and 
bipolar disorder (Bolea-Alamañac et al., 2014; Kessler et al., 2006).   In a general population sample 
of 3,199 adults the estimated rate of ADHD was 4.4%. Those with ADHD had significantly higher 
rates of comorbid disorders compared to those without ADHD (mood disorders: 38.3% ADHD vs 
11.1% non-ADHD, anxiety disorders: 47.1% vs 19.5%, substance use disorder: 15.2% vs 5.6%, 
intermittent explosive disorder: 19.6% vs 6.1%) (Kessler et al., 2006). Rates of ASD are also high: 
one multicentre study in adults found that 43% of adult patients diagnosed with autism had ADHD 
symptoms (Hofvander et al., 2009).  
 
Substance abuse is highly prevalent in ADHD (Bolea-Alamañac et al., 2014; Kessler et al., 2006). For 
example in 1761 adults with substance dependence, 5.22% had a diagnosis of ADHD versus 0.85% 
of individuals without substance dependence (Arias et al., 2008). In a smaller study (n=120) of 
adults with ADHD, lifetime risk for substance use disorder (SUD) was as high as 52% versus 27% in 
controls (Biederman et al., 1995). In a 10 year follow-up study of children with and without ADHD, 
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ADHD was found to be a significant risk factor for the development of substance use disorder 
(Wilens et al., 2011).  Research in non-clinical samples have found higher rates of substance abuse 
(compared to those without ADHD symptoms) in those with undiagnosed ADHD or with high levels 
of ADHD symptoms (Gudjonsson, Sigurdsson, Sigfusdottir, & Young, 2012; Young & Thome, 2011).  
In 10,987 adolescents, those with high levels of ADHD symptoms reported significantly higher rates 
of substance abuse compared to their non-ADHD peers (Gudjonsson et al., 2012). This suggests that 
those with undiagnosed ADHD may be attempting to self-medicate (Bolea-Alamañac et al., 2014). 
This will be discussed further in Section 1.3.2. 
 
1.1.6  Impairment  
ADHD in both childhood and adulthood is a severe and impairing disorder.  It is associated with 
increased rates of unemployment (Halmøy, Fasmer, Gillberg, & Haavik, 2009), sickness absence (de 
Graaf et al., 2008), drug and alcohol abuse (Kaye, Darke, & Torok, 2013), lack of academic 
achievement and higher rates of poor social adjustment, family or marital conflict (Biederman et al., 
2006; Fried et al., 2013; Wymbs, Jr, Gnagy, & Wilson, 2009). The excess cost of the condition (in 
terms of education, occupational impairment and medical treatment) was estimated at over $30 
billion in the United States in 2000 (Birnbaum et al., 2005). 
 
More recent research has focused on the link between ADHD and criminality.  Meta-analysis 
estimated a 25.5% prevalence of ADHD in prison populations (Young, Moss, Sedgwick, Fridman, & 
Hodgkins, 2014).  Compared with the prevalence in the general population, this translated to a five-
fold increase in ADHD in youth prison populations (30.1%) and a 10-fold increase in adult prison 
populations (Young et al., 2014).  Increased criminality in ADHD could be mediated by comorbid 
personality disorders, particularly antisocial personality disorders, as high rates of personality 
disorder are reported in prison populations (Rösler et al., 2004). Up to one third of personality 
disordered offenders screen positive for ADHD (Bolea-Alamañac et al., 2014; Young et al., 2011).  
Treatment of ADHD with stimulants or atomoxetine has, however, been found to reduce offending, 
suggesting that core ADHD symptoms play a key role in maintaining criminal behaviour. An 
epidemiological study of data from the Swedish National Register showed an approximately six-fold 
increase in criminal convictions associated with ADHD, which were reduced during periods of 
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targeted treatment for ADHD by around 32% in men and 41% in women; an effect that was not 
seen for treatment with antidepressants (Lichtenstein et al., 2012). 
 
1.1.7 Heritability 
Results from 20 twin studies in children and adolescents (with only one study including young 
adults)  have shown that ADHD is one of the most heritable of psychiatric disorders  (~ 76%) 
indicating a strong genetic architecture  (Faraone et al., 2005).  Some twin studies, using self-rated 
ADHD scales, have shown substantially lower heritabilitites in adults (~30–40%) (Boomsma et al., 
2010; Larsson et al., 2012; Van Den Berg, Willemsen, De Geus, & Boomsma, 2006). However this 
may be due to rater-effects resulting from the use of self-report measures in adults, whilst  
heritability estimates in children are generally based on self and informant reports (Larsson, Chang, 
D’Onofrio, & Lichtenstein, 2014).  More recent twin studies, one of which included adults with a 
clinical diagnosis, have combined self, parent or clinician ADHD ratings and found equivalent 
heritability estimates to those found in childhood (~72%-78%) (Chang, Lichtenstein, Asherson, & 
Larsson, 2013; Larsson et al., 2014). Given the high heritability of ADHD it is associated with high 
levels of familiality (Faraone et al., 2000; Manshadi, Lippmann, O’Daniel, & Blackman, 1983).  First 
degree relatives of those with ADHD are 2-8 times more likely than relatives of unaffected 
individuals to also have ADHD (Faraone et al., 2005), and may be around 10-fold when probands 
are restricted to the more severe combined type diagnosis (Chen et al., 2008).   Adoption studies 
have also found biological relatives of hyperactive children to show more ADHD traits than 
adoptive relatives (e.g. Cantwell, 1975; for a review see Thapar, Cooper, Eyre, & Langley, 2013).  
 
1.1.8 Categorical versus dimensional approaches to diagnosis 
The categorical classification of ADHD and other mental disorders in the DSM 5 has been criticised 
as failing to account for the heterogeneity of mental illness. It has therefore been argued that the 
classification of ADHD and other disorders may be better represented dimensionally. Dimensional 
classification describes the classification of a disorder along a continuum of symptoms rather than 
discrete categories (Brown & Barlow, 2005).  In line with this, evidence from quantitative genetic 
studies have suggested that ADHD may represent the extreme of one or more continuously 
distributed trait (Chen et al., 2008; Levy, Hay, McStephen, Wood, & Waldman, 1997).  For example, 
estimates of heritability remained high (0.75-0.91) regardless of whether ADHD was defined as a 
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continuum or discrete disorder (Levy et al., 1997). A recent review highlighted guidelines from the 
US National Institute of Mental Health which encourages researchers to use a dimensional 
approach when examining the cognitive and clinical features of ADHD and other disorders (Faraone 
et al., 2015; Sanislow et al., 2010).  Therefore, as a whole, both categorical and quantitative 
approaches are encouraged in the investigation of ADHD.  
 
1.1.9 Aetiology of ADHD 
 
1.1.9.1 Genetic studies 
Given the high heritability of ADHD, research has focused on elucidating the genetic architecture of 
this complex polygenic disorder (Gizer, Ficks, & Waldman, 2009).  Early candidate gene studies 
(which test for association between ADHD and genes thought likely to be involved in its 
pathophysiology)  focused on neurotransmitter systems, identifying a number of genes involved in 
dopaminergic and serotonergic neurotransmission (Faraone et al., 2005; Gizer et al., 2009; Li, 
Sham, Owen, & He, 2006; Smith, 2010; Yang et al., 2007). The strongest evidence of association 
from these studies is with the 7-repeat allele of the dopamine D4 receptor gene (Li et al., 2006).  
More recently converging evidence  has further suggested that genetic variation within a network 
of genes involved in neural growth increases risk for ADHD (Poelmans, Pauls, Buitelaar, & Franke, 
2011).   
 
Genome wide association studies (GWAS) explore the whole genome for common genetic variants. 
It was recently estimated that 28% of the variance in ADHD is explained by currently available 
genome-wide genetic marker arrays (Yang et al., 2013).  In polygenic risk score analysis, the genetic 
signals attributed to common variants derived from a discovery sample are used to predict 
phenotypic effects in a second sample (Faraone et al., 2015).  The polygenic risk for clinically 
diagnosed ADHD broadly predicts ADHD symptoms in the population (Martin, Hamshere, 
Stergiakouli, O’Donovan, & Thapar, 2014).  This suggests that the genes regulating the diagnosis of 
ADHD also regulate the expression of subclinical levels of ADHD symptoms (Faraone et al., 2015). 
This supports conclusions from family and twin studies which suggest that ADHD is an extreme and 
impairing tail of one or more heritable quantitative traits (Chen et al., 2008; Henrik Larsson, 
Anckarsater, Råstam, Chang, & Lichtenstein, 2012). Genetic overlap with other disorders has also 
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been found. For example, a combined GWAS of ADHD, autism spectrum disorders, depression, 
bipolar disorder and schizophrenia identified four shared genome-wide significant loci (Cross-
Disorder Group of the Psychiatric Genomics Consortium, 2013).  
 
Increased large, rare chromosomal deletions and duplications known as copy number variants 
(CNVs) have also been found in ADHD (Elia et al., 2012; Stergiakouli et al., 2012; Williams et al., 
2010, 2012). The first study to report case control differences for CNVs in ADHD found 15.6% of 
patients with ADHD carry large CNVs of > 500,000 base pairs in length, compared to 7.5% of 
individuals without the disorder (Williams et al., 2010), although similar  presentations have been 
found in children with ADHD with and without such CNVs  (Langley et al., 2011), and there is 
overlap of CNVs spanning the same genes in other psychiatric (neurodevelopmental) disorders (e.g. 
autism, schizophrenia) (Williams et al., 2010).  Therefore increased CNV burden is not unique to 
ADHD but may represent vulnerability to several psychiatric, particularly neurodevelopmental, 
disorders.  
 
1.1.9.2 Environmental associations 
Although a number of environmental factors have been associated with ADHD it is difficult to 
distinguish correlation from causality (see Thapar et al., 2013 for a review).  Prematurity and 
severe early deprivation appear to be the most conclusive risk factors to date with only severe early 
deprivation likely to be on the causal pathway (Bolea-Alamañac et al., 2014; Thapar et al., 2013). 
There is suggestive but not conclusive evidence for an association with maternal 
smoking/alcohol/substance misuse and stress during pregnancy, low birth weight, family adversity 
and low income, parent-child hostility and severe early deprivation.  However factors such as 
maternal smoking during pregnancy may reflect gene-environment correlation, since there is 
evidence that the association with offspring ADHD does not remain once genetic or other potential 
confounders are controlled for (Langley, Heron, Smith, & Thapar, 2012; Thapar et al., 2009).   A 
number of dietary factors (nutritional deficiencies (e.g. omega-3) or surpluses (e.g. sugar)) and 
environmental toxins (e.g. lead, NO2) have also been linked (Bolea-Alamañac et al., 2014; Thapar et 




1.1.9.3 Gene x environment interaction 
 Heritability estimates also include the interplay between the gene x environment (Rutter, 2006). 
Genetic risk may influence susceptibility to ADHD by altering individual sensitivity to 
environmental risks or protective factors.  Preliminary research has found that the dopamine and 
serotonin systems may interact with psychosocial risk factors (e.g. marital 
conflict/adversity/stress) and the dopamine system with pre-natal risk factors (e.g. maternal 
smoking) (see Nigg, Nikolas, & Burt, 2010 for review).  For example, a variant of the 5-HTTLPR, a 
polymorphic region located in the promoter of SLC6A4, is involved in the hyperactivity/impulsivity 
dimension of ADHD in interaction with stress (van der Meer et al., 2014).  However replication of 
these results is necessary before any conclusions can be drawn (Thapar et al., 2013).  More recent 
work has focused on the effect of the environment on gene expression, known as epigenetics (Mill & 
Petronis, 2008). For example, the proposed protective effect of exercise in ADHD could be mediated 
by alterations in gene expression (Rommel, Halperin, Mill, & Asherson, 2013; Rommel et al., 2015). 
Future research in this area may provide new insights into the pathogenesis of ADHD (Mill & 
Petronis, 2008). 
 
1.1.9.4 Neuroimaging studies  
The exact neurobiological mechanisms underlying ADHD are poorly understood.  One recent theory 
has focused on the association between ADHD and abnormal brain connectivity, for example within 
the brain’s default mode network which has been linked to attention regulation (Castellanos & 
Proal, 2012; Castellanos et al., 2008; Konrad & Eickhoff, 2010).  Several neural networks have been 
suggested to play a key role, although as yet there is very little in the way of causal modelling to 
convincingly demonstrate which reflect the key neural deficits leading to the symptoms and 
impairments of ADHD. These neural pathways include: (1) reduced connectivity in the ventral 
fronto-striato-parietal (cognitive control) circuit; (2) reduced connectivity in the dorsal fronto-
striato-parietal attention circuit; (3) reduced connectivity in inferior fronto-supplementary–motor-
area-parieto-cerebellar networks for timing function; (4) reduced connectivity in orbitofrontal-
ventral striatal (salience/reward) circuit; (5) reduced connectivity between the default mode 
network (DMN) and cognitive control circuits, reduced deactivation of the DMN during cognitive 
tasks and reduced connectivity between components of the DMN (Cortese et al., 2012; Faraone et 




Evidence from electroencephalography (EEG) studies has indicated increased theta activity and an 
increased theta to beta ratio in children and adults with ADHD compared to controls. This is said to 
indicate cortical underactiviation in ADHD due to the association between theta activity and 
drowsiness (Loo & Makeig, 2012; Tye, McLoughlin, Kuntsi, & Asherson, 2011), and has been linked 
to cognitive theories of sub-optimal arousal in ADHD (see Section 1.1.10.1).   This finding has 
recently led to the approval of an EEG-based diagnostic aid for ADHD in children which calculates 
the theta to beta ratio (FDA, 2014). However this has been criticised given that an increased 
theta/beta ratio is not a robust finding; it is estimated that up to 16% of children with ADHD will 
have typical theta/beta ratios (Bolea-Alamañac et al., 2014; Loo & Makeig, 2012) 
 
Previously, longitudinal data suggested delayed cortical maturation in children with ADHD (Shaw & 
Rabin, 2009).   Structural and functional brain abnormalities have been found to overlap between 
children and adults with ADHD (Schneider, Retz, Coogan, Thome, & Rösler, 2006), suggesting that 
when the disorder persists so do the underlying brain abnormalities.  Differences in grey and white 
matter have been reported (Shaw & Rabin, 2009), with meta-analyses (in children and adults with 
ADHD) finding various structural differences including: smaller right hemispheric grey matter 
volumes of the basal ganglia,  smaller grey matter volumes in total and right cerebral volume, 
cerebellum, corpus callosum, frontal lobes, prefrontal cortex, deep frontal white matter and 
temporal lobe and potential grey matter increases in the left posterior cingulate cortex/precuneus 
(Ellison-Wright, Ellison-Wright, & Bullmore, 2008; Frodl & Skokauskas, 2012; Nakao, Radua, Rubia, 
& Mataix-Cols, 2011). Although results from these meta-analyses are inconsistent, evidence for 
reductions in grey-matter in the dopamine-rich basal ganglia appears the most robust  (Bolea-
Alamañac et al., 2014).    
 
Single photon emission computed tomography (SPECT) studies have revealed altered dopamine 
receptor binding and potential differences in the density of the dopamine transporter in ADHD, 
particularly in the striatum (del Campo, Müller, & Sahakian, 2012; Hesse, Ballaschke, Barthel, & 
Sabri, 2009; Krause, la Fougere, Krause, Ackenheil, & Dresel, 2005; Krause, Dresel, Krause, Kung, & 
Tatsch, 2000). These findings support the well-established dopamine theory of ADHD, suggesting 
dysfunction in the dopamine neurotransmitter system may interfere with neuropsychological 
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functions such as in the domains of attention and motivation (Swanson et al., 2007). The main 
evidence for this is based on the effectiveness of treatment with stimulant medication (i.e. 
methylphenidate; see also Section 1.1.11 for discussion of treatment) that block the brain dopamine 
transporters, significantly enhancing extracellular dopamine (Volkow, Fowler, Wang, Ding, & 
Gatley, 2002).   
 
1.1.10 Cognitive deficits in ADHD 
A heterogeneous range of neurocognitive impairments are present in both children and adults with 
ADHD and are summarised in Table 1-1. Impairments include  deficits in executive function 
(Sonuga-Barke, Sergeant, Nigg, & Willcutt, 2008), reaction time variability (RTV)  (Kofler et al., 
2013), difficulties in state regulation (indexed by greater sensitivity to rewards (discussed below 
(Section 1.1.10.1.))  (Sonuga-Barke & Fairchild, 2012), and impaired temporal information 
processing (such as a reduced ability to discriminate between two time intervals that differ in 
duration (such as 500ms vs 600ms)) (Toplak, Dockstader, & Tannock, 2006; Toplak & Tannock, 
2005). 
 
The most consistent deficits in ADHD are thought to be in executive function and RTV (Bolea-
Alamañac et al., 2014; Kofler et al., 2013). Executive function, mainly associated with the prefrontal 
cortex, refers to the completion of goal directed tasks through the combination of higher order 
cognitive processes (Sonuga-Barke et al., 2008). In children and adults with ADHD,  meta-analyses 
have found deficits in executive function to include measures of attention, response inhibition, 
vigilance working memory and planning (Frazier, Demaree, & Youngstrom, 2004; Willcutt, Doyle, 
Nigg, Faraone, & Pennington, 2005). For example, omission errors (where a participant fails to 
respond when a response is required) and commission errors (where a participant responds on a 
task where a response is not required) are thought to measure sustained attention and response 
inhibition respectively (Frazier et al., 2004).  Numerous studies have reported increased 
commission and omission errors on computerised attention tasks in both children (Willcutt et al., 
2005) and adults (McLoughlin et al., 2010; Skirrow et al., 2015) with ADHD (for reviews see Bolea-
Alamañac et al., 2014; Frazier et al., 2004).  Reaction Time Variability (RTV) is another highly 
investigated cognitive deficit in ADHD.  Thought to be a measure of attentional lapses, impairments 
are consistently found in children (Andreou et al., 2007; Tye et al., 2013; Uebel et al., 2010) and 
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adults (McLoughlin et al., 2010; Skirrow et al., 2015)  with ADHD (for reviews see Frazier et al., 
2004; Karalunas, Geurts, Konrad, Bender, & Nigg, 2014; Kofler et al., 2013). 
 
1.1.10.1 State regulation in ADHD 
One theory of the cognitive deficits in ADHD is proposed by the 'cognitive energetic model'. This 
model proposes deficits in cognition to be the result of a reduced energetic state (Sergeant, 2000).  
In line with this, several studies in ADHD children have reported a significantly greater 
improvement in Mean Reaction Time (MRT) and RTV following the introduction of rewards and/or 
an increase in presentation rate on computerised attention tasks (Andreou et al., 2007; Cheung et 
al., under review; Slusarek et al., 2001; Uebel et al., 2010). Meta-analysis has estimated a small but 
significant effect (g=0.3-0.4) of incentives in reducing RTV (Kofler et al., 2013).  Evidence for 
sensitivity to rewards in adults with ADHD is limited, with one study showing no effect of rewards 





Table 1-1: Summary of the cognitive deficits found in ADHD in children, adolescents and adults 
(adapted from Bolea-Alamañac et al., (2014)) 









Executive function     
CPT commission errors Yes Moderate Yes Moderate 
CPT ommission errors Yes Moderate Yes Moderate 
SST-Reaction Time Yes Moderate Yes Small 
Spatial working memory Yes Moderate Yes Small 
Verbal working memory Yes Moderate Yes Small 
ToL/H Yes Moderate Yes Small 
Trials-B Yes Moderate Yes Moderate 
Stroop Inteference Yes Small Yes Small 
Reaction time     
RTV Yes Moderate/Large Yes Moderate 
Timing     
Time discrimination 
tasks  
No Moderate No Small/moderate 
Time reproduction tasks No Moderate No Small/moderate 
State regulation     
Varying event rate No Moderate No Small 
Reward  No Small No No effect 
Punishment No Small No No effect 
Note. Quantitative studies column describes the existence of quantitative reviews published for 
the named test. Strength of effect: no effect, Cohen’s d < .2, small effect, Cohen’s d .2–.4; moderate 
effect Cohen’s d .4–.7; large effect Cohen’s d .7–1.0; very large effect Cohen’s d > 1.0.  
Task domains in table: 
Executive Function (Sonuga-Barke et al., 2008): CPT = continuous performance test of sustained 
attention; SSRT = Stop signal reaction time measure of inhibitory control;  Tol/H = Tower of 
London/Hanoi: measure of planning; Trials-B =  a measure of planning; Stroop interference = a 
measure of attention/processing speed. 
Reaction time (Hervey, Epstein, & Curry, 2004; Kofler et al., 2013): RTV  = Reaction time 
variability - Variation in Mean Reaction Time, often measured on CPT tasks.  
Timing (temporal information processing) (Toplak et al., 2006): Time discrimination tasks = the 
participant is required to discriminate between two brief time intervals. Time reproduction tasks = 
the participant is required to reproduce a specified time interval.  
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State Regulation (Andreou et al., 2007; Sonuga-Barke, Bitsakou, & Thompson, 2010): ISI effects = 
Greater sensitivity to the effect of varying event rate on performance; Reward = measure of 
sensitivity to the effects of adding rewards to tasks; Punishment = measure of sensitivity to the 
effects of adding punishments to tasks. 
 
1.1.10.2 Cognitive deficits and diagnosis 
Although the DSM-5 includes cognitive deficits as an associated feature of ADHD (American 
Psychiatric Association, 2013) these deficits are heterogeneous, present in some but not all cases, 
and seen in controls and other mental health conditions (such as ASD) (Rommelse, Geurts, Franke, 
Buitelaar, & Hartman, 2011). They therefore lack the sensitivity and specificity to be used as 
accurate diagnostic tools (Bolea-Alamañac et al., 2014; Doyle et al., 2005). For example, tests for 
executive function lead to a high level of false negative cases (Nutt et al., 2007).  The association 
between cognitive impairments and ADHD is sometimes taken to imply a causal relationship.  In 
support of this, research has found a familial overlap between ADHD symptoms and RTV, indicating 
potential shared genetic underpinnings (Kuntsi et al., 2010).  However it is also proposed that many 
of the cognitive impairments associated with ADHD may arise as a consequence of the many 
potential outcomes of aetiological influences on ADHD (for example genetic pleiotropy), or may 
reflect epiphenomena of the disorder (Kendler & Neale, 2010).   
 
Given the heterogeneity of cognitive impairments in association with ADHD symptoms, research 
has suggested that multiple different mechanisms might underlie the symptoms and impairments 
of ADHD (Coghill, Rhodes, & Matthews, 2007).  Greater treatment effects (with stimulant 
medication) have been found for symptoms than cognition (Banaschewski et al., 2006; Coghill et al., 
2014; Faraone & Buitelaar, 2010).  Studies have also found a dissociation of the treatment effects on 
ADHD symptoms and cognitive performance, such that change in response to treatment does not 
appear to be correlated between cognitive and ADHD symptom measures (Bédard et al., 2014; 
Coghill et al., 2007; K. P. Schulz, Fan, & Be, 2014). Therefore there is currently little support for a 
direct causal relationship between symptoms and measures of cognitive performance in ADHD 
(Bolea-Alamañac et al., 2014). This is discussed in greater detail in the discussion section of Chapter 




1.1.11 Treatments in ADHD 
Stimulant medication is the first line treatment for both children and adults with ADHD, with 
around 70% of adults showing a positive response and even better responses seen in children 
(Biederman, Spencer, & Wilens, 2004; Bolea-Alamañac et al., 2014; Medori et al., 2008; Spencer et 
al., 2005).  Psychological treatments (e.g. cognitive behavioural therapy) are also recommended as 
an adjunctive or (particularly in children) mono-therapy (Young & Amarasinghe, 2010), with 
evidence suggesting the combination of pharmacological and psychological treatment to be 
superior to medication alone (Solanto et al., 2013; Young & Amarasinghe, 2010).  For 
pharmacological treatment, meta-analyses have found medium to high (d = ~0.6 – 0.9) effect sizes 
for stimulant and non-stimulant medication (Faraone & Buitelaar, 2010; Faraone & Glatt, 2010; 
Mészáros et al., 2009) with effect sizes above 1 for higher doses (Faraone, Spencer, Aleardi, Pagano, 
& Biederman, 2004).  In the most recent meta-analyses of drug treatments in adult ADHD, effect 
sizes were reported in to be in the region of d = 0.4 – 0.8 (Castells, Ja, Bosch, Nogueira, & Casas, 
2011; Castells et al., 2011; Cunill, Castells, Tobias, & Capella, 2013; Koesters, Becker, Kilian, Fegert, 
& Weinmann, 2009). Pharmacological treatment has been found to improve quality of life and daily 
functioning in addition to ADHD symptoms (Surman, Hammerness, Pion, & Faraone, 2013).  
 
The main mechanism of action of ADHD drugs is said to be through enhancement of dopaminergic 
and noradrenergic neurotransmission in brain areas associated with attention and impulsivity, 
including the prefrontal cortex, the striatum and the cerebellar vermis (Anderson, Polcari, Lowen, 
Renshaw, & Teicher, 2002; Arnsten & Dudley, 2005; Bolea-Alamañac et al., 2014; Volkow, Fowler, 
Wang, Ding, & Gatley, 2002). Meta-analysis of imaging studies has found stimulant medication to be 
associated with normalisation of structural abnormalities in ADHD (Nakao et al., 2011). In our own 
work, we found normalisation of very low frequency electroencephalography (VLF-EEG), thought 
to reflect synchronisation of neural oscillations within the brains organisational networks (Helps, 
Broyd, James, Karl, & Sonuga-Barke, 2009), after treatment with methylphenidate in adults with 






1.1.11.1 Difficulty in obtaining treatment 
Despite clear guidelines from NICE (NICE, 2008), there is difficulty in obtaining a diagnosis and 
treatment for adults with ADHD (Bolea-Alamañac et al., 2014).  This was a significant observation 
in the samples recruited for this thesis and is discussed in Chapter 7, Section 7.6.1. In the UK less 
than 10% of adults with ADHD who require medication are thought to receive treatment (Bolea-
Alamañac et al., 2014). Primary care prescription records show the use of medication to rapidly 
reduce once adolescents reach 16-18 years, with a significant discrepancy between numbers 
meeting full criteria for the disorder and numbers prescribed medication (McCarthy et al., 2009; 
McCarthy et al., 2012).  A lack of treatment for ADHD is associated with significant impairment. One 
marked example is the high rate of ADHD in prison populations which is significantly higher than in 
the general population (estimated at 25.5%) (see Section 1.1.6), yet we know that very few 
prisoners with ADHD are being treated for the condition (Young et al., 2014; Young & Thome, 
2011), despite evidence that this is likely to reduce impairment (Lichtenstein et al., 2012).   
 
 A number of factors may contribute to the difficulty in obtaining a diagnosis (Kooij et al., 2010):  
 
1) There may be unease within some mental health professionals in the identification and 
treatment of ADHD  (Bolea et al., 2012; Singh, 2008). For example, some hold the erroneous view 
that ADHD is a construct manufactured by the pharmaceutical industry (Goldstein, 2006).  
2) Lack of training in ADHD. 
3) Clinicians may be reluctant to widen the already overstretched psychiatric services to include 
adults with ADHD  (Bolea et al., 2012).  
 
Difficulties in obtaining the adult diagnosis and recommendations for improvement have been 
highlighted numerous times (Bolea et al., 2012; Bolea-Alamañac et al., 2014; Kooij et al., 2010; Nutt 
et al., 2007), yet with the significant issues found in the samples recruited for this thesis, it is clear 
that this remains a pertinent issue.  
 
1.1.11.2 Why is there a need to investigate alternative treatments? 
Pharmacological medication is the first line treatment for ADHD.  There are however a number of 
potential problems with the currently available medications, including non or partial response and 
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adverse effects. Not all patients are tolerant of the main drugs used to treat ADHD. Common side 
effects of stimulants include sleeplessness, loss of appetite, weight loss, lethargy, dysphoria and 
irritability (Faraone et al., 2015; Leonard, McCartan, White, & King, 2004; Sangal et al., 2006). A set 
of overlapping problems are also seen with atomoxetine which may have additional problems, such 
as erectile dysfunction. Serious adverse events may include the onset of tics, acute anxiety states, 
depression, psychosis and mania (Faraone et al., 2015).  In children, stimulants are also associated 
with small delays in growth (Faraone, Biederman, Morley, & Spencer, 2008). The recommended 
treatments for ADHD can all increase blood pressure, and this can present as a problem in some 
cases.  These more serious adverse-effects of stimulant treatment led to US Food and Drug 
Administration (FDA) warnings. From February 2007 all FDA-approved drug treatments for ADHD 
(methylphenidate, dexamphetamine and atomoxetine) have carried warnings that their use could 
involve risks of cardiovascular effects, growth suppression and the development of psychosis or 
other psychiatric conditions. Rare cases of sudden death have also been reported amongst children 
using stimulant medications for ADHD.  The FDA warns that the use of these medications by 
children with heart conditions should be avoided or undertaken with great caution (FDA, 2006).  
 
Participants recruited for this thesis reported a number of problems with stimulant medication.  
One said that the medication made him become aggressive to the point that his marriage broke 
down: “Completely unable to control my temper”.  
 
A number of participants felt that they lost their personality when on the medication or had a sense 
of depersonalisation: "It felt as if between me and the world was a plastic window. I was happy and 
content, but didn’t feel the urge anymore to show that. Friends/family told me that I had lost my 
spark." 
 
 Some felt that they did not want to take pharmacological medication in order to function: 
“Damaged my self-esteem…can I really only function if I am on drugs?” 
 
Some did not respond to the medication and research has found around 25% of patients are 
treatment resistant (Biederman et al., 1999): "I was also disappointed a bit as I had hoped I could 




There are, in addition, questions over the long-term efficacy and the potential for abuse of 
stimulants (Bolea-Alamañac et al., 2014; Dunnick & Hailey, 1995; Nasrallah et al., 1986).  There are 
also concerns over effects on physical health and (particularly in children) developmental effects: "I 
was (and am) concerned the effect it would have on for instance my kidneys over longer periods of 
time (and possibly pregnancy)." 
 
Given these problems with adverse events, partial response and long-term efficacy, it is important 
that alternative treatments for ADHD are investigated.  
 
1.1.12 Interim summary  
ADHD is a persistent neurodevelopmental disorder characterised by deficits in inattention, 
hyperactivity/impulsivity, cognition and EL.  ADHD affects around 5% of children and 2.5% of 
adults. It is associated with increased risk of comorbid psychiatric disorders and psychosocial 
impairments, including substance use disorder, educational, occupational and social problems and 
criminality. ADHD is highly heritable suggesting a strong genetic component. Although associations 
are starting to be identified with common genetic variants and rare CNVs, there is no single risk 
factor for ADHD. Genetic and environmental factors appear to act together to increase 
susceptibility. Neuroimaging studies have found numerous structural and brain abnormalities and 
more recent research has focused on abnormal brain connectivity in ADHD, yet it remains unclear 
which might play a causal role. Given the marked response to dopamine enhancing stimulant 
medications, abnormality of the dopamine system is a well-established hypothesis of ADHD. 
However, there are a number of problems with available medications, including both stimulants 
and atomoxetine, which includes both serious and common adverse events and partial or non-







1.2 Alternative treatments in ADHD: Omega-3 polyunsaturated fatty acid 
supplementation 
 
Omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation is an extensively studied 
alternative treatment for ADHD (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-Barke et 
al., 2013). Thought to affect monoamine neurotransmission (Chalon, 2006), numerous case/control 
and intervention studies have provided evidence for a small but significant benefit of n-3 PUFA in 
children with ADHD (Hawkey & Nigg, 2014; Bloch & Qawasmi, 2011; Sonuga-Barke et al., 2013). 
Given that n-3 PUFA supplementation has a significantly lower adverse effect profile than 
pharmacological treatment it has been concluded that it may be useful as an adjunctive treatment 
or monotherapy for those who do not wish to take pharmacological treatment.  
 
1.2.1 Physiological effects on n-3 PUFA  
Long-chain polyunsaturated Fatty Acids (PUFAs) are thought to be the most important for health 
and development, making up at least 35% of the 50-60% lipid content of the human brain (Gow & 
Hibbeln, 2014). The two major n-3 PUFAs are docosahexaenoic acid (DHA) and eicosapentaenoic 
acid (EPA) (Gow & Hibbeln, 2014). PUFAs cannot be synthesised by humans and must be either 
ingested or metabolised from their fatty acid precursors (Elmadfa & Kornsteiner, 2009; Haag, 2003; 
Innis, 2008). EPA and DHA are metabolised from their parent compound alpha linoleic acid (ALA). 
Whereas Omega-6 PUFAs (n-6 PUFA) are metabolised from their parent compound linoleic acid 
(LA) (Brenna, Salem, Sinclair, & Cunnane, 2009). This metabolism process is shown in Figure 1-1. 
EPA and DHA are thought to exert their effects through a number of important functions related to 
neural activity and brain development. This includes aiding cell membrane fluidity, 
neurotransmission, ion channels, enzyme regulation, gene expression, myelination, neurogenesis 
and synaptogenesis (Gow & Hibbeln, 2014; Gow, Hibbeln, & Parletta, 2015; Innis, 2008; Lauritzen, 
Hansen, Jorgensen, & Michaelsen, 2001; Janssen & Kiliaan, 2014). For example, DHA is the most 
abundant PUFA in the brain, making up 30% of the lipid cell membranes in grey matter, and may be 
important for optimal neural functioning (Brenna & Diau, 2007; Diau et al., 2005; Gow & Hibbeln, 
2014). PUFAs are also important building blocks of neuronal membranes; DHA and EPA being the 




PUFAs have also been linked to inflammation through production of eicosanoids. Eicosanoids are 
lipid mediators that are involved in a wide array of physiological functions, including inflammation 
(Janssen & Kiliaan, 2014; Schmitz & Ecker, 2008; Simopoulos, 2011). It is thought that, through 
production of different eicosanoids, n-3 PUFAs may limit neuroinflammation whereas n-6 PUFAs 
may promote inflammation (Gow & Hibbeln, 2014; Sinn, Milte, & Howe, 2010; Janssen & Kiliaan, 
2014; Simopoulos, 2002).  Inflammation has been linked to a number of mental health problems 
including ADHD, depression, schizophrenia and bipolar disorder (Dean, 2011; Raison & Miller, 
2013; Strickland, 2014). 
 
A balanced ratio of n-6 to n-3 PUFA is therefore required for optimal health and development 
(Hawkey & Nigg, 2014). However, a current deficit in n-3 intake in the western diet is well 
established (Gow & Hibbeln, 2014; Schuchardt, Huss, Stauss-Grabo, & Hahn, 2010; Simopoulos, 
1991).  Increasing consumption of vegetable oils and processed foods and decreasing consumption 
of fish, nuts and seeds has decreased the ratio of n-6:n-3 from around 1.1:2.1 to approximately 20:1 
(Kuipers et al., 2010; Simopoulos, 2002). Furthermore, excessive n-6 intake may inhibit n-3 PUFA 










Figure 1-1: Conversion of polyunsaturated fatty acids to their longer-chain metabolites 
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1.2.2 PUFA in the pathophysiology of ADHD 
It is relatively well established that blood levels of n-3 PUFA have been found to be lower in ADHD 
cases compared to controls (Hawkey & Nigg, 2014). A recent meta-analysis in 9 studies (n=586) 
compared blood (plasma and/or red blood cells) omega-3 levels in children and adults with ADHD 
to controls (Hawkey & Nigg, 2014). Results showed ADHD cases to have significantly lower total n-
3 PUFA (EPA, DHA, ALA and DPA) blood levels compared to controls (g = 0.42, p < .001).  The 
largest differences were found when looking at DHA alone (g = 0.59, p < .001) and EPA and DHA 
alone (g= 0.51, p < 0.001). Absence of heterogeneity and publication bias increased the reliability of 
these findings. Alongside this a number of studies have found a higher n-6:n-3 ratio in children and 
adults with ADHD compared to controls (Chen et al., 2004; Stevens et al., 1995; Germano et al., 
2007; Antalis et al., 2006). It is unclear as to whether differences in n-3 PUFA may be due to low 
dietary intake or an abnormality in PUFA metabolism (Gow & Hibbeln, 2014). Hawkey & Nigg 
(2014) found some evidence of reduced n-3 PUFA intake although firm conclusions could not be 
drawn (Hawkey & Nigg, 2014). It has been suggested that a genetic vulnerability could lead to 
disruption in PUFA metabolism (Brookes et al., 2006; Hawkey & Nigg, 2014).   However further 
research is required before any conclusions can be drawn. 
 
1.2.3 Effects of n-3 PUFA deficiency  
Through alterations of cellular communication, deficiencies in n-3 PUFA have been linked to altered 
neurotransmission particularly for dopamine and serotonin (Assisi et al., 2006; Chalon, 2006; Haag, 
2003; Young & Conquer, 2005). Omega-3 deficient animals have shown altered dopamine and 
serotonin neurotransmission in the frontal cortex and nucleus accumbens, brain areas implicated in 
ADHD (Delion, Chalon, Guilloteau, Besnard, & Durand, 1996; Bolea-Alamañac et al., 2014; Zimmer 
et al., 1998; Zimmer et al., 2000; Zimmer et al., 2002). For example, one study found a 40-60% 
decrease in dopamine in the frontal cortex of n-3 deficient rats (Delion et al., 1994).  
 
As discussed in Section 1.1.9.4, the theory that ADHD may be characterised by atypical dopamine 
levels is well established, supported mainly by the clinical response to dopamine-altering ADHD 
stimulant medication (Bolea-Alamañac et al., 2014), as well as imaging (e.g. del Campo et al., 2012), 
and genetic (Li et al., 2006) studies. Serotonergic genes have also been implicated in ADHD 
(Faraone et al., 2005; Gizer et al., 2009). Alterations in neurotransmission may also contribute to 
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altered cortical organisation and connectivity, an emerging theory of ADHD (Castellanos & Proal, 
2012; Grayson, Kroenke, Neuringer, & Fair, 2014; Hibbeln, Ferguson, & Blasbalg, 2006). Animal 
studies have found pre and postnatal DHA insufficiency to be associated with a variety of structural 
changes, such as delayed neuronal migration, disrupted dendritic arborisation and abnormal 
neuronal development in the hippocampus (Yavin, Himovichi, & Eilam, 2009).  
 
1.2.4 PUFA and other psychiatric disorders  
Omega-3 PUFA has also been investigated as a treatment for depression, schizophrenia and autism 
spectrum disorder (ASD). A number of meta-analyses have confirmed that there seems to be a 
small to medium effect of n-3 PUFA supplementation in improving symptoms of depression in 
clinical samples (Appleton, Rogers, & Ness, 2010; Grosso et al., 2014; Martins, Bentsen, & Puri, 
2012). Although one meta-analysis found no benefit of n-3 PUFA in treating depression (Bloch & 
Hannestad, 2011), this has been attributed to methodological issues such as the combining of 
clinical and subclinical depressive populations (Martins et al., 2012).  Meta-analyses have generally 
found little evidence of an effect of n-3 PUFA supplementation in psychosis (Freeman et al., 2006; 
Fusar-Poli & Berger, 2012; Irving, Mumby-Croft, & Joy, 2006). Randomised controlled trials have 
found a beneficial effect of n-3 PUFA supplementation in children with ASD (Amminger et al., 2007; 
Yui, Koshiba, Nakamura, & Kobayashi, 2012). Although these were small studies (each included 
only 13 children) and a meta-analysis is yet to be conducted, therefore the evidence remains 
inconclusive. The most promising evidence is therefore for the beneficial effect of n-3 PUFA in 
depression, with effects on psychosis appearing to be negligible, and further evidence required for 
ASD.  This is particularly relevant for ADHD which is highly comorbid with both depression and 
ASD (Bolea-Alamañac et al., 2014; Kessler et al., 2006).  
 
1.2.5 Intervention studies  
1.2.5.1 Omega-3 PUFA and ADHD symptoms 
It is now relatively well established that n-3 PUFA supplementation may have a small to moderate 
effect on reducing ADHD symptoms in children. To date four meta-analyses, using data from 
randomised placebo controlled trials, have been conducted. The first found a small but significant 
effect of n-3 PUFA supplementation on reducing ADHD symptoms in 699 (SMD = 0.31, p < 0.0001) 
(Bloch & Qawasmi, 2011) children with ADHD and related disorders (such as developmental 
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coordination disorder). The second, a Cochrane Review, pooled results separately for different 
study designs leading to small sample sizes. Their primary finding was of no significant effect of n-3 
PUFA on ADHD, although a sub-analyses in two studies did show a significant effect (risk ratio = 
2.19, 95% CI 1.04-4.62) (Gillies, Sinn, Lad, Leach, & Ross, 2012).  Negative outcomes in this review 
may have been due to small sample sizes. The third found a small effect on reducing symptoms in 
827 children with ADHD (SMD=0.21, p=0.007) (Sonuga-Barke et al., 2013). The most recent study 
in 1408 children with ADHD found a small but significant effect in reducing ADHD symptoms  
(g = 0.26, p < .001) (Hawkey & Nigg, 2014).  
 
These studies also found EPA to have greater efficacy in reducing ADHD symptoms (Bloch & 
Qawasmi, 2011; Hawkey & Nigg, 2014). This may be because many of the better-designed studies 
used a supplement containing a high EPA/DHA ratio (Gow et al., 2015). The Bloch paper also 
pointed out that most of the current trials are underpowered; they found that to have sufficient 
power (β = 80%, two-sided α=0.05) to detect a benefit of n-3 PUFA an approximate sample size of 
330 children would be required. In contrast, the included trials ranged from 26-117 participants. 
Therefore inconsistent findings are likely due to trials being considerably underpowered, in 
addition to wide variation in methodology, formulation and dose (Gow et al., 2015).  
 
Therefore n-3 PUFA supplementation in children with ADHD appears to improve ADHD symptoms. 
However whilst this effect appears to be genuine, it is also small in comparison to the effect size of  
stimulant and non-stimulant treatment in children with ADHD (d=~0.6–0.9) (Faraone & Buitelaar, 
2010; Faraone & Glatt, 2010; Mészáros et al., 2009). Therefore n-3 PUFA supplementation should 
either be used as an adjunctive treatment, or for those who are either unwilling or unable to use 
pharmacological treatment. The effect of n-3 PUFA supplementation in adults with ADHD remains 
unknown as there has yet to be a published treatment trial. 
 
1.2.5.2 Omega-3 PUFA, cognition and emotional lability. 
Neurocognitive impairments and EL are characteristic features of ADHD (see Sections 1.1.10 and 
1.1.3). Furthermore n-3 PUFA supplements are promoted to the general population as cognitive 
enhancers. However results from randomised controlled trials (RCTs) examining the effect of n-3 
PUFA supplementation on cognition (Manor et al., 2012; Milte et al., 2012; Sinn, Bryan, & Wilson, 
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2008; Stevens et al., 2003) and EL (Manor et al., 2012; Milte et al., 2012; Richardson, Burton, Sewell, 
Spreckelsen, & Montgomery, 2012; Richardson & Montgomery, 2005; Stevens et al., 2003; 
Widenhorn-Müller, Schwanda, Scholz, Spitzer, & Bode, 2014) in ADHD have been mixed.  These 
results are discussed in detail in Chapters 2 and 3 which present, to our knowledge, the first 
systematic review and meta-analysis of  the effect of n-3 PUFA supplementation on 1) cognition in 
typically developing populations and those with ADHD and related disorders (Cooper et al., 2015) 
and 2) EL in children with ADHD  (R E Cooper, Tye, Kuntsi, Vassos, & Asherson, 2016).  
 
1.2.5.3 Omega-3 PUFA in adults with ADHD 
The physiological effects of n-3 PUFAs are thought to be through a number of important functions 
related to neural activity and brain development (e.g. aiding cell membrane fluidity, 
neurotransmission, myelination, neurogenesis, synaptogenesis)(Gow & Hibbeln, 2014; Gow, 
Hibbeln, & Parletta, 2015; Innis, 2008; Lauritzen, Hansen, Jorgensen, & Michaelsen, 2001; Janssen & 
Kiliaan, 2014).  The proposed role of n-3 PUFA in the developing brain implicates them in the 
pathophysiology of ADHD in childhood. Given the finding of a small to moderate effect on reducing 
ADHD symptoms in children (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-Barke et al., 
2013), and that ADHD persists into adulthood in around two-thirds of cases (Faraone, Biederman, 
& Mick, 2006), it is important that the effect of n-3 PUFA in adults with ADHD be examined. In 
adulthood, around 70% of ADHD cases show a positive response to dopamine enhancing stimulant 
medication (Biederman, Spencer, & Wilens, 2004; Bolea-Alamañac et al., 2014; Medori et al., 2008; 
Spencer et al., 2005). This suggests that dysfunction in the dopamine neurotransmitter system 
could be linked to ADHD (Swanson et al., 2007). As discussed in Section 1.2.3, deficiency in n-3 
PUFA has been linked to altered dopamine neurotransmission (Assisi et al., 2006; Chalon, 2006; 
Haag, 2003; Young & Conquer, 2005). Furthermore there is evidence to suggest that adults with 
ADHD have significantly lower levels of  n-3 PUFA compared to controls (Hawkey & Nigg, 2014).  
Given this evidence for the potential role of n-3 PUFA in adult ADHD, it is important that a 





1.2.6 Interim summary 
Omega-3 PUFA is an extensively studied alternative treatment for ADHD with benefits also found 
for depression. The effects of n-3 PUFA are thought to be exerted through alterations in monoamine 
neurotransmission, membrane fluidity and reductions in inflammation. Supplementation is 
important given that 1) n-3 PUFA cannot be synthesised de novo and must be provided via the diet; 
2) Western diets typically have an increased n-6:n-3 PUFA ratio which may promote 
neuroinflammation and 3) Reduced n-3 PUFA and an increased n-6:n-3 PUFA ratio is typically 
found in children and adults with ADHD. Meta-analyses of placebo-controlled trials have found n-3 
PUFA supplementation to improve ADHD symptoms in children. Given this, it has been concluded 
that it may be useful as an adjunctive treatment or monotherapy for those who do not wish to take 
pharmacological treatment. However the effect of supplementation on related domains of cognition 
and EL are unclear as are the effects in adults with ADHD. Furthermore, effects on cognition are 
important to clarify given that supplements are often promoted as cognitive enhancers in the 


















1.3 Alternative treatments in ADHD: Cannabinoid medication 
Cannabis use in ADHD is high with patients reporting beneficial effects on their symptoms and 
impairments and some reporting a preference for this over their stimulant medication.  Given the 
evidence for lability of the dopamine system in ADHD and that cannabinoids may affect dopamine 
transmission it is important to investigate the utility of a cannabinoid medication as a treatment for 
ADHD. 
 
1.3.1 Properties and effects of cannabis 
The chemical compounds in cannabis are known as cannabinoids, and it is estimated that cannabis 
contains 108 different cannabinoids. The two most relevant for psychiatry are Δ9-
tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD).   Δ9-THC can induce acute psychotic 
symptoms in medicated schizophrenic patients and healthy controls (D’Souza, Sewell, & 
Ranganathan, 2009; Englund et al., 2012).  However CBD is thought to have the opposite effects; it 
has been found to reduce Δ9-THC induced psychotic symptoms and cognitive impairments 
(Englund et al., 2012) and has shown promise as a possible antipsychotic (Leweke et al., 2012; 
Zuardi, Crippa, Hallak, Moreira, & Guimaraes, 2006). 
 
Given this, recent research has found that the established link between cannabis and psychosis 
(Casadio, Fernandes, Murray, & Di Forti, 2011; Henquet, Murray, Linszen, & Van Os, 2005; Moore et 
al., 2007) may be specific to cannabis that is high in THC (known as sinsimella (skunk)) but not that 
which contains similar levels of THC to CBD (known as cannabis resin (‘hash’)).  In a case/control 
study, 410 patients with first-episode psychosis were compared to 370 controls. A significantly 
higher risk of developing a psychotic disorder was related to the use of sinsemilla everyday but not 
to cannabis resin (‘hash’) (Di Forti et al., 2015).  However sinsemilla dominates the UK black market 
with levels of THC appearing to rise year on year (see  
Figure 1-2) and cannabis resin becoming increasingly difficult to obtain (Cascini, Aiello, & Di Tanna, 





Figure 1-2: A comparison of the ranges of THC contents of Sinsemilla seized in the UK and analyzed 
by the Forensic Science Service in 1996–8 (n = 145) and samples seized by police in Derbyshire (n = 
15), Kent (n = 58), London Metropolitan (n = 96), Merseyside (n = 44) and Sussex (n = 34) in 2004 
⁄ 5 (total n = 247). Reproduced from Potter, Clark, & Brown, (2008). 
 
1.3.2 Self-medication 
Substance abuse is highly prevalent in ADHD (Gudjonsson et al., 2012; Susan Young & Thome, 
2011) (see Section 1.1.5). High rates of substance abuse has been found in those with undiagnosed 
ADHD  compared to those without ADHD symptoms (Gudjonsson et al., 2012; Susan Young & 
Thome, 2011). This could suggest an attempt to self-medicate in those with undiagnosed ADHD 
(Bolea-Alamañac et al., 2014). In support of this, stimulant drugs are commonly diverted for 
cognitive enhancement as well as being abused, and alongside stimulants, cannabis is one of the 
most prominent drugs of abuse (Biederman et al., 1995). For example in a large epidemiological 
study (n = 10,987 adolescents) 5.4% met screening criteria for ADHD of which 21.1% vs 4.2% (non-
ADHD) used marijuana and 12.1% vs 2.1% used amphetamines (Gudjonsson et al., 2012).  
Figure 1-3 shows, in a prison population, significantly higher proportions of cannabis and stimulant 
use (but not alcohol or opiate use) were seen in prisoners who met clinical criteria for ADHD 
compared to prisoners who did not have ADHD (Asherson et al., currently unpublished data).  In a 
large sample of adolescents (n=600) who either abused or were dependent on cannabis, 38% had 
ADHD, the second most common comorbidity (Dennis et al., 2004).  Exclusion due to substance use 
disorder (SUD) was common in the OCEAN study in this thesis, with cannabis the most used drug 




Research has found different motivations behind drug use in ADHD cases compared to controls. 
Adolescents with SUD who screened positive for ADHD were more likely to report improved self-
image following drug use than were those with SUD without ADHD. The ADHD group were also 
more likely to report using drugs to alter their mood whereas the non-ADHD group to 'getting high' 
(Horner & Scheibe, 1997). This was corroborated in a separate study where young adults with 
ADHD were more likely than controls to report drug use in order to change their mood and 
improve sleep (Wilens, 2004). These differences in motivations could support the hypothesis of 
self-medication in ADHD. 
 
Patients with ADHD in our studies (Chapters 5 and 6) report an improvement in behavioural 
symptoms when using cannabis. They report feeling reduced EL, restlessness and distractibility, 
with improved concentration, ability to sustain focus and sleep. Furthermore some patients report 
a preference for cannabis over stimulant medication in the treatment of their symptoms.  
 
 
Figure 1-3: Proportion of drug and alcohol use in young offenders with and without ADHD (from 
the Concerta In Adult ADHD (CIAO) study, Asherson et al., currently unpublished data, reported at 




1.3.3 Cannabis in the pathophysiology of ADHD  
The dopamine theory of ADHD is well established, based largely on the immediate and rapid 
reduction of ADHD symptoms with stimulant medications (see Section 1.1.11). Children and adults 
with ADHD have dysfunctions that suggest the involvement of the dopaminergic circuits, mainly in 
the basal ganglia and frontal cortex, with deficits in executive function and in the reward system 
(see Section 1.1.9.4). The striatum is of particular interest in ADHD due to it being rich in 
dopaminergic synapses and neuroimaging studies have suggested reduced availability of dopamine 
in the striatum (Cheon et al., 2003; Dougherty et al., 1999; Krause et al., 2005; Krause et al., 2000; 
Spencer et al., 2005).  Stimulant medication, the first line treatment in ADHD, acts to increase the 
synaptic availability of neurotransmitters, including noradrenaline and dopamine (Leonard et al., 
2004; Volkow et al., 2002).   
 
One way in which cannabinoids exert their effect on the mind is through interaction with the 
endogenous cannabinoid system (ECS) (Devane, Dysarz, Johnson, Melvin, & Howlett, 1988). The 
ECS mediates the psychoactive effects of cannabis and refers to a set of endogenous ligands, their 
receptors, and the enzymes that synthesise and degrade them (Di Marzo, Bifulco, & De Petrocellis, 
2004). Since striatal DA signalling may modulate the ECS and dopamine abnormalities have been 
found in ADHD, investigation of the ECS is of potential interest to our understanding of the 
processes that lead to the cognitive and behavioural dysfunctions seen in ADHD. A recent study 
investigating cannabinoid CB1 receptor (CB1R) function in a mouse model of ADHD obtained by 
triple point-mutation in the dopamine transporter (DAT) gene revealed that the sensitivity of 
cannabinoid receptors (CB1Rs) controlling GABA-mediated synaptic currents in the striatum was 
completely lost, and the mice had a marked hyperactive phenotype. These results point to a 
potential role of the ECS in neurobiological pathways underlying cognitive and behavioural deficits 
seen in ADHD (Castelli et al., 2011). 
 
Although debated, there is evidence to suggest cannabis may affect dopamine production in brain 
areas implicated in ADHD.  Animal studies have found administration of ∆9-THC to increase 
prefrontal dopamine levels  (Chen, Paredes, Lowinson, & Gardner, 1990; Pistis et al., 2002). Human 
studies have found Δ9-THC administration to increase dopamine in the striatum in healthy 
volunteers (Bossong et al., 2009, 2015), and in patients with schizophrenia and their relatives 
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(Kuepper et al., 2013), with the latter finding the most pronounced release in the caudate nucleus. A 
PET study in healthy volunteers also found a significant increase in dopamine release following 
THC administration in the right middle frontal gyrus, left superior frontal gyrus and left superior 
temporal gyrus (Stokes et al., 2010). Although other studies in healthy volunteers have found no 
significant increase of dopamine in the striatum following administration of Δ9-THC (Barkus et al., 
2011; Bloomfield et al., 2014; Stokes, Mehta, Curran, Breen, & Grasby, 2009).  
 
Overlap between the action of THC and stimulant medication on the dopaminergic system have also 
been suggested (Piccini, Pavese, & Brooks, 2003; Stokes et al., 2010). Recent research using single 
photon emission computed tomography (SPECT) in participants with ADHD, ADHD and SUD, and 
healthy controls found no difference between striatal dopamine transporter density in controls and 
those with ADHD and SUD, whereas those with ADHD without SUD had significantly higher striatal 
dopamine transporter density than both groups. Higher density of dopamine transporters suggests 
lowered dopamine levels, suggesting self-medication in those with ADHD and SUD may act to 
normalise dopamine levels (Silva et al., 2013).    
 
1.3.4 Cannabis and cognition 
There is evidence to suggest cannabis impairs cognitive function. This may be due to the high to 
moderate densities of CB1 receptors in key areas of cognition, such as the hippocampus and frontal 
cortex (Glass, Dragunow, & Faull, 1997). Longitudinal studies have shown a significant decline in IQ 
in individuals who were heavy users of cannabis in adolescence (Meier et al., 2012; Mokrysz et al., 
2014); although it is difficult to interpret any causal effects of cannabis use due to the possibility of 
confounding variables such as past history of other drug use, academic achievement and mood 
disorders (Schoeler & Bhattacharyya, 2013).  For example, in one study the link between cannabis 
use and reduced IQ became non-significant after controlling for alcohol, tobacco, other drugs, 
gender, socioeconomic factors, maternal factors and mental health (Mokrysz et al., 2014). Research 
in typically developing participants suggests cannabis use leads to significant cognitive 
impairments including impairments in executive function, memory, sustained attention measured 
with omission errors), impulsivity (measured with commission errors), reaction time and motor 
function (Englund et al., 2012; Grant, Chamberlain, Schreiber, & Odlaug, 2012; Ramaekers et al., 
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2006). However, this is not consistent with the subjective account of patients with ADHD, who may 
potentially show paradoxical benefits on brain function.  
 
Furthermore, the degree of cognitive impairment may depend on the Δ9THC:CBD ratio as CBD may 
protect against impairment. In animal models of cognitive impairment CBD has been found to 
improve cognition (Avraham et al., 2011; Barichello et al., 2012; Fagherazzi et al., 2012; Magen et 
al., 2010), and protect against the memory impairing effects of  Δ9-THC (Fadda, Robinson, Fratta, 
Pertwee, & Riedel, 2004). Studies in humans have also suggested CBD may cognitively protect 
against Δ9-THC induced impairments (Englund et al., 2012; Morgan, Schafer, Freeman, & Curran, 
2010; Morgan et al., 2012). Research has also found participants who smoked cannabis higher in 
CBD to not show any impairments in immediate or delayed recall while intoxicated however 
participants who smoked cannabis with only Δ9-THC were significantly impaired (Morgan et al., 
2010).  
 
1.3.5 Sativex Oromucosal Spray: A case study of the prescription of a controlled 
cannabinoid medication  
Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK), a standardised cannabinoid medication, 
was recently prescribed for a one month period to a patient at the Maudsley Adult ADHD Clinic. The 
reason was that the patient, who had a severe level of symptoms and impairments related to ADHD, 
found stimulants and atomoxetine to be ineffective, and even to exacerbate, his ADHD symptoms. 
Furthermore he had been using cannabis to control his ADHD symptoms with highly favourable 
accounts of an effective treatment response from both the patient and his mother. In this one case, 
treatment with Sativex resulted in improved control of ADHD symptoms, behaviour and cognitive 
function, reported by the patient and corroborated by his mother.  The properties of Sativex are 
similar to cannabis resin (containing a 1:1 ratio of Δ9-THC:CBD).   
 
1.3.6 Interim summary  
Based on research and subjective patient accounts, self-medication with cannabis appears to be 
common in ADHD. Patients report improvements in concentration, restlessness, and EL. One theory 
of ADHD is that it is due to abnormalities in dopamine. A number of studies in animals and humans 
have found cannabis to increase dopamine production in brain areas implicated in ADHD. This has 
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suggested a potential role of the ECS in the neurobiological pathways underlying ADHD.  The use of 
cannabis from the black market carries risk. In comparison to cannabis resin (which contains 
relatively equal Δ9-THC:CBD) sinsimella  (which is high in Δ9-THC) has been linked to symptoms of 
psychosis and neurocognitive impairment.  However it is becoming increasingly difficult to obtain 
cannabis resin. Therefore the investigation of a cannabinoid medication with a 1:1 ratio of Δ9-



























1.4 Overall conclusions and aims of thesis  
ADHD is a severe and impairing disorder that affects both children and adults. Although current 
pharmacological treatment has high levels of efficacy, some elect against this treatment due to 
adverse events, non-response, or an unwillingness to take pharmacological treatment. Two 
alternative treatments have been proposed. Omega-3 PUFA supplementation has been found to 
have a small to moderate benefit in reducing symptoms of ADHD in children. However the effects 
on cognition and EL remain unclear as do effects in adults with ADHD.  Cannabis appears to be used 
to self-medicate by a number of adults with ADHD, some of whom report a preference for this over 
their stimulant medication. To our knowledge there has yet to be a controlled investigation of a 
cannabinoid medication in ADHD. 
   
Aim 1: To document the effect of n-3 PUFA supplementation on cognition and emotional 
lability  
In light of mixed findings, the first main aim of this thesis was to provide a more conclusive picture 
as to the effect of n-3 PUFA on cognition and EL. This was achieved in two ways. First, a systematic 
review and meta-analysis examining the effect of n-3 PUFA supplementation on cognition in 
healthy populations, and those with ADHD and related disorders, was conducted. Second, a 
systematic review and meta-analysis examining the effect of n-3 PUFA supplementation on EL, 
oppositional behaviour and conduct problems in children with ADHD and related disorders was 
conducted.  The following hypothesis was tested: 
 That supplementation with n-3 PUFA will improve cognition and EL. 
 
 
Aim 2: The effect of n-3 PUFA supplementation in adults with ADHD: The OCEAN Study (Oils 
and Cognitive Effects in adult ADHD Neurodevelopment) 
To the best of our knowledge a trial of n-3 PUFA supplementation in adults with ADHD is yet to be 
conducted.  The second main aim of this thesis is to provide preliminary data on the relationship of 
n-3 PUFA to symptoms and cognition in adults with ADHD and controls.  In order to do this a 6-
month placebo-controlled trial of n-3 PUFA supplementation in 81 adults with ADHD was 
conducted, with 42 participants receiving the n-3 PUFA supplementation and 39 receiving the 
placebo. Outcome measures included cognitive and behavioural function. A group of 30 typically 
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developing controls additionally completed baseline assessments. The following hypotheses were 
tested:  
 At baseline, we expected the ADHD group to have more severe ADHD symptoms, higher EL 
and impaired cognition, compared to the control group.  
 We predicted reduced n-3 PUFA levels and an increased n-6:n-3 PUFA ratio in ADHD cases 
compared to controls.   
 We expected supplementation with n-3 PUFA to improve ADHD symptoms, EL, and 
cognition.  
 
Aim 3: The effects of Sativex on neurocognitive and behavioural function in adults with 
attention-deficit/hyperactivity disorder: the EMA-C study (Experimental Medicine in ADHD – 
Cannabinoids): 
Despite the wide use of cannabis in ADHD and positive subjective patient reports, to our knowledge 
the effect of a cannabinoid based medication on cognitive and behavioural function in ADHD has yet 
to be tested. In line with this, the third main aim of this thesis is to provide preliminary data on the 
relationship of a short-term cannabinoid-based treatment (Sativex Oromucosal Spray) on 
symptoms and cognition in adults with ADHD.  In order to do this, a 6-week double blind placebo 
controlled trial, with a group of 30 adults meeting research diagnostic criteria for ADHD was 
conducted. The group was divided into 15 participants who received Sativex and 15 who received 
the placebo. Outcome measures were cognitive performance, ADHD symptoms and EL.  The 
following hypotheses were tested: 
 That treatment with Sativex will improve cognitive performance.  




















Chapter 2: Omega-3 Polyunsaturated Fatty Acid Supplementation 


































































































































































































































































































































































































2.1 Chapter 2: Interim summary  
Chapter 2 addressed part of the first aim of this thesis (see Section 1.4), to document the effect of n-
3 PUFA supplementation on cognition. We found no evidence of a beneficial effect of n-3 PUFA on 
cognitive performance in the general population or in children with ADHD or with a related 
disorder. Marginal evidence for effects was found in those who were n-3 PUFA deficient. This 
evidence (Cooper et al., 2015) combined with research of the effects of n-3 PUFA on ADHD 
symptoms in children (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-Barke et al., 2013), 
provides us with the most accurate possible estimate of the effect of n-3 PUFA on ADHD symptoms 
(a small to moderate effect) and associated cognitive impairments (no effect aside from a potential 
(small) effect in those who are n-3 PUFA deficient) in children with ADHD.  I will now address the 
remainder of the first aim of this thesis: to document the effect of n-3 PUFA supplementation on 





Chapter 3: The Effect of Omega-3 Polyunsaturated Fatty Acid 
Supplementation on Emotional Lability, Oppositional 
Behaviour and Conduct Problems in ADHD: A Systematic 
Review and Meta-Analysis 
 
3.1 Summary 
A number of randomised controlled trials report a beneficial effect of omega-3 polyunsaturated 
fatty acid (n-3 PUFA) supplementation on emotional lability (EL) and related domains (e.g. 
oppositional behaviour, conduct problems). Given that n-3 PUFA supplementation shows a 
significant effect on reducing symptoms of attention-deficit/hyperactivity disorder (ADHD) and 
that EL and related behaviours commonly co-occurs with ADHD, it is important that there is a more 
conclusive picture as to the effect of n-3 PUFA on these co-occurring clinical domains.   The 
databases (Ovid Medline, Embase, Psychinfo) were searched for trials assessing the effects of n-3 
PUFA on EL, oppositional behaviour, aggression and conduct problems. We included trials in 
children who had ADHD or a related neurodevelopmental disorder.  Of the 1775 identified studies, 
10 were included in the meta-analysis. In the primary analyses n-3 PUFA supplementation did not 
show improvements in measures of EL, oppositional behaviour, conduct problems or aggression.  
However subgroup analyses of higher quality studies and those meeting strict inclusion criteria 
found a significant reduction in EL and oppositional behaviour.  A number of treatment effects may 
have failed to reach statistical significance due to small sample sizes and within and between study 
heterogeneity in terms of design and study participants. These results exclude the possibility of 
moderate to large effects. They provide suggestive evidence of small effects of n-3 PUFA on 
reducing EL and oppositional behaviour in subgroups of children with ADHD. 
 
3.2 Introduction 
Omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation is one of the most studied 
alternative treatments for ADHD (Bloch & Qawasmi, 2011).  Two recent meta-analyses of 
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randomised placebo-controlled trials have found n-3 PUFA supplementation to have a small but 
significant effect of reducing ADHD symptoms of inattention and hyperactivity/impulsivity (Bloch 
& Qawasmi, 2011; Sonuga-Barke et al., 2013). The DSM-5 also lists emotional lability (EL; defined 
as low frustration tolerance, irritability and mood lability) and cognitive impairment (defined as 
problems on tests of attention, executive function or memory) as associated features of ADHD that 
support the diagnosis of ADHD (American Psychiatric Association (2013).  We recently found little 
evidence for an effect of n-3 PUFA on cognition in children with ADHD or a related-
neurodevelopmental disorder (Cooper et al., 2015). Emotional lability, characterised by irritable 
moods with volatile and changeable emotions, relates to the common co-occurrence of conduct, 
oppositional and emotional behaviour problems found in ADHD (Bolea-Alamañac et al., 2014). 
However the response of EL to n-3 PUFA is not yet clear.  
 
Deficiency in n-3 PUFA status has been associated with EL.  Prenatal and childhood deficiency of n-3 
PUFA may impair neuronal migration, connectivity, timed apoptosis (cell death) and dendritic 
arborization (neuronal branching), leading to disruption of the neuronal pathways that regulate 
behaviour (for review see Hibbeln et al., 2006). Deficiencies may also result in  altered serotonin 
and dopamine levels (Assisi et al., 2006; Chalon, 2006; Haag, 2003; Hibbeln et al., 2006; Young & 
Conquer, 2005); neurotransmitters implicated in the pathophysiology of ADHD (Bolea-Alamañac et 
al., 2014; del Campo et al., 2012; Faraone et al., 2005; Gizer et al., 2009; Li et al., 2006). Low 
concentrations of serotonin have been related to impulsive, violent, suicidal, hostile and aggressive 
behaviours (Hallahan & Garland, 2004; Hibbeln et al., 1998).   
 
Epidemiological and cross-sectional studies have linked violent behaviour with low seafood 
consumption or low blood n-3 PUFA levels (Corrigan et al., 1994; Hibbeln, 2001; Iribarren et al., 
2004). In children and adolescents with ADHD and symptoms of conduct-disorder low omega-3 
blood levels were found to be negatively related to high scores of callous and unemotional traits 
(Gow et al., 2013). A greater number of behaviour problems and temper tantrums were found in 
children (with and without ADHD) with lower total n-3 PUFA blood levels (Stevens, Zentall, Abate, 




However, evidence from trial data of n-3 PUFA supplementation has been mixed. One of the most 
prominent findings was from a trial conducted in a prison. Gesch et al., (2002) supplemented a total 
of 231 prison inmates with PUFAs (omega-3 and 6), vitamins and minerals or placebo. A 26.3% 
reduction in disciplinary offences was found in the active versus the placebo group (p< 0.03). Meta-
analysis of eight placebo-controlled trials in healthy populations and those with various mental 
health conditions found aggression to be reduced in those taking n-3 PUFA supplements (Benton, 
2007). However, this meta-analysis had several limitations, including the combination of a range of 
heterogeneous measures and study populations, and 5 of the 8 studies were from the same 
research group (Hamazaki et al., 1998, 2002; Hamazaki et al., 1996; Hirayama, Hamazaki, & 
Terasawa, 2004; Itomura et al., 2005).  Results from placebo-controlled trials, in those with ADHD 
or who had overlapping neurodevelopmental disorders (such as specific reading difficulties), have 
been more variable, with some finding improvements on rating scale measures of EL and 
oppositional behaviour (Richardson et al., 2012; Richardson & Montgomery, 2005; Stevens et al., 
2003), while other studies failed to find such effects (Manor et al., 2012; Milte et al., 2012; 
Widenhorn-Müller et al., 2014). 
 
Given the finding of a small but significant effect of n-3 PUFA on ADHD with an effect size (Cohen’s 
d) in the region of 0.2–0.3 (Bloch & Qawasmi, 2011; Sonuga-Barke et al., 2013), yet mixed findings 
on associated comorbid symptoms of EL and oppositional behaviour, it is important to clarify 
whether there is a role for n-3 PUFA in the management of these associated features. To answer 
this question we conducted a systematic review and meta-analysis of randomised placebo-
controlled trials which examined the effect of n-3 PUFA supplementation on EL, oppositional 
behaviour, conduct problems, and aggression in children with ADHD and related 
neurodevelopmental disorders (ADHD+RND). 
 
3.3 Methods 
We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher, Liberati, Tetzlaff, & 
Altman, 2009) and used a predetermined protocol. We considered the analyses to be exploratory; 
assessing effects on six separate domains: of parent rated EL, teacher rated EL, parent rated 
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oppositional behaviour, teacher rated oppositional behaviour, parent rated conduct problems and 
parent-rated aggression (teacher-ratings were not available for conduct problems or aggression) 
.Parent and teacher ratings were considered separate due to the established discrepancy between 
these measures (Goodman, 1997).  
3.3.1 Eligibility criteria and data extraction 
Studies were included if: 1) they were randomised double blind placebo-controlled trials of n-3 
PUFA supplementation including docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) or 
alpha-linoleic acid (ALA; although those supplementing with ALA only were excluded as ALA is 
thought to have limited impact on behaviour compared to DHA and EPA (Kalmijn et al., 2004); 2) 
Participants were school aged children (4-12 years), adolescents (13-17 years), or adults (18-55 
years) who had a diagnosis of ADHD, had high  levels of ADHD-symptoms or related 
neurodevelopmental traits such as developmental coordination disorder; and 3) the study 
contained at least one outcome measure which targeted EL, oppositional behaviour, conduct 
problems or aggression using a validated rating scale (see Appendix B, Table AB-1). There were no 
language restrictions on trial eligibility.  
The databases Ovid Medline (1946 to September week 3 2014), Embase (1974 to 2014 September 
29th), and Psychinfo (1806 to September week 4 2014) were searched.  References of eligible trials 
and appropriate reviews were searched for additional citations. Unpublished or ongoing trials were 
searched on the ClinicalTrials.gov website and authors contacted to request relevant data. The 
search was updated in January 2015. The search terms used are listed in Appendix B, Table AB-2.  
Risk of bias to determine study quality was assessed independently by two authors (REC and CT) 
according to PRISMA guidelines and the Cochrane Handbook of Systematic Reviews (Higgins & 
Green, 2011) (see Appendix B, Table AB-3 and AB-4).  REC and CT then met to discuss their 
assessments and reach a consensus on study inclusion. Decision to include was based on risk of bias 
(classed as low, unclear or high); those which were classed as high overall risk of bias were 
excluded. 
Data extraction was performed by REC and checked by a research assistant. The main outcome 
measures were the mean and standard deviation (SD) of the pre-and post-treatment measures of 
EL, oppositional behaviour, conduct problems and aggression for active and placebo arms, with 
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intent to treat (ITT) analysis preferentially reported. Additional measures investigated participant 
characteristics, study design, and the type and dose of the supplement used. If multiple treatment 
arms were present, only those supplementing with n-3 PUFA or placebo were included. With regard 
to missing data, we contacted authors. Missing data that remained unavailable was not imputed. 
3.3.2 Statistical Analyses 
Analyses were carried out in STATA (StataCorp, 2009). An initial analyses in the full sample across 
the six domains of parent and teacher rated oppositional behaviour and emotional lability, teacher 
rated conduct problems and aggression was first run, following this four subgroup analyses 
(discussed below) were conducted. Where a study contained two active groups which were both 
eligible for inclusion (for example when the active groups differed in the dose of n-3 PUFA), they 
were combined with the method presented in the Cochrane handbook: Section 16.5.4 (Higgins & 
Green, 2011). Effect sizes were estimated as the standardised mean difference (SMD), calculated as 
the mean pre-to-post-treatment change, minus the mean pre-to-post-placebo group change, divided 
by the pooled pre-test standard deviation (SD) with a bias adjustment (see Morris, (2007), pg 369 
‘effect size estimate using pooled pretest SD’ for a detailed description of this method). The 
equation for this method is detailed below.  
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Note. dppc2 = Standardised Mean Difference (SMD), Cp = bias adjustment, M = Mean, T = treatment, C 
= Control, Post = Post-treatment, Pre = Pre-treatment, SD = Standard deviation, n = number of 
participants. 
 
Effect sizes were classed according to Cohen’s d (0.2=small, 0.5=medium, 0.8=large) (Cohen, 1992).  
Where SD was not provided, it was calculated from sample size and standard error (SE). For 
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individual studies that contributed multiple assessments for one domain, a single SMD was derived 
from a meta-analysis of these assessments (see Appendix B, Table AB-1); hence an individual study 
was counted only once per domain. Cross-over trials were treated as parallel group trials using the 
pre-cross over data, because insufficient data were provided to permit analysis of within-individual 
change (i.e. correlations of scores between conditions were not given). This approach is considered 
conservative (studies are under-rather than over-weighted), and is equivalent to setting the 
between-condition correlation to zero (Elbourne et al., 2002). SMDs in each domain were combined 
using the inverse variance method where the reciprocal of their variance is used to weight the SMD 
from each trial before being combined to give an overall estimate (Higgins & Green, 2011).  
 
Given the between-study heterogeneity in terms of study design, participant characteristics and 
outcome measures, we chose  a priori to use random effects models (Field & Gillett, 2010).  When 
setting the significance level, we corrected for 6 domains (see ‘selection of studies’) of 
emotional/behavioural instability (Bonferroni correction set at p < .008). This was despite the fact 
that more than 6 statistical tests were conducted (i.e. four subgroups containing multiple analyses 
were also conducted), because the 6 behavioural domains are highly correlated. The significance 
level of p<.008 was therefore considered indicative and not evidence of association for the sub-
group analyses (this is similar to our method used in Cooper et al., (2015). A nominal level of 
significance was set at p<.05. The I2 statistic assessed heterogeneity between studies. Publication 
bias was assessed using the Egger regression asymmetry test, inspection of the regression 
asymmetry plot and the Begg adjusted rank correlation test. Metaregression was used to examine 
the association between treatment effect and trial duration and dose of EPA and DHA.   
 
3.3.3 Subgroup analyses 
1) Strict inclusion:  All studies that met the inclusion criteria were included in the initial analysis. 
As one study supplemented with the phospholipid molecule phosphatidylserine (Manor et al., 
2012) in addition to n-3 PUFA, we performed subgroup analyses excluding this study. 
2) High quality: Quality appraisal demonstrated the majority of studies included in the main 
analyses to contain design errors (overall risk of bias rated as unclear or unclear to high). Therefore 
the analysis was re-run in the four studies whose overall risk scores were low (equating to high 
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quality) (Manor et al., 2012; Richardson et al., 2012; Richardson & Montgomery, 2005; Richardson 
& Puri, 2002) (see Appendix B, Table AB-3 and AB-4).  
3) Adequate EPA: A significant association between dose of EPA (but not DHA) and improvement 
in ADHD symptoms has previously been found (Bloch & Qawasmi, 2011).  Given this, it has been 
suggested that EPA may be more active than DHA in terms of its effect on brain and behaviour.  The 
analysis was therefore run in the seven studies which supplemented participants with > 100mg 
EPA (Dean, Bor, Adam, Bowling, & Bellgrove, 2014; Gustafsson et al., 2010; Milte et al., 2012; 
Richardson & Montgomery, 2005; Richardson & Puri, 2002; Sinn & Bryan, 2007; Widenhorn-Müller 
et al., 2014) (this cut-off was estimated from Figure 3 in Bloch and Qawasmi's (2011) paper). 
4) High EL and related domains: Heterogeneity in EL and its related domains, across study 
populations, may reduce the effect size of treatment response. The analysis was run in 2 studies 
that included those with elevated impairments in these domains. Gustafsson et al., (2010) analysed 
a subgroup of children who had oppositional problems at a clinical level and Manor et al., (2012) 
analysed a subgroup of children who were more labile and hyperactive, and who tended to suffer 
from mood and behavioural dysregulation. 
3.4 Results 
3.4.1 Selection of studies 
The search strategy (conducted by REC) identified 1775 publications. Of these, 149 relevant 
abstracts were screened, of which 97 were excluded because the studies were not a randomised 
clinical trial (N=40); or they used an unsuitable outcome (N=28) (e.g. looked only at treatment 
effects on PUFA blood levels), study population (N=23) or supplement (N=6).  Fifty-two full text 
articles were subsequently quality appraised and 40 excluded because of failure to report the 
placebo group (N=1), unsuitable supplementation (N=4), unsuitable populations (N=11), or use of 
unsuitable outcome measures (N=24) (see Appendix B, Table AB-5).  Twelve trials met the 
inclusion criteria for this study; however, due to missing data (after writing to the authors), the 
statistical information required for meta-analysis was available for 10 of the studies which made up 
the final dataset for the meta-analysis. Of these 10 studies, 7 were in those who met diagnostic 
criteria for ADHD or were selected for high levels of ADHD symptoms and 3 were in those with a 
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developmental disorder known to overlap with ADHD (developmental coordination disorder, 







Figure 3-1: PRISMA flow diagram 
 
3.4.2 Outcome measures  
Six outcome domains were included in the meta-analysis (parent-rated EL, teacher-rated EL, 
parent-rated oppositional behaviour, teacher-rated oppositional behaviour, parent-rated conduct 
problems and aggression).  EL, oppositional behaviour and conduct problems were mainly 
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measured using the parent-or teacher-rated Conners’ scales (Conners, 1990), or the Strengths and 
Difficulties Questionnaire (Goodman, 1997). Aggression was parent-rated and was measured using 
various rating scales; the Child Behaviour Checklist (CBCL) (Arbeitsgruppe Deutsche Child 
Behavior Checklist, 1993a), Modified Overt Aggression Scale (MOAS) (Connor, 2002) or the 
Children’s Aggression Scale (CAS) (Halperin, McKay, & Newcorn, 2002). Appendix B, Table AB-1 
contains a detailed list of measures used in these six domains.   
 
3.4.3 Quality and characteristics of studies included in qualitative synthesis 
Study quality was assessed independently by two authors (REC and CT).  Twelve studies were 
agreed to be of sufficient quality and suitability and were included in the qualitative synthesis. As 
there were no studies in adolescents or adults, the qualitative synthesis was limited to school-aged 
children (4-12). Randomisation and allocation concealment were explicitly described in 10 studies.  
In the remainder this was absent or unclear. All studies were double blind, although above chance 
guessing of group allocation occurred in one study (Milte et al., 2012). In one study 18% dropped 
out because their parents wanted pharmacotherapy and it is unclear whether this was equally 
distributed between the placebo and active groups (Gustafsson et al., 2010).  Four studies did not 
report the appropriate statistics (Bélanger et al., 2009; Gustafsson et al., 2010; Hirayama et al., 
2004; Widenhorn-Müller et al., 2014). For example, one study reported only medians (Hirayama et 
al., 2004) and another failed to report means and SDs for 2 of the 3 outcome variables (Widenhorn-
Müller et al., 2014) (see Appendix B, Table AB-3 and AB-4). One study used supplementation with 
phosphatidylserine (a phospholipid component) (Manor et al., 2012) in addition to n-3 PUFA.  
Children were unmedicated in nine studies, medicated in two studies and in one study this was 
unspecified. Study characteristics are detailed in Appendix B, Table AB-7.  
3.4.4 Quantitative meta-analysis 
Main effects from the meta-analysis are summarised in Figure 3-2, a detailed description of these 
results is available in Appendix B, Supplement AB-1.  Pre-and post-treatment means and SDs were 
not available for two studies (Bélanger et al., 2009; Hirayama et al., 2004). Therefore 10 studies 




In children with ADHD+RND n-3 PUFA supplementation had no significant effect on parent- and 
teacher-rated symptoms of EL or oppositional behaviour, parent-rated conduct problems, and no 
effect on aggression (although there was a trend for supplementation to improve parent rated 
oppositional behaviour (8 studies, N=875, SMD = 0.13; 95% CI: -0.01 to 0.27, z =1.77, p = 0.08)).  
There was no evidence of heterogeneity. There was no evidence of publication bias (the Egger test 
could not be run for parent rated conduct problems or aggression due to too few studies).  Meta-
regression found no effect of treatment duration or dose of EPA or DHA (meta-regression could not 
be run for duration or dose (EPA or DHA) for aggression and parent rated conduct problems and 
EPA dose for teacher rated EL due to there being too few studies).  
 
Sub-group analyses: In the subgroup analysis of studies that met strict inclusion criteria, a small 
treatment effect was found for parent-rated EL after exclusion of one study which supplemented 
with n-3 PUFA and phosphatidylserine (4 studies, 515 participants, SMD = 0.25; 95% CI: 0.08 to 
0.43, z = 2.81, p = 0.005), with no evidence of heterogeneity (x 2 = 1.78, I2 = 0.0%, p = 0.62).  In the 
subgroup of high quality studies a small treatment effect was found for parent-rated oppositional 
behaviour (3 studies, 532 participants, SMD = 0.20; 95% CI: 0.03 to 0.38, z = 2.26, p = 0.02), with no 
heterogeneity (x 2 =2.00, I2 =0.2%, p = 0.37). There was a trend for supplementation to improve 
parent-rated oppositional behaviour after exclusion of one study which supplemented with n-3 
PUFA and phosphatidylserine (7 studies, N=734, SMD = 0.15; 95% CI: -0.006 to 0.31, z =1.89, p = 
0.06).  There was also a trend for supplementation to improve teacher-rated oppositional 
behaviour in 3 studies that supplemented with > 100mg EPA (N = 279, SMD = 0.22; 95% CI: -0.02 to 
0.45, z =1.79, p = 0.07). The only evidence of heterogeneity was in those with high EL (and related 
domains) for teacher rated oppositional behaviour (x 2 = 4.85, I2 = 79.4%, p = 0.03). Main effects 









Figure 3-2: Forest plots for meta-analyses across the 6 behavioural domains 







Table 3-1: Subgroup meta-analyses of those studies which: 1) strictly met inclusion criteria, 2) 
were high quality, 3) supplemented with > 100mg EPA or 4) included those with elevated 




Studies N  P SMDe  
 
95% CI Heterogeneity 
      P I2 (%) 
1. Strict Inclusiona         
Emotional lability  
(parent rated) 
1–4 515 0.005 0.25 0.08 to 
0.43** 
0.62 0.0 
Emotional lability  
(teacher rated) 
3,5 464 0.79 0.05 -0.34 to 
0.44 
0.07 68.7 
Oppositional behaviour  
(parent rated) 
1–4,6–8 734 0.06 0.15 -0.006 to 
0.31 
0.37 8.0 
Oppositional behaviour  
(teacher rated) 
3,5–8 673 0.55 0.05 -0.11 to 
0.20 
0.40 1.4 
2. High Qualityb        
Emotional lability  
(parent rated) 
2,3,9 526 0.36 0.16 -0.18 to 
0.50 
0.09 58.2 
Emotional lability  
(teacher rated) 




 (parent rated) 
2,3,9 532 0.02 0.20 0.03 to 
0.38* 
0.37 0.2 
Oppositional behaviour  
(teacher rated) 
3,5,9 596 0.86 0.02 -0.19 to 
0.23 
0.25 28.6 
3. Adequate EPAc        
Emotional lability 
 (parent rated) 
1,2,4 153 0.30 0.17 -0.15 to 
0.50 
0.48 0.0 
Oppositional behaviour  
(parent rated) 
1,2,4,6,8 337 0.46 0.09 -0.14 to 
0.31 
0.36 8.3 
Oppositional behaviour  
(teacher rated) 
 5,6,8 279 0.07 0.22 -0.02 to 
0.45 
0.87 0.0 
Aggression  8,10 111 0.48 -0.12 -0.47-
0.22 
0.61 0.0 
4. High EL and Related Domainsd 
Oppositional behaviour (teacher 
rated) 
6,9 117 0.20 0.57 -0.30 to 
1.43 
0.03* 79.4 
Note. N = Number of participants 
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a. Conduct problems (parent rated) and aggression (parent rated) were not included in this as 
these domains did not include the study which was to be excluded for this analysis (Manor et al., 
2012). 
b. Conduct problems (parent rated) and aggression did not include any high quality studies so these 
sub-group analyses could not be run. 
c. Emotional lability (teacher rated) and conduct problems (parent rated) included only one study 
that supplemented with > 100mg EPA so analyses could not be run. 
d. Data from the two included studies (Gustafsson et al., 2010; Manor et al., 2012) were only 
available for teacher rated oppositional behaviour therefore the analyses could be run only in this 
domain. 
e. + tive SMD favours a treatment effect for the n-3 PUFA group; - tive SMD favours a treatment 
effect for the placebo group  
* Significant at nominal level (p <.05) 
**Significant after correction for multiple testing (p<.008) 
Studies 
1 = Milte et al., (2012), 2 = Richardson and Puri, (2002), 3 = Richardson et al., (2012), 4 = Sinn and 
Bryan (2007), 5 = Richardson & Montgomery (2005), 6= Gustafsson et al., (2010), 7 = Stevens et al., 
(2003), 8 = Widenhorn-Müller et al., (2014), 9 = Manor et al., (2012), 10 = Dean et al., (2014).   
 
3.5 Discussion 
This systematic review and meta-analysis examines the efficacy of n-3 PUFA supplementation on 
EL, oppositional behaviour, conduct problems, and aggression in children with ADHD and related 
neurodevelopmental disorders (ADHD+RND).  The initial analyses found no significant treatment 
effects on EL, oppositional behaviour and conduct problems and aggression.  However, evidence 
from the subgroup analyses suggests effects could be present.  Significant effects emerged for n-3 
PUFA supplementation on parent rated EL in studies that met strict inclusion criteria, and parent 
rated oppositional behaviour in high quality studies (although the latter effect did not withstand 
correction for multiple testing and is seen as indicative of an effect).  There was also a trend for 
supplementation to improve; teacher-rated oppositional behaviour in studies that supplemented 
with adequate EPA and parent-rated oppositional behaviour in studies that met strict inclusion 
criteria.  An important observation from this analysis is that despite public interest into omega-3 as 
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a treatment for ADHD and related disorders, we only identified a small number of studies with 
sufficient data to be included in the analysis (n=10). This demonstrates the need for further 
research to be conducted in this area in order to gain a more conclusive picture. 
 
The subgroup analyses suggest the possibility of a small effect (SMDs ranged from 0.15-0.25) of n-3 
PUFA on EL and oppositional behaviour.  The effect, which remained significant after correction for 
multiple testing (p=.005), was found for n-3 PUFA on parent-rated EL, but only after removal of one 
study that supplemented with phosphatidylserine (PL) containing omega-3 (Manor et al., 2012). 
Previous research has found superior effects of n-3 PUFA + PL (compared to n-3 PUFA alone) on 
ADHD symptoms (Vaisman et al., 2008). Therefore although it is unlikely that adding PL to n-3 
PUFA would diminish the effect size, given the current finding, it is possible that PL could have the 
opposite effect on EL that it had on ADHD symptoms by some as yet unknown mechanism.  As a 
whole, the effects and trends found here emerged in higher quality studies that supplement with n-
3 PUFA only or with higher levels of EPA.  This could provide a basis for methodological 
recommendations for future studies. There was no evidence of heterogeneity suggesting these 
effects or trends to be consistently spread across the various independent studies.  
 
The suggestion of a possible effect of n-3 PUFA on EL and oppositional behaviour is in line with 
epidemiological and cross-sectional studies which have associated deficiencies in n-3 PUFA with 
conduct problems, temper tantrums and violent behaviour in children, adolescents and adults with 
and without ADHD (Corrigan et al., 1994; Gow et al., 2013; Hibbeln, 2001; Iribarren et al., 2004;  
Stevens et al., 1996).  The mechanisms behind this link are proposed to be through disruption of 
neural pathways that regulate behaviour and alterations in serotonin and dopamine levels (Assisi 
et al., 2006; Haag, 2003; Hibbeln et al., 2006; Young & Conquer, 2005). Alterations in dopamine 
seem particularly plausible given that abnormalities in this neurotransmitter may underlie ADHD 
(Bolea-Alamañac et al., 2014) and that EL is a characteristic feature of the disorder (American 
Psychiatric Association, 2013).  
 
The results here are also in line with a previous meta-analysis in eight studies by Benton, (2007) 
which found a significant reduction in aggression after supplementation with n-3 PUFA (SMD=0.61) 
in children and adults who were either healthy or had various mental health conditions. This meta-
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analysis was however, subject to a number of limitations and differences from the current analysis. 
Only one of the eight studies from Benton’s paper were deemed suitable for the current study 
(Hirayama et al., 2004) of which we could not obtain data. We combined similar rating scale 
measures, whereas Benton combined studies which employed psychological tasks (e.g. the picture 
frustration study) (Hamazaki et al., 2002; Hamazaki et al., 1996) with rating scale measures.  We 
analysed only an ADHD+RND group, whereas Benton combined populations who were typically 
developing or had various psychiatric diagnoses (e.g. ADHD and borderline personality disorder).  
One of the papers included in Benton’s paper also failed to report results from the placebo group 
(Fontani et al., 2005).  Finally, five of the papers included by Benton were from the same research 
group (Hamazaki et al., 1998, 2002; Hamazaki et al., 1996; Hirayama et al., 2004; Itomura et al., 
2005). Therefore further evidence is required to support our interpretation. Two studies which 
were included in the qualitative but not quantitative synthesis failed to find treatment effects which 
may be due to small sample sizes (n=37-40) and heterogeneous study populations. Hirayama et al., 
(2004) found no effect on parent- and teacher- rated aggression after eight weeks of 
supplementation in children with ADHD.  Bélanger et al., (2009) found no improvement in parent 
ratings of oppositional behaviour and emotional lability after supplementation for 16 weeks in 
children with ADHD.   
 
Here we do not find significant effects in our primary analysis, although in exploratory secondary 
analyses we do find suggestive evidence for small effects of n-3 PUFA supplementation on 
improving EL and oppositional behaviour.  One potential limitation leading to non-significant 
effects is that the majority of studies included in the meta-analysis were underpowered to detect 
small effects.  Effect sizes ranged from 0.15-0.25, in line with previous meta-analyses which found 
small but significant effects of n-3 PUFA on ADHD symptoms in 699 (SMD=0.31, p < .0001)          
(Bloch & Qawasmi, 2011) and 827 (SMD=0.21, p=0.007) (Sonuga-Barke et al., 2010) children with 
ADHD.  With such modest effect sizes around 0.3, we would require a sample size of around 352 
participants (β=80%, two tailed α=0.05) and around 548 after correction for multiple testing 
(β=80%, two tailed α=0.008).  In the current study, the  included trials ranged from 21 to 362 
participants, with only one study in children with reading difficulties being  adequately powered (N 
= 362) (Richardson et al., 2012).  Further large-scale studies are therefore needed to confirm or 




Another limitation is that participants within the various studies are heterogeneous with regard to 
EL and related behavioural domains. This heterogeneity would then account for reduced effect 
sizes for the outcome measures of interest here, since most of the study samples were selected for 
high levels of ADHD and RNDs, which show uniform deficits for core ADHD features (Coghill et al., 
2007).  Similarly, such between subject heterogeneity for secondary outcomes may have affected 
the results of our recent meta-analysis of n-3 PUFA supplementation on cognitive performance 
deficits, which are found in some but not all children with ADHD and related disorders (Cooper et 
al., 2015).  Such effects might explain why one study found significant treatment effects on 
aggression for a prison population who had higher and more homogenous symptoms of aggression 
(Gesch et al., 2002; Zaalberg, Nijman, Bulten, Stroosma, & van der Staak, 2010).  We therefore 
completed one subgroup analyses across two studies which analysed those with more homogenous 
deficits in emotional lability and oppositional behaviour (Gustafsson et al., 2010; Manor et al., 
2012). Although this did lead to a higher estimated effect (SMD=0.57) of n-3 PUFA on teacher rated 
oppositional behaviour, this finding failed to reach statistical significance, yet this could potentially 
be explained by the very small sample sizes in the individual studies (n=48 and 69).   
 
Another limitation was the substantial between study variation with respect to patient groups, 
assessment procedures, outcome measures, treatment formulations, and quality in methods 
adopted for the different studies. This necessitated the use of random effects models that produced 
wider confidence intervals.  Due to reporting deficiencies, the present study used pre-treatment SD 
instead of SD of the change (the difference before and after the intervention) in the calculation of 
the effect size (Morris, 2007). This could have resulted in an underestimation of the true effect size 
(Ortego & Botella, 2010).  A sensitivity analysis of two studies of parent rated EL which gave the SD 
of the change gave a similar, non-significant result, albeit this analyses is limited due to the small 
number of included studies (see Appendix B, Supplement AB-1).The studies used in this meta-
analysis varied in supplement composition and dosage. According to meta-analyses, higher EPA 
rather than DHA concentrations are associated with symptom reduction in children diagnosed with 
ADHD (Bloch & Qawasmi, 2011; Puri & Martins, 2014).  The current study somewhat supported 
this, as a trend for supplementation to improve teacher rated oppositional behaviour emerged in 
studies that supplemented with adequate EPA (>100mg); although meta-regression found no effect 
159 
 
of EPA dose on any of the examined behavioural domains.  Therefore further evidence is required 
to support this claim. There are also inherent problems with blinding in studies which supplement 
with n-3 PUFA due to the fishy flavour of the capsules. Above chance guessing occurred in a number 
of studies, although this would be expected to inflate rather than reduce any treatment effects 
(Long & Benton, 2013; Milte et al., 2012; Zaalberg et al., 2010).  Identical flavouring of the placebo 
and active capsules must be used to reduce this limitation. A large number (N=6) of the studies 
included in the qualitative synthesis used an olive oil placebo. Olive oil contains a high 
concentration of oleic acid, a precursor of oleamide that has been shown to have psychoactive 
properties (Richardson, 2006). Stevens et al. (2003) found their olive oil placebo to be ‘active’ in 
that a significant increase in the n-3 PUFA, ALA, was found following supplementation (p < .05). An 
inert substance such as liquid paraffin oil could be more suitable (Peet & Horrobin, 2002).  
 
Length of supplementation has been proposed as a factor to explain a lack of significant treatment 
effects. However, we found no relationship between length of supplementation and treatment 
effects. This is in line with a recent meta-analysis which found no relationship between trial 
duration and efficacy of n-3 PUFA in reducing ADHD symptoms (Bloch & Qawasmi, 2011), 
providing good evidence that the included trials were of adequate length and that outcomes were 
unlikely to be influenced by trial duration.  
 
It has also been proposed that treatment effects may occur only in those with low n-3 PUFA blood 
levels at baseline.  We recently found, in typically developing children and adults with low n-3 PUFA 
status, n-3 PUFA supplementation to improve short-term memory (Cooper et al., 2015). Only one of 
the 12 studies included in the qualitative synthesis examined effects in those with low PUFA. 
Stevens et al., (2003) supplemented children with ADHD and low blood n-3 PUFA levels (compared 
to a TD control group) and found a significant treatment effect  for conduct problems (a primary 
outcome), although this was only one of two treatment effects out of 16 outcome measures and was 
only nominally significant. Other studies have examined the effects of supplementation on 
cognition or mood in typically developing children who were either malnourished (Osendarp et al., 
2007) or had low fish consumption (Kennedy et al., 2009) and found no treatment effects.  Future 





In conclusion, although these results do not provide a conclusive picture, they provide suggestive 
evidence that a small effect of n-3 PUFA supplementation on EL and oppositional behaviour might 
be present.  They are however sufficient to exclude moderate to major effects across the samples 
suggesting that supplementation is unlikely to be an effective general approach to reducing EL, 
oppositional behaviour, and conduct problems in children with ADHD.  Potential effects are very 
small and therefore of questionable clinical significance, although it remains feasible that there are 
larger effects in a subgroup.   In order to clarify the presence of clinically meaningful effects in 
clinical subgroups, future studies are required which would ideally employ larger sample sizes 
(>352 participants), supplement with > 100mg EPA, recruit those who are deficient in n-3 PUFA 
with high levels of emotionally labile behaviour and follow stringent procedures for blinding and 
other trial procedures.  
 
3.6 Chapter 3: Interim summary  
Chapter 3 addressed the final section of the first aim of this thesis (see Section 1.4), to document 
the effect of n-3 PUFA supplementation on emotional lability (EL). We found suggestive evidence of 
a small effect of n-3 PUFA supplementation on reducing EL and oppositional behaviour in children 
with ADHD or with a related neurodevelopmental disorder (Cooper et al., 2016).  This evidence, 
combined with the results of Chapter 2 (Cooper et al., 2015) and existing evidence (Bloch & 
Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-Barke et al., 2013), provide us with the most up to 
date estimates of the effect of n-3 PUFA supplementation on ADHD symptoms and associated 
impairments in cognition and emotional lability. There appears to be a small to moderate effect of 
n-3 PUFA supplementation on reducing symptoms of ADHD, no effect (aside from a potential small 
effect in those who are n-3 PUFA deficient) on cognitive performance, and suggestive evidence of a 
small effect on reducing EL and oppositional behaviour.  Results from the reviews in Chapters 2 and 
3 showed that there are as yet no published trials of the effect of n-3 PUFA supplementation in 
adults with ADHD.  In line with this, the second aim of this thesis was to examine the effect of n-3 
PUFA supplementation in adults with ADHD (see Section 1.4). The following data chapter (Chapter 
5) therefore examined, through the use of a randomised controlled trial (RCT) design with baseline 
case/control comparisons, the effect of n-3 PUFA supplementation on ADHD symptoms, cognitive 
performance and EL in adults with ADHD.  The final data chapter (Chapter 6) examines the effect of 
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another alternative treatment, the cannabinoid medication Sativex oromucosal spray, in adults with 
ADHD (the link between this and previous chapters will be discussed in the interim summary of 
Chapter 5).  The following chapter (Chapter 4) discusses the methodologies used in these two 





Chapter 4: Methods 
4.1 Aims 
Data presented in the following two chapters (Chapters 5 and 6) are taken from the OCEAN study 
(Oils and Cognitive Effects in Adult ADHD Neurodevelopment) and the EMA-C study (Experimental 
Medicine in ADHD - Cannabinoids). The specific aim of this chapter is to provide a brief summary of 
the methodologies of these studies. An overview of the outcome measures obtained in these 
samples is provided in this chapter, however only a number of these measures, relevant to the aims 
of this thesis, were analysed in Chapters 5 and 6. The remaining data is to be analysed at a later 
date.   
 
4.2 Part 1: OCEAN Study 
4.2.1 Background 
4.2.1.1 Location of study, funding and ethical approval 
The OCEAN study was conducted at the MRC Social Genetic and Developmental Psychiatry (SGDP) 
Centre at the Institute of Psychiatry Psychology and Neuroscience (IoPPN) in conjunction with the 
Adult Attention Deficit Hyperactivity Disorder (ADHD) clinic at the South London and Maudsley 
Hospital NHS Trust (SLaM). The study was funded by Vifor Pharma (grant number: PADWUDB), 
awarded to Prof Philip Asherson (Primary Investigator) as an investigator led project (with King's 
College London as the sponsors).  Research ethics approval for this study was granted by the 
National Research Ethics Service (NRES) Committee London - Camberwell St Giles (reference: 
11/LO/1042). Full informed consent was given by all subjects participating in the study. 
 
4.2.1.2 Design 
The study was a single-centre 6-month double-blind, placebo controlled, parallel-group pilot study 
of n-3 PUFA supplementation in 81 adults with ADHD. Testing sessions occurred at time 1 
(baseline), time 2 (3 months) and time 3 (6 months).  A sample of 30 psychiatrically healthy control 
participants took part in the baseline assessments in order for case/control comparisons to be 





4.2.2.1 Inclusion and exclusion criteria 
Eligible participants were adults aged between 18 and 55 years. They had either a formal (a pre-
existing diagnosis by a psychiatrist) or research (previously undiagnosed patients (see research 
diagnosis Section 4.2.2.4) diagnosis of ADHD. Participants met criteria for ADHD with either the 
combined type presentation or inattentive (with some hyperactive/impulsive symptoms) type 
presentation. We excluded cases that only presented with inattentive symptoms as there is some 
evidence this might reflect a separate condition (Barkley, 2014).  Age of onset was set at age 12 or 
below, in accordance with DSM-5 (American Psychiatric Association, 2013). They met all other 
criteria for DSM-5 ADHD at baseline including pervasive impairments from the symptoms in more 
than one setting. Participants were either on stable treatment (> 1 month) with ADHD medication 
(stimulant or non-stimulant treatment such as atomoxetine), or no medication, and could also be 
taking a low dose of a concomitant medication for depression or anxiety disorders. Participants on 
stimulant medication must have been willing to come off this medication for 48 hours before the 
baseline and final (6 month) testing sessions.  
 
Combined type 
In childhood: ≥ 6 symptoms of inattention; and ≥ 3 symptoms of hyperactivity-impulsivity. 
In adulthood: ≥ 5 symptoms of inattention; and ≥ 3 symptoms of hyperactivity-impulsivity. 
 
Inattentive type 
In childhood: ≥ 6 symptoms of inattention; and ≥ 3 symptoms of hyperactivity-impulsivity. 
In adulthood: ≥ 5 symptoms of inattention; and ≥ 2 symptoms of hyperactivity-impulsivity. 
 
Participants were excluded who had a current or historical diagnosis of autism spectrum disorder 
(ASD), tourette’s syndrome, bipolar I disorder, any psychotic disorder, obsessive compulsive 
disorder (OCD), frequent panic attacks, or general learning difficulties (defined as a IQ < 80).  As a 
lifetime history of depression is so common amongst this population, only those with recurrent 
depression or those in a current depressive episode at the time of contact were excluded.  
Neurological problems, head injury, current or previous substance abuse or frequent substance use 
(more than 8 units (6 units for females) of alcohol consumed daily or recreational drug use more 
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than twice weekly) were also excluded; as were participants with any major physical health 
problems (including diabetes, thyroid problems, cancer, or an infectious disease). Participants with 
fish allergies or who had taken omega-3 or 6 supplements in the previous 3 months were excluded. 
 
4.2.2.2 Recruitment sources 
Controls 
Controls were recruited via recruitment circulars and advertisements in the local community. 
Eligible controls were age, gender and IQ matched to the patient sample and fulfilled all the same 
exclusion criteria.  Additionally, control participants screened below threshold for ADHD on the 




Recruitment occurred through four sources: 
 
1. Recruitment through South London and Maudsley NHS Trust (SLaM): The medical records 
of patients (either follow-up patients or those on the waiting list) from the SLaM Adult ADHD 
Service were screened for eligibility, using the inclusion and exclusion criteria, by a member of the 
OCEAN research team (myself, CS or RS) who held honorary clinical contracts. In addition previous 
ADHD study databases were also screened for suitable participants. Those deemed eligible were 
sent study information sheets, invitations, a response slip and a stamped addressed envelope. 
Where no response slip was returned, participants were contacted by telephone to determine their 
interest in participating. Those who expressed an interest in participating in the study completed a 
telephone screening (detailed in Section 4.2.2.4). If deemed suitable following the telephone 
screening and if a Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID: a structured 
clinical interview for the 18 ADHD symptoms in childhood and adulthood) (Epstein, Johnson, & 
Conners, 2001) had been completed as part of their diagnostic assessment at SLaM, then they were 
invited into the trial and their baseline assessment was booked. If a CAADID were not completed as 
part of their diagnostic assessment it was completed over the phone by a member of the research 
team (RS or CS). If the patient was on the waiting list then a research diagnostic assessment was 




2.  Online questionnaire: In order to recruit undiagnosed patients an online screening 
questionnaire was set-up (http://neuroknowhow.com/adhdoraddquestionnairepage/) (although 
this link has now been disabled). This was established by a study participant who runs the website 
‘neuroknowhow’ (http://neuroknowhow.com/aboutus/) which provides services and online help 
for those with neurodevelopmental difficulties such as ADHD, dyslexia, and dyspraxia. The 
screening questionnaire consisted of the six questions in Part A of the(ASRS) which have been 
found to be the most predictive of ADHD (Kessler, Adler, Ames, et al., 2005) (Appendix C, Table AC-
2).  Those who screened above the threshold for ADHD were asked to complete the Barkley 
Childhood Behaviour Scale (Appendix C, Table AC-3). If they scored positive for 6 or more 
symptoms of either or both domains of inattention or hyperactivity/impulsivity then a research 
assessment was conducted (see Section 4.2.2.4). 
 
3. Online advertisements: Participants were also recruited from advertisements on the ADHD 
support websites AADD-UK (Adult ADHD-UK) (http://aadduk.org/about/) and ADDISS (The 
National Attention Deficit Disorder Information and Support Service) (http://www.addiss.co.uk/). 
We were also contacted from participants who saw the trial registered on clinical trials.gov 
(identifier: NCT01750307). If these participants had an existing diagnosis we asked them to send us 
a copy of their diagnostic assessment report. If inclusion/exclusion criteria were met then the 
CAADID (Epstein et al., 2001) was completed by RS or CS. If the participants did not have an 
existing diagnosis and screened above threshold for ADHD on the ASRS (Kessler, Adler, Ames, et al., 
2005) and Barkley’s Childhood Behaviour Scales (Barkley, 1998) then a research assessment was 
conducted (see Section 4.2.2.4). 
 
4. Recruitment through other doctors: We attended the clinical team meetings at the Maudsley 
Adult ADHD Clinic to communicate the study to members of the healthcare team and ask if they had 
any suitable patients and if they could let their patients know about the study. The study was also 
circulated to clinicians on the email list of the UK Adult ADHD Network (UKAAN).  Figure 4-1 








Figure 4-1: Flow diagram of recruitment and exclusions for the OCEAN study (see Appendix C, 
Table AC-4 for a more detailed breakdown of exclusions). 
Note. ASD = Autism Spectrum Disorder, Participants who overlapped mental health/substance 







4.2.2.3 Telephone screening 
Both ADHD and control participants underwent a structured telephone screening of exclusionary 
criteria, which consisted of detailed questions assessing any previous or current mental health 
problems including: presence, treatment for or diagnosis of anxious, depressive and 
manic/hypomanic symptoms, physical health problems, neurological problems, drinking and drug 
habits, use of omega-3 or 6 supplements, and any known allergies to fish (See Appendix C, 
Supplement AC-1).  
 
4.2.2.4 Research assessment 
Undiagnosed participants who met inclusion/exclusion criteria were asked to complete (over the 
telephone with myself) the CAADID (Epstein et al., 2001). In line with DSM-5, symptom onset and 
chronicity was established before age 12 and in adulthood, the presence of a minimum of 5 
symptoms of inattention and 3 symptoms of hyperactivity/impulsivity were established (American 
Psychiatric Association, 2013). The CAADID was also completed (over the telephone by myself) 
with someone who knew the participant in childhood, most commonly a parent.  The CAADID was 
then reviewed by Prof Philip Asherson, an experienced consultant psychiatrist specialising in adult 
ADHD, who approved the participants prior to inviting them into the study. In addition, Prof 
Asherson met participants at their baseline assessment to review and confirm the diagnosis. 
Participants were then provided with a letter from Prof Asherson detailing the outcome of the 
research assessment.  Participants who had not yet been referred or diagnosed for adult ADHD 
could then, if they wished, use this letter to help gain a referral for a formal adult ADHD assessment, 




The recruitment path and reasons for exclusions are shown in Figure 4-1 and in detail in Appendix 
C, Table AC-4. Of the 1616 individuals screened for the study 916 were excluded. The main reason 
for exclusion was due to co-occurring mental health conditions (40.4% of the total excluded 
sample). The most common being either diagnosed with or having suspected ASD (23%), 
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anxiety/panic disorder and depression (5.0%), OCD (3.7%), psychosis/schizophrenia (2.0%), 
bipolar disorder (2.5%) and those with complex comorbid conditions (1.9%).  The next most 
common reason for exclusion was due to the individual not being diagnosed with ADHD on 
assessment or having too few symptoms (18.2%), head injuries, neurological problems or cognitive 
impairment (11.7%), substance abuse or dependence (10.5%) (most commonly cannabis (5.7%) 
use), and use of psychoactive medications (6.1%) were other common reasons for exclusion. 
 
4.2.2.6  Alteration to exclusion criteria 
Due to the high levels of comorbidity in adults with ADHD, mid-way through the study the exclusion 
criteria were altered, so that patients taking antidepressant medication were included, so long as 
they met research diagnostic criteria for ADHD and all other inclusion and exclusion criteria.  The 
final sample for the OCEAN study was therefore a relatively representative sample including some 
(N=14) cases with comorbid difficulties with mild depression and anxiety without panic symptoms, 
and the sample was also mixed sex. There was no difference in ADHD symptom severity between 
those who were taking concomitant antidepressant medication and the remaining sample (who 
were either unmedicated or medicated with stimulant or non-stimulant medication) (p > .05) (see 
Appendix C, Table AC-5). 
 
4.2.3 Participants 
The participants were 81 adults with ADHD (mean age = 33.5 years (10.26)) and 30 typically 
developing control participants, matched roughly in age (p=0.06) and IQ (p=0.41), although there 
was a trend for the controls to be slightly younger than the ADHD cases (for further details see 
Chapter 5, Section Error! Reference source not found.). 
 
4.2.4 Research assessment tools  
The following is an overview of the measures used in the three testing sessions (Baseline, Time2 
and Time 3). Table 4-1 summarises which assessments were made at each time point.  A detailed 






Baseline only measures 
- The MINI 6.0 (Mini International Neuropsychiatric Interview) diagnostic interview 
(Lecrubier et al., 1997): The MINI was used to screen for comorbid disorders.  
- The Weschler Abbreviated Scale of Intelligence – II (WASI-II) (Weschler, 2005): Two 
subtests (vocabulary and matrix reasoning) of the WASI-II were used to measure IQ. 
- Socio-economic status (SES): SES was assessed by collecting information on participants’ 
level of education, occupation and income. 
- Information regarding the participants’ medication and when they were diagnosed with ADHD 
was also collected. 
 
Assessment of efficacy 
Primary efficacy measure 
Sustained Attention to Response Task (SART) (O’Connell et al., 2009): The SART is a 
computerised go/no go task. The primary outcome was performance measured through number of 
commission errors (where the participant responds where a response is not required) (see Chapter 
5, Section 5.3.6.1 for further details).   
 
Secondary efficacy measures 
ADHD symptoms: 
- Conners’ Adult ADHD Rating Scales (CAARS) (Conners, Erhardt, & Sparrow, 1999) and 
Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADS) (Wender, 1995) 
combined (investigator rated): Assessed investigator rated ADHD symptom severity. 
Self-report questionnaires:   
- Executive function: Behavioural Rating Inventory of executive function – Adult Version (Brief-
A) (Roth, Isquith, & Gioia, 2005). 
- Common psychopathology: Symptom Checklist-90 (SCL-90) (Derogatis & Unger, 2010). 
- Sleep:  The Pittsburgh Sleep Quality Index (PSQI) (Buysse, Reynolds, & Monk, 1989). 
- Thoughts: The Depressive Thoughts Questionnaire (DTQ) (Clark & De Silva, 1985) assesses 
levels of depressive thoughts; and the Cognitive Control Questionnaire (CCQ) (Asherson, 
unpublished report) assesses the control they have over their thoughts, a concept similar to 
excessive mind wandering.  
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- Life Stress: The Brief COPE questionnaire (Carver, 1997) assesses how they are coping with 
stressful life events and the Brief Life Events Questionnaire (BLEQ) (Brugha & Cragg, 1990) 
assesses the occurrence of stressful life events over four months.  
- Functional Impairment Questionnaires: The Weiss Functional Impairment Rating Scale Self 
Report (WFIRS-S) (Weiss, 2007) and the Adult ADHD Quality of Life Scales (AAQoL) (Brod, 
Johnston, Able, & Swindle, 2006) cover various aspects of social and cognitive function, 
productivity, health and relationships.  
- Reading: The word reading and spelling subtests of the Wechsler Individual Achievement Test 
(WIAT-II) (Wechsler, 2005) were used to assess reading and spelling ability. 
- Fish frequency questionnaire (FFQ): This is a brief questionnaire which asks participants to 
rate their average fish intake for the prior 6-months.   
 
Cognitive function measured by electroencephalography 
- An electroencephalography (EEG) recording session lasting approximately 1.5 hours was 
carried out. Conditions or tasks implemented during the EEG recording are outlined below and 
were administered in the order with which they are described. All tasks were administered 
using the presentation software package (www.neurobs.com). A brief description of each task 
is provided below. 
 
Two resting state conditions (first eyes open, then eyes closed), lasting 3 minutes each were 
carried out at the beginning and end of each recording session.  Measures of sustained 
attention, inhibition, reaction time, and reaction time variability were obtained using the 
Sustained Attention to Response Test (SART) (task duration was 15 minutes) (O’Connell et al., 
2009), and the Cued Continuous Performance Test (CPT-OX) with flankers (McLoughlin et al., 
2010; Valko et al., 2009) (task duration was 11 minutes).  Measures of reaction time and 
reaction time variability were obtained using the Fast Task (Andreou et al., 2007; Kuntsi et al., 








- Mood self-report questionnaires: The Centre for Neurologic Study Lability Scale (CNS-LS) 
(Moore, Gresham, Bromberg, Kasarkis, & Smith, 1997) and Affective Lability Scale-Short Form 
(ALS-SF) (Oliver & Simons, 2004) measured emotional lability.   
- The Computerized Paced Auditory Serial Addition Task (PASAT-C (Lejuez, 2003)): This is a 
computerised mental arithmetic task used to elicit frustration (a more detailed description of 
this task is available in Chapter 5).  
 
4.2.5 Blood samples 
In order to monitor compliance 2 x 10ml blood were collected from each of the ADHD cases at all 
three time points. In order for case/control comparisons to be made 2 x 10ml blood were collected 
from each control at the baseline assessment. Omega-3 and 6 blood levels were measured. 
 
4.2.6 Randomisation 
Randomisation was carried out (by Vifor Pharma) (see Chapter 5, Section 5.3.9 for further details). 
 
4.2.7 Supplementation 
Participants in the active group were supplemented with Equazen High concentrated (Equazen 
HC). Participants in the placebo group were supplemented with medium chain triglycerides (an 
inert fatty acid).  
 
4.2.8 Testing procedure 
The testing procedure is detailed in Chapter 5, Section 5.3.7.  Table 4-1 details the assessments and 











Table 4-1: OCEAN assessments and timing 











EEG  1.5-hours  X  X 
WIAT-II 30 minutes X  X 
IQ (WASI) 20 minutes X   
PASAT 20 minutes X  X 
MINI  30 minutes X   
SES + Medication info 10 minutes X   
CAARS/WRAADDS 10 minutes X X X 
Blood sample 10 minutes X X X 
Fish frequency 
questionnaire* 
5 minutes X X X 
BRIEF-A* 5 minutes X X X 
SCL-90* 5 minutes X X X 
CNS-LS* 5 minutes X X X 
ALS-SF* 5 minutes X X X 
WFIRS-S* 5 minutes X X X 
PSQI* 5 minutes X X X 
DTQ* 5 minutes X X X 
CCQ* 5 minutes X X X 
Brief-cope* 5 minutes X X X 
BLEQ* 5 minutes X X X 
AAQoL* 5 minutes X X X 
Total time  4 h 40m 1h 20m 3h 40m 
Note. * = Completed at home, EEG = electroencephalography, WIAT-II = Weschler Individual 
Achievement Test (2nd edition), IQ = Intelligence quotient, WASI = Weschler Abbreviated Scale of 
Intelligence, PASAT = Paced Auditory Serial Addition Task, MINI = Mini International 
Neuropsychiatric Interview, SES = Socio-Economic Status, CAARS = Conners’ Adult ADHD Rating 
Scales, WRAADDS = Wender-Reimher Adult Attention Deficit Disorder Scale, BRIEF-A = Behavior 
Rating Inventory of Executive Function –Adult Version, SCL-90 = Symptom Checklist-90, CNS-LS = 
Centre for Neurologic Study Lability Scale, ALS-SF = Affective Lability Scale-Short Form, WFIRS = 
Weiss Functional Impairment Rating Scale Self Report, PSQI = The Pittsburgh Sleep Quality Index, 
DTQ = Depressive Thoughts Questionnaire, CCQ = Cognitive Control Questionnaire, BLEQ = Brief 
Life Events Questionnaire, AAQoL = Adult ADHD Quality of Life Scales. SGDP = Testing sessions 





Safety measures during the study involved: 
- A full clinical history taken at the time of recruitment, including both medical and 
psychiatric disorders (and new symptoms arising during the course of the study). 
- History of allergy to fish oil products (an exclusion from the study). 
- Vital Signs (pulse, blood pressure) and body weight were measured at all study visits.  
 
4.2.10 Preparatory work 
4.2.10.1 Power 
See Chapter 5, Section 0. 
4.2.10.2 Piloting 

















4.3 Part 2 EMA-C Study 
4.3.1 Background 
4.3.1.1 Location of study, funding and ethical approval 
This was a single-centre trial conducted between November 2014 and July 2015 at the SGDP 
Centre, London in conjunction with the Adult Attention Deficit Hyperactivity Disorder (ADHD) 
clinic at SLaM. The study was funded by a department research account for PA, with the active and 
placebo medication provided free of charge by GW Pharma. Research ethics approval for the study 
was granted by the National Research Ethics Service (NRES) Committee London – London Bridge 
(reference: 14/LO/0606). The study was conducted in compliance with the principles of the 




The study was a 6 week double blind, placebo controlled, parallel group pilot study of Sativex 
oromucosal spray in 30 adults with ADHD (for further details see Chapter 6, Section 6.4.1) Testing 
sessions occurred at baseline and 6 weeks.  
 
4.3.2 Recruitment 
4.3.2.1 Inclusion and exclusion criteria 
The study was open to males and females aged 18-55 who met DSM-5 criteria for ADHD (N=30).  
Participants had either a formal (pre-existing diagnosis by a psychiatrist) or research (previously 
undiagnosed patients) diagnosis of ADHD. In both cases the diagnosis was checked by PA to ensure 
they met DSM-5 criteria (see research diagnosis Section 4.3.2.4). Participants were required to have 
the combined type presentation of ADHD and we excluded those with only inattentive symptoms. 
The following criteria were applied:  
 
In childhood: ≥ 6 symptoms of inattention; and ≥ 3 symptoms of hyperactivity/impulsivity.  
In adulthood: ≥ 5 symptoms of inattention; and ≥ 3 symptoms of hyperactivity/impulsivity. 
 
Age of onset was set at 12 or below, in accordance with DSM-5 criteria (American Psychiatric 
Association, 2013). All cases met other criteria for ADHD at the time of the baseline assessment (i.e. 
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pervasive impairment from the symptoms in more than one setting). Participants were required to 
score > 24 on the 18-item Conners’ Adult ADHD Rating Scale (CAARS) (Conners et al., 1999). 
Participants were either unmedicated or medicated with stimulant medication only and were 
willing to come off this medication for 1 week before and for the duration of the study. To ensure 
this did not disadvantage patients, we carefully telephone screened participants in order to include 
those who did not take their stimulant medication on a regular basis, and where short periods 
without medication were not thought by both the patient and psychiatrist to represent a clinical 
problem in the overall control of the symptoms and impairments. Participants were also asked to 
not use any other prescription or non-prescription medication or recreational drugs during the 
study. 
 
Exclusion criteria were as follows: a current and primary diagnosis of ASD; recurrent major 
depression, panic/anxiety disorder; bipolar I disorder; any psychotic disorder; OCD; tourette’s or 
general learning difficulties defined as an IQ < 70; Neurological problems; a known or suspected 
history of drug or alcohol dependence; a first degree relative with a psychotic disorder or use of 
non-stimulant ADHD medication; those who were using or had used cannabis or cannabis based 
medications in the 30 day period prior to study entry; concurrent history of renal, hepatic, 
cardiovascular or convulsive disorders; females who were pregnant or breastfeeding or female 
participants of child bearing potential, and male subjects whose partner was of child bearing 
potential, who were unwilling to ensure that they or their partner used two effective forms of 
contraception (for example, oral contraception, double barrier, intra-uterine device) during the 
study and for three months thereafter (this is because there is not enough information to say that 
Sativex is safe in pregnancy). 
 
4.3.2.2 Recruitment sources 
There were three main sources of recruitment for the ADHD cases: 
 
1. Recruitment through SLaM or 2. Recruitment from previous research studies: The medical 
records of patients (either follow-up patients or those on the waiting list) from the SLaM Adult 
ADHD Service were screened for eligibility (initial screening) using the above inclusion and 
exclusion criteria by a research assistant (EW) who held an honorary clinical contract. Those 
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deemed eligible were sent study information sheets, invitations, a response slip and a stamped 
addressed envelope. Suitable participants from the OCEAN study and two other studies which 
recruited adults with ADHD (Female Experiences and Brain Activity (FEBA) and Mood Instability 
Research in ADHD (MIRIAD)) also underwent an initial screening and were either posted letters or 
emailed. Where no response slip or email reply was received, participants were contacted by 
telephone to determine their interest in participating. Those who expressed an interest in 
participating in the study completed a telephone screening (detailed below). If deemed suitable 
following the telephone screening, and a Diagnostic Interview for ADHD in Adults DIVA  (Kooij & 
Francken, 2010) had been completed as part of their diagnostic assessment at SLaM or as part of 
the research study then they were invited into the trial and their baseline assessment was booked. 
If a DIVA was not completed it was completed over the phone by EW. If the patient was on the 
waiting list and therefore undiagnosed then a research assessment was carried out by EW, and in a 
face to face interview with Prof Asherson (detailed in Section 4.3.2.4). 
 
3. Online advertisements, 4. Recruitment through other doctors: Participants were recruited 
from advertisements on the ADHD support websites AADD-UK (http://aadduk.org/about/) and 
ADDISS (http://www.addiss.co.uk/). We were also contacted from participants who saw the trial 
registered on clinical trials.gov (identifier: NCT02249299). The study was also communicated to 
clinicians who were part of the UK Adult ADHD Network (UKAAN). Interested participants with an 
existing diagnosis were asked to send a copy of their diagnostic assessment report. An initial 
screening was carried out and if inclusion/exclusion criteria were met, then a telephone screening 
(Section 4.3.2.3) and then the DIVA were completed by EW. If the participants did not have an 
existing diagnosis then a research assessment was conducted including a face to face diagnostic 











Figure 4-2: Flow diagram of recruitment and exclusions for the EMA-C study (see Appendix C, 
Table AC-6 for a more detailed breakdown of exclusions). 
Note. ASD = Autism Spectrum Disorder, Participants with overlapping mental health/substance 







4.3.2.3 Telephone screening 
ADHD participants underwent a structured telephone screening for exclusionary criteria, which 
consisted of detailed questions assessing any previous or current mental health problems 
(including presence, treatment for or diagnosis of anxious, depressive and manic/hypomanic 
symptoms), physical health problems, neurological problems, drinking and drug habits. 
Participants were also asked about their use of ADHD medication. It was also reiterated to 
participants that there was a 50% chance of receiving the placebo and then asked whether it would 
be a problem for them to not be on any ADHD medication for the 7 week study (1 week before and 
the 6 week trial). Participants were also asked about their cannabis use and any previous problems 
following cannabis use. Finally they completed the 18-item CAARS (Conners et al., 1999) (see 
Appendix C, Supplement AC-2). 
 
4.3.2.4 Research assessment 
Undiagnosed participants who met other inclusion/exclusion criteria were asked to complete (over 
the telephone with a research assistant (EW1)) the DIVA (Kooij, 2012). The DIVA is a structured 
clinical interview for the 18 ADHD symptoms in childhood and adulthood. Symptom onset and 
chronicity were established before age 12 and the presence of more than 5 symptoms of inattention 
and 3 of hyperactivity/impulsivity were established in adulthood (in accordance with recent DSM-5 
criteria (American Psychiatric Association, 2013). Prof Philip Asherson then spoke to the 
participants over the phone and met with them at their baseline assessment in order to confirm the 
diagnosis and approve the participants to enter the study. At the end of the trial these patients were 
offered treatment for ADHD when this was appropriate. They were registered with SLaM and 
treated for their ADHD, generally with stimulant medication, by Prof Asherson or another member 
of the clinical team. 
 
4.3.2.5 Exclusions 
The recruitment path and reasons for exclusions are shown in Figure 4-2 and in detail in Appendix 
C, Table AC-6. Of the 233 individuals screened for the study 99 were excluded. The main reasons for 
exclusions were that the participant did not have ADHD on assessment or did not have enough 
                                                                




symptoms (19.2%), or the presence of a co-occurring mental health condition (15.2%), commonly 
psychosis or schizophrenia (4%), ASD (3%) or bipolar disorder (3%). Other reasons for exclusion 
included participants who were unwilling to come off their ADHD medication (12.1%), substance 
abuse or dependence (9.1%), the current use of psychoactive medication (11.1%), or that they 
were unwilling to take a cannabis-based medication (5.1%). 
 
4.3.3 Participants 
The participants were 30 adults with ADHD (11 female, 19 male, mean age = 37.9 years (SD = 
11.46) (further details are given in Chapter 6, Section 6.5.1). 
 
4.3.4 Research assessment tools 
The following is an overview of the measures used in the two testing sessions (baseline and 6 
weeks). Table 4-1 summarises which assessments were made at each time point. A detailed 
description of the data used in the analyses is presented in Chapter 6, Section 6.4.6). 
 
Baseline only measures  
- The MINI 6.0 (Mini International Neuropsychiatric Interview) diagnostic interview 
(Lecrubier et al., 1997):  The MINI was used to screen for comorbid disorders.  
- The Weschler Abbreviated Scale of Intelligence – II (WASI-II) (Weschler, 2005): Two 
subtests (vocabulary and matrix reasoning) of the WASI-II were used to measure IQ. 
- Socio-economic status (SES): SES was assessed by collecting information on participants’ 
level of education, occupation, and income. 
- Information regarding the participants’ medication, when they were diagnosed with ADHD and 











Assessment of efficacy 
Primary efficacy measure 
QbTest (Quantitative Behaviour Test) (Bijlenga, Jasperse, Gehlhaar, & Kooij, 2015; Iberstadt, 
2012): The Qb Test is a 20 minute, unconditional identical pairs test (see Chapter 6, Section 6.4.6.2 
for further details). 
 
Secondary efficacy measures 
ADHD symptoms: 
- Conners’ Adult ADHD Rating Scales (CAARS) (Conners et al., 1999) and Wender-Reimher 
Adult Attention Deficit Disorder Scale (WRAADS) (Wender, 1995) combined (investigator 
rated): Assessed ADHD symptom severity. 
Self-report questionnaires:   
- Executive function: Behavioural Rating Inventory of executive function – Adult Version (Brief-
A) (Roth et al., 2005). 
- Common psychopathology: Symptom Checklist-90 (SCL-90) (Derogatis & Unger, 2010). 
- Sleep:  The Pittsburgh Sleep Quality Index (PSQI) (Buysse et al., 1989). 
- Thoughts: The Depressive Thoughts Questionnaire (DTQ) (Clark & De Silva, 1985) assesses 
levels of depressive thoughts and the Cognitive Control Questionnaire (CCQ) (Asherson, 
unpublished report) assesses the control they have over their thoughts. 
- Life Stress: The Brief COPE questionnaire (Carver, 1997) assesses how they are coping with 
stressful life events and the Brief Life Events Questionnaire (BLEQ) (Brugha & Cragg, 1990) 
assesses the occurrence of stressful life events over four months.  
- Functional Impairment Questionnaires: The Weiss Functional Impairment Rating Scale Self 
Report (WFIRS-S) (Weiss, 2007) and the Adult ADHD Quality of Life Scales (AAQoL) (Brod et 
al., 2006) cover various aspects of social and cognitive function, productivity, health and 
relationships.  
- Emotional lability: The Centre for Neurologic Study Lability Scale (CNS-LS) (Moore et al., 
1997) and Affective Lability Scale-Short Form (ALS-SF) (Oliver & Simons, 2004) measured 





Sustained Attention to Response Task (SART) (O’Connell et al., 2009): The SART is a 
computerised go/no go task (See Chapter 6, Section 6.4.6.3 for further details). 
 
4.3.5 Randomisation 
The randomisation list was produced by an independent statistician using a random number 




Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contained: 
2.7 mg delta-9-tetrahydrocannabinol (9-THC) and 2.5 mg cannabidiol (CBD). 
 
Placebo treatment 
The placebo treatment was an oromucosal spray, containing ethanol, propylene glycol (50:50) 
excipients, with peppermint oil (0.05%) flavouring and colourings. 
 
For further details see Chapter 6, Section 6.4.5. 
 
4.3.7 Testing procedure 














Table 4-2: Assessments and timings for the EMA-C study 
 
 
Note. SGDP = Testing sessions occurred at the Social, Genetic and Developmental Psychiatry Centre 
Note. WASI = Weschler Abbreviated Scale of Intelligence, MINI = Mini International 
Neuropsychiatric Interview, CAARS = Conners’ Adult ADHD Rating Scales, WRAADDS = Wender-
Reimher Adult Attention Deficit Disorder Scale SES = Socio-Economic Status, BRIEF-A = Behavior 
Rating Inventory of Executive Function –Adult Version, SCL-90 = Symptom Checklist-90, CNS-LS = 
Centre for Neurologic Study Lability Scale, ALS-SF = Affective Lability Scale-Short Form, WFIRS = 
Weiss Functional Impairment Rating Scale Self Report, PSQI = The Pittsburgh Sleep Quality Index, 
DTQ = Depressive Thoughts Questionnaire, CCQ = Cognitive Control Questionnaire, BLEQ = Brief 
Life Events Questionnaire, AAQoL = Adult ADHD Quality of Life Scales. SART = Sustained Attention 






Consent 5 minutes X  
Information/ 
demographics 
10 minutes X X 
WASI  30 minutes X  
MINI 6.0 diagnostic 
interview 
30 minutes X  
CAARS/WRADDS 10 minutes X X 
BRIEF-A 5 minutes X X 
SCL-90 5 minutes X X 
CNS-LS 5 minutes X X 
ALS-SF 5 minutes X X 
WFIRS 5 minutes X X 
PSQI 5 minutes X X 
DTQ 5 minutes X X 
CCQ 5 minutes X X 
Brief-cope 5 minutes X X 
BLEQ 5 minutes X X 
AAQoL 5 minutes X X 
SART 20 minutes X X 
QB test 30 minutes X X 
Total time  3 hours 10 
minutes 




to Response Task, Qb Test = Quantitative Behaviour Test, SGDP = Testing sessions occurred at the 
Social, Genetic and Developmental Psychiatry Centre. 
 
4.3.8 Safety 
Safety measures during the study involved: 
- A full clinical history taken at the time of recruitment, including both medical and 
psychiatric disorders (and new symptoms arising during the course of the study). 
- History of cannabis use with no adverse effects. 
- Vital Signs (pulse, blood pressure) measured at each study visit. Safety monitoring during 
dose titration (day 1-14) and days 14-42 (see Section 4.3.8). 
- Participants were provided with a ‘study card’ which stated they were taking part in a 
clinical trial with a cannabinoid medication. The card contained contact details and two 24 
hour emergency phone numbers. The emergency phones were held by myself and Prof 
Asherson. 
 
4.3.9 Adverse events 
Serious adverse events were reported to and investigated by Prof Asherson.  Adverse events 
included any untoward medical occurrence, including any occurrence that is new in onset or 
aggravated in severity or frequency from the baseline condition. Serious adverse events were 
recorded and reported by Prof Asherson in line with NRES (National Research Ethics Service) 
specifications for non-CTIMPs (non-Clinical Trials of an Investigational Medical Product): A safety 
report form was obtained and completed (from: http://www.hra.nhs.uk/resources/during-and-
after-your-study/progress-and-safety-reporting/) and was sent to the study sponsor (King’s 
College London), GW Pharma and the National Research Ethics Service (NRES) Committee London 
– London Bridge.  If necessary Prof Asherson would communicate with the participant’s general 
practitioner or other medical healthcare professional. 
   
4.3.10 Preparatory work 
4.3.10.1 Power 




Before testing commenced the study assessments were piloted on four volunteers who were 








































Chapter 5: The OCEAN Study: A Randomised Controlled Trial of 
Omega-3 Supplementation in Adults with ADHD 
 
5.1 Abstract 
Stimulants, atomoxetine and other ADHD medications can be difficult to tolerate or only partially 
effective or ineffective in some cases. Research into alternative or adjunctive treatments for ADHD 
is therefore important. One of the most studied alternative treatments in ADHD is omega-3 
polyunsaturated fatty acid (n-3 PUFA) supplementation.  Deficiencies in n-3 PUFA blood levels have 
been commonly found in children and adults with ADHD. Subsequent meta-analyses of n-3 PUFA 
supplementation in children with ADHD estimate small to moderate effects on reducing ADHD 
symptoms, and provide suggestive evidence for reductions in associated symptoms of emotional 
lability (EL) and weak evidence for effects on cognition. The effect of n-3 PUFA supplementation in 
adults with ADHD has yet to be established. Given this, we present results from a randomised 
placebo-controlled trial (RCT) of n-3 PUFA supplementation in 81 adults with ADHD. The study also 
included baseline case/control comparisons which showed that the ADHD cases had significantly 
impaired cognitive performance (increased omission and commission errors, RTV2, MRT3 and CV4) 
and more severe symptoms of ADHD and EL compared to healthy controls. However no 
case/control difference in n-3 PUFA blood levels were found. Results from the primary intent-to-
treat analysis for the RCT found supplementation did not improve cognition, EL, or symptoms of 
ADHD. Using a per protocol analysis, marginal evidence for improvement was found for inattention, 
and to a lesser extent EL, in those who strictly adhered to the protocol. In conclusion, despite the 
ADHD group showing increased symptoms and impairment compared to the control group, no 
evidence for n-3 PUFA deficiency was found. Results from the RCT are interpreted in light of 
limitations due to a high drop-out rate, as providing limited evidence for an effect of n-3 PUFA on 
inattention and potentially symptoms of EL in adults with ADHD.  
 
                                                                
2 Reaction time variability. 
3 Mean reaction time. 




Attention-deficit/hyperactivity disorder (ADHD) is characterised by the core behavioural 
symptoms of impulsivity, hyperactivity and/or inattention. The DSM-5 also lists emotional lability 
(EL; defined as low frustration tolerance, irritability and mood lability) and cognitive impairment 
(defined as problems on tests of attention, executive function or memory) as associated features of 
ADHD that support the diagnosis of ADHD (American Psychiatric Association, 2013). ADHD affects 
around 5% of children (Polanczyk et al., 2007, 2014), continuing into adulthood in around two-
thirds of cases with a prevalence of around 2.5% (Faraone et al., 2006; Simon et al., 2009).   
 
The cognitive impairments which characterise ADHD in both children and adults are diverse, with 
the greatest evidence for deficits in executive function and reaction time variability (RTV) (Bolea-
Alamañac et al., 2014; Kofler et al., 2013) (see Chapter 1, Section 1.1.10 for a more detailed 
discussion). Executive function, referring to the completion of goal-directed tasks, includes 
measures of sustained attention (commonly measured as omission errors5) and response inhibition 
(commonly measured as commission errors6) (Frazier et al., 2004; Willcutt et al., 2005). Deficits in 
omission and commission errors are commonly found in both children (Willcutt et al., 2005) and 
adults (McLoughlin et al., 2010; Skirrow et al., 2015) with ADHD.  Reaction Time Variability (RTV), 
thought to be a measure of attentional lapses, is consistently found to be higher (indicating longer 
and more variable reaction times) in both children (Andreou et al., 2007; Tye et al., 2013; Uebel et 
al., 2010) and adults (McLoughlin et al., 2010; Skirrow et al., 2015)  with ADHD.  Although 
commission errors are thought to be related to impulsivity and omission errors and RTV, 
inattention this relationship is not clear. For example previous studies have failed to find a 
relationship between commission errors and hyperactivity/impulsivity and omission errors and 
inattention (Bédard et al., 2014; Coghill et al., 2007; Kuntsi et al., 2010).  It is therefore important 
that the relationship between these cognitive performance measures and ADHD symptoms be 
examined. 
 
Although RTV has been found to be a relatively robust deficit in adults with ADHD (Kofler et al., 
2013), less well investigated in adults, is the observation that individuals with ADHD show a 
                                                                
5 Where a participant fails to respond when a response is required on a computerised cognitive 
task. 
6 Where a participant responds when a response is not required on a computerised cognitive task. 
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significantly greater reduction in RTV under a rewarded task condition compared to individuals 
without ADHD (Kuntsi et al., 2012). This is in line with the ‘state regulation’ theory of ADHD, which 
proposes cognitive deficits in ADHD to be the result of a reduced energetic state, which in turn can 
be manipulated in the presence of rewards or a faster event rate  (Kuntsi et al., 2012; Sergeant, 
2000) (see also Chapter 1, Section 1.1.10.1). Reward sensitive improvements in MRT and RTV is a 
relatively robust finding in children (Kofler et al., 2013). However there has been limited research 
into reward sensitivity in adults, despite the importance of this finding in terms of implications for 
lifestyle management, in order to improve function (for example it suggests individuals with ADHD 
to work best in fast paced, incentive driven environments).  
 
Along with cognitive impairments the DSM-5 also lists EL as an associated feature of ADHD 
(American Psychiatric Association, 2013) (for a general discussion of EL see Chapter 1, Section 
1.1.3). One characteristic of EL is emotional overreactivity in response to stressful events. In 
children, completion of a ‘frustration task’ (which commonly asks the child to construct a puzzle 
which is missing several critical pieces (Martel, 2009)) has found a greater level of ineffective 
emotion regulation and reduced frustration tolerance in ADHD children compared with controls 
(Martel, 2009; Melnick & Hinshaw, 2000; Scime & Norvilitis, 2006; Walcott & Landau, 2004). For 
example, children with ADHD were found to exhibit more intense emotional expression (such as 
slamming their fist or sighing) (Melnick & Hinshaw, 2000), or were more likely to quit the 
frustration task early (Scime & Norvilitis, 2006).  Evidence for emotional overreactivity in adults 
with ADHD has been found in a recent  ‘real-world’   study (Skirrow et al., 2014). This study used 
experience sampling, in which adults with ADHD and controls were asked to rate their mood in real 
time, multiple times a day, during a typical working week. Emotional over-reactivity (for example in 
anger, frustration and irritability) to perceived ‘bad events’ along with increased instability of 
frustration and irritability were found in ADHD cases compared to controls.  However no study has 
yet investigated whether emotional overreactivity occurs during a frustration task in adults with 
ADHD. Given that this has been commonly found in children, such a study would indicate the 
developmental stability of this trait. 
 
The first line treatment for ADHD is stimulant medication which has been  found to have the 
highest efficacy in treating adults with ADHD (Bolea-Alamañac et al., 2014). However some patients 
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have concerns regarding undesirable side-effects, partial or no response, and questions regarding 
the long-term efficacy and adverse effects (Faraone et al., 2008; Leonard et al., 2004; Sangal et al., 
2006). Patients may therefore look to alternative treatments. Omega-3 polyunsaturated fatty acid 
(n-3 PUFA) supplementation is one of the most studied alternative treatments for ADHD (Bloch & 
Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-Barke et al., 2013).   
 
Results from a meta-analysis and individual studies have found an increased omega 6 to omega 3 
(n-6:n-3) PUFA ratio (Chen et al., 2004; Stevens et al., 1995; Germano et al., 2007; Antalis et al., 
2006) and reduced blood levels of n-3 PUFA, particularly eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) (Hawkey & Nigg, 2014) in children and adults with ADHD compared 
to controls. Deficiencies in n-3 PUFA may lead to inflammation (Gow & Hibbeln, 2014) and 
alterations in serotonin and dopamine (Assisi et al., 2006; Chalon, 2006); mechanisms implicated in 
the pathophysiology of ADHD  (Bolea-Alamañac et al., 2014; Gizer et al., 2009; Strickland, 2014). 
 
Meta-analyses have found a small to moderate effect of n-3 PUFA supplementation in reducing 
ADHD symptoms in children with ADHD (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-
Barke et al., 2013). We recently showed there to be little evidence for any beneficial effect of n-3 
PUFA supplementation on cognition in children with ADHD and related disorders and typically 
developing children and adults (Cooper et al., 2015) (Chapter 2).  We also found suggestive 
evidence for a small effect of n-3 PUFA on reducing EL and oppositional behaviour in children with 
ADHD (R E Cooper et al., 2016) (Chapter 3). As yet no study has investigated the effect of n-3 PUFA 
supplementation in adults with ADHD. 
 
5.2.1 Objectives 
The main aim of this pilot study was first to, investigate cognitive performance deficits (in 
particular reward sensitivity) and symptoms of EL (in particular emotional overreactivity during a 
‘frustration task’) in adults with ADHD, and second to, provide preliminary data as to whether 
supplementation with n-3 PUFA improves cognition, ADHD symptoms and EL in adults with ADHD. 
The following hypotheses were tested: 1) That compared to controls, adults with ADHD would 
show impaired cognitive performance (including reward sensitivity) and increased symptoms of 
ADHD and EL (including emotional overreactivty)  at baseline; 2) That adults with ADHD compared 
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to controls would have reduced plasma and red blood cell levels of n-3 PUFA and a higher n-6:n-3 
PUFA ratio; 3) That supplementation with n-3 PUFA in adults with ADHD would improve cognitive 




ADHD cases: Participants in the clinical trial were 81 adults with ADHD (44 male, 37 female, mean 
age = 33.5 years (10.26), research diagnosis: N=10, clinical diagnosis: N=71), 23 (28.4%) had 
previously been diagnosed with ADHD in childhood while the rest (N=58) were first time diagnoses 
in adulthood. The majority of participants had combined type ADHD (N=73) with only a small 
number with inattentive type (N=8).  
 
Controls: Thirty healthy control participants (16 male, 14 female,), matched roughly in age (mean 
age = 29.51 years (SD = 8.80), t = -1.90 (p = 0.06)) and IQ (t = 0.83 (p = 0.41)) (although there was a 
trend for controls to be slightly younger than the ADHD cases) completed baseline assessments 
(see  Table 5-1) 
 
5.3.2 Design 
In order to test hypothesis three (that supplementation with n-3 PUFA in adults with ADHD will 
improve cognitive performance, ADHD symptoms and EL) a single-centre 6-month double-blind, 
placebo controlled, parallel-group pilot study with balanced randomisation (1:1) was conducted. In 
order for hypotheses one and two to be tested, a sample of 30 typically developing control 
participants undertook the baseline assessments of the trial (see Figure 5-1). For hypothesis one 
case/control comparisons were made for measures of EL, ADHD symptoms and cognitive 
performance.  Measures that showed at least nominally significant (p< .05) case/control differences 
were taken forward as outcome measures in the RCT analysis. For hypothesis two, case/control 
differences in plasma and red blood cell levels of the n-3 PUFAs:  (EPA),  (DHA), docosapentaenoic 
acid (DPA), alpha-linoleic acid (ALA) and the n-6:n-3 PUFA ratio were examined. These PUFAs were 
chosen due to previous research including a meta-analysis, finding case/control differences on 
these measures (reduced EPA, DHA, DPA and ALA and an increased n-6:n-3 ratio)  (Antalis et al., 
2006; Chen et al., 2004; Germano et al., 2007; Hawkey & Nigg, 2014; Stevens et al., 1995) (the study 
design is shown in Figure 5-1). The RCT analysis was presented in accordance with guidance from 
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Figure 5-1: OCEAN study design 








(n = 81 ADHD) 
ADHD (n=81)  
Baseline assessment  
(T1: 4-5 hours) 
Placebo 
(n = 39) 
Active 
(n = 42) 
3 month 
assessment 
(T2: 1.5 hours) 
3 month 
assessment 
(T2: 1.5 hours) 
6 month 
assessment 
(T3: 3-4 hours) 
6 month 
assessment 
(T3: 3-4 hours) 
Controls (n=30) 
Baseline assessment  





5.3.3 Inclusion and exclusion criteria 
See Chapter 4, Section 4.2.2.1. 
 
5.3.4 Study setting, funding and ethical approval 
See Chapter 4, Section 4.2.1.1. 
 
5.3.5 Supplementation 
Participants in the active group were supplemented with Equazen High concentrated (Equazen HC) 
taken as four capsules per day of 279 mg EPA, 87 mg DHA, 30 mg GLA: stable ratio EPA:DHA:GLA 
(9:3:1) which equates to 1,116 mg of EPA, 348mg DHA, and 120mg GLA per day. Participants in the 
placebo group received four capsules each containing 648mg medium chain triglycerides (an inert 
fatty acid). Following completion of the trial, individuals on the placebo were offered a 6-month 
supply of n-3 PUFA supplements. The placebo was matched to the active supplement for taste, 
colour, and size. 
 
5.3.6 Outcomes 
Baseline only measures 
- The MINI 6.0 (Mini International Neuropsychiatric Interview) diagnostic interview 
(Lecrubier et al., 1997): The MINI was used to screen for comorbid disorders.  
- The Weschler Abbreviated Scale of Intelligence – II (WASI-II) (Weschler, 2005): Two 
subtests (vocabulary and matrix reasoning) of the WASI-II were used to measure IQ. 
- Socio-economic status (SES): SES was assessed by collecting information on participants’ 
level of education, occupation and income. 
- Information regarding the participants’ medication and when they were diagnosed with ADHD 
was also collected. 
 
5.3.6.1 Primary outcome  
Sustained Attention to Response Task (SART) (O’Connell et al., 2009; Skirrow et al., 2015): The 
primary outcome was  commission errors on the SART task (a measure of inhibition (Frazier et al., 
2004)). This was considered the primary outcome as inhibitory control deficits are known to be 
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associated with ADHD, and a previous case/control comparison using the SART found adults with 
ADHD to be significantly impaired on this measure compared with controls (Skirrow et al., 2015). 
   
The SART is a computerised go/no go task measuring both response inhibition and sustained 
attention. It consists of nine digits presented in random order on a computer monitor. Participants 
are instructed to withhold responses to the digit 3 (no-go trial) but to respond with a button press 
after all other digits (go trial). Participants completed the SART over three blocks, each lasting 
approximately 5 min. Individual blocks consisted of 225 digits, with each digit presented 25 times. 
Stimuli were presented in five digit sizes (font size 100, 120, 140, 160 and 180 in Arial text), 
subtending approximately 1.7, 2.1, 2.4 and 2.7 respectively in the vertical plane. Digits were 
presented .31 above a central white fixation cross on a grey background for 150 ms, followed by 
an inter-stimulus interval of 1000ms. Measures recorded were as follows: commission errors 
(where the participant responds where a response is not required) and omission errors (where a 
participant fails to respond when a response is required) were added across the three trials. For 
mean reaction time (MRT), reaction time variability (RTV) (as indexed by the standard deviation of 
reaction time) and the coefficient of variation (CV) (RTV/MRT) the average was computed across 
the three trials.  
  
 
5.3.6.2 Secondary outcomes 
ADHD symptoms: 
- Conners’ Adult ADHD Rating Scales (CAARS) (Conners et al., 1999) and Wender-Reimherr 
Adult Attention Deficit Disorder Scale (WRAADS) (Wender, 1995) combined (investigator 
rated): Assessed ADHD symptom severity. Total scores for each category of inattention, 
hyperactivity/impulsivity, and emotional lability were used in the analysis. 
Emotional lability: 
- Rating scales:  The Centre for Neurologic Study Lability Scale (CNS-LS) (Moore et al., 1997) 
and Affective Lability Scale-Short Form (ALS-SF) (Oliver & Simons, 2004) measured emotional 
lability.  Total score from each was used in the analysis. 
- The Computerized Paced Auditory Serial Addition Task (PASAT-C (Lejuez, 2003)): The 
PASAT is a computerised task designed to elicit frustration. Participants are asked to sum 
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numbers sequentially as they appear on a computer screen. The speed of the task increases 
over time and, with each error, negative feedback is provided (a loud noise). In order to control 
for cognitive ability the PASAT utilizes a titration level where participant skill level is measured 
during the first round which then determines the speed for the more difficult rounds.  In the 
second round the task begins and ends with computerised rating scales where the participant 
was asked to rate their levels of frustration and irritability. The numbers are presented the 
fastest in the third round. This round times out at a set time (7 minutes) but participants have 
the option to quit the task at any time. In order to increase frustration levels, the following 
socio-evaluative components were added: 1) the participant was made aware that the task was 
being filmed; 2) an evaluative audience was present during the task (the experimenter) 
although not during ratings of frustration/irritability; 3) A negative social comparison was 
made as participants were informed that scores on this task were recorded and ranked against 
other participants. They were told that if the total number of points earned was greater than 
the average of the other participants they would receive a prize in the post (Dickerson & 
Kemeny, 2004).   All participants received a £2.50 supermarket voucher in the post around 4 
weeks after the testing session.  
 
Cognition: 
- Cued Continuous Performance Test (CPT-OX) with flankers (McLoughlin et al., 2010; Valko 
et al., 2009): The task consisted of 400 black letters, including cue letter ‘O’, target letter ‘X’, and 
distractors ‘H’, ‘B’, ‘C’, ‘D’, ‘E’, ‘F’, ‘G’, ‘J’, and ‘L’. Letters were presented centrally on the 
computer, subtending approximately 0.5°. Letters were flanked on either side by the letters ‘X’ 
or ‘O’, and cue and target letters (O and X) were flanked by the incompatible letter (X and O). 
Participants were instructed to ignore the flanking letters and respond as quickly as possible to 
cue-target sequences (O-X). 80 cues (O) were followed by the target letter (X) in 40 trials (go 
condition), and neutral distractors in the remaining trials (no-go condition). In 40 trials a letter 
X was not preceded by a cue O and had to be ignored. Letters were presented every 1.65s for 
150 ms in pseudo-random order. Ten practice trials preceded the main task. Task duration was 
11 minutes. Omission errors, commission errors, MRT, RTV and CV were recorded. 
 
- The Fast Task (Andreou et al., 2007)  
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The Fast Task is a computerised standard warned four-choice RT task. The baseline (slow-
unrewarded) condition consisted of the following: A warning signal (four empty circles, 
arranged side by side) first appeared on the screen. At the end of the fore-period (presentation 
interval for the warning signal), the circle designated as the target signal for that trial was filled 
(coloured) in. The participant was asked to make a compatible choice by pressing the response 
key that directly corresponded in position to the location of the target stimulus. Following a 
response, the stimuli disappeared from the screen and a fixed inter-trial interval of 2.5s 
followed. Speed and accuracy were emphasized equally. If the participant did not respond 
within 10 seconds, the trial terminated. A practice session was first administered followed by 
the baseline condition, with a fore-period of 8s and consisting of 72 trials.  
 
To investigate the extent to which a response style characterized by slow and variable speed of 
responding can be maximally reduced, the task includes a comparison (reward) condition that 
uses a fast event rate (fore-period of 1s) and incentives. This condition started immediately 
after the baseline condition and consisted of 80 trials and a fixed inter-trial interval of 2.5 s. 
Speed and accuracy were emphasized equally. The participant was told to respond really 
quickly one after another, to win smiley faces and earn a real prize at the end. The participant 
won a smiley face for responding faster than their own MRT during the baseline (first) 
condition consecutively for three trials. The smiley faces appeared below the circles in the 
middle of the screen and were updated continuously. The fast-incentive condition is always 
administered after the baseline condition and, as such, does not involve a similar learning 
phase. Participants earned a £2.50 supermarket voucher after the task battery.  Measures of 
MRT, RTV and CV were obtained from the baseline and reward condition. Change scores were 
calculated as baseline minus the fast-incentive condition. 
 
5.3.6.3 Blood PUFA analysis 
In order to analyse case/control differences and monitor compliance during the trial a trained 
phlebotomist (myself) collected 2 x 10ml blood from controls at time 1 (baseline), and from each of 
the ADHD cases entering the trial at time 1 (baseline), time two (3 months), and time three (6 
months). Blood was collected in lithium heparin vacutainers and taken immediately to the 
laboratory at the SGDP centre. Five mls of whole blood were pippeted into 1ml matrix tubes. The 
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remaining blood was centrifuged at 1500g for 10 minutes. Five mls of plasma were then pippeted 
into 1ml matrix tubes. An equivalent volume of saline (0.85% sodium chloride) was added to the 
remaining red blood cells and the tubes were inverted. The tubes were then centrifuged (1500g) 
for 10 minutes and the supernatant was discarded. This process (saline and centrifugation) was 
then repeated and 4mls of red blood cells were pippeted into 1 ml matrix tubes. The whole blood, 
plasma and red blood cells were then stored at -80°c. The blood fatty acid analysis was conducted 
at the National Institute of Health, Maryland, United States. Blood samples were shipped by courier 
in two batches. The plasma and red blood cells were assayed for total fatty-acid composition 
utilising a high throughput robotic direct methylation coupled with fast gas-liquid chromatography 
(see Lin et al., 2012 for a detailed description of this methodology).  Omega-3 PUFA levels were 
reported in both the plasma and red-blood cells: plasma levels reflect more recent fluctuations 




All participants were sent a letter by post, confirming their agreed appointment time and date. 
Letters included the questionnaire measures (outlined in Section 4.2.4) to be completed and 
brought to appointments. For the time 1 and time 3 assessments participants (ADHD cases) on 
stimulant medication were asked to stop taking their medication for 48 hours before the 
assessment, and they were also asked to refrain from drinking caffeine or smoking on the day of 
each study session, and to refrain from consuming alcohol on the day of the study session or during 
the preceding evening. Instructions to this effect were included in the appointment confirmation 
letter, and were also given by telephone during appointment reminders, which were either one or 
two days before each research appointment.  
 
At the time 1 visit participants (ADHD cases and controls) first underwent the cognitive-
electrophysiological session (which involved completion of the cognitive tasks (data not analysed 
here)). They then completed the IQ test and the WIAT-II (data not analysed here), before taking a 
20 minute lunch break.  After lunch participants completed the PASAT frustration task, the MINI 
and the self-report questionnaires (Section 4.2.4). Finally a blood sample was taken (Section 
5.3.6.3).  At the end of the baseline session the ADHD cases received a 6 month supply of either the 
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placebo or active supplements and received full instructions on how to take them.  At the time 2 
visit participants (ADHD cases) completed the same questionnaires as at baseline and gave a blood 
sample.  At the time 3 visit participants (ADHD cases) completed an identical testing session to the 
time 1 visit although they did not complete the IQ test or the MINI. All participants were 
compensated for travel and received £20 after the time 1 and time 3 testing sessions. 
 
5.3.8 Sample size 
For the case/control comparison with a sample size of 80 cases and 30 controls and with 80% 
power we were able to detect a medium effect at a nominal level of significance (d=0.6, α = 0.05).  
The study was therefore reasonably powered to detect case/control differences for the primary 
outcome, commission errors on the SART which has been estimated to be at medium effect (d=0.7). 
We are also relatively well powered to detect differences in n-3 PUFA blood levels which have been 
generally estimated at medium effect (d=0.4-0.6) (Hawkey & Nigg, 2014). 
 
As our randomised controlled trial was a pilot study, examining feasibility and trends in treatment 
effects, a formal power calculation was not required. However, with a total sample size of 80 
participants and 80% power, we are able to detect a medium effect at a nominal level of 
significance (d=0.6, α = 0.05).     
 
5.3.9 Randomisation 
Randomisation and blinding were carried out by Vifor Pharma. The randomisation list was 
generated using blockwise randomisation with a fixed block size of 10 using the Randlist software 
(RandList®, DatInf GmbH, Tu¨bingen, Germany).  Random number generation was based on the 
algorithm of Park and Miller with a Bays-Durham correction (Park & Miller, 1988). Two different 
randomisation lists were produced for males and females.  Each randomisation list was double-
checked to ensure there were no issues (i.e. size of block, random repetition between different 
arms).  
 
5.3.9.1 Randomisation: allocation concealment mechanism 
The Equazen HC and placebo were in capsule form and were identical in appearance, smell, and 
taste. They were pre-packed in bottles and consecutively numbered in two separate blocks for each 
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male and female according to the randomisation schedule. The capsules were then given out in 
consecutive order as each participant began the trial. The allocation sequence was kept in 
sequentially numbered, opaque, sealed envelopes in a locked drawer in the Social, Genetic and 
Developmental Psychiatry Centre. 
 
5.3.10 Blinding 
Investigators, participants and those assessing outcomes were all blind to treatment allocation. 
Post-intervention, participants were asked whether they believed they had been taking the active 
or placebo supplements and these estimates were used to assess the maintenance of blinding 
(although this process was initiated halfway through the study and therefore only a small number 
of participants (n=31) were asked to guess their group allocation). At the end of each final 
assessment participants were unblinded and were provided with a 6-month supply of active 
supplements if they had been taking the placebo. 
    
5.3.11 Statistical methods 
All analyses were completed in SAS® 9.3 Software (Statistical Analysis Software) and STATA®  
(StataCorp, 2009).  For all analyses a nominal level of significance was set at p < .05. The 
significance level after correction for multiple testing is detailed in each of the below sections. 
 
5.3.11.1 Case/control baseline comparisons 
Comparisons of blood PUFA levels, ADHD symptoms, cognition, and emotional lability were 
conducted using T-tests or Mann-Whitney two sample rank sum tests (if data were non-normal).  
Repeated measure comparisons (for the baseline to incentive condition on the Fast Task and 
pre/post task scores of frustration and irritability on the PASAT) were conducted using either 
paired samples t-tests (normal data) or the Wilcoxon matched-pairs signed-ranks test (non-normal 
data).  Case/control differences in change scores (baseline minus fast incentive condition) were 
then conducted using Mann-Whitney two sample rank sum tests (for non-normal data) to assess 
whether the change was greater in cases or controls (Andreou et al., 2007). Pearson or Spearman 
(for non-normal data) correlations were used to examine the relationship between the cognitive 
task data (omission/commission errors) or frustration task data and ADHD symptoms including EL.  
Normality for baseline comparisons was assessed by conducting the skewness and kurtosis tests 
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for normality (if p< .05 for both skew and kurtosis, data was considered to be non-normal) , 
examination of the value of skew (1 to -1 was considered normal), and inspection of the histogram. 
For blood PUFA levels the significance level was corrected for 12 statistical tests (Bonferroni 
correction set at p < .004). For ADHD symptoms, cognition, and emotional lability the significance 
level was corrected for 31 statistical tests (Bonferroni correction set at p ≤ .002). 
 
5.3.11.2 RCT analysis  
Examination of blood PUFA change:  Changes in blood PUFA levels over the three time points 
during the trial were examined between the placebo and active arms by group (using SAS) and at 
an individual level (using Microsoft Excel). In order to assess group changes the covariance 
structure of the data was examined, and no discernible pattern was found. Therefore treatment 
effects were estimated using a linear marginal model to account for intra-patient correlation in 
repeated measures,  with an unstructured covariance matrix (Kincaid, 2005) (the procedure MIXED 
was used). Linear models are robust to deviations from  normality (Hamer & Simpson, 2000), and 
modelling the covariance structure of repeated measures is considered an effective method to 
handle missing data without the need for multiple imputation (MI) (Gadbury, Coffey, & Allison, 
2003).  A significant group x time interaction indicated a greater PUFA increase in the active over 
the placebo group. Where effects were significant post-hoc comparisons using the least-square 
means (LS-MEANS) were conducted (using the LSMEANS/PDIFF statement). LS-Means are the 
regression adjusted means estimated from the linear model.  Least square means represent a 
statistical average  which have been adjusted for missing data and are therefore more appropriate 
to use for contrasts than the raw means. The significance level was corrected for eight statistical 
tests (Bonferroni correction set at p ≤ 0.006). At an individual level, time 1-time 2, and time 1-time 
3 changes in EPA (the main n-3 PUFA included in the supplements) were assessed. An increase of ≥ 
50% was considered to indicate compliance (Hibbeln, personal communication). 
 
Examination of treatment effects: The Intent-to-treat (ITT) and per-protocol analyses were 
conducted in SAS®.  The ITT analysis included every participant who was randomised to the trial 
(and for whom follow-up data was available), regardless of protocol deviations, including 
compliance (Lewis & Machin, 1993), and was considered the primary analysis. The per-protocol 
analysis included only those patients who adhered to the protocol (Lewis & Machin, 1993).  We 
159 
 
defined this as those who returned for their time 2 (for variables measured at time 1 to time 2) or 
time 3 (for variables measured at time 1 and time 3) assessment and who were considered 
compliant according to their blood PUFA (described above). This was considered the secondary 
analysis. For both the ITT and per-protocol analyses no discernible pattern to the covariance 
structure of the data was found therefore treatment effects were estimated using a linear marginal 
model to account for intra-patient correlation in repeated measures, with an unstructured 
covariance matrix (Kincaid, 2005). A significant group x time interaction indicated the presence of a 
treatment effect. Where effects were significant (for the variables measured at 3 time points), post-
hoc comparisons using LS-MEANS were conducted (as above). Linear models are robust to 
deviations from normality and considered to be an effective method to handle missing data without 
the need for multiple imputation (MI) (Gadbury et al., 2003). Multiple imputation was therefore 
implemented in the ITT analysis as a sensitivity analysis only (Allison, 2012; Twisk, De Boer, De 
Vente, & Heymans, 2013). Multiple imputation was conducted using the PROC MI procedure in SAS 
using an arbitrary simulation (as data was missing in an arbitrary pattern given that drop-out 
occurred at two time-points) with the Fully Conditional Specification (FCS) method (which imputes 
data at baseline and follow-up).  The imputation model included all variables in the outcome 
analyses. Missing data was assumed to be missing at random (MAR).  The significance level was 
corrected for 25 statistical tests (Bonferroni correction set at p ≤ 0.002). 
 
5.3.12  Losses and exclusions 
Blood PUFA analysis: Blood could not be obtained at baseline from four cases and one control, and 
at time 2, from one case.  Technical problems at the PUFA processing stage meant that data was 
missing for one control and two cases at time 1 (one case was missing red blood cells (RBC) only) 
and one case at time 2 (RBC only).   
 
Outcome measures: At baseline: one ADHD case could not tolerate the EEG and failed to complete 
the Fast Task, CPT and SART, eleven cases were excluded from the CPT as extreme omission or 
commission errors (> 3.5 SDs from the mean) indicated they had not understood the task (Skirrow 
et al., 2015), and one case was excluded from the SART due to extreme omission errors (> 3.5 SDs 
from the mean). One case failed to complete the CNS-LS and ALS at baseline.  At time 3 one case was 




5.4 Chapter outline 
The remainder of this Chapter has been sectioned into two;  
 
Part one (results, discussion) - case/control comparisons in order to meet objectives: 
  1) That compared to controls, adults with ADHD would show impaired cognitive performance and 
increased symptoms of ADHD and emotional lability. 
 
2) That adults with ADHD compared to controls would have reduced plasma and red blood cell 
levels of n-3 PUFA and a higher n-6:n-3 PUFA ratio.  
 
Part two (results, discussion) - RCT of n-3 PUFA supplementation in adults with ADHD, in 
order to meet objective:  
 
3) That supplementation with n-3 PUFA in adults with ADHD will improve cognitive performance, 
ADHD symptoms and emotional lability.  
 
5.5 Part One: A case-control comparison of cognitive performance, ADHD symptoms, 
emotional lability and n-3 PUFA blood levels in adults with ADHD compared to 
controls  
 
5.5.1 Results (Part one): Hypothesis 1- Compared to controls, adults with ADHD will have 
impaired cognitive performance and increased symptoms of emotional lability and ADHD   
Table 5-1 details the case/control comparisons. Variables that showed at least a nominally 
significant (at p < .05) case/control difference were taken forward as outcomes for the RCT analysis 
(as stated in Section 5.3.2). There was no significant difference in age (t=-1.90, p=.06) and IQ 
(t=0.83, p=.41) between cases and controls, although there was a trend for participants in the 




5.5.1.1.1 Cognitive outcomes  
SART and the CPT: ADHD cases compared to controls had increased omission (OE) and 
commission (CE) errors on the SART (OE: t =-4.40, p<.0001; CE: t=-4.93, p<.0001) and the CPT (OE: 
z = -2.91, p = 0.004; CE: Z = -3.83 p = 0.0001). Cases had increased RTV and CV on the SART (RTV: z 
= -4.32, p <.0001; CV: z = -4.11, p <.0001) and the CPT (RTV:  z = -2.81, p = 0.01; CV: z = -3.37, p = 
0.0007) compared to controls. All differences withstood correction for multiple testing (p≤.002). No 
differences were found in MRT on the CPT and SART (p> .05) (although there was a trend for ADHD 
cases to have longer reaction times on the CPT (z = -1.74, p = 0.08).   
 
Pearson correlations in ADHD cases and controls (conducted separately) found there to be no 
relationship between commission errors (in the SART and CPT tasks) and symptoms of 
hyperactivity/impulsivity and omission errors (In the SART and CPT tasks) and symptoms of 
inattention (all p > .05) (see Appendix D, Tables AD-1 – AD-2). 
 
Fast task: Cases compared to controls had increased MRTs, RTVs and CVs on the Fast Task in both 
the baseline (MRT: z = -3.71, p = 0.0002; RTV: z=-2.98, CV: p = 0.003; z = -2.21, p=0.03) and fast-
incentive (MRT: z = -2.30, p = 0.02; RTV: z=-2.91, p=0.004; CV: z=-2.58, p = 0.01) conditions.  Only 
the baseline MRT difference withstood correction for multiple testing (p≤.002).  
 
The fast incentive condition led to significantly reduced MRT in both ADHD cases (z=7.60, p < 
.0001) and controls (z=4.78, p < .0001), examination of change score (baseline – fast-incentive) 
showed that the reduction was greater in ADHD cases (z=-2.90, p=0.004). Significantly reduced RTV 
was found in both cases (z=6.77, p < .0001) and controls (z=4.78, p < .0001) with a trend for a 
greater reduction in cases (z=-1.72, p=0.09). Finally, CV reduced equally (p=0.83) in both cases 
(z=5.27, p < .0001) and controls (z=4.33, p < .0001). 
 
5.5.1.1.2 ADHD symptoms and emotional lability  
ADHD Symptoms: Cases had significantly higher symptoms of ADHD (inattention (t=-17.36, 
p<.0001), hyperactivity/impulsivity (t=-12.79 p<.0001) and emotional lability (t=-10.80, p<.0001) 




Emotional lability: Cases had significantly higher levels of emotional lability on the CNS-LS (t=-
8.75, p < .0001) and the ALS (t=-8.84, p< .0001), which withstood correction for multiple testing 
(p≤.002).  
 
PASAT: ADHD cases compared to controls had significantly higher ratings of pre (z=-3.10, p = 
0.002) and post (t=-3.31, p=0.001) task frustration, and pre (z=-3.99, p = 0.0001) and post (t=-3.25, 
p=0.002) task irritability, all of which withstood correction for multiple testing (p≤.002). Cases 
chose to quit the PASAT quicker than controls (z=2.19, p = .03), indicating reduced frustration 
tolerance (at nominal significance).  
 
The PASAT led to significant increases in frustration (f) and irritability (i) in both cases (f: t=13.59, 
p< .0001; i: t=-8.80, p< .0001) and controls (f: t=-7.35, p< .0001; i: t=-5.06, p< .0001)7, which 
withstood correction for multiple testing (p≤.002).  There was a trend for ratings of frustration to 
increase more in cases compared to controls (t=-1.80, p =.08), this trend was much weaker for 
ratings of irritability (t = -1.46, p = 0.15).   
 
Spearman correlations in ADHD cases found there to be a significant positive relationship between 
post-task ratings of irritability (rs = 0.29, p =0.008), frustration (rs =0.45, p < .0001), and EL rated 
with the CAARS/WRAADS. There was also a significant positive relationship between post-task 
frustration and the CNS-LS (rs=0.30, p =0.006). In cases there was no relationship between post-
task irritability and the CNS-LS and ALS or between post-task frustration and the ALS (all p> .05).  
In controls there was no relationship between post-task ratings of irritability and frustration and 
EL measured with the CAARS/WRAADS, the CNS-LS and the ALS (all p>.05) (see Appendix D, Tables 







                                                                
7 for this analysis as the pre-test variables were non-normal and the post-test normal, both parametric and 
non-parametric tests were run with identical ‘p’ values therefore I report the parametric analysis 
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t(p) MW z(p) Cohen’s d 
Age 81 30 33.52 (10.26) 29.51 (8.80) -1.90 (0.06) - - 
IQ 80 30 109.38 (13.68) 111.70 (11.44) 0.83 (0.41) - - 
Cognition        
SART CE  79 30 34.48 (12.80) 21.27 (11.69) -4.93 (<.0001)** - 1.07 
SART OE  79 30 23.09 (27.01) 10.17 (23.05) - -4.40 (<.0001)** 0.5 
SART RTV  79 30 132.86 (62.28) 85.41 (33.22) - -4.32 (<.0001)** 0.86 
SART MRT 79 30 327.40 (52.45) 310.30 (40.33) - -1.36 (0.17) 0.35 
SART CV  79 30 0.41 (0.18) 0.28 (0.13) - -4.11 (<.0001)** 0.78 
CPT CE  68 30 2.94 (2.78) 1.07 (1.36) - -3.83 (0.0001)** 0.77 
CPT OE  68 30 1.87 (2.23) 0.83 (2.44) - -2.91 (0.004)* 0.46 
CPT MRT 68 30 408.93 (65.81) 387.02 (51.47) - -1.74 (0.08) 0.36 
CPT RTV  68 30 139.60 (64.65) 109.40 (78.53) - -2.81 (0.01)* 0.44 
CPT CV  68 30 0.34 (0.14) 0.25 (0.17) - -3.37 (0.0007)** 0.61 
Fast task MRT 80 30 713.15 (246.62) 561.27 (112.96) - -3.71 (0.0002)** 0.7 
Fast task RTV  80 30 206.04 (192.53) 132.11 (88.14) - -2.98 (0.003)** 0.44 
Fast task CV 80 30 0.26 (0.13) 0.22 (0.11) - -2.21 (0.03)* 0.32 
Fast task reward MRT 80 30 514.63 (146.81) 450.76 (69.66) - -2.30 (0.02)* 0.49 
Fast task reward RTV  80 30 111.24 (72.59) 79.29 (45.36) - -2.91 (0.004)* 0.49 











t(p) MW z(p) Cohen’s d 
Fast task change MRTa 80 30 198.52 (176.61) 110.51 (67.80) - -2.90 (0.004)* 0.57 
Fast task change RTVa 80 30 94.80 (172.86) 52.82 (59.17) - -1.72 (0.09) 0.28 
Fast task change CVa 80 30 0.06 (0.12) 0.06 (0.07) - -0.22 (0.83) 0.00 
ADHD Symptoms        
CW Inattention 81 30 27.16(6.13) 6.23 (3.99) -17.36 
(<.0001)** 
- 3.74 
CW Hyp/Imp 81 30 20.09 (5.80) 5.33 (4.08) -12.79 
(<.0001)** 
- 2.76 
CW EL 81 30 17.99 (7.13) 3.33 (3.36) -10.80 <.0001)**  2.33 
Emotional lability        
CNS-LS 80 30 32.75 (16.49) 5.67 (6.12) -8.75 (<.0001)** - 1.89 
ALS 80 30 24.31 (12.09) 4.17 (4.86) -8.84 (< .0001)** - 1.91 
PASAT time to quit  81 30 325.64 (143.47) 378.43 (110.36) - 2.19 (0.03)* 0.39 
PASAT Frustration pre-
task  
81 30 12.64 (18.77) 2.77 (2.80) - -3.10 (0.002)** 0.62 
PASAT Frustration post-
task  
81 30 62.81 (32.53) 40.67 (27.81) -3.31 (0.001)** - 0.71 
PASAT Irritability pre-
task  
81 30 13.80 (20.70) 2.67 (3.77) - -3.99 (0.0001)** 0.63 
PASAT Irritability post-
task  
81 30 48.14 (32.61) 26.70 (25.60) -3.25 (0.002)** - 0.7 
PASAT Frustration 
changeb  
81 30 50.17 (33.24) 37.90 (28.23) -1.80 (0.08) - 0.39 
PASAT Irritability 
changeb  
81 30 34.33 (35.10) 24.03 (26.03) -1.46 (0.15) - 0.32 
Note. CE = Commission errors, OE = Omission errors, a. Change scores calculated as baseline minus fast-incentive  




5.5.2 Hypothesis 2: Adults with ADHD compared to controls will have 
reduced n-3 PUFA and a higher n-6:n-3 PUFA ratio 
Case/control comparisons found no difference in red blood cell (RBC) or plasma 
levels of total n-3 PUFA, EPA, DHA, ALA or n-6:n-3 PUFA ratio (p > .05). ADHD cases 
had significantly higher levels of the n-3 PUFA DPA in RBC's (t=-3.15, p = 0.002) and 




Table 5-2: Blood PUFA comparison between cases and controls 




t(p) MW z(p) Cohen’s d 
Plasma        
Total n-3 HUFA µg/mL 76 28 63.32 (34.27) 52.91 (32.46) -1.39 (0.17) - 0.31 
EPA (20:5n3 µg/ml) 76 28 19.51 (11.68) 16.00 (12.61) - -1.69 (0.09) 0.3 
DHA (22:6n3 µg/ml) 76 28 31.52 (19.39) 27.51 (16.43) -0.97 (0.33) - 0.22 
ALA (18:3n3 µg/ml) 76 28 25.77 (11.84) 24.60 (10.65) -0.46 (0.65) - 0.1 
DPA (22:5n-3 µg/ml)  76 28 12.29 (6.55) 9.39 (6.43) -2.02 (0.05)* - 0.45 
 n-6:  n-3 PUFA 76 28 3.84 (1.41) 4.45 (2.04) - 1.12 (0.26) 0.38 
Red blood cells        
Total n-3 HUFA µg/g 75 28 88.36 (25.08) 79.22 (22.84) -1.69 (0.10) - 0.38 
EPA (20:5n3 µg/g) 75 28 11.19 (4.56) 9.86 (5.52) -1.24 (0.22) - 0.28 
DHA (22:6n3 µg/g) 75 28 47.17 (16.19) 44.47 (12.52) - -0.38 (0.71) 0.18 
ALA (18:3n3 µg/g) 75 28 2.28 (1.02) 2.09 (0.86) -0.89 (0.38) - 0.2 
DPA (22:5n-3 µg/g)  75 28 30.00 (7.28) 24.88 (7.48) -3.15 (0.002)* - 0.7 
 n-6:   n-3 PUFA 75 28 2.65 (0.55) 2.98 (1.09) - 0.76 (0.45) 0.45 




5.6 Discussion (PART A) 
5.6.1 Compared to controls, adults with ADHD will show impaired cognitive performance 
and increased symptoms of ADHD and emotional lability. 
 As expected, adults with ADHD compared to controls had impaired cognitive task performance 
(increased omission and commission errors, RTV, MRT and CV) and significantly higher levels of 
ADHD symptoms and emotional lability.  Given that alongside the core symptoms of inattention and 
hyperactivity/impulsivity, the DSM-5 also lists emotional lability and cognitive impairment as 
associated features of ADHD (that support the diagnosis of ADHD) (American Psychiatric 
Association, 2013), this illustrates that the sample used in this study appear to be representative of 
typical ADHD clinic patients and therefore generalisable to typical ADHD clinical populations. 
 
Adults with ADHD in this sample showed characteristic deficits in cognitive performance compared 
with controls. This was indexed by increased commission errors (the inability to withhold a 
prepotent response) and omission errors (failing to respond when a response is required) on the 
SART and the CPT task, longer mean reaction times (MRT) on the Fast Task, and greater  RTVs and 
greater CVs (RTV controlling for MRT) on the SART, CPT, and the Fast Task.  
 
A number of studies have reported increased commission and omission errors on the same or 
similar tasks in both children (Willcutt et al., 2005) and adults (McLoughlin et al., 2010; Skirrow et 
al., 2015) with ADHD (for reviews see Bolea-Alamañac et al., 2014; Frazier et al., 2004). It has been 
proposed that commission errors  reflect impulsivity, whereas omission errors reflect impaired 
ability in focused and sustained attention (Frazier et al., 2004). However correlations in both cases 
and controls between omission errors and symptoms of inattention and commission errors and 
hyperactivity/impulsivity are non-significant. Therefore the data here does not support this 
proposal. Indeed, previous studies do not find any specific relationship between commission errors 
and hyperactivity-impulsivity, and omission errors and inattention (Bédard et al., 2014; Coghill et 
al., 2007; Kuntsi et al., 2010).  Furthermore, it has been widely assumed that cognitive deficits seen 
in ADHD such as commission errors, omission errors, and RTV have a direct causal role to play in 
the generation of the ADHD symptoms of inattention and hyperactivity/impulsivity (Cheung et al., 
2015). However, many different mechanisms may be responsible for change in cognitive 
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performance and change in behavioural symptoms (Coghill et al., 2007). For example, studies 
investigating the clinical response to methylphenidate have found a dissociation of the treatment 
effects on ADHD symptoms and cognitive performance in children and adolescents with ADHD 
(Bédard et al., 2014; Coghill et al., 2007; K. P. Schulz et al., 2014). 
   
The impairments in RTV, MRT, and CV reported here are commonly found in children (Andreou et 
al., 2007; Tye et al., 2013; Uebel et al., 2010) and adults (McLoughlin et al., 2010; Skirrow et al., 
2015)  with ADHD (for reviews see Frazier et al., 2004; Kofler et al., 2013). This indicates this 
sample to have slower and more variable performance compared to the control group. Increased 
RTV is one of the most investigated and consistent cognitive performance deficits in ADHD research 
(Kofler et al., 2013; Kuntsi & Klein, 2011).  Although slower MRTs are also found in ADHD (Lipszyc 
& Schachar, 2010) these differences are thought to be driven by the influence of RTV (Kofler et al., 
2013).  Increased RTV is thought to represent intraindividual variability in reaction time responses, 
described as an increase in moment-to-moment (within-subject) fluctuations in task performance 
(Tamm et al., 2012).  Increased intraindividual variability in cognitive task performance may be due 
to occasional lapses in attention as a result of ‘poor state regulation’ (Leth-Steensen, Elbaz, & 
Douglas, 2000; Russell et al., 2006; van der Meere, 2002).  The ‘state regulation’ theory of ADHD 
proposes the cognitive deficits in ADHD to be the result of a reduced energetic state. This theory 
further proposes that cognitive performance can be manipulated in the presence of rewards or a 
faster event rate (Kuntsi et al., 2012; Sergeant, 2000). 
 
In line with the ‘state regulation’ theory, introduction of a fast-incentive condition in the Fast Task 
led to significant reductions of RTV, MRT, and CV in both cases and controls, with cases showing a 
significantly greater reduction of MRT and a trend for a greater reduction of RTV. In agreement 
with these findings, several studies in ADHD children have reported a significantly greater 
improvement in MRT and RTV following the introduction of the rewards and or an increased 
presentation rate (Andreou et al., 2007; Cheung et al., under review; Slusarek et al., 2001; Uebel et 
al., 2010). Meta-analysis has estimated a small but significant effect (g=0.3-0.4) of incentives in 
reducing RTV (Kofler et al., 2013), although the Fast Task was designed to maximise these  
improvements by combining rewards with an increase in presentation rate.  In line with our 
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findings, Andreou et al also reported the greatest reductions for MRT but no difference in the 
reduction of CV.  
 
To our knowledge, this is the first time the effects of reward and presentation rate of stimuli has 
been reported in adults with ADHD, suggesting that this is a developmentally stable deficit seen in 
both children and adults with ADHD. This sensitivity to the fast-incentive condition on the Fast 
Task shows the malleability of RTV and MRT, which is thought to reflect alterations in arousal or 
‘state regulation’ and their impact on attentional fluctuations (Banaschewski et al., 2003). In 
accordance with the ‘state regulation’ hypothesis the fast-rewarded condition served to optimise 
our participant’s 'energetic' state (Andreou et al., 2007; Konrad, Gauggel, Manz, & Schöll, 2000). 
Recently, it was reported that while sensitivity to the fast-rewarded condition was seen on the fast 
task in children with ADHD, this was not observed in a sample of children with autism, suggesting 
that this finding may be specific to ADHD (Tye et al., under review). Our results therefore 
emphasise the advantages of incorporating fast-paced activities and incentives into the 
environment of both children and adults with ADHD (Cheung et al., under review.), and suggest that 
this might reflect a developmentally stable deficit with some specificity to ADHD. Further studies 
are needed to rigorously evaluate the causal role of state regulation factors in ADHD across the 
lifespan.    
 
As expected, increased levels of emotional lability including self (CNS-LS, ALS) and investigator-
rated scales (CAARS/WRAADS measure of EL) were seen in the adult ADHD cases compared to 
controls. In addition, frustration and irritability ratings on a computerised mental arithmetic task 
designed to elicit frustration (PASAT-C) showed case-control effects. For the PASAT-C, pre and post 
task ratings of frustration and irritability were significantly higher in ADHD cases compared with 
controls.  The task led to significant (pre to post task) increases in ratings of irritability and 
frustration in both cases and controls, with a trend for greater increases in frustration (and a 
weaker trend for irritability) in the ADHD group. ADHD cases also chose to ‘quit’ the frustration 
task quicker than controls, indicating a reduced ability to tolerate frustration. This suggests that 
along with increased self-ratings of frustration and irritability, adults with ADHD show emotional 
over-reactivity to stressful events under experimental conditions, and a reduced ability to tolerate 




To our knowledge only one previous study has used the PASAT-C in adults with ADHD. Krause-Utz 
et al., (2013) compared pre and post task ratings of self-reported stress in a small sample (n=15) of 
adults with ADHD compared to controls, as well as a sample of adults with Borderline Personality 
Disorder. Significant increases in pre to post-task stress in both ADHD cases and controls were 
found which is somewhat in line with the current results. However given that the current study 
measured ‘frustration’ and ‘irritability’ and Krause-Utz et al., ‘stress’, it is difficult to compare the 
two findings. Furthermore Krause-Utz et al examined neither the change in stress levels nor the 
time taken to quit the task between ADHD cases and controls. Aside from this study to our 
knowledge there is no other research using frustration tasks in adults with ADHD. Therefore the 
current findings of potential difficulties in emotion regulation and reduced frustration tolerance in 
adults with ADHD are novel. 
 
The current results are in line with findings in children with ADHD. A number of studies, which 
have asked ADHD cases and controls to complete a ‘frustrating puzzle’ task, have found children 
with ADHD to exhibit more ineffective emotion regulation and reduced frustration tolerance 
compared with controls  (Martel, 2009; Melnick & Hinshaw, 2000; Scime & Norvilitis, 2006; Walcott 
& Landau, 2004). For example, children with ADHD were found to exhibit more intense emotional 
expression (such as slamming their fist or sighing) (Melnick & Hinshaw, 2000), or were more likely 
to quit the frustration task early (Scime & Norvilitis, 2006). This is in line with the current finding of 
emotional overreactivity/emotion regulation deficits and reduced frustration tolerance in adults 
with ADHD. Therefore the current results provide preliminary evidence for the stability of these 
traits over time. 
 
We also found significant positive correlations in ADHD cases, but not controls, between post-task 
ratings of irritability and frustration and investigator (CAARS/WRAADS) and self-report (CNS-LS) 
ratings of emotional lability (the latter correlated with post-task frustration only).  This suggests 
these objective reactions to the frustration task map onto more subjective behavioural measures. 
This finding relates closely with a previous ‘real-world’ study using experience sampling, in which 
adults with ADHD and controls were asked to rate their mood in real time, multiple times a day, 
during a typical working week (Skirrow et al., 2014). Emotional over-reactivity (for example in 
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anger, frustration and irritability) to perceived ‘bad events’ along with increased instability of 
frustration and irritability were found in ADHD cases compared to controls. Here we have 
replicated these findings under experimental conditions, providing objective evidence for increased 
emotional lability and difficulties in emotion regulation in adults with ADHD. We therefore propose 
that the PASAT-C could be used as an objective test for emotional lability in adults with ADHD. 
 
One limitation to our findings here is that we had over double the number of ADHD cases compared 
with controls. This imbalance may have inflated differences in the cases compared with controls. 
This potential inflation of effect size must be taken into account when interpreting our results.    
 
In conclusion the ADHD participants included in this treatment trial, along with deficits of 
inattention and hyperactivity/impulsivity, showed the expected impairments in emotional lability 
(both self-rated and during an experimental task) and cognitive performance. The ADHD 
participants included in this trial are therefore representative of the general ADHD population as 
defined by the DSM-5, which along with the core symptoms of inattention and 
hyperactivity/impulsivity, also lists EL and cognitive impairment as associated features of ADHD 
that support the diagnosis of ADHD (American Psychiatric Association, 2013). The outcome 
measures which showed these case/control differences were examined as outcomes in the 
treatment trial.  We have further reported two novel findings; the effect of incentives and stimulus 
presentation rate in the Fast Task, and emotional over-reactivity and reduced ability to tolerate 
frustration using an experimental paradigm. These or similar findings have been reported in 
children but not adults before. We therefore show these traits to be developmentally stable and 
persistent.  
 
5.6.2  Adults with ADHD compared to controls will have reduced n-3 PUFA and a higher n-
6:n-3 PUFA ratio 
This study failed to find evidence that adults with ADHD had significantly different baseline levels 
of blood n-3 PUFA (total n-3 PUFA, EPA, DHA, ALA and n-6:n-3 ratio) than controls.  The only 
significant finding was of higher levels of the n-3 PUFA DPA in both the RBCs and plasma (albeit 
nominally significant plasma levels). Therefore adults with ADHD appear to have similar, if not 




This result goes against a recent meta-analysis (Hawkey & Nigg, 2014) and individual studies (Chen 
et al., 2004; Stevens et al., 1995; Germano et al., 2007; Antalis et al., 2006) which have found 
reduced blood levels of n-3 PUFA (particularly EPA and DHA), and an increased n-6:n-3 PUFA ratio,  
in children and adults with ADHD compared to controls.   
 
One explanation for our findings is that there may not be n-3 PUFA differences in adults with ADHD 
compared to controls, at least in this UK population. The meta-analysis which found significant 
differences in n-3 PUFA levels did so across children and adults with ADHD and did not provide 
separate estimates for the two groups (Hawkey & Nigg, 2014).  Due to developmental effects and 
heterogeneity between samples, the analysis could also have been presented separately for 
children and adults (as was carried out in Chapter 2 (Cooper et al., 2015)).  Only three of the studies 
included in this meta-analysis were conducted in adults (Antalis et al., 2006; Laasonen, Hokkanen, 
Leppämäki, Tani, & Erkkilä, 2009b; Young, Maharaj, & Conquer, 2004) with the remaining six in 
children (Chen et al., 2004; Colter, Cutler, & Meckling, 2008; Joshi et al., 2006; Spahis et al., 2008; 
Stevens et al., 1995; Stevens et al., 2003).  Examination of the significance of individual effect sizes 
of the studies conducted in adults showed them to be at trend (p=.06-0.11), whereas three of the 
studies in children were significant (p=.006 -.05).  Given these trend effects of n-3 PUFA differences 
in previous studies of adults with ADHD, and the negative results in this study, it is possible that a 
sub-analysis of studies conducted only in adults (including the current findings) may give an overall 
non-significant effect. Furthermore an increased n-6:n-3 ratio has mainly been found in studies in 
children (e.g. Chen et al., 2004; Stevens et al., 1995; Germano et al., 2007) rather than adults (only 
Antalis et al., 2006 appears to have examined this). Therefore n-3 PUFA differences appear to be 
more likely to be seen in children than adults with ADHD. 
 
The suggestion of n-3 PUFA differences as more apparent in children than adults may question the 
proposed causal relationship between symptoms of ADHD and n-3 PUFA levels. It may be the case 
that due to differences in eating habits, children consume diets that are lower in n-3 PUFA than 
adults, and that this is a separate factor to symptoms of ADHD. However this is not supported by 
meta-analytic data, which has suggested a significant effect of n-3 PUFA supplementation in 
reducing symptoms of ADHD in children (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-
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Barke et al., 2013).  It may be that n-3 PUFA deficiencies are one factor that contributes towards 
ADHD symptom severity in childhood.  Given that some but not all (~60%) of ADHD cases persist 
into adulthood (Faraone et al., 2006), n-3 PUFA deficiency may not be one of the factors that 
contributes to adult ADHD. Another possible explanation that is potentially linked is the recent 
controversial suggestion that in at least some cases adult ADHD may be a different disorder from 
childhood-onset forms of the condition (Moffitt et al., 2015).  These are all potential explanations 
and future work should aim to test these hypotheses.  
 
In further support of the negative case/control differences found in the current sample is the fact 
that this  study has examined n-3 PUFA case/control differences in adults with ADHD in a much 
larger sample (n=76) than has been previously investigated in this population (samples included 
12-36 cases) (Antalis et al., 2006; Laasonen, Hokkanen, Leppämäki, Tani, & Erkkilä, 2009a; Young et 
al., 2004). This should have increased not decreased the chance of finding a significant effect.   
Furthermore, as discussed in Section 5.6.1, we had over double the number of ADHD cases 
compared with controls. Such an imbalance would have been expected to inflate differences rather 
than mask them.  Therefore the finding of a negative effect, despite the larger sample size which 
was weighted towards ADHD cases, increases the reliability of these null results. 
 
An alternative explanation is that our sample was biased towards those with a high n-3 PUFA intake 
at baseline.  Given that this study was an intervention study participants who were motivated to 
take part may have had a prior interest in n-3 PUFA as an ADHD treatment and may have therefore 
had higher levels of omega-3 consumption at baseline. The previous three studies that found a 
trend for reduced n-3 PUFA were cross-sectional studies, which may have been less prone to biased 
samples.  In support of this the only significant finding was that ADHD cases had higher levels of the 
n-3 PUFA DPA. Although we tried to limit the recruitment of a sample who already had high n-3 
PUFA levels (one of the exclusion criteria to the study was consumption of n-3 or n-6 supplements 
in the previous 3 months), we perhaps should have also included limitations on dietary fish 
consumption.  
 
In summary, we did not find evidence for reduced n-3 PUFA in ADHD cases compared to controls.  
Instead we found an indication that adults with ADHD had higher n-3 PUFA than controls. This 
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suggests that deficiencies in n-3 PUFA may be more prevalent in a childhood rather than an adult 
sample, and that n-3 PUFA may not lie on the causal path in adult ADHD. An alternative explanation, 
in light of the slightly higher n-3 PUFA levels, could be that the null results here are a product of 
selection bias, with participants with high n-3 PUFA intake entering the study. In order to clarify 
results, future large cross-sectional case/control comparison studies, and subsequent meta-
analyses need to be conducted.  Longitudinal studies examining n-3 PUFA levels and ADHD 
symptoms from childhood to adulthood will also be required in order to examine any causal models 
of n-3 PUFA and ADHD symptoms.    
 
5.7 Part two: A randomised controlled trial of n-3 PUFA supplementation in adults with 
ADHD 
5.7.1 Results (part two): Hypothesis 3 - Supplementation with n-3 PUFA in adults with 
ADHD will improve ADHD symptoms, emotional lability, and cognition 
5.7.1.1 Participant flow 
Participant flow through the study is shown in Figure 5-2, and detailed reasons for exclusions at the 
screening stage are shown in Figure 4-2 and Appendix C, Table AC-4. Of the 1616 participants 
assessed for eligibility 1272 were excluded due to: not meeting inclusion criteria (n=877), did not 
respond to invitation to participate (n=356), not enough information to contact or screen (n=86), 
recruited then declined (n=14), declined to participate (n=163) or other reasons (n=39) (most 
commonly due to potential participants having been already recruited to other research projects or 
undergoing another treatment such as cognitive behavioural therapy (CBT) (n=14). 
 
We randomised 81 participants (42 = active, 39 = placebo) into the trial. By the second follow-up (3 
months), eleven participants had dropped-out of the active group, and two had dropped out of the 
placebo group. For the active group we lost contact with 4 participants, 3 cancelled multiple times 
before losing contact, one could not tolerate the EEG session and did not wish to return, one did not 
take the supplements, and 2 experienced personal difficulties. For the placebo group we lost 
contact with 1, and 1 cancelled multiple times before failing to return. Therefore 31 participants in 
the active and 37 in the placebo groups completed time 2 assessments. There was a significantly 




Before the time 3 (6 month) follow-up, 5 participants had dropped out of the active group and 8 
participants in the placebo group. For the active group we lost contact with one participant due to 
their number being disconnected, 2 had personal difficulties, 1 experienced migraines attributed to 
the supplements, 1 could not tolerate being medication free for 48 hours before the testing session 
and declined to return. For the placebo group, we lost contact with 5 participants: 1 left the country, 
the number was disconnected for 1 participant, and 1 cancelled multiple times before failing to 
return for their assessment. Therefore 26 participants in the active and 29 in the placebo 
completed the final (time 3) assessment.   There was no significant difference in drop-outs between 
the placebo and active groups from time 2 to time 3. There was no significant difference in the 
overall number of drop-outs between the placebo (n=10) and active group (n=16) and no 
difference in ADHD symptom severity between drop-outs and non-drop-outs (see Appendix D, 
Table AD-5 – AD-6).  Drop-outs were therefore assumed to be missing at random (MAR). 
        
5.7.1.2 Numbers analysed 
In the blood PUFA analysis numbers analysed were as follows: at baseline for plasma 76 cases and 
for RBC 75 cases, at time 2, 67 cases for plasma and 65 for RBC and at time 3, 55 cases for both 
plasma and RBC’s.  
 
For the primary outcome (commission errors on the SART) the ITT analysis included 26 
participants in the active group and 29 in the placebo group. The per-protocol analysis (excluding 
nine participants from the active group whose blood PUFA levels were indicative of non-
compliance) included 17 participants in the active group and 29 in the placebo group. 
 
5.7.1.3 Recruitment 
Participants were recruited between June 2012 and March 2014 and testing sessions ran from 
October 2012 to November 2014. Participants attended testing sessions at baseline, time 2 (3 










Figure 5-2: CONSORT flow diagram for the OCEAN study 
Note. T2 = time 2, T3 = time 3 
Allocation 
Assessed for eligibility  
(n= 1616) 
Excluded (n=916) 
 Not meeting inclusion 
criteria (n=877) 
 Other reasons (n=39) (e.g. 
part of other 
research/treatment (n=14) 
Lost to follow-up (n=8) 
 Lost contact (n=5) 
 Left the country (n=1) 
 Number disconnected (n=1) 
 Multiple cancellations (n=1) 
Discontinued intervention (n=0) 
 
Lost to follow-up (n=2) 
 Lost contact (n=1), multiple 
cancellations (n=1) 
Discontinued intervention (n=0) 
Allocated to placebo intervention (n=39) 
 Received allocated intervention (n=39) 
 Did not receive allocated intervention 
(n= 0 ) 
Lost to follow-up (n=7) 
 Lost contact (n=4), multiple 
cancellations (n=3) 
Discontinued intervention (n=4) 
 Could not tolerate EEG (n=1) 
 Did not take supplements (n=1) 
 Personal difficulties (n=2) 
 
Allocated to active intervention (n=42) 
 Received allocated intervention 
(n=42) 
 Did not receive allocated (n= 0) 
Lost to follow-up (give reasons) (n=1) 
 Number disconnected (n=1) 
Discontinued intervention (n=4) 
 Personal difficulties (n=2) 
 Migraines (n=1) 
 Could not tolerate being 






Did not respond (n=356) 
Not enough information to 
contact/screen (n=86) 
Recruited then declined (n=14)  





 Excluded from analysis (n=0) 
Analysed (n=26) 





 Excluded from analysis (n=0) 
Analysed (n=31) 




5.7.1.4 Baseline data 
The baseline demographics for the placebo and active groups are shown in Table 5-3. There were 
no significant differences between the groups on age, sex, IQ, medication status 
(medicated/unmedicated), income, employment status, education level, or presence of comorbid 
mental health conditions.  Table 5-4 shows baseline comparisons for all primary and secondary 
outcome measures. The active group had a significantly higher RTV and CV on the baseline level of 
the fast task than the placebo group (p < .05) (this is potentially a chance finding, given the large 
number of statistical tests that were conducted, and was only nominally significant).  No differences 
were found in any of the other baseline measures (p > .05). 
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Table 5-3: Baseline demographics 
 N A/P Active  Placebo t(p) MW z(p) X2 (p) 
Age (years, months) (M(SD)) 42/39 33.97 (9.68) 33.04 (10.96) -0.40 (0.69) - - 
Sex (female/male)(n) 42/39 19/23 18/21 - - 0.01 (0.93) 
IQ (M(SD)) 41/39 110.56(13.21) 108.13(14.22) -0.79(0.43) - - 
Medication statusa 
(medicated/unmedicated) (n) 
42/39 28/14 27/12 - - 0.06(0.81) 







Employed (n) 42/39 27 22 - - 0.52(0.47) 
Unemployed (n) 42/39 8 11 - - 0.94(0.33) 
Full-time student (n) 42/39 7 6 - - 0.02(0.88) 
Highest level of education 42/39      
GCSE/Vocational 42/39 12 12 - - 0.05(0.83) 
AS-Level/A-Level 42/39 12 11 - - 0.001(0.97) 
Degree 
(undergraduate/postgraduate) 
42/39 18 16 - - 0.03(0.87) 
1 or more comorbid condition 
(MINI)b 
42/39 33 26 - - 1.45(0.23) 
Note. MW = Mann-whitney two sample rank-sum test, N A/P = Number of participants in active/placebo group. 
a. A breakdown of medication status is available in Appendix D, Table AD-7. 




Table 5-4: Baseline outcome measure comparison between the placebo and active groups in 
measures that showed a case/control difference.  




t(p) MW z(p) 
Primary outcome      
SART RTV  40/39 129.24 (62.72) 136.58 (62.42) - 0.47 (0.64) 
Secondary outcomes      
Cognition      
SART CE  40/39 34.73 (12.84) 34.23 (12.92) -0.17 (0.87) - 
SART OE  40/39 20.88 (20.02) 25.36 (32.80) - 0.005 
(0.996) 
SART CV  40/39 0.40 (0.19) 0.41 (0.16) - 0.46 (0.65) 
CPT CE  36/35 3.11 (3.40) 4.11 (4.87) - 0.38 (0.71) 
CPT OE  36/35 1.81 (2.30) 2.09 (2.16) 0.53 (0.60) - 
CPT RTV  36/35 137.36 (59.25) 142.36 (67.96) - 0.23 (0.82) 
CPT CV  36/35 0.34 (0.13) 0.35 (0.14) 0.32 (0.75) - 




- -1.58 (0.11) 






Fast task CV 41/39 0.29 (0.15) 0.24 (0.10) - -2.26 
(0.02) 




- 0.33 (0.74) 
Fast task reward RTV 41/39 112.04 (78.52) 110.40 (66.81) - -0.05 (0.96) 
Fast task reward CV 41/39 0.20 (0.07) 0.20 (0.08) - -0.01 (0.99) 




- -1.78 (0.08) 
ADHD Symptoms      
CW Innattention 42/39 27.10 (6.79) 27.23(5.42) 0.10 (0.92) - 
CW Hyp/Imp 42/39 20.17 (5.45) 20.00(6.22) -0.13 (0.90) - 
CW EL 42/39 17.79 (7.20) 18.21 (7.15) 0.26(0.79) - 
Emotional lability      
CNS-LS  41/39 32.37 (16.74) 33.15 (16.42) 0.21 (0.83) - 
ALS 41/39 24.51 (11.24) 24.10 (13.07) -0.15 (0.88) - 




- -0.54 (0.59) 
PASAT Frustration pre-task  42/39 10.93 (17.18) 14.49 (20.40) - 1.25 (0.21) 
PASAT Frustration post-task  42/39 63.05 (32.02) 62.56 (33.49) -0.07 (0.95) - 
PASAT Irritability pre-task  42/39 13.17 (21.61) 14.49 (19.93) - 1.31 (0.19) 
PASAT Irritability post-task  42/39 47.02 (33.11) 49.33 (32.46) 0.32 (0.75) - 
Note.  N A/P = Number of participants in active/placebo group, OE = Omission errors, CE = 
Comission errors. 








5.7.1.5 Blood PUFA changes 
Changes in Blood PUFA levels over the three time points are shown in Table 5-5.  At baseline there 
was no difference between the placebo and active group in any of the n-3 (EPA and DHA), or n-6 
PUFAs (GLA), or in the n-6:n-3 PUFA ratio (all at p > .05), in either the plasma or red-blood cells.  In 
plasma a significant increase in the active over placebo group was found for EPA (p< .001). Post-hoc 
analysis showed the active compared to placebo group to have significantly higher levels of plasma 
EPA at time 2 (t=-5.69, p=<.0001) and time 3 (z=-4.03, p=0.0001).  Examination of change over time 
showed there to be no change in the placebo group (p > .05) but a significant increase in the active 
group from time 1 to time 2 (t = -7.61, p < .0001), and time 1 to time 3 (t=-5.20, p = < .0001), with a 
decrease from time 2 to time 3 (t=2.46, p = 0.02). A significant decrease in the total n-6:n-3 ratio 
was found in the active compared with placebo group (p< .001). Post-hoc analysis showed the 
active group to have a significantly lower ratio at time 2 (t=7.35, p < .0001) and time 3 (t=4.34, 
p=0.0001). Examination of the change showed there to be no change in the n-6:n-3 ratio in the 
placebo group but a significant reduction in the active group from time 1 to time 2 (t=7.87, p< 
.0001) and time 1 to time 3 (t = 5.12, p < .0001), with a slight increase from time 2 to time 3 (t=-
2.76, p =0.007). 
 
For the red blood cells, a significant increase in the active over the placebo group was found for EPA 
(p < .0001). Post-hoc analysis showed the active compared to placebo group to have significantly 
higher levels of EPA at time 2 (z=-5.71, p < .0001), and time 3 (z=-4.38, p < .0001). Examination of 
change showed a significant reduction of EPA in the placebo group from time 1 to time 3 (t=1.95, p 
= 0.05) but no change between the other time points.  For the active group there was a significant 
increase in EPA from time 1 to time 2 (t=-9.14, p < .0001) and time 1 to time 3 (t=-6.33, p < .0001), 
with a slight reduction from time 2 to time 3 (t=3.70, p =0.0004). A significant decrease in the n-6:n-
3 ratio was found in the active over the placebo group (p < .001). Post-hoc analysis showed the 
active group to have a significantly lower ratio at time 2 (t=7.25, p < .0001) and time 3 (t=4.90, p< 
.0001). Examination of the change showed there to be no change in the n-6:n-3 ratio in the placebo 
group (p > .05) but a significant reduction in the active group from time 1 to time 2 (t=10.59, p< 
.0001) and time 1 to time 3 (t = 8.27, p < .0001) with a slight increase from time 2 to time 3 (t=-
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2.27, p =0.03). In both the plasma and RBCs there was no significant change in GLA or DHA (see 
Table 5-5).   
 
Examination of individual change for blood levels of EPA found 2 participants in the active group 
who had < 50% increase from time 1 to time 2, and 1 participant in the placebo who had > 50% 
increase from time 1 to time 2.  These participants were removed from the per-protocol analysis 
(for outcomes that were measured at time 1- time 2). For time 1 to time 3, 9 participants in the 
active group had < 50% increase indicative of non-compliance. These participants were removed 






















Table 5-5: Blood PUFA comparison by placebo and active group by the three time-points   
 Time 1 
M(SD) 
 Time 2  
M(SD) 
 Time 3 
M(SD) 






































































0.79b 0.20 0.89 0.69 -0.48 to 2.26 
n-6d: 
n-3e 





















































































 < .0001a < .001** -0.23 0.05 -0.33 to -0.13 
c = Comprised of EPA, DHA and DPA, d = Comprised of DGLA, AA, Adrenic acid and docosapentaenoic acid, e = n6 hufa µg per ml/n3 hufa µg per ml, f = n6 hufa µg per 
g/n3 hufa µg per g, * Significant at nominal level (p ≤ .05), ** Significant after correction for multiple testing (p ≤ .006) , MW – Mann-Whitney two sample rank sum test, 
time 1 = baseline, time 2 = 3 months, time 3=6 months  
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5.7.1.6 ITT analysis 
The ITT analysis is shown in Table 5-6. There were no significant treatment effects on either the 
primary or secondary outcomes (all p>.05). 
 
5.7.1.7 Sensitivity analysis 
The ITT analysis after multiple imputation is in Appendix D, Table AD-9. Outcomes did not differ 
from the primary ITT analysis, with no significant treatment effects on either the primary or 
secondary outcomes (all p>.05). 
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Table 5-6: Intent to treat analysis 



















Est SE Est  
95% CI 
p  d 
Primary outcome 














Cognition               








26/29 2.87 2.60 -2.30 to 
8.05 
0.27 0.31 








26/29 -50.75 49.11 -148.55 to 
47.05 
0.30 0.28 








26/29 -0.11 0.12 -0.36 to 
0.13 
0.36 0.26 











-0.37 0.46 -1.30 to 
0.55 
0.42 0.22 








25/29 0.25 0.41 -0.57 to 
1.07 
0.54 0.17 









25/29 13.10 11.70 -10.20 to 
36.40 
0.27 0.31 









25/29 0.03 0.03 -0.03 to 
0.08 
0.33 0.27 









26/28 7.54 27.93 -48.05 to 
63.14 
0.79 0.07 

































Est SE Est  
95% CI 
p  d 








26/28 0.01 0.02 -0.03 to  
0.04 
0.75 0.09 












26/28 3.97 12.16 -20.25 to 
28.19 
0.75 0.09 










26/28 12.04 15.66 -19.13 to 
43.22 
0.44 0.21 










26/28 0.01 0.02 -0.02 to  
0.05 
0.47 0.2 


























25/29 -0.93 0.80 -2.53 to 
0.67 
0.25 0.32 













25/29 -0.43 0.63 -1.68 to 
0.82 
0.49 0.19 












25/29 -0.03 0.63 -1.29 to 
1.22 
0.96 0.01 
Emotional lability            











































-1.61 1.14 -3.87 to 
0.66 
0.16 0.39 
















































Est SE Est  
95% CI 








































26/29 -2.81 3.79 -10.36 to 
4.74 
0.46 0.2 
Note. OE = Omission errors, CE = Commission errors, MRT = Mean Reaction Time, RTV = Reaction Time Variability, CV = Coefficient of Variation (RTV/MRT), 




5.7.1.8 Per-protocol analysis 
The per-protocol analysis is shown in Table 5-7. The primary outcome showed no evidence of a 
treatment effect. For the secondary outcomes, there was a treatment effect at a nominal level on 
symptoms of inattention (p =0.04, d = 0.68).  There was a trend for a reduction in emotional lability 
measured with the ALS (p=0.06, d=0.59), and also trends for reductions in pre-task frustration (p = 
0.09, d=0.55), and post-task irritability (p=.09, d=0.57) in the active group compared to the placebo 
group. There was also indication of a treatment effect on pre-task irritability, mainly due to an 
increase in this rating in the placebo group at follow-up (p=0.10, d=0.52). Post-hoc analysis for the 
treatment effect on inattention showed in both the active and placebo group there was a significant 
reduction in symptoms of inattention from time 1 to time 2 and from time 1 to time 3. There was an 
indication for a reduction in the active (p =0.15) but not placebo group (p = 0.63) between time 2 
and time 3 which will have led to the significant time x group interaction. This effect will have 
become non-significant in the post-hoc analysis due to the reduction in power when examining 













Table 5-7: Per-protocol analysis (for variables measured at T1-T3: participants with > 50% PUFA T1-T3 increase; for variables measured at T1, T2 and T3: 
participants with > 50% PUFA increase T1-T2 and T1-T3).  



















Est SE Est 
95% CI 
p  d 
Primary outcome               




17/29 - - - 35.35 (12.15) 34.66 
(14.09) 
17/29 -1.76 1.35 -4.48 to 
0.95 
0.20 0.41 
Secondary outcomes           
Cognition               




17/29 - - - 19.88 (14.18) 18.52 
(20.81) 
17/29 1.95 3.45 -5.00 to 
8.89 
0.58 0.17 

















17/29 - - - 0.71 (0.62) 1.01 (1.00) 17/29 -0.18 0.14 -0.46 to 
0.10 
0.20 0.41 




16/23 - - - 2.13 (2.66) 2.72 (3.09) 16/29 -0.57 0.64 -1.86 to 
0.71 
0.37 0.29 




16/23 - - - 2.81 (4.68) 1.69 (2.14) 16/29 0.38 0.50 -0.63 to 
1.38 
0.45 0.24 
















16/23 - - - 0.40 (0.26) 0.30 (0.13) 16/29 0.03 0.03 -0.04 to 
0.10 
0.33 0.31 








17/28 27.23 27.24 -27.67 
to 82.12 
0.32 0.31 















Fast task CV 0.29 0.24 17/29    0.28 (0.21) 0.22 (0.10) 17/28 0.01 0.02  -0.03 to 0.78 0.09 
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Est SE Est 
95% CI 





   0.04 
 










17/28 -1.81 14.34 -30.71 
to 27.10 
0.90 0.04 























17/29 - - - 0.21 (0.21) 0.18 (0.08) 17/28 0.02 0.02 -0.03 to  
0.06 
0.42 0.26 










17/28 29.13 18.52 -8.20 to  
66.46 
0.12 0.49 
ADHD Symptoms               








29/36 22.06 (8.66) 24.55 
(6.54) 
16/29 -1.65 0.78 -3.20 to 
-0.09 
0.04 0.68 








29/36 15.50 (6.03) 17.48 
(5.68) 
16/29 -0.63 0.62 -1.86 to 
0.60 
0.31 0.32 








29/36 13.63 (5.71) 14.59 
(6.34) 
16/29 -1.03 0.63 -2.30 to 
0.23  
0.11 0.52 
Emotional lability               








29/36 26.06 (10.98) 29.00 
(16.70) 











29/36 18.82 (10.10) 22.24 
(13.06) 
17/29 -2.27 1.20 -4.67 to 
0.12 
0.06 0.59 

















17/29 - - - 2.59 (2.50) 12.55 
(16.69) 









17/29 - - - 47.41 (30.11) 55.31 
(26.19) 
17/29 -1.80 4.58 -11.03 








17/29 - - - 6.35 (11.71) 17.76 
(21.65) 
























Est SE Est 
95% CI 







17/29 - - - 32.71 (30.57) 45.69 
(29.49) 
17/29 -7.52 4.16 -15.91 
to 0.86 
0.08 0.57 
Note. OE = Omission errors, CE = Commission errors, MRT = Mean Reaction Time, RTV = Reaction Time Variability, CV = Coefficient of Variation (RTV/MRT), 
CW = CAARS/WRAADS, time 1 = baseline, time 2 = 3 months, time 3=6 months. 




Midway through the study we asked participants to guess whether they thought they were taking 
the active or placebo medication. Blinding appeared to have been successful in the 12 participants 
asked in the active group, with 6 correct guesses, 5 incorrect guesses and 1 participant who did not 
know. In the 19 participants asked in the placebo group, 13 guessed correctly, 3 incorrectly and 3 
did not know, there was no difference in the number of correct and incorrect guesses between the 
placebo and active group (x2 = 2.23, p = 0.14). 
 
5.7.1.10 Adverse events 
An equal number (n=3 in each) of minor adverse events occurred in both the active and placebo 
group. In the active group one participant reported migraines and dropped out of the study, one 
participant said the supplements caused bloating, and one participant reported a 'gag' reflex when 
swallowing the capsules. 
 
In the placebo group one participant reported weight gain, one participant said the supplements 
made them feel sick, and one participant reported feeling very anxious and unsettled after starting 
the trial, which may have been due to the supplements or to coming off ADHD medication for 48 
hours before entering the study. 
 
 
5.7.2 Discussion: Supplementation with n-3 PUFA in adults with ADHD will improve ADHD 
symptoms, emotional lability and cognition 
This is, to our knowledge, the first randomised controlled trial of n-3 PUFA supplementation in 
adults with ADHD. We failed to find a significant treatment effect for our primary outcome, 
commission errors on the SART task.  
 
For the secondary analyses examining changes in cognition (measured with the SART, CPT 
(commission (CPT only)/omission errors, RTV and CV) and the Fast Task (in the baseline and fast-
incentive condition (MRT and RTV)), ADHD symptoms, and emotional lability (measured with self-
rating scales and a frustration task (the PASAT)), we failed to find any treatment effects in the ITT 
analysis.  The per-protocol analysis gave an indication that supplementation may have improved 
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symptoms of inattention at a moderate effect (d=0.68), albeit this was nominally significant. There 
was also an indication of a trend for supplementation to have reduced emotional lability, again at a 
moderate effect (d=~0.5) (measured with the ALS) and ratings of irritability and frustration on the 
PASAT with a trend for reductions in pre-task frustration and post-task irritability (d=~0.6). There 
was also an indication of a treatment effect on pre-task irritability (d=~0.5). The supplements were 
well tolerated with equal numbers (3) of mild adverse events reported in the placebo and active 
groups. 
 
We failed to find a treatment effect of n-3 PUFA supplementation on our primary outcome, 
cognition, measured by performance on the SART task. We also failed to find treatment effects for 
our secondary cognitive performance outcomes (measured as performance on the CPT and the Fast 
Task). For all three variables neither the ITT nor per-protocol analysis showed any significant 
treatment effects. This finding is in line with our recent research where we conducted a meta-
analysis examining the effect of n-3 PUFA supplementation on cognition in children with ADHD or 
who had a related-neurodevelopmental disorder and typically developing children and adults (see 
Chapter 2 (Cooper et al., 2015)). We failed to find evidence of a treatment effect across nine 
cognitive domains (which encompassed the outcomes employed in this study: inhibition 
(commission errors), attention (omission errors), MRT and RTV) in either the ADHD or the TD 
group. A treatment effect was found in the secondary analysis for only one of the domains (short-
term memory) only in those with low n-3 PUFA status (across the TD and ADHD group).  This meta-
analysis did not include studies in adults with ADHD, and, to our knowledge, this is the first study to 
investigate n-3 PUFA supplementation in this population.  Therefore conclusions regarding the lack 
of effect of n-3 PUFA on cognition were limited only to children with ADHD. The results here 
provide preliminary evidence to suggest the conclusions from our meta-analysis may also apply to 
adults with ADHD.   
 
The per-protocol but not the ITT analysis indicated that supplementation may improve ADHD 
symptoms of inattention.  Given this was found in only the per-protocol analysis and similar 
reductions in hyperactivity/impulsivity were not found it is possible that this is a chance finding. 
Despite this, an indication of improvement (in the per-protocol but not ITT) was found for 
emotional lability on one of the self-rating scales (the ALS), and also a trend for reductions in pre-
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task frustration, and pre-and post-task irritability. Indications of improvement in two domains 
strengthen the possibility that these may be indications of real treatment effects.  Although this 
cannot be deemed as sufficient evidence given that this study was underpowered to detect the 
small to moderate effects of n-3 PUFA supplementation on ADHD symptoms which have been 
predicted by prior meta-analyses (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-Barke et 
al., 2013) (see limitations section for discussion of this).  Despite this, these preliminary results of 
potential effects are in line with previous research (Bloch & Qawasmi, 2011; Cooper et al., 2016; 
Hawkey & Nigg, 2014; Sonuga-Barke et al., 2013) and indicate that further studies are warranted 
with either emotional lability or inattention as the primary outcome. 
 
Differences in results between the per-protocol and ITT analyses are not uncommon. The per-
protocol analysis includes only participants who strictly adhered to the protocol and therefore best 
reflects the optimum effects of n-3 PUFA supplementation. Whereas the ITT analysis includes all 
cases and is thought to best reflect practice in the real-world, where some but not all people will be 
treatment adherent.  The ITT analysis is thought to be less prone to bias, whereas the per-protocol 
analysis may be more prone to bias towards a treatment effect. For example, due to selection bias, if 
withdrawal is due to adverse effects or non-response, this will not be included in the treatment 
estimate therefore inflating the effect size. Drop-outs in this study were considered to be missing at 
random (MAR) (this is further discussed in the limitations section), and so we therefore expect 
treatment effect estimates from both the ITT and per-protocol analysis to be relatively free from 
bias, with the per-protocol analysis reflecting the optimum effects of supplementation. However the 
null effects found in the ITT analysis weaken the indication of the potential treatment effects found 
in the per-protocol analysis.   
 
The potential finding of a treatment effect of n-3 PUFA on inattention and potentially EL  is further 
supported, given that previous research, including a study conducted by ourselves (R E Cooper et 
al., 2016), has suggested that n-3 PUFA supplementation could help improve symptoms of ADHD 
and potentially EL. Meta-analyses using data from randomised placebo-controlled trials have 
relatively consistently found a small but significant effect of n-3 PUFA supplementation in reducing 
ADHD symptoms in children with ADHD (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-
Barke et al., 2013). We recently conducted a meta-analysis that provided suggestive evidence of 
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small effects of n-3 PUFA on reducing EL and oppositional behaviour in subgroups of children with 
ADHD (Chapter 3: (R E Cooper et al., 2016). 
  
One potential explanation for the null effect of n-3 PUFA supplementation on cognition, and only 
potential indications for effects on ADHD symptoms and to a lesser extent emotional lability is that 
levels of n-3 PUFA and the n-6:n-3 PUFA ratio were similar in ADHD cases compared to controls, 
with ADHD cases even having slightly higher n-3 levels.  Given results from our recent meta-
analysis which found a treatment effect on short-term memory in those who were n-3 PUFA 
deficient. The seemingly 'typical' levels of n-3 PUFA at baseline in the ADHD sample may have 
rendered any effect of supplementation as relatively null.  
 
The predominately negative results for the effect on cognition, and more suggestive evidence for an 
effect on the behavioural domains of inattention and, potentially, emotional lability, is in line with 
the suggestion that ADHD treatment may be more effective for the behavioural symptoms (such as 
inattention and emotional lability) than cognitive performance measures (Coghill et al., 2014). For 
example, smaller treatment effects for stimulant medication have been found for cognitive 
performance (d=~0.2-0.6) (Coghill et al., 2014) than for ADHD symptoms (d=~0.8-1.0) 
(Banaschewski et al., 2006; Faraone & Buitelaar, 2010). This is also illustrated by the findings from 
this trial and meta-analyses with a generally null effect of n-3 PUFA on cognition (Cooper et al., 
2015), but suggestive evidence for an effect on emotional lability (R E Cooper et al., 2016) and 
established evidence for an effect on ADHD symptoms in children (Bloch & Qawasmi, 2011; 
Hawkey & Nigg, 2014; Sonuga-Barke et al., 2013). It has also been suggested that different neural 
mechanisms may be responsible for change in cognitive performance and change in behavioural 
symptoms (Coghill et al., 2007); following the observation that during the clinical response to 
methylphenidate there is a dissociation of the treatment effects on ADHD symptoms and cognitive 
performance in children and adolescents with ADHD (Bédard et al., 2014; Coghill et al., 2007; K. P. 
Schulz et al., 2014). 
 
Potential effects of n-3 PUFA on the behavioural symptoms of ADHD may be due to reduced 
inflammation and alterations in neurotransmission; mechanisms implicated in the pathophysiology 
of ADHD. Through production of eicosanoids (lipid mediators that are involved in a wide array of 
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physiological functions including inflammation) (Janssen & Kiliaan, 2014; Schmitz & Ecker, 2008; 
Simopoulos, 2011), n-3 PUFAs may limit neuroinflammation whereas n-6 PUFAs may promote 
inflammation (Gow & Hibbeln, 2014; Sinn, Milte, & Howe, 2010; Janssen & Kiliaan, 2014; 
Simopoulos, 2002). Alongside ADHD, inflammation has been linked to a number of other mental 
health problems including depression, schizophrenia and bipolar disorder (Dean, 2011; Raison & 
Miller, 2013; Strickland, 2014). Through altered cellular communication, n-3 PUFA deficiencies  
may lead to altered neurotransmission particularly for dopamine and serotonin (Assisi et al., 2006; 
Chalon, 2006; Haag, 2003; Young & Conquer, 2005). Disrupted dopamine signalling is a well-
established theory of ADHD (see Section 1.1.9.4) with serotonergic genes having also been 
associated with the disorder (Faraone et al., 2005; Gizer et al., 2009).  
 
There are several important limitations to be considered before conclusions can be drawn. This 
study was limited by a high drop-out rate, with a total drop-out of 16% by time 2 and 32% by time 
3. This high drop-out rate will have considerably reduced power in the analysis.  Although more 
drop-outs occurred in the active than placebo group (16 vs 10) this difference was not statistically 
significant and reasons for drop-out appeared to be similar across both groups. Furthermore, ADHD 
symptom severity did not differ between drop-outs and non-drop-outs, providing some evidence to 
suggest that those who remained in the trial were no less severe in their symptoms than those who 
dropped-out. We therefore considered data to be missing at random (MAR), and used a linear 
model to assess outcomes. Linear models are said to reliably yield unbiased estimates of treatment 
effect (Bell, Kenward, Fairclough, & Horton, 2013; Molenberghs et al., 2004). Therefore we feel that 
despite the high drop-out rate, the results presented here may be relatively free from bias.  
 
The main reason for drop-outs was due to loss of contact. This is a problem that could be 
considered inherent to the disorganised nature of the ADHD condition. Appointment cancellations 
and no-shows were a common part of the study, increasing the difficulty of the research process. It 
is estimated that around 30-40% of participants cancelled or re-arranged their appointments, often 
at short notice. For some of these participants, multiple cancellations were made before we lost 
contact.  It is interesting to note that a 6-month placebo-controlled RCT examining the effects of 
stimulant medication in adults with ADHD also had a high drop-out rate with a 38% completion 
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rate in the active, and 50% completion rate in the placebo group. The main reason for drop-outs, as 
in the current study, was loss of patient contact (Adler et al., 2008).  
 
Another reason for drop-outs may have been the longer length of the trial (6 months) during which 
time patients may have lost interest or found it too demanding to take the supplements every day.  
In line with this, although increases in blood n-3 PUFA levels were found in the active group from 
baseline to the final visit, this was primarily driven by increase from baseline to time 2 (3 months). 
Slight decreases in blood PUFA levels were found between 3 months and 6 months. This suggests 
participants were less likely to adhere to taking the supplements in the second half of the study.  
Furthermore, in the per-protocol analysis 9 participants from the active group were excluded 
whose n-3 PUFA blood levels did not increase from baseline to the final visit. When examining time 
1 to time 2 changes, only 2 participants from the active group were excluded.  Future studies in this 
population may consider a trial of shorter length (3-4 months).   
 
It is also possible that drop-outs may have occurred because the baseline testing sessions were long 
and cognitively demanding, which may have caused unwillingness for participants to return. One 
participant could not tolerate the EEG session, and a number of other participants expressed that 
they found this session difficult to complete.  It is of note that the second trial conducted in this 
thesis (Chapter 6) employed shorter testing sessions (~3 hours versus ~5 hours) and a shorter 
follow-up period  (6-weeks vs 6-months) than this study and had a significantly lower drop-out rate 
(17% versus 32%).  
 
From the sub-sample of those that were asked to guess which medication they were taking, 
blinding appeared to have been more successful in the active than placebo group (although this 
difference was not statistically significant).  Given that a larger number of participants (12 versus 
19) were asked in the placebo than the active group, it is difficult to draw a firm conclusion. Failure 
of the blinding in the placebo group could potentially have led to an underestimation of the 
treatment effect.  Although greater bias as a result of failure of the blind is often observed more for 
subjective outcomes, therefore rating scale measures of EL and ADHD symptoms may have been 




The main limitation to this study is that we were underpowered to detect the small to moderate 
effects estimated from previous meta-analyses.  Meta-analysis examining the effect of n-3 PUFA 
supplementation in children with ADHD have estimated the effect to be at around d=0.3 (Bloch & 
Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-Barke et al., 2013).  At this effect a sample size of 
352 participants would be required to detect an effect at a nominal level of significance (α = 0.05). 
However, given that this was a pilot study, the main aim was to evaluate the feasibility of the study, 
and potential trends and effect sizes, which would indicate positive effects of n-3 PUFA 
supplementation in order to guide a future, larger study.  This has been achieved, as the per-
protocol analysis indicated potential treatment effects on inattention and emotional lability which 
is in line with previous meta-analysis (Bloch & Qawasmi, 2011; Cooper et al., 2016; Hawkey & Nigg, 
2014; Sonuga-Barke et al., 2013).  Observations from running the experiment can also be used for 
future trials such as the need for a shorter follow-up period and testing sessions in order to attempt 
to limit drop-out rate. 
 
In conclusion, this pilot study has found no evidence for an effect of n-3 PUFA supplementation on 
cognition, and only an indication of possible improvements in inattention, and to a lesser extent 
emotional lability. These conclusions are limited by the high drop-out rate and low power in this 
study. Future studies should investigate treatment effects in a larger sample size, with a shorter 
follow-up period (~ 3-4 months) and shorter, less cognitively demanding testing sessions (~ 2 
hours total).  
 
5.8 Overall conclusion 
This chapter has found a sample of adults with ADHD to have more severe symptoms of inattention, 
hyperactivity/impulsivity, emotional lability, and impaired cognitive performance, compared to a 
control group. This supports the DSM-5 diagnostic criteria which alongside typical ADHD 
symptoms, lists emotional lability and cognitive impairment as associated features of ADHD; 
demonstrating that the sample here is characteristic of ADHD clinical populations and the data is 
therefore generalisable to other ADHD samples.   Alongside this we have found evidence supporting 
the developmental stability of sensitivity to reward and presentation rate on cognitive (reaction 
time) performance in ADHD. We have also provided objective evidence for emotional overreactivity 
in adults with ADHD and proposed that the PASAT-C could be used as an objective measure of 
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frustration in this group. We then did not find any evidence that adults with ADHD had deficiencies 
in n-3 PUFA blood levels, even finding evidence contrary to this hypothesis with slightly higher 
levels of the n-3 PUFA DPA. Following this we found no evidence that supplementation with n-3 
PUFA effects cognition with marginal evidence for effects on inattention and to a lesser extent 
emotional lability.  A larger trial would be needed in order to gain a more conclusive picture. As a 
whole we have found only very marginal evidence to support the efficacy of n-3 PUFA as an 
alternative treatment in adults with ADHD. 
 
5.9  
Chapter 5 interim summaryChapter 5 addressed the second aim of this thesis (see Section 1.4), to 
examine the effect of n-3 PUFA supplementation in adults with ADHD. In agreement with the first 
hypothesis suggested in this aim, at baseline the ADHD group compared to controls had more 
severe symptoms of ADHD, higher EL and impaired cognition.  Against the second hypothesis, no 
differences in n-3 PUFA blood levels were found that might have indicated a role for dietary 
deficiency. Going only slightly in support of the third hypothesis, no evidence for an effect of n-3 
PUFA on cognition was found with very limited evidence for an effect of n-3 PUFA on inattention 
and potentially EL.  These results, combined with evidence from Chapters 2 and 3 (see sections 2.11 
and 3.6) and prior studies (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-Barke et al., 
2013), have increased our understanding of the effect of n-3 PUFA supplementation in children and 
adults with ADHD. We know that in children with ADHD, n-3 PUFA supplementation appears to 
have a small effect on improving symptoms of ADHD with suggestive evidence for a small effect on 
reducing symptoms of EL and oppositional behaviour. Effects on cognition appear to be negligible 
in both the general population and children with ADHD (aside from a potential small effect in those 
who are n-3 PUFA deficient). In line with this pattern of larger treatment effects on behavioural 
symptoms than cognition, this chapter has suggested, in adults with ADHD, there is no indication 
for an effect of n-3 PUFA supplementation on cognitive performance, with limited evidence for an 
effect on inattention and potentially EL.  We have also shown that whilst case/control differences in 
n-3 PUFA levels may be present in children (Hawkey & Nigg, 2014), this may not be the case in 
adulthood. We have finally given evidence to build on the presence of cognitive impairments 
(including evidence of reward sensitivity) and increased symptoms of EL (including objective 
evidence of problems with emotion regulation/emotional overreactivity) in adults with ADHD. 
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Given the weak evidence that we have found in this chapter for n-3 PUFA as an alternative 
treatment for adults with ADHD, it is important that other treatments are investigated. In line with 
this and aim 3 of this thesis (see Section 1.4) the following chapter, using a similar RCT design, 
investigates the cannabinoid medication, Sativex Oromucosal Spray, as an alternative treatment for 
adults with ADHD. In line with previous chapters, treatment effects on cognition, ADHD symptoms 






























Chapter 6: The effects of Sativex on neurocognitive and 
behavioural function in adults with attention-
deficit/hyperactivity disorder: The EMA-C Study 
(Experimental Medicine in ADHD – Cannabinoids) 
 
6.1 Abstract 
A number of adults with ADHD appear to 'self-medicate' with cannabis, sometimes reporting a 
preference for cannabis over their stimulant medication. Treatment with stimulants is not always 
effective or tolerated, and long term treatment may be a concern in some cases; investigation of 
alternative treatments is therefore vital. Given this, here we report, to our knowledge, the first 
randomised placebo-controlled trial examining the effect of cannabinoids, using Sativex 
Oromucosal Spray, on ADHD associated cognitive impairments and symptoms in 30 adults with 
ADHD.  A significant treatment effect was found for improvements in hyperactivity/impulsivity, 
with non-significant trends indicating potential effects in inattention and to a lesser extent 
cognitive performance.  Adults with ADHD may represent a subgroup of individuals that gain 
cognitive enhancement and reduction of impairing symptoms from cannabinoid treatments.  These 
data suggest that Sativex has potential as an alternative treatment for adults with ADHD.  Future 
research is required in order to gain a more conclusive picture.  
 
6.2 Introduction 
Attention deficit/hyperactivity disorder (ADHD) affects around 5% of children (Polanczyk et al., 
2007, 2014), continuing into adulthood in around two-thirds of cases with a prevalence of around 
2.5% (Faraone et al., 2006). Adult ADHD is associated with significant clinical and psychosocial 
impairment with the presence of a comorbid disorder in around 75% of cases (Kooij et al., 2010). 
Substance use disorder (SUD) is a common comorbidity of ADHD (Arias et al., 2008; Biederman et 
al., 1995) with the most common drugs of abuse appearing to be stimulants and cannabis 
(Asherson, Evans, Kuntsi, & Young, 2015; Joseph Biederman et al., 1995; Dennis et al., 2004; 
Gudjonsson et al., 2012; Huntley et al., 2012). One theory posited to explain the increased risk of 




Several key points underpin the self-medication hypothesis for substance abuse in ADHD. High 
rates of substance abuse have been found in those with undiagnosed ADHD compared to those 
without ADHD symptoms (Gudjonsson et al., 2012; Young & Thome, 2011), and it has been 
suggested that this may be related to self-treatment (Bolea-Alamañac et al., 2014). There might be 
improved function with drug use. For example, different motivations behind drug use have been 
found, with ADHD cases more likely to use drugs to improve their mood and sleep whereas those 
without ADHD for ‘getting high’ (Horner & Scheibe, 1997; Wilens, 2004). Taking into account that 
stimulant medication is the recommended first line treatment in ADHD and, alongside cannabis, 
stimulants are one of the most common classes of drugs of abuse (Biederman et al., 1995; Dennis et 
al., 2004; Gudjonsson et al., 2012; Huntley et al., 2012), this may indicate that those with ADHD are 
more likely to use drugs that have been found to alleviate symptoms of ADHD.  This is further 
supported by the potential overlap in neurotransmitter action between stimulant medication 
(Leonard et al., 2004; Volkow et al., 2002) and cannabis (Bossong et al., 2009, 2015; Kuepper et al., 
2013), both of which may act as dopamine agonists (see Chapter 1, Section 1.3.3 for further 
discussion).  
 
In line with the self-medication hypothesis, a number of individuals with ADHD report a preference 
for cannabis over stimulant medication in the treatment of their symptoms. Some patients have 
reported an improvement in behavioural symptoms when using cannabis (Asherson, personal 
communication). They report feeling reduced emotional lability, restlessness and distractibility, 
with improved concentration, ability to sustain focus and sleep.  Sativex Oromucosal Spray (GW 
Pharma Ltd, Salisbury, UK), a standardised cannabinoid medication, was recently prescribed for a 
one month period to a patient at the Maudsley ADHD Clinic, since the patient found stimulants to be 
ineffective and even to exacerbate his ADHD symptoms. Treatment with Sativex resulted in 
improved control of ADHD symptoms, behaviour and cognitive function, reported by the patient 
and corroborated by his mother. Although impairments in, for example, cognition (e.g. increased 
omission8 and commission9 errors and mean reaction times) have been found in healthy   
                                                                
8 Where a participant fails to respond where a response is required during a cognitive task  
9 Where a participant responds when a response is not required during a cognitive task 
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recreational cannabis users following acute administration of Δ9-THC10  (McDonald, Schleifer, 
Richards, & de Wit, 2003; Ramaekers, Kauert, Theunissen, Toennes, & Moeller, 2009; Ramaekers et 
al., 2006), this is not consistent with the subjective accounts of patients with ADHD who may 
potentially represent a subgroup that respond more positively to cannabinoids.  
 
Research into alternative treatments in ADHD is important.  Stimulant medication, the first line 
treatment for adults with ADHD, can have a number of adverse-effects including sleeplessness, loss 
of appetite, and mood effects (Faraone et al., 2015; Leonard et al., 2004; Sangal et al., 2006). In 
other cases they have been associated with cardiovascular effects, growth suppression, and the 
development of psychosis or other psychiatric conditions (FDA, 2006). Furthermore partial 
response is common (Bolea-Alamañac et al., 2014) and clinical trials indicate that not all cases of 
ADHD respond to stimulant medications.     
 
6.3 Objectives 
Despite the wide use of cannabis in adults with ADHD, positive subjective patient reports, and 
beneficial effects found from the treatment of one patient with Sativex (Asherson, personal 
communication), to our knowledge the effect of a cannabinoid based medication on cognitive and 
behavioural function in ADHD has yet to be tested. In line with this the main objective of this study 
is to provide preliminary data on the relationship of short-term cannabinoid-based treatment (with 
Sativex Oromucosal Spray) on cognitive and behavioural measures in adults with ADHD. The 
following hypotheses were tested: 1) That treatment with Sativex would improve cognitive 
performance and 2) That treatment with Sativex would improve symptoms of ADHD and emotional 
lability.   
 
     
                                                                





The study was a 6 week11 double-blind, placebo controlled, parallel group pilot study with balanced 
randomisation in 30 adults with ADHD. Participants were divided into 15 who received the active 
Sativex treatment and 15 who received the placebo. Participants underwent a 2 week titration 
period before continuing at their optimum dosage for 4 weeks.  Outcomes were assessed at 
baseline and 6 weeks (day 42) (see Figure 6-1). The RCT analysis was presented in accordance with 
guidance from the CONSORT Statement (Consolidated Standards of Reporting Trials) (Schulz, 
Altman, Moher, & Group, 2010). 
 
6.4.2 Changes to trial design 
The original protocol included outcomes at 3 time-points (baseline (time 1), 2 weeks (time 2) and 6 
weeks (time 3)). Participants attended the Social, Genetic and Developmental Psychiatry (SGDP) 
Centre for their time 1 and time 3 assessments. For the time 2 assessment, participants were 
provided with questionnaires and a stamped addressed envelope and asked to complete and post 
these back to us after 2weeks.  However only 16/30 participants did this. Furthermore it became 
clear that due to a large amount of individual variation during the titration phase of the protocol, a 
2 week period was too short-a-time to assess medication efficacy. Therefore the time 2 assessment 










                                                                
11 6 weeks was chosen in line with the duration of previous RCTs of Sativex in patients with 
Multiple Sclerosis; or who had neuropathic pain, which found efficacy of Sativex after 5-6 weeks 
(Collin et al., 2007; Nurmikko et al., 2007) (there are no studies of Sativex in adults with ADHD 











6.4.3 Inclusion/exclusion criteria 
The inclusion/exclusion criteria is reported in Chapter 4, Section 4.3.2.1. 
 
6.4.4 Study settings, funding and ethical approval 
Study settings, funding and ethical approval are reported in Chapter 4, Section 4.3.1.1. 
 
6.4.5 Interventions 
The active and placebo medication were stored and dispensed by the Maudsley Hospital pharmacy 
(part of The South London and Maudsley NHS Foundation Trust (SLaM)). Both the active and 
placebo medications were flavoured with peppermint and were identical in appearance and 
method of administration (oromucosal sprays). Treatments were prescribed by one of two 
qualified medical doctors experienced in the diagnosis and treatment of ADHD (Prof Philip 
Asherson or Dr Céline Ryckaert). Participants were asked to begin the medication the morning after 
the baseline visit. 
 
Active treatment 
Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains the 
cannabinoids: 2.7 mg delta-9-tetrahydrocannabinol (Δ9-THC) and 2.5 mg cannabidiol (CBD). 
Sativex has similar properties to cannabis resin ('hash') which is commonly used recreationally.  
Δ9-THC and CBD are thought to have opposite effects with  Δ9-THC associated with the 
psychoactive effects of cannabis (i.e. euphoria, alteration of perception, psychotic symptoms (in 
some individuals)) and CBD, the anxiolytic effects (Englund et al., 2012). CBD has been found to 
offset the psychoactive effects of Δ9-THC (Englund et al., 2012) (See also Chapter 1, Section 1.3.1). 
 
Placebo treatment 
The placebo treatment was an oromucosal spray containing ethanol, propylene glycol (50:50) 




Both the active and placebo treatment were identical in appearance and flavour (peppermint). They 
were stored in the pharmacy of the Maudsley Hospital and were prescribed by either Prof Philip 
Asherson (MBBS) or Dr Céline Ryckaert. 
 
6.4.5.1 Titration period and dosing 
All participants in both arms of the study underwent a two week titration period, after which they 
continued at the final optimal dose.  At the end of the baseline assessment they received a ‘dosing 
diary’. The diary contained titration and dosing instructions and asked the participant to record the 
number of sprays taken each day. The two week titration period was conducted according to a 
standardised dosing schedule (advised by GW Pharma) whereby treatment was increased daily 
(see Appendix E, Supplement AE-1). The maximum dose for the study was 14 sprays per day.  
During the titration and remaining 4-week period safety monitoring and evaluation of the effects of 
the spray were carried out on days 4, 8, 12, 14 and 28. On these days participants were called by a 
researcher (myself, supervised by Prof Asherson) and asked to complete a standard side-effect 
rating scale, the 18-item Conners’ Adult ADHD Rating Scale (Conners et al., 1999), and general 
questions regarding their current dosage and whether they were finding any effects or adverse 
effects from the treatment (see Appendix E, Supplement AE-2 for titration documents). If in the 
opinion of the participant or myself, there were minor adverse effects that could be exacerbated at 
a higher dose, the participant was advised to either stay at the dose they were at or reduce to a 
lower dose. Titration upwards was also stopped if all ADHD symptoms were scored as negligible or 
absent (score of 0 or 1 on all items of the CAARS).  Participants were advised to spread the doses 
out throughout the day as best suited them, taking into account any minor adverse events, 
symptom score on the CAARS, and the length of time the effect from each spray lasted. On day 14 it 
was decided between the participant and myself as to the optimal dose for them to continue for the 
remaining four weeks of the trial. Those who did not report effects from the spray were advised to 
titrate up to the maximum dosage and then continue at a dose they felt they could manage to take 




6.4.5.2 Alteration to titration period and dosing   
After the first 2-3 participants had begun the trial it became clear that the titration schedule 
advised by GW Pharma was too high for adults with ADHD. This is most likely because this 
recommended schedule was advised for symptom relief in Multiple Sclerosis (Sativex is licensed for 
treatment of MS). It was found that participants in this trial required around 4-8 sprays (mean 
number of sprays used = 4.73 (range = 1-13)) instead of 14. In a few cases patients double dosed 
and found this was associated with minor adverse experiences. In addition, the medication effects 
were reported as lasting around 3-4 hours in most cases.  We therefore altered the protocol by 
informing patients at the end of the baseline session, that for some people the titration schedule 
was too high, and that if they found a beneficial effect from the medication they should not take 
another dose until that effect had started to wear off. The close monitoring of participants during 
the titration period (described above) ensured participants remained aware of this and that the 
titration process was individualised to the reported response from each patient.    
 
6.4.6 Outcomes 
6.4.6.1 Baseline only measures 
- The MINI 6.0 (Mini International Neuropsychiatric Interview) diagnostic interview was used to 
screen for comorbid disorders (Lecrubier et al., 1997). 
- Two subtests (vocabulary and matrix reasoning) of The Weschler Abbreviated Scale of 
Intelligence – II (Weschler, 2005) were used to measure IQ. 
- Socio-economic status (SES) was assessed by collecting information on participants’ level of 
education, occupation and income. 
- Information regarding the participants’ medication, ADHD diagnostic status and cannabis use 
was also collected. 
 
6.4.6.2 Primary outcome  
The Quantitative Behavioural Test (Qb Test) (Bijlenga et al., 2015; Iberstadt, 2012): The Qb Test is a 
20 minute, unconditional identical pairs test.  During the test four different stimuli (red and blue 
squares; red and blue circles) are presented in a random order for 200 ms with a 2- second inter-
stimulus interval. If a stimulus matches the previous stimulus it is a target, otherwise it is a non-
target. In total 600 stimuli are shown at a 25% target ratio. The participant is asked to respond to a 
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target by pressing a clicker with the thumb of the dominant hand and to inhibit responses to non-
targets. During the test head movements are measured by means of a high-resolution motion 
tracking system that consists of an infra-red camera and a reflector attached to the participant’s 
headband. Outcome measures are calculated per test quartile, each representing five minutes of the 
test duration. The first quartile is not taken into account in the outcome measures because it is least 
indicative for ADHD. Three cardinal outcomes are computed as Q-scores (z-scores after comparison 
of the participant’s raw scores to the normative data matched for age and sex):  QbInattention 
(containing omission errors, reaction time and reaction time variation), QbActivity (containing time 
active, distance, area, and micro-events), and QbImpulsivity (containing commission errors and 
normalized commission errors). The primary outcome was the mean of these three cardinal 
outcomes (this measure has been found previously to be sensitive to medication effects in adults 
with ADHD (Bijlenga et al., 2015)), with post-hoc analyses conducted on each outcome separately. 
 
6.4.6.3 Secondary outcomes 
ADHD symptoms: 
- Conners’ Adult ADHD Rating Scales (CAARS) (Conners et al., 1999) and Wender-Reimher 
Adult Attention Deficit Disorder Scale (WRAADS) (Wender, 1995) combined 
(CAARS/WRAADS: investigator rated): Assessed ADHD symptom severity. Total scores for 
each category of inattention, hyperactivity/impulsivity, and emotional lability were used in the 
analysis. 
Emotional lability: 
- Emotional lability: : The Centre for Neurologic Study Lability Scale (CNS-LS) (Moore et al., 
1997) and Affective Lability Scale-Short Form (ALS-SF) (Oliver & Simons, 2004) measured 
emotional lability .  Total score from each was used in the analysis. 
Cognition: 
− Sustained Attention to Response Task (SART) (O’Connell et al., 2009): The SART is a 
computerised go/no go task measuring both response inhibition and sustained attention. It consists 
of nine digits presented in random order on a computer monitor. Participants are instructed to 
withhold responses to the digit 3 (no-go trial) but to respond with a button press after all other 
digits (go trial). Participants completed the SART over three blocks, each lasting approximately 5 
minutes. Individual blocks consisted of 225 digits, with each digit presented 25 times. Stimuli were 
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presented in five digit sizes (font size 100, 120, 140, 160 and 180 in Arial text), subtending 
approximately 1.7, 2.1, 2.4 and 2.7, respectively in the vertical plane. Digits were presented .31 
above a central white fixation cross on a grey background for 150 ms followed by an inter-stimulus 
interval of 1000ms. Measures recorded were as follows: commission (where the participant 
responds where a response is not required) and omission (where a participant fails to respond 
when a response is required) errors were added across the three trials. For reaction time 
variability (RTV) and the coefficient of variation (CV) (SDRT/MRT) the average was computed 
across the three trials (mean reaction time (MRT) was not used as an outcome variable as our 
previous study (Chapter 5) found no difference in SART MRT between ADHD cases and controls). 
 
Functional impairment 
- The Weiss Functional Impairment Rating Scale Self Report (WFIRS-S) (Weiss, 2007): 




All participants were sent a letter by post, confirming their agreed appointment time and date. For 
the baseline (day 1) assessment, participants were reminded to stop taking their ADHD stimulant 
medication for 1 week before and for the 6-week duration of the study (7 weeks in total). For the 
final (day 42) assessment participants were asked to bear in mind that they would be asked to take 
a dose of their study medication as soon as they arrived at the appointment. For the baseline and 
final assessment, participants were asked to refrain from consuming alcohol on the day of the study 
session or the day before. Appointment reminders were given the day before the first and the final 
research appointment. 
 
At the baseline visit participants read the study information sheet and completed the consent form. 
They then completed the investigator-rated CAARS/WRAADS, general information sheet (e.g. SES 
and cannabis use) and questionnaires, following this the cognitive testing session (QB Test and the 
SART) was carried out and lastly the IQ test and the MINI. At the end of the baseline visit 
participants received: a 7-week supply of either the placebo or active medication, a study diary 
(which contained instructions for the titration period and remaining four weeks of the study and 
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where participants were asked to record the number of sprays they used per day) and a  
confirmation letter for their final visit.   
  
At the final (day 42) visit, participants completed an identical testing session to the baseline visit 
although they did not complete the IQ test or the MINI. At this final assessment participants were 
asked to take one dose of the medication when they first arrived, they then began the cognitive 
testing session 1 hour later.  Therefore at time 1 and time 3, if the questionnaires took longer than 
one hour to complete, they would be filled out at the end of the testing session. The assessments 
and timings for the baseline and final assessment are detailed in Chapter 4, Table 4-2. The study 
design is detailed in Figure 6-1. All participants were compensated for their travel. 
 
6.4.8 Sample size 
As this was an initial pilot study, examining feasibility and trends in drug effects, formal power 
calculations were not required. Furthermore, as there were no prior estimates of the effects of 
Sativex (or indeed any cannabinoid medication) in adults with ADHD, initial estimates of an effect 
size for power calculations were not available. We were also conscious of the low cost-benefit ratio 
for participants, since this study did not meet the criteria for a clinical trial of a CTIMP under MHRA 
regulations (following a formal review of the protocol) and we were not able to recommend Sativex 
as a treatment for ADHD, even for participants who found the medication to be effective. A 
relatively small study aimed at large clinical effects therefore seemed warranted for such an early 
investigation of the effects of Sativex in adults with ADHD.   
 
With a sample size of 30 participants and 80% power we are able to detect large effects at both 
nominal levels of significance (d = 1.06, α = 0.05) and at trend level (d = 0.95, α = 0.09).  This 
seemed a reasonable target effect size for an initial exploratory study on the basis that patients who 
self-medicate with cannabis report marked improvements in ADHD symptoms, similar to that when 
using stimulant medication. The effect size around d=1.0 is comparable to that reported in some, 
but not all, meta-analyses (range d ~ 0.6-1.0) for stimulant medication on ADHD symptoms 




6.4.9 Randomisation  
6.4.10 Sequence generation 
The randomisation list was produced by an independent statistician who produced a treatment 
allocation schedule to two equal-sized blocks (treatment and placebo) at random via a random 
number generator in the R statistical package (using the sample.int() function).  
 
6.4.11 Allocation concealment 
The randomisation list was sent to the hospital pharmacy where the medication was labelled and 
blinded before being dispensed. Each participant ID (1-30) corresponded to an equivalent 
medication number (1-30). Randomisation lists were held by the SLaM pharmacy and the 
independent statistician. The allocation sequence was concealed from the researchers in 
sequentially numbered, opaque, sealed envelopes which were kept in a locked drawer in the SGDP 
Centre.    Neither the statistician who produced the randomisation schedule nor the pharmacist 
who labelled and blinded the medication were involved in any other aspect of the study. Emergency 
unblinding was possible with 24 hour access to a mobile phone number with a member of the 
research team and access to a trained clinician (Professor Asherson or Dr Céline Ryckaert).  
 
6.4.12 Blinding 
Investigators and participants were all blind to treatment allocation. Post-intervention participants 
were asked which group they thought they were allocated to. These estimates were used to assess 
the maintenance of blinding. The study was unblinded only after all data had been collected and 
cleaned (the final cleaned anonymised datafile was stored and sent to colleagues unrelated to the 
trial prior to unblinding).  
 
6.4.13 Statistical methods 
Baseline comparisons were carried out using STATA (StataCorp, 2009). For categorical data, either 
a Chi-squared or Fisher’s Exact (if expected frequencies were 5 or less) test were used. For 
continuous data either a T-test or Mann-Whitney two sample rank sum test (if data were non-
normal) were used. Normality for baseline comparisons was assessed by conducting the skewness 
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and kurtosis tests for normality, examination of the value of skew (-1 to 1 considered normal) and 
inspection of the histogram.   
 
The Intent-to-treat (ITT) and per-protocol analyses were conducted in SAS®.  The ITT analysis 
included every participant who was randomised to the trial, regardless of protocol deviations, 
compliance and withdrawal (Lewis & Machin, 1993), and was considered the primary analysis.  
Per-protocol analysis included only those patients who adhered to the protocol (Lewis & Machin, 
1993), and was considered the secondary analysis.  The covariance structure of the data was 
examined and no discernible pattern was found: therefore treatment effects were estimated (in 
both the per-protocol and ITT analysis) using a repeated measures linear model (with fixed effects: 
Group, Time and the interaction of these two terms) with an unstructured covariance matrix 
(Kincaid, 2005) (the procedure MIXED was used). A significant group x time interaction indicated a 
treatment effect. Linear models are robust to deviations from normality (Hamer & Simpson, 2000) 
and modelling the covariance structure of repeated measures is considered an effective method to 
handle missing data without the need for multiple imputation (MI) (Gadbury et al., 2003).  
 
To examine whether or not the missing data influences the linear model estimates, multiple 
imputation (MI) was implemented (using the PROC MI procedure in SAS) as a sensitivity analysis, 
and performed using the ITT populations.  Two types of MI analyses were performed: 1) the first 
assumed that missing data were missing at random  (MAR) and 2) the second method of imputation 
assumed that the missing data might relate to the value  and thus is missing not at random (MNAR) 
(Allison, 2012; Twisk et al., 2013; White, Carpenter, & Horton, 2012; Yuan, 2014).  Given that data 
was missing in both monotone and arbitrary patterns,  two separate MIs under the MAR 
assumption were conducted; the first used a monotone simulation (which imputed only data that 
were missing at follow-up), and the second used an arbitrary simulation with the Fully Conditional 
Specification (FCS) method (which imputed data at baseline and follow-up).  Both the monotone 
and FCS MIs used all available observations to derive the imputation model.  Imputation under the 
MNAR assumption used a control-based pattern mixture model which assumed data to be missing 
in a monotone pattern (and imputed values only at follow-up). Under this model it was assumed 
that individuals who dropped out of the treatment group would no longer be receiving treatment 
and would have outcomes similar to the placebo group. Therefore imputation in both the placebo 
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and active group was based only on the placebo group (Yuan, 2014).  A nominal level of significance 
was set at p < .05 and at p < 0.004 after correction for multiple testing (Bonferroni correction for 14 
statistical tests). Given this was a pilot study we also examined trends (p < .09) and indications (p< 
.20) of treatment effect. Effect sizes were classified according to Cohen's d (0.2 = small, 0.5 = 
medium, 0.8 = large) (Cohen, 1988).  
 
6.5 Results 
6.5.1 Participant flow, losses and exclusions 
Participant flow through the study is shown in Figure 6.1, and detailed reasons for exclusions in 
Chapter 4 (Figure 4-2 and Appendix C, Table AC-6).  Of the 233 potential participants that were 
screened 203 were excluded due to: not meeting inclusion criteria (n=99), declined to participate 
(n=18), other reasons which included non-response to being contacted about the trial (n=56), not 
sufficient information to screen (n=25), and recruited for the study and then declined before being 
booked to begin (n=5).  For those who failed to meet inclusion criteria the main reasons were: that 
they did not have enough ADHD symptoms (n=19), presence of a co-occurring mental health 
condition (n=15), unwilling or unable to come off current ADHD medication (n=12), current 
psychoactive medication (other than stimulants) (n=11), history of current or past substance 
abuse/dependence (n=9), physical health problems (n=7), and unwillingness to take a cannabinoid 
medication (n=5). 
 
The participants were 30 adults with ADHD (11 female, 19 male, mean age = 37.9 years (SD = 
11.46), research diagnosis N=7, clinical diagnosis N=22, childhood diagnosis and adult research 
diagnosis N=1). The majority of participants met criteria for the combined type presentation of 
ADHD (N=26) with only a small number with the inattentive type presentation (N=4). Of the 23 
with a prior clinical diagnosis, five had been diagnosed in childhood and 18 in adulthood. The 
participants were randomised in a 1:1 ratio (15 active, 15 placebo).   
 
Of the 30 participants, complete follow-up data was not obtained from two participants in the 
placebo group. One participant experienced an adverse event (see section 6.5.10 ’Adverse events’). 
Contact was lost with the second participant.  Partial follow-up data was obtained from two other 
participants who failed to return for follow-up, however, both completed the CAARS/WRAADS, 
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CNS-LS, and ALS-SF over the telephone. Of these participants, one failed to attend due to a head 
injury which meant they stopped taking the study medication. The second failed to attend their 
final appointment for logistical reasons. In the active group, one participant experienced an adverse 
event two weeks into the trial and stopped taking the study medication, but attended their follow-
up session as scheduled (see section 6.5.10 ’Adverse events’).  At baseline one participant in the 
active and one in the placebo group could not tolerate the Qb Test. Due to technical difficulties two 


























































Assessed for eligibility (n= 233) Excluded (n= 203) 
 Not meeting inclusion 
criteria (n= 99) 
 Declined to participate  
(n= 18) 
 Other reasons (n=86) 
o No response 
(n=56) 
o No information to 
screen (n=25) 
o Recruited then 
declined (n=5) 
Analysed ITT analysis (n=15) 
 Excluded from analysis (n= 0) 
Analysed per-protocol analysis (n=14) 




Lost to follow-up (give reasons) (n=0) 
Discontinued intervention due to adverse 
event (n=1) – Although returned for follow-
up 
Allocated to active group (n=15) 
 Received allocated intervention (n=15) 
 Did not receive allocated intervention  
(n=0) 
Lost to follow-up (lost contact) (n= 3) 
Although 2 completed secondary 
measures by telephone 
Discontinued intervention due to 
adverse event (n= 1) 
 
Allocated to placebo group (n=15) 
 Received allocated intervention 
(n=15) 
 Did not receive allocated 
intervention  (n=0) 
Analysed ITT analysis (n=11) 
 Excluded from analysis (n=0 ) 
Analysed per-protocol analysis (n=11) 












Eligible participants were recruited from July 2014 to May 2015. Participants came to the SGDP 
Centre for baseline (time 1) and 6 week (time 3) testing sessions. 
 
6.5.3 Baseline data 
The baseline demographics for the placebo and active groups are shown in Table 6-1. There were 
two minor differences between the groups: significantly more participants were unemployed in the 
placebo (n=5/15) than the active (n=0/15) group (p = .04), and a significantly higher number of 
participants in the placebo group had GCSEs or vocational qualifications than the active (6 vs 1, p = 
.04). Aside from these minor differences the groups were similar on age, sex, IQ, medication status, 
other measures of education and employment, comorbid mental health conditions, and previous 
cannabis use.  Baseline comparisons for the primary and secondary outcomes are shown in Table 































X2 (p) Fishers 
Exact (p) 




- - - 
Sex (f/m)  15/15 6/9 5/10 - - 0.14(0.
71) 
- 






- - - 
Medication  
(med/unmed)  
15/15 8/7 7/8 - - 0.13 
(0.72) 
- 









       
Employed  15/15 14 9 - - - .08 
Unemployed  15/15 0 5 - - - .04* 
Full-time student  15/15 1 1 - - - 1.00 
Highest level of education 
No qualifications 15/14 1 0 - - - 1.00 
GCSE/Vocational 15/14 1 6 - - - .04* 




15/14 10 7 - - 0.83(0.
36) 
- 
One or more 
comorbid 
condition (MINI) 
15/15 10 12 - - - 0.68 
Cannabis use        
No use 15/15 5 5 - - - 1.00 
Daily (present) 15/15 3 1 - - - 0.60 
Daily (past) 15/15 1 3 - - - 0.60 
Weekly (past) 15/15 1 0 - - - 1.00 
Monthly (present) 15/15 0 1 - - - 1.00 
Monthly (past) 15/15 3 3 - - - 1.00 
Yearly (past) 15/15 2 2 - - - 1.00 
Note. N A/P = Number of participants in the Active/Placebo group, y/m = years/months, f/m = 






Table 6-2: Baseline comparisons of primary and secondary outcomes 




t(p) MW z(p) 
Primary outcome      
Qb Test  14/14 1.73 (0.66) 1.71 (0.95) -0.06 (0.95) - 
Post-hoc      
Qb Activity 14/14 2.66 (0.79) 2.61 (0.87) -0.18 (0.86) - 
Qb Inattention 14/14 1.58 (1.31) 1.71 (1.46) 0.25 (0.81) - 
Qb Impulsivity 14/14 0.95 (1.32) 0.82(1.25) -0.26 (0.79) - 
Secondary outcomes      
ADHD Symptoms      
CW Inattention 15/15 27.27(4.42) 27.33(6.17) 0.03(0.97) - 
CW Hyp/Imp 15/15 19.4(4.24) 19(7.44) -0.18(0.86) - 
CW EL 15/15 15.6(5.53) 19.07(6.26) 1.61 (0.12) - 
Cognition      
SART CE 15/14 36.53 
(16.24) 
32.71 (16.55) -0.63 (0.54) - 
SART OE 15/14 51.8 
(53.67) 
41 (53.10) - -1.31 (0.19) 




-1.47 (0.15) - 
SART CV 15/14 0.55 (0.20) 0.43 (0.16) -1.73 (0.09) - 
Emotional lability      
CNS-LS 15/15 30.67 
(15.43) 
30.2 (16.95) -0.08 (0.94) - 
ALS 15/15 22.33 
(11.14) 
22.2 (9.51) -0.04 (0.97) - 
Functional impairment 
WFIRS Total 15/15 1.17 (0.52) 1.11 (0.33) -0.36 (0.72) - 
Note. N A/P = Number of participants in the Active/Placebo group, OE = Omission errors, CE = 











6.5.4 Numbers analysed 
For the primary outcome (the QB Test): the ITT analysis included 15 participants in the active and 
11 in the placebo group. The per-protocol analysis included 14 participants in the active and 11 in 
the placebo group.   
 
6.5.5 Drop-outs 
Analysis of drop-outs for the per-protocol analysis shows that although there were more drop-outs 
in the placebo (n=4/15) than active (n=1/15) group this did not differ significantly (p=0.33). 
 
6.5.6 Dosing 
Average doses of the placebo and active medication in the final 4 weeks of the study were 
compared. Participants in the active group took significantly less sprays than those in the placebo 
group (mean = 4.73 vs 8.48 respectively, p = .02) (see Table 6-3). 
 
Table 6-3: Average dose per day taken by participant in the final 4 weeks of the study (obtained 
from the study diary).  





Dose p/d 4.73  (1-13, 3.33) 8.48 (2.1-14, 3.80) 2.46 (0.02)** 
M=Mean, SD = Standard Deviation 
** p < .05 
 
6.5.7 Outcomes and estimation 
6.5.7.1 ITT analysis 
The intent-to-treat analysis is shown in Table 6-4. In the active group, the primary outcome 
performance on the QB Test showed an indication of improvement (p = 0.16, 95% CI = -0.40 to 0.07, 
d=0.59). Post-hoc comparisons of the individual domains of activity, inattention, and impulsivity 
showed this was driven mainly by reductions in activity during the Qb Test, though this effect was 
non-significant (p=0.24, d = 0.50).   
 
For the secondary outcomes, a nominally significant reduction in symptoms of 
hyperactivity/impulsivity (p = .03, d=0.90) was found, although this did not withstand adjustment 
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for multiple testing (p> .004). Indications of improvement in symptoms of inattention (p = 1.0, 
d=0.66) and emotional lability (CNS-LS: p = 0.11, d = 0.65; ALS: p = 0.19, d = 0.52) were found in the 
active group although both failed to reach significance. Improvement on EL measured by the 
CAARS/WRAADS showed no indication of improvement. In the SART task there was an indication 
of improvement in the active group for CV (p = 0.14, d = 0.64). Treatment effects were not found for 
any of the other SART performance measures. There was no evidence of improvement in functional 
impairment. 
 
6.5.7.2 Per-protocol analysis 
The secondary per-protocol analysis is shown in  
Table 6-5. In the active group, the primary outcome (performance on the Qb Test) showed an 
improvement at trend level (p=0.06, d = 0.84).  Post-hoc analysis showed this effect appeared to be 
driven mainly by an indication of a reduction in activity during the Qb Test (p = 0.15, d = 0.63) and 
potentially improvements in impulsivity (p = 0.23, d = 0.52) although both these effects were non-
significant.    
 
For the secondary analysis, a nominally significant improvement in the active group in symptoms of 
hyperactivity/impulsivity (p=0.02, d =1.03) was found, although this did not withstand adjustment 
for multiple testing (p> .004).  An improvement at trend level was also found for symptoms of 
inattention (p=0.09, d =0.74). For emotional lability, there was an indication of improvement on the 
CNS-LS (p=0.13, d =0.67), but not on the ALS or on EL measured by the CAARS/WRAADS. In the 
SART task there was an indication of improvement in the active group for CV (p = 0.14, d = 0.67), 
but no other treatment effects on the SART performance measures were shown.  There was no 
indication of improvement in functional impairment. 
 
6.5.7.3 Sensitivity analysis  
Monotone imputation (MAR assumption) 
Outcomes with MI conducted using the monotone imputation are reported in Appendix E, Table AE-
2. There was no indication of an effect for the primary outcome (the Qb Test) (p = 0.69). Post-hoc 




For the secondary outcomes, a nominally significant reduction in symptoms of 
hyperactivity/impulsivity remained (p=0.02), although this did not withstand adjustment for 
multiple testing (p< .004). A trend for improvement was found for inattention (p=0.08) and an 
indication of improvement for emotional lability (measured with the CNS-LS (p=0.12)). Treatment 
effects were not present for: emotional lability (measured with the CAARS/WRAADS and ALS), any 
measures from the SART (commission, omission errors, RTV, CV), or functional impairment.  
 
Arbitrary (FCS) imputation (MAR assumption) 
Outcomes with MI conducted using the arbitrary (FCS) imputation are reported in Appendix E, 
Table AE-3.  As before, there was no indication for an effect on the primary outcome (p > .05). For 
the secondary outcomes, the treatment effect on hyperactivity/impulsivity was at trend (p=0.08), 
and treatment effects on emotional lability (measured with the CNS-LS) were now at trend 
(p=0.09). All other trends and non-significant effects remained the same as when using the 
monotone imputation method. 
 
Imputation under the MNAR assumption 
Outcomes under the MNAR assumption remained the same as those under the MAR assumption 
(monotone imputation method). This indicates the MAR assumption could be accepted (See 






Table 6-4: Intent to treat analysis 
 Pre-treatment (M(SD)) Post-treatment (M(SD)) Time x treatment  
 Active Placebo N A/P Active Placebo N A/P Est SE Est 95% CI p  d 
Primary outcome      
Qb Test  1.73 (0.66) 1.71 ( 0.95) 14/ 11 1.32 (0.53) 1.46 (0.91) 15 / 11 -0.17 0.12 -0.40 to  0.07 0.16 0.59 
Post-hoc            
Qb Activity 2.66 (0.79) 2.61 (0.87) 14/14 2.13 (1.09) 2.43 (0.87) 15/11 -0.22 0.19 -0.61 to 0.16 0.24 0.5 
Qb Inattention 1.58 (1.31) 1.71 (1.46) 14/14 0.91 (0.90) 1.05 (1.10) 15/11 -0.11 0.17 -0.46 to 0.25 0.55 0.25 
Qb Impulsivity 0.95 (1.32) 0.82 (1.25) 14/14 0.91 (0.87) 0.91 (1.37) 15/11 -0.13 0.22 -0.57 to 0.31 0.55 0.25 
Secondary outcomes      
ADHD Symptoms            
CW Inattention 27.27 (4.42) 27.33 (6.17) 15/ 15 17.60 (8.87) 21.92 (7.52) 15/13 -2.41 1.43 -5.34 to  0.52   0.10 0.66 
CW Hyp/Imp 19.40 (4.24 19.00 (7.44) 15/ 15 10.20 (5.58) 13.85 (7.46) 15/ 13 -2.45 1.07 -4.65 to -0.26    0.03** 0.90 
CW EL 15.60 (5.53) 19.07 (6.26) 15/ 15 8.47 (5.45) 12.08 (5.75) 15/ 13 -0.16 1.17 -2.56 to 2.24   0.89 0.05 
Cognition            
SART CE 36.53 (16.24) 
 
32.71 (16.55) 15/ 14 28.93 (17.41) 23.00 (15.55) 15/ 10 -1.23 2.19 -5.73 to  3.27   0.58 0.24 
SART OE 51.80 (53.67) 41.00 (53.10) 15/ 14 43.07 (51.95) 20.20 (28.56) 15/ 10 2.11 5.99 -10.18 to  14.40   0.73 0.15 
SART RTV 186.85 (51.56) 156.32 
(59.88) 
15/ 14 177.04 (58.41) 134.60 (48.64) 
 
15/ 10 -1.09 7.88 -17.25 to  15.06 0.89 0.06 
SART CV 0.55 (0.20) 0.43 (0.16) 15/ 14 0.49 (0.20) 0.38 (0.16) 15/ 10 -0.03 0.02 -0.07 to  0.01 0.14 0.64 
Emotional lability          
CNS-LS 30.67 (15.43) 30.20 (16.95) 
 













-7.41 to  1.58  0.19 
 
0.52 
Functional impairment      
WFIRS Total 1.17 (0.52) 1.11 (0.33) 15/15 0.83 (0.49) 0.77 (0.26) 15/11 -0.02 0.09 -0.20 to 0.15 0.81 0.10 
 ** p ≤ .05 (nominally significant). Note. A lower score indicates an improved outcome for all measures, M = Mean, SD = Standard deviation, SE = Standard 




Table 6-5: Per-protocol analysis 
 Pre treatment (M(SD))  Post-treatment (M(SD))  Time x treatment 
 Active (M(SD)) Placebo   
(M(SD)) 




N (A/P) Est SE Est 95% CI p  d 
Primary outcome      
QB Test  1.75 (0.68) 1.41 (0.93) 13/10 1.30 (0.55) 1.46 (0.91) 14/11 -0.24 0.12 -0.48 to 0.01 0.06* 0.84 
Post-hoc            
Qb Activity 2.68 (0.83) 2.41 (0.93) 13/10 2.09 (1.12) 2.43 (0.87) 14/11 -0.29 0.20 -0.70 to  0.11 0.15 0.63 
Qb Inattention 1.47 (1.30) 1.32 (1.43) 13/10 0.86 (0.91) 1.05 (1.10) 14/11 -0.16 0.18 -0.54 to 0.21 0.38 0.38 
Qb Impulsivity 1.10 (1.25) 0.50 (1.13) 13/10 0.95 (0.89) 0.91 (1.37) 14/11 -0.27 0.22 -0.72 to 0.18 0.23 0.52 
Secondary outcomes      
ADHD Symptoms      
CW Inattention 27.21 (4.58) 25.91  (6.52) 14/11 16.86 (8.71) 21.00 (7.86) 14/11 -2.72 1.55 -5.93 to 0.48 0.09* 0.74 
CW Hyp/Imp 19.50 (4.38) 16.18 (6.42) 14/11 9.93 (5.69) 12.27 (7.00) 14/11 -2.83 1.16 -5.23 to -0.44 0.02** 1.03 
CW EL 15.07 (5.33) 17.64 (6.34) 14/11 7.50 (4.11) 11.00 (5.53) 14/11 -0.47 1.26 -3.07to 2.13 0.71 0.16 
Cognition            
SART CE 36.07 (16.75) 28.55 (15.69) 14/11 28.57 (18.01) 23.00 (15.55)a 14/10 -1.57 2.28 -6.28 to  3.15 0.50 0.30 
SART OE 45.43  (49.46) 35.27 (44.54) 14/11 38.79  
(51.09) 
20.20 (28.56)a 14/10 2.33 6.08 -10.24 to 14.91  0.70 0.17 




14/10 -1.25 8.08 -17.97 to 15.47 0.88 0.07 
SART CV 0.55  (0.21) 0.38  (0.13) 14/11 0.50  (0.21) 0.38  (0.16)a 14/10 -0.03 0.02 -0.08 to 0.01 0.14 0.67 
Emotional lability      
CNS-LS 30.29  (15.94) 29.73 (16.87) 14/11 18.50  
(14.64) 
25.09 (11.27) 14/11 -3.57 2.25 -8.24 to  1.09 0.13 0.67 
ALS 22.50   (11.54) 23.91 (10.11) 14/11 14.79  (9.54) 20.36  (8.00)  14/11 -2.08 2.41 -7.07 to  2.90 0.40 0.36 
Functional impairment      
WFIRS Total 1.15 (0.54) 1.01 (0.26) 14/11 0.78 (0.47) 0.77 (0.26) 14/11 -0.06 0.09 -0.25 to 0.12 0.48 0.30 




6.5.8 Assessment of blinding 
Fourteen participants in the active group and thirteen in the placebo group were asked to guess the 
medication they were taking. In the active group 13 (93%) and in the placebo group 11 (85%) 
correctly guessed their allocation status. There was no difference in the correct guess rate between 
the two groups (Fisher's exact p = 0.60).  
 
6.5.9 Qualitative feedback  
Qualitative feedback from the participants in the active medication group (in response to the open 
question “How has the medication made you feel overall?”) is detailed in Table 6-6 and Appendix E, 
Table AE-5. There were more reports of positive effects (n=36) than negative (n=17). Positive 
effects generally included: feeling calmer (n=8), improved focus/concentration (n=6), more relaxed 
(n=4), improved sleep (n=4), and reduced anxiety (n=2). For example, participants stated:  
 
“Sustained periods of concentration which would have been difficult to achieve unmedicated. Effects 
were positive overall. Didn't like the taste, but no dry mouth or insomnia like I get from usual ADHD 
meds. Slept well and woke rested - major benefit. Stayed on tasks for longer, generally would prefer to 
take over ADHD meds.” 
 
“Just feels like it had an effect on me. Everything becomes more focused, clearer, thoughts are clearer. 
Also lessens anxiety I have from time to time. Less of a come down than Ritalin and effects probably 
last for 1 to 2 hours.” 
 
Negative feedback was generally regarding the sedative effects of the medication (n=6) and atypical 
feelings (e.g. odd thoughts, detachment) (n=5) (which could have been at higher doses).  For 
example one participant stated the side-effects to include:  
 







Table 6-6: Qualitative feedback from participants in the active group (in response to the open 





Calm  8 Spacey 1 
Clearer 2 Slows you/thoughts down 3 
Focused/improved concentration 6 Slightly stoned 1 
Relaxed 4 Does not help attention 1 
Energetic 1 No effect 1 
Improved sleep 4 Mouth ulcers 1 
Improved side-effect profile to 
ADHD medication (no 
insomnia/dry mouth/less of a  
'come down') 
2 Sedating 3 
Felt better/happier 1 Felt a bit odd 1 
Reduced anxiety/panic 2 Vulnerability to anxiety 1 
Woke-up rested 2 Altered clarity/focus of vision 1 
More engaged in activities and 
work 
1 Headaches 1 
Better able to sustain interest 1 At a higher dose: Odd thoughts, 
detached, 'couldn't be 
bothered, forgetful, in their 
own world, talkative confused, 
restless, 'trapped in own head', 
'saying wrong things' 
2 
Steadied thought processes 1 -  
Slightly improved productivity 1 -  
Total 36  17 
 
6.5.10 Adverse events 
Two serious adverse events occurred during the study, one of which was thought to be due to study 
medication (both were reported to GW Pharma, King’s College Research and Development Office, 
and NRES Committee London-London Bridge). One participant on the active medication (two 
weeks into the trial) reported sudden onset of muscular seizures/spasms and stopped taking the 
medication. This has not been previously reported with Sativex and therefore may have been an 
atypical reaction to the medication or may have reflected an anxiety attack. The second participant 
was taking the placebo medication (15 days into the trial) and experienced an increased heart rate, 
tightness of chest and breathing.  This required hospital investigation with no obvious cause 
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identified.  As the participant was taking the placebo it was very unlikely that this was due to the 
medication. A mild adverse event was experienced by three participants in the active group. Two 
rang the emergency phone to report that they were experiencing light-headedness, reporting this 
as feeling “very weird” and “spaced out”. One participant had taken two sprays at once in the first 
week of the trial. The other participant was in the fourth week of the trial and had stopped the 
medication for 6 days as he had a minor operation. He experienced symptoms after taking two 
sprays with a gap of a few hours in between.  The symptoms in both participants resolved after a 
few hours and they continued with the trial. One participant reported diarrhoea and stopped taking 
the medication for 4 days, on resuming the medication there were no complications and this may 
have been unrelated.   
 
Table 6-7 shows a comparison of the side effects reported by the active and placebo group on day 
28 (although for 4 participants this was reported on day 14 and for 1, day 12 due to their either 
dropping out or difficulty in contacting). There were no significant differences in side effects 
between the two groups (p > .05), although there were trends for those in the active group to report 

















Table 6-7: Comparison of side effects of the active versus placebo medication (rated using the 
Adverse Events Scale) 





Headache  15/15 0.07 (0.26) 0.2 (0.41) 1.06 (0.29) 
Dryness of the skin  15/15 0.27 (0.46) 0.4 (0.91) -0.20 (0.84) 
Dryness of the eyes  15/15 0.13 (0.35) 0.13 (0.52) -0.52 (0.60) 
Dryness of the mouth  15/15 0.4 (0.63) 0.33 (0.62) -0.36 (0.72) 
Thirst  15/15 0.6 (0.91) 0.27(0.70) -1.44 (0.15) 
Sore throat  15/15 0.33 (0.62) 0.07 (0.26) -1.47 (0.14) 
Dizziness  15/15 0.2 (0.41) 0.00 (0.00) -1.80 (0.07) 
Nausea  15/15 0.00 (0.00) 0.00 (0.00) - 
Stomach aches  15/15 0.00 (0.00) 0.07 (0.26) 1.00 (0.32) 
Vomiting  15/15 0.00 (0.00) 0.07 (0.26) 1.00 (0.32) 
Sweating  15/15 0.00 (0.00) 0.13 (0.52) 1.00 (0.32) 
Appetite reduction  15/15 0.00 (0.00) 0.2 (0.77) 1.00 (0.32) 
Weight loss  15/15 0.07 (0.26) 0.13 (0.52) 0.05 (0.96) 
Weight gain  14/15 0.29 (0.47) 0.13 (0.52) -1.40 (0.16) 
Diarrhea  15/15 0.00 (0.00) 0.00 (0.00) - 
Frequent urination  15/15 0.13 (0.35) 0.13 (0.35) 0.00 (1.00) 
Tics  15/15 0.00 (0.00) 0.00 (0.00) - 
Sleep difficulties  15/15 0.2 (0.41) 0.4 (0.83) 0.51 (0.61) 
Mood instability  15/15 0.2 (0.41) 0.2 (0.41) 0.00 (1.00) 
Irritability  15/15 0.2 (0.41) 0.2 (0.41) 0.00 (1.00) 
Agitation/excitability  15/15 0.33 (0.62) 0.2 (0.56) -0.83 (0.40) 
Sadness  15/15 0.47 (0.74) 0.07 (0.26) -1.85 (0.07) 
Heart palpitations  15/15 0.00 (0.00) 0.2 (0.77) 1.00 (0.32) 
Sexual dysfunction  15/15 0.00 (0.00) 0.07 (0.26) 1.00 (0.32) 
Feeling worse or different 
when the medication 
wears off (rebound)  
15/10 0.13 (0.52) 0.2 (0.63) 0.30 (0.77) 
Paranoia 6/8 0.00 (0.00) 0.00 (0.00) - 






To our knowledge, this is the first randomised controlled trial of a cannabinoid medication 
(Sativex) in ADHD.  Our objective was to provide preliminary data on the relationship of short-term 
treatment with a cannabinoid-based medication on cognitive and behavioural measures in adults 
with ADHD. Although there was no significant effect for the primary outcome, performance on the 
Qb Test, trend effects were seen for the ITT and per-protocol analyses; with medium to large effect 
sizes of d= 0.59 and d= 0.84 respectively.  In both the ITT and per-protocol analysis, these effects 
appeared to be driven by reductions in the activity score (d = 0.5 and d = 0.63 respectively).  In the 
per-protocol analysis effects also appeared to be driven by reductions in commission errors 
(d=0.52). However, effects on the Qb test did not withstand the sensitivity analyses (under both the 
MAR and MNAR assumption), whereby all missing data was imputed. Given that data was missing 
mainly from the placebo group, this suggests that potential bias towards positive effects should be 
taken into account when interpreting results. 
 
For the secondary exploratory analyses for ADHD symptoms, a nominally significant treatment 
effect was found for symptoms of hyperactivity/impulsivity in both the ITT and per-protocol 
analyses with large estimates of effect sizes of d = 0.90 and d =1.03 respectively. The effect on 
hyperactivity/impulsivity, although weaker, remained in the sensitivity analysis. Symptoms of 
inattention also showed a non-significant trend to improvement in the ITT and per-protocol 
analyses, with medium effect sizes at d=0.66 and d=0.74 respectively. These trends remained in the 
sensitivity analysis. For emotional lability, there was a non-significant trend for improvement in the 
ITT analysis (measured with the CNS-LS (d = 0.65) and ALS (d = 0.52)), which was weaker in the 
per-protocol analysis (observed only for the CNS-LS). In the sensitivity analysis, trends remained 
for the CNS-LS only. For cognition measured with performance on the SART task, there was a non-
significant trend for improvements in the coefficient of variation (CV) for both the ITT and per-
protocol analysis at medium effect (d = 0.64 and d = 0.67 respectively). This trend did not remain in 
the sensitivity analysis. No other effects were observed for the SART. No treatment effects were 
observed for functional impairment in either the ITT, per-protocol or sensitivity analyses. None of 
the significant effects for either the primary or secondary outcomes withstood correction for 




As a whole this study failed to identify significant changes from baseline to endpoint for the 
primary and secondary variables, using conventional levels of significance and adjusting for the 
number of cognitive and behavioural variables investigated.  Nevertheless the findings are of 
interest because effects were in the expected direction for a positive effect for most variables, some 
showed nominal significance, and estimates of effect size were moderate to large, raising the 
expectation that further larger investigations would show significant effects. On this basis, the 
findings provide preliminary evidence that Sativex may reduce hyperactivity/impulsivity and 
perhaps inattention in adults with ADHD. Evidence for improvements in cognition measured by the 
Qb Test and the SART and emotional lability were weaker although still appeared to be promising. 
There was no evidence of change in functional impairment, although the short duration of the study 
may have not been appropriate for measuring any change in functional impairment.  
 
Greater estimates of effect size were found in the per-protocol than the ITT analysis. The per-
protocol analysis includes participants who adhered strictly to the protocol. The ITT analysis is 
considered to be less prone to bias by including all participants who were randomised (and for 
whom follow-up data were available) (Gupta, 2011).  Therefore effect sizes found in the per-
protocol analysis are generally larger than those found in the ITT. Effects found in both the per-
protocol and ITT analysis provide preliminary evidence for the presence of a treatment effect. 
Therefore this study found evidence for potential effects of Sativex to improve symptoms of 
hyperactivity/impulsivity. Indications of improvement for inattention and the Qb Test were 
stronger in the per-protocol than the ITT analysis, providing overall weaker evidence. However, 
given the small sample size these initial findings are promising. 
 
The greatest improvement in this study was found for symptoms of hyperactivity/impulsivity, with 
treatment effects on inattention at trend. One possible explanation for improvement in 
hyperactivity/impulsivity may be due to the calming and anxiolytic effects of cannabidiol (CBD) and 
Δ9-THC, the two cannabinoids found in Sativex (Zuardi et al., 2006).  Research administering acute 
doses of these cannabinoids (in placebo-controlled designs) in typically developing controls and 
cannabis users find effects to include feeling “calm” and “relaxed” (D’Souza et al., 2008; Zuardi et al., 
2006). The calming effect of cannabis in those who are non-ADHD symptomatic may be impairing 
and sedating, whereas those with ADHD, who have increased levels of restlessness and impulsivity, 
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may show differences in response. The calming effect may help to alleviate these symptoms and 
allow for improved outcomes. Reduction in symptoms of hyperactivity/impulsivity may also lead to 
'top-down' improvements in inattention due to better ability to remain still and therefore focus 
(which could account for the larger effect size found for hyperactivity/impulsivity). Differences in 
response may be due to the proposed effect of cannabinoids on dopamine levels and differences in 
these levels between adults with ADHD and controls (this will be discussed later). The theory of 
differential response to Sativex between adults with ADHD and controls highlights the need to 
include a control group in either a future treatment trial, or in a study that administers acute doses 
of Sativex, in order to clarify this proposal. 
 
This study has indicated that Sativex could have a positive effect on cognition. Preliminary evidence 
for effects on the Qb test were found for improvements in activity and potentially commission 
errors, and for the SART for improvements in CV, although these trends for improvement did not 
withstand the sensitivity analysis whereby data was imputed for all participants. This suggests that 
the increased rate of drop-outs in the placebo than the active group may have biased results in 
favour of the treatment group. Despite this limitation, multiple imputation is conservative therefore 
these results may be indicative of a potential treatment effect on these measures. A larger trial 
where a greater number of participants are randomised to the placebo arm (to account for 
potential drop-out) will be required to provide more definitive evidence.  
 
Indications of improvements in commission errors (inhibition) and RTV (indexed by CV) is a 
somewhat surprising result given that reviews have associated cannabis use with impaired 
cognitive function including inhibitory deficits (Crean, Crane, & Mason, 2011; Solowij & Battisti, 
2008).  Acute Δ9-THC administration has been associated with significant impairments in response 
inhibition (McDonald et al., 2003; Ramaekers et al., 2009), commission and omission errors and 
reaction time (McDonald et al., 2003; Ramaekers et al., 2009; Ramaekers et al., 2006). Although this 
is not a robust finding as for example, the same study that found deficits in response inhibition did 
not find deficits in omission and commission errors  (McDonald et al., 2003).  Despite this mixed 
evidence, to our knowledge there is no evidence, from a sample of both naive and regular users, 





This preliminary evidence to suggest that cannabinoids improve behavioural and potentially 
cognitive function in adults with ADHD could be explained in terms of individual differences in 
response to cannabinoids. The ADHD population may represent a subgroup of people who more 
commonly respond positively to cannabinoid medication than would a sample from the general 
population.  The presence of individual differences in response to cannabis is well established 
(Block, Erwin, Farinpour, & Braverman, 1998; Green, Kavanagh, & Young, 2003).  For example, 
experimental studies of intravenous Δ9-THC administration in typically developing participants 
find some but not all (~40-50%) will experience psychotic symptoms (Englund et al., 2012; 
Morrison et al., 2009).  
 
Subjective accounts from patients in this trial, who commonly reported improvements in focus and 
concentration, gives support to the proposal that adults with ADHD respond more positively to 
cannabinoids than those in the general population. The high levels of ADHD symptoms seen in the 
ADHD population may moderate the effects of cannabinoids on behavioural and potentially 
cognitive function, leading to a more positive response (Meier et al., 2012; Mokrysz et al., 2014).  
Interestingly, heavy cannabis users have been found to show less cognitive impairment following 
cannabis use than occasional users (D’Souza et al., 2008; Ramaekers et al., 2009), although one 
possibility is that heavy users have developed tolerance to the drug. This explanation is unlikely for 
the current trial which may have been too short for the development of tolerance. A recent trial 
found no evidence of tolerance development after 1-3 years of Sativex use in patients with multiple-
sclerosis (Serpell, Notcutt, & Collin, 2013). Furthermore a baseline level of tolerance to 
cannabinoids is unlikely, given that the majority of participants were either cannabis naive (33%), 
or were not currently using the drug (50%), with only 13% currently using on a daily basis. 
Therefore regular users who may have a tolerance to the drug were in a minority. An alternative 
explanation for the potential beneficial effect of cannabinoids on behaviour and cognition is that 
those who are drawn to cannabis may be 'innately' protected from the negative effects of the drug 
(D’Souza et al., 2008). Given the high incidence of ADHD which has been found in those who abuse 
or are dependent on cannabis (Dennis et al., 2004), the theory of being 'innately' protected from the 




Potential improvements in cognition could also be linked to the high concentration of the 
cannabinoid cannabidiol (CBD) found in Sativex (which contains Δ9-THC and CBD in a 1:1 ratio).  
Studies in humans have suggested Δ9-THC to be responsible for the cognitive deficits induced by 
cannabis and that CBD may protect against these impairments (Englund et al., 2012; Morgan et al., 
2012; Morgan et al., 2010). A potential explanation is that possible cognitive improvements are a 
combination of the CBD concentration and more positive response to the cannabinoid medication 
in adults with ADHD. Investigation of the differential effects of CBD and Δ9-THC in adults with 
ADHD would be important to clarify this proposal. 
 
The physiological effects of cannabis may also underpin the theory that those with ADHD show 
individual variation in response to cannabinoids. One mechanism of action of cannabis is thought to 
be through alterations in dopamine.   Abnormalities in dopamine levels, particularly in the striatum, 
is a common theory of ADHD (del Campo et al., 2012; Hesse et al., 2009; Krause et al., 2005; Krause 
et al., 2000),  evidenced mainly by the positive effects of dopamine-enhancing stimulant medication 
(Leonard et al., 2004;  Volkow et al., 2002).  Striatal dopamine is thought to modulate the 
endocannabinoid system (ECS) (Centonze et al., 2009), and a number of studies have found Δ9-THC 
administration to increase dopamine in the striatum (Bossong et al., 2009, 2015; Kuepper et al., 
2013) and in other brain areas implicated in ADHD, such as the prefrontal cortex in animal studies 
(Chen et al., 1990; Pistis et al., 2002), and the right middle frontal gyrus and left superior frontal 
gyrus in human studies (Stokes et al., 2010). Other studies have, however, contradicted the 
dopamine-agonist effects of cannabis (Barkus et al., 2011; Bloomfield et al., 2014; Stokes et al., 
2009).  Further research into the mechanism of action of Sativex is therefore important in order to 
clarify the effects on dopamine. 
 
Although this study found only nominally significant effects or trends, effect sizes on ADHD 
symptoms were medium to large (d=0.7-1), which is equivalent to those found for stimulant 
medication on ADHD symptoms (d ~ 0.6-1.0) (Faraone & Buitelaar, 2010; Faraone & Glatt, 2010; 
Faraone et al., 2004; Mészáros et al., 2009).  Effects on cognition (Qb impulsivity and SART CV) 
(d=0.5-0.7) were also equivalent to that found for stimulant medication on cognition (d =~0.2-0.6) 
(Coghill et al., 2014).  These are promising results, since the lack of significant effects may be due to 
the small sample size employed in this study.  Power calculations, taking the smallest effect on 
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ADHD symptoms (d = 0.7), indicate a total sample size of 68 participants would be required (α = 
0.05, power = 0.81) to detect an effect at a nominal level of significance, and 118 participants after 
correction for multiple testing (α = 0.004, power = 0.80). For cognition, a total sample of 128 
participants would be required (d = 0.05, α = 0.05, power = 0.80), and 226 after correction for 
multiple testing. A future trial should include fewer outcome measures in order to increase the α 
after correction for multiple testing and aim to recruit 150-200 participants in order to gain a 
definitive answer to whether Sativex may improve symptoms and cognition in ADHD. 
 
Results here have provided objective preliminary evidence which goes towards explaining the 
subjective reports of adults with ADHD. Such patients have reported an improvement in their 
symptoms following cannabis use including feeling reduced restlessness and distractibility with 
improved concentration and ability to sustain focus.  Subjective accounts from patients in the active 
group are reported in Table 6-6 and Appendix E, Table AE-5. Positive feedback was more than 
double the negative feedback and most commonly included: feeling calmer, improved 
focus/concentration, more relaxed, improved sleep and reduced anxiety. Negative feedback was 
generally regarding the sedative effects of the medication and atypical feelings (e.g. odd thoughts, 
detachment) at higher doses.  Furthermore, we did not find any change in impairment between the 
active and placebo groups. This is important given that cannabis is often associated with functional 
impairment in the general population.  The results here are therefore in line with the theory that 
individuals with ADHD may be using cannabis to self-medicate (Horner & Scheibe, 1997; Wilens, 
2004).   
 
Here we have given preliminary evidence that Sativex could be an alternative treatment for adults 
with ADHD.  Given the high rates of cannabis use in ADHD, it is important that a licensed, safer 
medication is investigated. The main psychoactive chemicals in cannabis are Δ9-THC and CBD.  As 
previously discussed, the more harmful effects of cannabis use such as the association between 
cannabis and psychosis and cannabis and cognitive impairments, has been linked to Δ9-THC 
(D’Souza et al., 2009; Englund et al., 2012).  However, CBD is thought to have more protective 
effects and has been found to reduce Δ9-THC induced psychotic symptoms and cognitive 
impairments (Englund et al., 2012). Recent research has found the link between cannabis and 
psychosis may be specific to cannabis that is high in Δ9-THC (known as sinsimella (skunk)), but not 
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that which contains similar levels of Δ9-THC to CBD (known as cannabis resin (‘hash’)) (Di Forti et 
al., 2015). Sativex contains Δ9-THC and CBD in a 1:1 ratio, whereas the UK black market is currently 
dominated by Sinsemilla, with levels of Δ9-THC appearing to rise year on year, and cannabis resin 
increasingly difficult to obtain (Potter et al., 2008). The prescription of Sativex would therefore 
provide a safer alternative to the black market cannabis that is most likely being used in the ADHD 
population.  
 
A number of important limitations must be considered when taking the current results into 
account. One of the main limitations of this study is that, although participants and study staff were 
blinded throughout the trial, correct rates of guessing allocation status were high with 93% of 
participants in the active and 85% in the placebo group guessing correctly (albeit responses from 3 
participants were missing).  This is a problem inherent to the use of a cannabinoid medication as 
firstly, the majority of participants having previously used cannabis, were therefore familiar with 
its effects and secondly, the effects of the spray being noticeable even at a low dose.  Lack of 
blinding is associated with exaggerated estimates of intervention effects (Pildal et al., 2007).  
However  greater bias is observed in trials with more subjective outcomes (Wood et al., 2008). 
Therefore failure of the blind may have biased the behavioural outcomes (e.g. ADHD symptoms) 
more so than cognitive performance. Potential exaggeration of treatment effects must be taken into 
account when interpreting our results. Future trials are vital and should compare Sativex to current 
ADHD stimulant medication to reduce the chance of breaking the blind.  
  
A further important limitation to this study is that of a greater number of drop-outs in the placebo 
than the active group.  Despite sensitivity analysis indicating no difference between outcomes 
under the MNAR and MAR assumption (meaning that the MAR assumption can be accepted), 
increased drop-out in the placebo group is indicative of non-random drop-out due to lack of 
treatment effect, although this is not clear from the reasons given by the participants who dropped-
out (see Section 6.5.10  'adverse events'). Therefore, although an increased rate of drop-out in the 
placebo group may be non-random, due to lack of benefit from the study medication, we cannot say 
for certain that this is the case.  However the possibility of non-random drop-out in the placebo 
group cannot be ruled out. This is especially given that participants were required to come off their 
ADHD medication for the duration of the trial, which may have been more difficult for those who 
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were not deriving benefit from the study medication, although of the two participants who were 
lost to follow-up, only one was currently taking ADHD medication. Despite this, data imputation in 
the sensitivity analysis gave an overall negative effect for the Qb Test.  This indicates  that increased 
drop-out in the placebo compared to the active group may have inflated effect size for the Qb test in 
the ITT and per-protocol analysis due to increased power in the active group.  Although it is 
important to note that an increased drop-out rate in the placebo group supports our finding of a 
treatment effect indicating that those in the active group were more likely to derive benefit from 
the study medication, and therefore to remain in the trial.  
 
Another limitation to this trial is that the optimum dose of Sativex may not have been used by every 
participant. This experimental pilot study was, to our knowledge, the first study examining Sativex 
as a treatment for ADHD. Therefore at the start of the trial the required dose in this group of 
patients was unknown. In Section 6.4.5.2 we discuss how it quickly became clear that the titration 
schedule recommended by GW Pharma was too high (the schedule increased to 14 sprays per day 
whereas the average number of sprays taken in the active group was 4.7 (range 1-13)). Participants 
were verbally informed at the baseline session and also during regular telephone monitoring (on 
days 4, 8, 12, 14 and 28) that they should remain at a lower dose if they were finding an effect of the 
medication. However at the final testing session a small number of participants had taken a high 
dose for the majority of the trial, and verbally reported that they did not derive benefits. This may 
have been compounded by there often being difficulty in contacting participants in order to 
monitor their progress. Failure to maintain an optimum dose in every participant may have led to a 
reduced effect size in the active group. A new titration schedule which increases to a maximum 
dose of ~8-9 sprays per day but recommends an optimum dosage of 3-5 sprays should be 
developed for future trials.  
 
Furthermore, participants in the placebo group on average took a significantly higher (around 
double) number of sprays a day than those in the active group.  This could have introduced bias; 
overestimating effects in the placebo group due to a perceived 'dosing' effect. However due to the 
failure of the blind this is unlikely. As advised above, a future study should use a titration schedule 
which increases to 8-9 sprays instead of 14 sprays in the current study. This will reduce the 
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possibility of participants in the placebo group taking a dose that is considerably higher than that of 
the active group.  
 
Two serious adverse events (AE) occurred during the study. One participant in the active group 
experienced muscular seizures/spasms which may have been an atypical reaction to the 
medication or anxiety related.  The second participant in the placebo group experienced cardiac 
problems. A meta-analysis of the safety of Sativex in patients with MS found a small number of 
participants to report cardiac problems in the placebo group (n=2/303).  With such a small number 
of cardiac events it is unlikely but not implausible that the AE was due to the placebo medication.  
Although the side-effect rating scale showed no significant difference in side-effects between the 
placebo and active groups, three participants in the active group experienced a mild adverse event 
(AE) during the study. One had diarrhoea, and two participants experienced 'lightheadedness' after 
taking two sprays of Sativex either in quick succession or in the space of a few hours having not 
taken the spray for 6 days previously.  These mild AEs (e.g. gastrointestinal complaints, dizziness) 
have been experienced in other clinical studies of Sativex (Johnson, Lossignol, Burnell-Nugent, & 
Fallon, 2013; Novotna et al., 2011; Nurmikko et al., 2007; Wade, Collin, Stott, & Duncombe, 2010) 
and are listed as a common side-effect of the medication. Future trials in adults with ADHD need to 
take the AEs related to dosage (i.e. feeling 'weird', lightheadedness) into account when developing 
the titration schedule. It must be stressed to participants that they should not take two sprays at 
once. Participants should also be advised that if they stop taking the medication for a number of 
days they will need to titrate back onto the spray (i.e. begin at 1 spray per day).  The occurrence of 
only one serious adverse event in the active group suggests that as a whole the medication was well 
tolerated.  
 
Another point to consider in the proposal that Sativex could be an alternative treatment for adults 
with ADHD is the potential for abuse of this drug and development of tolerance. The potential for 
abuse of Sativex at varying dosages was examined in a treatment trial with recreational cannabis 
users (Schoedel et al., 2011). At a dose of 4 sprays there was no more potential for abuse than the 
placebo medication. Higher doses of Sativex (8-16 sprays) showed more potential for abuse than 
placebo.  Sativex may not therefore be suitable for those with a history of abuse. It is important to 
point out, however, that stimulant medication which is currently prescribed for adult ADHD is a 
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controlled drug which also has potential for abuse.  Tolerance has been discussed previously with a 
study investigating the long-term use of Sativex finding no evidence of tolerance-dependence in 
patients with MS who remained on the spray for between to 1-3 years.  This is a promising result, 
although given the different patient population, this would need to be assessed in adults with 
ADHD.  
 
In conclusion, this experimental pilot study has given preliminary evidence for the efficacy of 
Sativex in treating the symptoms, and to a lesser extent cognitive deficits, in adults with ADHD. The 
medication was relatively well tolerated without causing any significant impairment. This 
corroborates the subjective accounts of patients who may be currently self-medicating with 
cannabis.  This evidence has provided a basis for the suggestion that Sativex could be suitable as a 
treatment for those who either cannot tolerate or find current ADHD medication to be ineffective.  
A large trial (150-200 participants) comparing Sativex with current stimulant medications is vital 


















Chapter 7: Overall conclusions and future directions 
7.1 Summary 
Treatments for ADHD in the form of stimulants and atomoxetine have moderate to large effects on 
both symptoms and impairments, and provide good control of the condition for the majority of 
cases. Yet there remains a significant group for whom treatment is sub-optimal, either due to 
partial or no clinical response, or to adverse effects. This has led to the continued search by 
clinicians, researchers and patient’s to find effective alternative treatments. The aim of this thesis 
was to investigate the effect of two such alternative treatments: Omega-3 Polyunsaturated Fatty 
Acids (n-3 PUFAs) and a cannabinoid medication (Sativex Oromucosal Spray) on ADHD symptoms 
and associated impairments of cognitive performance and emotional lability (EL).   
 
This thesis presents four novel studies. A systematic review and meta-analysis of the effects of n-3 
PUFA supplementation on cognition showed no evidence for an effect in the general population or 
in children with ADHD or with a related disorder. Marginal evidence for effects was found in those 
who were n-3 PUFA deficient. A further meta-analytic study found suggestive evidence of a small 
effect of n-3 PUFA supplementation on reducing emotional lability (EL) and oppositional behaviour 
in children with ADHD or with a related neurodevelopmental disorder. The thesis then presents the 
first randomised controlled trial (RCT) of n-3 PUFA supplementation in adults with ADHD. Baseline 
case/control comparisons showed the ADHD group to have significant impairments in cognitive 
performance, as well as severe levels of ADHD symptoms and EL. However, no differences in n-3 
PUFA blood levels were found that might have indicated a role for dietary deficiency. 
Supplementation gave marginal (non-significant) evidence for improvements in inattention and 
potentially EL, but no apparent effects on cognition. The negative results should be interpreted with 
caution given a high drop-out rate, yet the findings suggest that any possible effects are likely to be 
small and might therefore lack clinical significance.  The final part of this thesis presented the first 
RCT of a cannabinoid medication, Sativex Oromucosal Spray, in adults with ADHD. Sativex was 
found to lead to nominally significant improvements in hyperactivity/impulsivity, with a trend for 
improvements in inattention and to a lesser extent cognitive performance.  The small sample size 
used in this preliminary investigation, combined with the moderate to large effects observed, 
provide a promising initial set of findings.  
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As a whole this thesis does not support the proposed efficacy of n-3 PUFA supplementation on 
cognition in either children or adults with ADHD. The trial and also meta-analysis data identifies 
possible effects on EL and inattention, yet any potential effects are likely to be small and may 
therefore lack clinical relevance. The evidence from the Sativex trial is more promising.   
 
7.2 Overview of findings  
Table 7-1 restates the original hypotheses from each chapter with a brief summary of the relevant 
findings and an indication of whether each hypothesis was supported. Of the 14 proposed 
hypotheses, one was supported, partial evidence was provided for five, weak evidence for one, and 










Table 7-1: Summary of findings in relation to original study hypotheses (n.b. Support for hypothesis from low-high: No, Weak Evidence, Partially, Yes) 
Hypothesis Supported? Specific Results 
Chapter 2: Omega-3 polyunsaturated fatty acid supplementation and cognition: a systematic review and meta-analysis 
Primary hypotheses   
1) Omega-3 PUFA supplementation will improve 
cognitive performance in children with ADHD or 
with a related neurodevelopmental disorder (e.g. 
dyslexia) (ADHD + RND group). 
No  Supplementation did not lead to improvements in any of the cognitive 
performance measures in children with ADHD+RND. 
2) Omega-3 PUFA supplementation will improve 
cognitive performance in typically developing 
children and adults (TD group). 
No  Supplementation did not lead to improvements in any of the cognitive 
performance measures in the TD Group. 
Secondary hypotheses (subgroup analysis)   
3) Omega-3 PUFA supplementation will improve 
cognitive performance in the ADHD+RND/TD group 
in those who are n-3 PUFA deficient. 
Partially  Supplementation in those who were n-3 PUFA deficient led to improvements in 
short-term memory across the TD and ADHD+RND group. 
 Supplementation in those who were n-3 PUFA deficient did not lead to 
improvements in inhibition, working memory, reading, or mean reaction time. 
4) Omega-3 PUFA supplementation will improve 
cognitive performance in ADHD+RND/TD group in 
studies that met strict inclusion criteria or were of 
high quality.  
No  Supplementation did not improve cognitive performance in these subgroups. 
5) Omega-3 PUFA supplementation will improve 
cognitive performance in ADHD+RND/TD group in 
studies that supplemented with adequate EPA or 
included participants with more homogenous 
cognitive impairments.  
No  Supplementation did not improve cognitive performance in these subgroups. 
Chapter 3: The effect of omega-3 polyunsaturated fatty acid supplementation on emotional lability, oppositional behaviour and conduct problems in 
ADHD: A systematic review and meta-analysis. 
Primary hypothesis   
6) Omega-3 PUFA supplementation will improve EL, 
oppositional behaviour, conduct problems, and 
aggression in children with ADHD or with a related 
disorder (e.g. disruptive behaviour disorder) 
No  Supplementation did not lead to improvements in EL and related domains of 




Hypothesis Supported? Specific Results 
(ADHD+RND group). 
Secondary hypothesis (subgroup analysis)   
7) Omega-3 PUFA supplementation will improve EL 
and oppositional behaviour in children with 
ADHD+RND in studies that met strict inclusion 
criteria or were of high quality. 
Partially  In studies that met strict inclusion criteria supplementation was found to have a 
small effect on EL. There was a trend for an effect on oppositional behaviour.  
 In high quality studies there was an indication of an effect on oppositional 
behaviour. No effects were found for EL. 
8) Omega-3 PUFA supplementation will improve EL, 
oppositional behaviour and aggression in children 
with ADHD or with a related disorder in studies that 
included participants with elevated levels of EL or 
supplemented with adequate EPA. 
Partially   In studies that supplemented with adequate EPA there was a trend for 
supplementation to improve oppositional behaviour. There was no effect on 
aggression or EL. 
 In studies that supplemented children with elevated levels of EL there was no 
effect on oppositional behaviour, no other domains could be examined. 
Chapter 5: The OCEAN study: A randomised controlled trial of omega-3 supplementation in adults with ADHD. 
9) Compared to controls, adults with ADHD will 
show impaired cognitive performance and 
increased symptoms of emotional lability (as well as 
ADHD symptoms). 
Yes  Adults with ADHD compared to controls had impaired cognitive task performance 
and significantly higher levels of ADHD symptoms and emotional lability. 
10) Adults with ADHD compared to controls will 
have reduced blood n-3 PUFA levels and a higher n-
6:n-3 PUFA ratio. 
 
No  Adults with ADHD did not have reduced n-3 PUFA or a higher n-6:n-3 ratio 
compared with controls. 
 In contrary to the hypothesis adults with ADHD compared with controls had 
higher levels of the n-3 PUFA DPA. 
11) Supplementation with n-3 PUFA in adults with 
ADHD will improve cognition. 
 
No  Supplementation did not improve cognitive performance in either the ITT or per-
protocol analysis. 
12) Supplementation with n-3 PUFA in adults with 
ADHD will improve ADHD symptoms and EL. 
Weak 
evidence 
 Supplementation had no effect on ADHD symptoms or emotional lability in the 
ITT analysis. 
 Supplementation showed a nominally significant improvement in inattention and 
a trend for improvement in EL. 
Chapter 6: The effects of Sativex on neurocognitive and behavioural function in adults with attention-deficit/hyperactivity disorder: The EMA-C study 
(Experimental Medicine in ADHD - Cannabinoids) 
13) Treatment with Sativex in adults with ADHD 
will improve cognitive performance.  
Partially  Treatment resulted in a trend for improved cognitive performance in the ITT and 
per-protocol analysis. 
 Results interpreted in light of potential bias from an increased drop-out rate in 
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Hypothesis Supported? Specific Results 
the placebo group 
14) Treatment with Sativex in adults with ADHD 
will improve symptoms of ADHD and emotional 
lability. 
Partially  Treatment resulted in a nominally significant improvement in 
hyperactivity/impulsivity and a trend for improvement in inattention in both the 
ITT and per-protocol analysis. 
 Treatment resulted in a trend for improvement in EL in both the ITT and per-
protocol analysis (albeit evidence for improvement was weaker than for 
symptoms of ADHD). 















Chapters 2 and 3 examined the effect  of n-3 PUFA supplementation on cognitive performance 
(Cooper et al., 2015) and EL (and related domains of oppositional behaviour, conduct problems and 
aggression) (R E Cooper et al., 2016) using a systematic review and meta-analysis.  Effects on EL 
and cognitive performance were investigated in children with ADHD (or who had a 
related/overlapping neurodevelopmental disorder such as dyslexia or disruptive behavioural 
disorder (ADHD+RND group). This was on the basis that meta-analyses have found a small to 
moderate effect of n-3 PUFA supplementation on reducing symptoms of ADHD, however no study 
has yet summarised effects on the associated impairments of cognition and EL. We further included 
typically developing children and adults (TD group) in the cognition study. This was on the basis 
that, despite limited evidence, omega-3 products are often promoted as cognitive enhancers and 
are widely consumed in the general population.  Results were as follows: 
 
Chapter 2: The effect of n-3 PUFA supplementation on cognitive performance in a TD and 
ADHD+RND group was examined.  Cognitive performance was classed into nine domains: IQ, 
inhibition, attention (measured with omission errors), working memory, short-term memory, 
reading, spelling, mean reaction time and reaction time variability. Twenty four studies (14 in TD 
children and adults and 10 in ADHD+RND children) were included in the quantitative synthesis.  
Results showed no effect of n-3 PUFA supplementation in either the whole sample, or the TD or 
ADHD+RND group when analysed separately.  The only significant outcome was for a small 
improvement in short-term memory in those who may have been deficient in n-3 PUFA (SMD=0.3; 
across the TD and ADHD+RND groups). It was concluded that future treatment trials should 
consider recruiting only participants who are n-3 PUFA deficient. It was further concluded that 
regulators and producers of n-3 products should take this evidence, of a generally null effect on 
cognition, into account when promoting their products.  
 
Chapter 3: The effect of n-3 PUFA supplementation on emotional lability, oppositional behaviour, 
conduct problems, and aggression in an ADHD+RND group was investigated.  Ten studies in 
children were included in the quantitative synthesis. Although the initial analysis in the whole 
sample found no significant treatment effects, subgroup analyses suggested small effects 
(SMD=0.15-0.25) could be present. In studies that met strict inclusion criteria a small but 
significant effect of supplementation was found for EL and a trend for an effect on oppositional 
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behaviour.  In high quality studies a nominally significant effect on oppositional behaviour was 
found. In studies that supplemented with adequate EPA there was a trend for an improvement in 
oppositional behaviour. It was concluded that small effects of n-3 PUFA supplementation on EL and 
oppositional behaviour are possible, however, given the size of these effects, n-3 PUFA may not be 
appropriate as a monotherapy for reducing these symptoms.  Future studies in larger samples are 
required to clarify effects. 
 
Results from these reviews showed that there are as yet no published trials of the effect of n-3 
PUFA supplementation in adults with ADHD. The following chapter therefore presented results 
from an RCT of n-3 PUFA supplementation in adults with ADHD.   
 
Chapter 5: This chapter presented results from a case/control comparison and RCT of n-3 PUFA 
supplementation in 81 adults with ADHD and 30 typically developing controls. Baseline 
comparisons showed the ADHD cases to have significantly impaired cognitive performance and 
more severe symptoms of EL (as well as ADHD) compared to controls.  We also found two novel 
results. First, we found evidence for sensitivity to reward and presentation rate of stimuli during a 
reaction time task, the Fast Task, for adults with ADHD.  This has previously only been found in 
children with ADHD (Andreou et al., 2007; Cheung et al., under review.; Slusarek et al., 2001; Uebel 
et al., 2010), and therefore suggests developmental stability of this trait.  Sensitivity to rewards is 
consistent with the 'state regulation' hypothesis of ADHD which proposes cognitive deficits in 
ADHD are the result of a reduced energetic state and are therefore malleable in the presence of 
rewards or a faster event rate (this will be discussed in more detail in section 7.4.5) (Kuntsi et al., 
2012; Sergeant, 2000). We have therefore provided evidence to suggest the persistence of deficient 
state regulation from childhood to adulthood in ADHD.  The second novel finding was objective 
evidence under task conditions of difficulties with emotion regulation/over-reactivity and reduced 
frustration tolerance in adults with ADHD, during a task designed to induce frustration.  Baseline 
comparisons then showed there to be no difference in the blood n-3 PUFA levels of adults with 
ADHD compared with controls that might potentially have contributed to the observed case-control 
differences as suggested by some authors. On the contrary, there was an indication of slightly 
higher n-3 PUFA levels (for docosapentaenoic acid (DPA)) in the ADHD group. Results from the RCT 
showed no indication of a treatment effect on cognition, ADHD symptoms, or EL in the intent-to-
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treat (ITT) analysis, but marginal evidence for improvement in inattention and, to a lesser extent 
EL, in the per-protocol analysis. These results should be interpreted cautiously in light of 
limitations due to a high drop-out rate. They provide only very limited evidence for an effect of n-3 
PUFA on inattention and potentially EL in adults with ADHD, with any possible effects likely to be 
small. 
 
Chapter 6: This chapter presented results from an RCT of the cannabinoid medication Sativex 
Oromucosal Spray in 30 adults with ADHD. Sativex was found to lead to nominally significant 
improvements in hyperactivity/impulsivity and a trend for improvement in inattention. There were 
further indications for improvement in cognition for commission errors and the coefficient of 
variation (CV). While these effects on cognition were non-significant in this study, the effect was a 
positive one and in the opposite direction to previous findings of impaired cognitive performance in 
non-ADHD subjects. A sensitivity analysis suggested however that these results might have been 
biased towards a treatment effect due to an increased drop-out rate in the placebo group. As a 
whole, given the small sample size and potentially moderate to large effects, this initial evidence is 
promising. Further investigations into the role of cannabinoids in the treatment of ADHD symptoms 
and associated impairments, and the underlying mechanisms, is therefore warranted on the basis 
of these results.   
 
7.3  How results relate to each other  
7.3.1 Differences in the treatment response of cognitive and behavioural symptoms 
One recurrent theme that has been supported in all four chapters is that of a greater response of the 
behavioural rather than cognitive symptoms to treatment in adults and children with ADHD. 
Chapter 2 found no effect of n-3 PUFA supplementation on cognitive performance in children with 
ADHD, while Chapter 3 found preliminary evidence that supplementation may have a small effect 
on reducing symptoms of EL and oppositional behaviour. Chapter 5 followed this pattern: finding 
no indication for an effect of n-3 PUFA supplementation on cognitive performance, but some 
preliminary evidence for an improvement in inattention and to a lesser extent EL. Finally Chapter 6 
followed a similar pattern with stronger treatment effects for ADHD symptoms (and potentially EL) 
than cognitive performance.  Differential response of the behavioural and cognitive symptoms to 
treatment is in line with previous meta-analyses and systematic reviews, which have found a 
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smaller treatment effect of stimulant medication on cognitive performance (d=~0.2-0.6) (Coghill et 
al., 2014) than on ADHD symptoms (~0.8-1.0) (Banaschewski et al., 2006; Faraone & Buitelaar, 
2010).  It has also been observed that during the clinical response to methylphenidate there is a 
dissociation of the treatment effects on ADHD symptoms and cognitive performance in children and 
adolescents with ADHD (Bédard et al., 2014; Coghill et al., 2007; K. P. Schulz et al., 2014).  This, and 
the evidence of differential response to treatment in this study, supports the proposal that different 
mechanisms could be responsible for change in cognitive performance and change in behavioural 
symptoms (Coghill et al., 2007). 
 
Differences in treatment response of behavioural symptoms and cognitive performance may reflect 
the neuropsychological heterogeneity typically seen in ADHD. This is on the basis that the ADHD 
diagnosis is made on behavioural not cognitive symptoms and therefore the participants included 
in this thesis, whilst being relatively homogenous for symptoms of inattention and 
hyperactivity/impulsivity, will be more heterogeneous for cognitive deficits and symptoms of EL. 
This is illustrated by the effect sizes of the case/control differences with the largest being for ADHD 
symptoms (the selection variable): d=2.8-3.7, then rating scale measures of EL d=1.9-2.3 and the 
smallest for cognitive performance: d=0.3-1.0. Reduced baseline impairments in cognitive 
performance will lead to a reduced effect size from treatment. Future work, which has cognitive 
performance as the primary outcome, could screen participants for deficits in these measures and 
recruit those who are above a certain threshold of impairment. This would allow for better 
investigation of treatment effects on cognition.   
 
7.3.2 Sativex and n-3 PUFA supplementation as a treatment for adults with ADHD 
This thesis has examined two potential alternative treatments for ADHD; n-3 PUFA 
supplementation, and Sativex Oromucosal Spray. Results from the RCT indicate that Sativex has 
more potential as treatment than n-3 PUFA supplementation.  Sativex resulted in a trend for 
improvement in cognitive performance (at a moderate effect: d=~0.5-0.6) whereas n-3 PUFA 
supplementation showed no effect on this measure. Sativex, in both the ITT and per-protocol 
analysis, showed a nominally significant effect of improving symptoms of hyperactivity/impulsivity 
(at large effect: d=~0.9-1.00) and a trend for improving inattention (at moderate effect: d=~0.6-
0.7) whereas n-3 PUFA supplementation showed a nominally significant effect on improving 
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inattention in the per protocol analysis only (although the moderate effect size was equivalent to 
that found for Sativex: d=0.7). Both treatments showed only trends for improvements in EL, 
although for Sativex this was found in both the per-protocol and intent-to-treat (at moderate effect: 
d=~0.5-0.6), whereas for n-3 PUFA supplementation this was only in the per-protocol (although 
again, the moderate effect sizes were equivalent: d=~0.5). Therefore as a whole, results from this 
thesis give preliminary evidence for a moderate effect of n-3 PUFA supplementation on reducing EL 
and inattention but stronger evidence for moderate to large effects of Sativex on improving ADHD 
symptoms, EL, and to a lesser extent cognitive impairments in adults with ADHD. An RCT of Sativex 
in a larger sample (150-200 people: based on power calculations in the discussion of Chapter 6 
(section 6.6)) will be required to confirm these promising results.  
 
7.3.3 Mechanism of action of n-3 PUFA and Sativex  
One of the theories behind the mechanism of action of the two treatments researched in this thesis 
is that they act through the dopamine system. Through alterations of cellular communication, 
deficiencies in n-3 PUFA have been linked to altered neurotransmission including dopamine (Assisi 
et al., 2006; Chalon, 2006; Haag, 2003; Young & Conquer, 2005). A number of studies in animals and 
humans have found administration of the cannabinoid Δ9-THC to increase dopamine in the 
striatum (Bossong et al., 2009, 2015; Kuepper et al., 2013) and in other brain areas implicated in 
ADHD (Chen et al., 1990; Pistis et al., 2002; Stokes et al., 2010).  Given that a common theory of 
ADHD is that of dopamine abnormalities (del Campo et al., 2012; Hesse et al., 2009; Krause et al., 
2005; Krause et al., 2000), and that this thesis has given promising results for Sativex as a 
treatment for adult ADHD, preliminary evidence for n-3 PUFA supplementation as a treatment in 
children with ADHD, and to a lesser extent adults, we have provided some evidence to warrant 
further investigation of the mechanisms of action of n-3 PUFA and Sativex, to ascertain whether any 







7.4 How results relate to other research findings 
7.4.1 The effect of Omega-3 PUFA on cognition and emotional lability 
Results from Chapter 2, of there being no evidence for an effect of n-3 PUFA supplementation on 
cognition in TD children, and adults and children with ADHD+RND, is in agreement with the mixed 
evidence from individual studies (Antypa, Van der Does, Smelt, & Rogers, 2009; Dalton et al., 2009; 
Hirayama et al., 2004; Jackson, Deary, Reay, Scholey, & Kennedy, 2012; Parletta, Cooper, Gent, 
Petkov, & O’Dea, 2013; Sinn et al., 2008; Vaisman et al., 2008; Voigt et al., 2001). These results go 
against narrative reviews which have suggested n-3 PUFA to improve cognitive performance (Assisi 
et al., 2006; Bryan et al., 2004; Horrocks & Yeo, 1999; Stonehouse, 2014).  However these reviews 
failed to provide a critical examination of the literature and, as they were narrative and therefore 
did not include meta-analyses, were limited in their ability to provide firm conclusions. 
 
Results from Chapter 3 provide evidence for small effects of n-3 PUFA on EL and oppositional 
behaviour in children with ADHD+RND. This is in line with epidemiological and cross-sectional 
studies which have associated deficiencies in n-3 PUFA with emotionally labile behaviour in 
children adolescents and adults with and without ADHD (Corrigan et al., 1994; Gow et al., 2013;  
Hibbeln, 2001; Iribarren et al., 2004; Stevens et al., 1996).  Results are also in line with a meta-
analysis which found n-3 PUFA supplementation to lead to significant reductions in aggression in 
children, adolescents, and adults with and without ADHD (Benton, 2007). This meta-analysis found 
a larger effect size (SMD =0.61) than was found in Chapter 3 (SMD=0.15-0.25) which was attributed 
to a number of limitations to the study by Benton, including the combining of a range of 
heterogeneous measures (e.g. psychological tasks with rating scales), and study populations (e.g. 
ADHD and Borderline Personality Disorder).  
 
Taken as a whole, results from Chapters 2 and 3 (Cooper et al., 2015, 2016), combined with 
previous meta-analyses (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-Barke et al., 2013), 
mean that we now have the most accurate idea possible of the effects of n-3 PUFA supplementation 
on ADHD symptoms and associated impairments in cognitive performance.  Omega-3 PUFA 
supplementation, in children with ADHD appears to have a small but significant effect on reducing 
symptoms of ADHD (SMD=0.21-0.31), and to a lesser extent EL and oppositional behaviour 
(SMD=0.15-0.25). Supplementation does not appear to affect cognitive performance aside from 
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potentially in children with ADHD who are deficient in n-3 PUFA (SMD=0.26). Effects on behaviour 
have been proposed to be mediated through alterations in neurotransmitters, particularly 
dopamine, a neurotransmitter which has been implicated in ADHD (Bolea-Alamañac et al., 2014), 
although there is currently no direct evidence to support this. Therefore n-3 PUFA supplementation 
could be used as a treatment for ADHD in children, although given the small effect sizes in 
comparison to pharmacological treatment it is advised that it be used as augmentation to 
traditional treatment, or as a monotherapy for those who do not wish to use pharmacological 
treatment. 
 
7.4.2 Omega-3 PUFA as a treatment for adults with ADHD 
The finding of no difference, or even potentially higher, levels of n-3 PUFA in adults with ADHD 
compared with controls (Chapter 5) goes against a recent meta-analysis (Hawkey & Nigg, 2014) 
and individual studies (Chen et al., 2004; Stevens et al., 1995; Germano et al., 2007; Antalis et al., 
2006). These studies have found reduced blood levels of n-3 PUFA (particularly EPA and DHA) and 
an increased n-6:n-3 PUFA ratio in children and adults with ADHD compared to controls.  Although 
on closer examination of the meta-analysis the majority (6/9) of included studies were conducted 
in children. The effect sizes from studies in children were also generally more significant than those 
conducted in adults. Therefore it is possible that n-3 PUFA differences may be more apparent in 
children than in adults. This weakens the proposed causal relationship between n-3 PUFA levels 
and symptoms of ADHD in adults, although this may still hold true in children. Large cross-sectional 
studies examining case/control differences in n-3 PUFA levels and longitudinal studies examining 
n-3 PUFA levels and ADHD symptoms from childhood to adulthood are required to clarify the role 
of n-3 PUFA in ADHD; although the previously reported treatment trials in children do suggest they 
play some role.   
 
Supplementation with n-3 PUFA gave weak evidence of improvements in inattention and 
potentially EL, and no evidence for improvements in cognition. As previously discussed this is in 
line with meta-analyses conducted by myself and other research groups which have found small 
effects of supplementation on ADHD symptoms in children (Bloch & Qawasmi, 2011; Hawkey & 
Nigg, 2014; Sonuga-Barke et al., 2013), and to a lesser extent EL (Cooper et al., 2016), and no effect 
of supplementation on cognitive performance (Cooper et al., 2015).  To our knowledge this is the 
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first study in adults with ADHD. Our conclusions of weak evidence for an effect of supplementation 
on inattention and EL were limited by a high drop-out rate and low power and as such no firm 
conclusions can be drawn. We can only exclude large effects and it may still be the case that smaller 
effects, similar to those seen in children, may emerge.  A further study in a larger sample is 
therefore warranted.  In line with this, a second RCT in 60 adults with ADHD is currently being 
conducted by Michael Rösler's group at Saarland University (Germany). This group have used the 
same outcome measures for ADHD symptoms (CAARS/WRADDS (Conners et al., 1999; Wender, 
1995)) and EL (CNS-LS (Moore et al., 1997)/ALS (Oliver & Simons, 2004)) as those used in the 
current study, and we will be combining our data in the near future.   
 
7.4.3 Sativex as a treatment for adults with ADHD 
Our study of the effects of the cannabinoid medication Sativex in adults with ADHD, is to our 
knowledge, the first of its kind, and therefore direct comparisons to previous research studies 
cannot be made. However the subjective accounts of patients which provided the impetus for this 
study suggested symptom improvement might be substantial and perhaps similar to that found in 
response to traditional ADHD medications. This was supported by the effect sizes found in this 
study of d=0.7-1.0 for ADHD symptoms, and d=0.5-0.7 for cognition, which are similar to the effect 
sizes found on these domains for stimulant medication (Coghill et al., 2014; Faraone & Buitelaar, 
2010; Faraone & Glatt, 2010; Faraone et al., 2004; Mészáros et al., 2009). This study has therefore 
provided initial evidence to support the 'self-medication' hypothesis in ADHD. This hypothesis 
suggests that the high rates of substance abuse found in ADHD is due to patients attempting to 'self-
treat' with substances such as stimulants or cannabis (Bolea-Alamañac et al., 2014; Horner & 
Scheibe, 1997; Wilens, 2004). In light of evidence that heavy cannabis users show a more positive 
response to cannabis than occasional users it was suggested that those who are 'drawn' to cannabis 
could be 'innately' protected from the negative effects of the drug (D’Souza et al., 2008; Ramaekers 
et al., 2009). Given the high incidence of cannabis use in adults with ADHD, it is possible those with 






7.4.4 Emotional lability and cognitive performance in adults with ADHD 
Case/control differences in symptoms of ADHD, EL, and cognitive performance found in adults with 
ADHD (Chapter 5) are supported by numerous research results. This is highlighted best by the DSM 
5 diagnostic criteria which, along with elevated symptoms of hyperactivity/impulsivity and 
inattention, also lists EL and cognitive impairment as associated features that support the diagnosis 
of ADHD (American Psychiatric Association, 2013). This investigation also gave two novel results in 
adult ADHD relating to this.  
 
7.4.5 Reward sensitivity in adults with ADHD  
The first novel result, found evidence of reward/presentation rate sensitive improvements in 
cognitive performance on the Fast Task. This is the first time this has been found in an adult ADHD 
sample, and is supported by repeated evidence of the same association in children with ADHD 
(Andreou et al., 2007; Cheung et al., under review; Slusarek et al., 2001; Uebel et al., 2010). 
Furthermore, the recent finding that such sensitivity to reward and presentation rate was not 
present in a sample of children with ASD  (Tye et al., under review) suggests this to be a 
developmentally stable deficit with some specificity to ADHD. This finding is in support of the state 
regulation hypothesis of ADHD (Sergeant, 2000). This model proposes deficits in cognition to be the 
result of a reduced energetic state.  Reward sensitivity in ADHD highlights the malleability of RTV 
(Kuntsi et al., 2012); supporting the advantages of incorporating fast-paced activities and 
incentives into the environment of children and adults with ADHD, in order for them to function at 
an optimal level (Cheung et al., under review).  From a theoretical perspective this finding indicates 
a potential role of state regulation deficits in the symptoms and impairments of ADHD across the 
lifespan.  From a clinical perspective, observations of ADHD patients included in the studies in this 
thesis and more generally (Asherson, personal communication) show that patients with ADHD can 
function well in stimulating environments or situations. For example adults with ADHD often do 
well in entrepreneurial professions or as successful sports persons. The beneficial effects of 
exercise in ADHD is a growing but important area of research (Rommel et al., 2013; Rommel et al., 
2015).  Furthermore, I have been involved in a qualitative research project during this PhD which 
has asked adults with ADHD about the positive aspects of their diagnosis.  It is important to 
understand the optimum ways in which ADHD can be managed, in order to give the best advice 




7.4.6 Emotional overreactivity in adults with ADHD 
The second novel result was that of objective evidence of difficulties in emotion 
regulation/overreactivity and reduced frustration tolerance in adults with ADHD in response to a 
frustration task. Post-task ratings of irritability and frustration also mapped onto more subjective 
rating scale measures of EL.  This is, to our knowledge, the first study to examine response to a 
frustration task in adults with ADHD during experimental task conditions. Results are in agreement 
with findings in children with ADHD which have found deficiencies in emotion regulation and 
reduced frustration tolerance in response to a 'frustrating' puzzle-task (Martel, 2009; Melnick & 
Hinshaw, 2000; Scime & Norvilitis, 2006; Walcott & Landau, 2004).   Results are also in agreement 
with a previous 'real world' study using experience sampling that found emotional overreactivity 
and instability in adults with ADHD in response to perceived 'bad events' (Skirrow et al., 2014). Our 
results combined with these previous findings suggest developmental stability of difficulties with 
emotion regulation and management. The PASAT-C could be used as an objective test for emotional 
lability in adults with ADHD.  
 
7.5 Strengths and weaknesses 
7.5.1 Power 
One of the main limitations noted in Chapters 2 and 3 was that the majority of RCTs examining the 
effects of n-3 PUFA supplementation in both TD and ADHD+RND populations were underpowered. 
In both the cognition and EL meta-analysis, the treatment effects were small (~d=0.3). With this 
modest effect size a sample size of around 352 participants (β=80%, two-tailed α = 0.05) would be 
required to confirm or refute these small effects. In Chapter 2, trials in the ADHD+RND group 
ranged from 40-362 participants and included only one study that was adequately powered. Trials 
in the TD group ranged from 38-422 participants and included only two studies that were 
adequately powered. In Chapter 3, trials ranged from 21 to 362 participants and included only one 
study that was adequately powered.  This undermines our ability to provide conclusions of the lack 
of or presence of treatment effects in Chapters 2 and 3 respectively.  Future studies should be 




Both the EMA-C and OCEAN studies were underpowered. It was estimated that in order to detect 
the expected small effect (d=~0.3) of n-3 PUFA supplementation on symptoms of ADHD a future 
RCT in adults with ADHD would require a sample size of 352 participants. For the EMA-C study a 
sample size of 150-200 participants was recommended for future studies, based on the medium to 
large effect sizes that were found (d=0.5-0.7). Although lack of power is a significant limitation, as 
both these studies were exploratory pilot studies it is not unusual for them to be underpowered.  
The aim of the pilot study is to guide future, larger studies through the examination of study-
feasibility, trends in treatment effect, and exact effect sizes for future power/sample size 
calculations. This has been achieved, with promising effects from Sativex and weaker, albeit 
potential, effects of n-3 PUFA supplementation on ADHD symptoms. Observations from running the 
studies can also be used to improve future trials, such as the need for a shorter follow-up period 
and testing sessions in order to attempt to limit drop-out rate and alteration of the dosing 
guidelines for the EMA-C study. 
 
7.5.2 Effect sizes 
The clinical application of results from the OCEAN study are limited by the high drop-out rate, lack 
of power and small effect sizes. Results gave limited evidence for a small treatment effect of n-3 
PUFA supplementation on improving symptoms of inattention and EL, with no evidence for effects 
on cognitive performance (see Section 7.4.2 for a more detailed discussion).  This is in line with the 
meta-analyses conducted in this thesis (Cooper et al., 2016; Cooper et al., 2015), and previously 
(Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014; Sonuga-Barke et al., 2013). It is also in line with 
mixed evidence from individual placebo-controlled trials which have examined the effects of n-3 
PUFA supplementation on ADHD symptoms (Sinn & Bryan, 2007; Voigt et al., 2001), cognitive 
performance (e.g. Milte et al., 2012;Sinn et al., 2008), and EL (Stevens et al., 2003; Widenhorn-
Müller et al., 2014). Given that potential treatment effects are likely to be small, the data from this 
thesis does not suggest that n-3 PUFA supplementation could be a clinically relevant treatment for 
ADHD in adulthood, especially as a monotherapy.  Although in light of the high drop-out rate, 
further, fully powered studies (in ~ 352 adults with ADHD) are required before we can say whether 
these findings are robust.  In order to overcome potential problems from drop-outs leading to 
reduced power a future study could consider over-recruiting or using a sequential trial design. For 
example, sequential trials conduct a number of interim analyses and stop recruitment once the trial 
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is fully powered (in this case once 352 participants have completed the trial) (Sedgwick, 2012).  
Such a design could ensure that a fully powered study of n-3 PUFA supplementation in adults with 
ADHD is conducted and could further establish whether the indications of small effect sizes found 
in this thesis are robust.  
 
7.5.3 The role of pilot studies in meta-analyses 
Given the work described in this thesis consists of meta-analyses and pilot-RCTs it is important to 
discuss the link between these two research methods.  The meta-analyses in chapters 2 and 3 
combined a number of small and large RCTs in order to produce a weighted effect. The majority of 
studies included in these meta-analyses, similarly to the OCEAN and EMA-C studies, were 
underpowered to detect the expected small effects of n-3 PUFA supplementation on cognitive 
performance and EL (for further discussion see  Chapter 2 (discussion section) and Section 3.5). For 
example, a number of the studies of n-3 PUFA supplementation in children with ADHD had a similar 
or smaller sample size to the OCEAN study (e.g. Milte et al., 2012; Richardson & Puri, 2002;  Stevens 
et al., 2003; Vaisman et al., 2008; Voigt et al., 2001). Therefore pilot or feasibility studies such as the 
OCEAN and EMA-C studies reported in this thesis can be included in meta-analyses as they provide 
some indication of trends in treatment effect.  However one limitation that must be taken into 
account when including underpowered studies in meta-analyses is that combining these studies 
does not give the same power that one fully powered study would have. For example the meta-
analysis in Chapter 3 found a small treatment effect of n-3 PUFA supplementation on EL across four 
studies which included a total sample of 515 participants. Although this was found in a large total 
sample this is not equivalent to or as robust as the same finding in one study of 515 participants. 
Therefore meta-analysing a number of smaller studies does not make up for lack of power.  Once 
initial pilot or feasibility studies have been conducted researchers must aim to conduct large fully 
powered studies to gain the most reliable estimates of treatment effect.     
 
7.5.4 Drop-out rate 
A limitation to both of the RCTs (Chapters 5 and 6) is that of small sample size and loss to follow-up.  
In the OCEAN study (Chapter 5) we experienced a high drop-out rate across both the placebo and 
active groups which will have considerably reduced power. The reasons for drop-outs were similar 
across both groups, and there was no significant difference in number of drop-outs between the 
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active and placebo groups. Drop-outs were therefore presumed to be at random which limits 
potential bias caused by drop-out. Reasons for drop-outs and measures to avoid this in future 
studies are detailed below in Section 7.6.2. 
 
In the EMA-C study (Chapter 6), a higher drop-out rate was observed in the placebo than the active 
group.  Given the failure of the blinding (since participants were able to correctly guess which arm 
they were in) and observations from running the study, this drop-out may have been non-random 
due to the relative lack of any effect of the placebo.  Although data imputation under the missing not 
at random (MNAR) and missing at random (MAR) assumption gave similar results, this is likely due 
to the small number of drop-outs. A future larger study could consider recruiting a higher number 
of participants into the placebo group to try and limit any bias caused by non-random drop-out.  
 
 
7.5.5 Heterogeneity of EL and cognitive deficits in ADHD 
Another limitation noted in both Chapters 2 and 3 is that the participants included in the various 
studies will have been heterogeneous with regard to EL and related behavioural domains and also 
cognitive impairments. This heterogeneity will lead to a reduced treatment effect in comparison to 
ADHD symptoms where there is a more uniform deficit (Coghill et al., 2007).  Future studies, 
especially where the primary outcome is EL or cognitive performance, should ensure a certain 
threshold of impairments in these domains when recruiting participants. 
 
7.5.6 Blinding 
The EMA-C study was limited by the difficulties in blinding the medication due to the obvious 
effects of Sativex to most participants. Blinding in the OCEAN study was, however, more successful. 
The failure of the blind in the EMA-C study is a problem inherent to the use of a cannabinoid 
medication, the effects of which appear to be apparent to many participants. Lack of blinding is 
associated with exaggerated estimates of treatment effect (Pildal et al., 2007), in particular for 
subjective outcome measures (Wood et al., 2008).  Failure of the blind could therefore have biased 
the behavioural outcomes (such as ADHD symptoms) more so than the objective outcomes 
(cognitive performance). Given the failure of the blind and also non-random drop-out, potential 
exaggeration of treatment effects must be taken into account when interpreting results. Future 
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trials should compare Sativex to current ADHD stimulant medication to reduce the chance of 
breaking the blind.  
 
7.5.7 Concomitant medication 
The use of concomitant medication (e.g. stimulants, antidepressants) in the OCEAN study was a 
limitation.  Concomitant medication may have reduced the severity of ADHD symptoms and 
associated cognitive deficits leading to reduced effect sizes for the effect of treatment with n-3 
PUFA. This may have been especially so for participants taking non-stimulant or antidepressant 
medication, as they could not come off this medication for the testing sessions  (nb. those on 
stimulant medication stopped taking this for 48 hours before testing sessions).  Therefore one of 
the strengths of the EMA-C study was that the participants were unmedicated for a week before and 
throughout the 6 week trial. This meant that we could effectively investigate the effects of Sativex 
as a monotherapy in the presence of high levels of ADHD symptoms. 
 
7.5.8 Dosage 
One strength of the OCEAN study was the use of a high EPA dose n-3 PUFA supplement. The 
supplementation (Equazen High Concentrated: 1,116 mg EPA, 348mg DHA, and 120mg GLA per 
day) was high in EPA and taken at a dose which was at the upper limit of recommended daily n-3 
PUFA intake (~1500mg per day) (Hibbeln, Nieminen, Blasbalg, Riggs, & Lands, 2006; Molendi-
Coste, Legry, & Leclercq, 2011).  Previous meta-analyses have found EPA to have greater efficacy in 
reducing ADHD symptoms in children (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014) and advised 
the use of high EPA supplementation in future trials  (Bloch & Qawasmi, 2011). Therefore a 
strength of the OCEAN study is that, based on previous evidence, the optimum doage of n-3 PUFA 
for ADHD treatment was used.  
 
One weakness however of the OCEAN study is that the evidence for dosage is based on studies in 
children with ADHD not adults (Bloch & Qawasmi, 2011; Hawkey & Nigg, 2014).  The OCEAN study 
was the first trial conducted in adults with ADHD.  Although a high EPA supplement has been found 
to be efficacious in children, this may not be the case in adults whose brains may no longer be 
developing.  Furthermore whilst previous research has found children and adults with ADHD to 
have reduced blood levels of n-3 PUFA (particularly EPA and DHA) (Hawkey & Nigg, 2014), this was 
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not the case for the sample included in the OCEAN study who appeared to have similar, if not 
slightly higher, levels of blood n-3 PUFA than controls (see Section 5.6.2).  Closer examination of the 
adult studies included in the meta-analysis (which showed reduced n-3 PUFA levels in ADHD) 
suggests that had this analysis been conducted separately for children and adults, evidence for n-3 
PUFA deficiencies in adults may have been weaker than that in children (Hawkey & Nigg, 2014).  
Evidence from this thesis therefore suggests that different dosages of n-3 PUFA supplementation 
could be required in children and adults. In order to clarify the required dose, future large cross-
sectional case/control comparison studies, and subsequent meta-analyses need to be conducted in 
order to establish whether an n-3 PUFA deficiency is present in adults. If this is established suitable 
doses of n-3 PUFA need be developed and trialled in future, adequately powered (n=~352) trials.   
 
Dose was also a potential limitation in the EMA-C study where the optimum dose of Sativex may not 
have been used by every participant (see Section 6.6 for a more detailed discussion). Given this 
study was, to our knowledge, the first to examine Sativex as a treatment for ADHD, the dose at the 
start of the trial was unknown. The titration schedule we used was provided by GW Pharma and 
was for symptom relief in patients with multiple sclerosis.  It became clear early on in the trial that 
this titration schedule was unsuitable for adults with ADHD: it increased too quickly, to too high a 
dose (see Section 6.4.5.2).  Although patients were verbally informed (at the baseline testing 
session and during regular telephone monitoring) to remain at a lower dose if they were finding 
effects from the medication, at follow-up a small number of participants had taken a high dose for 
the majority of the trial, reporting that they had not derived benefits.  Failure to maintain an 
optimal dose in each participant may have reduced the treatment effect in the active group.   It is 
important that a new titration schedule (which increases to a maxmum dose of 8-9 sprays as 
compared to 14 in the EMA-C study) be developed for a future trial in order to clarify the effect of 
Sativex in adults with ADHD when taken at a more optimal (lower) dose.      
 
7.5.9 Blood n-3 PUFA levels in adults with ADHD 
As discussed above (Section 7.5.88), the sample of adults with ADHD included in the OCEAN study 
had similar if not slightly higher levels of blood n-3 PUFA than controls.  This went against 
hypothesis (see section 5.2.1) and previous research (Antalis et al., 2006; Chen et al., 2004; 
Germano et al., 2007; Hawkey & Nigg, 2014; Stevens et al., 1995).  This lack of n-3 PUFA deficiency 
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is a limitation for the OCEAN study as it may have reduced the chance of observing a treatment 
effect following supplementation with n-3 PUFA.  For example, the meta-analysis in Chapter 2  
found the only evidence for effects of supplementation to be in those who were n-3 PUFA deficient 
(albeit at small effect) (Cooper et al., 2015).   
 
Closer examination of previous research suggests evidence for n-3 PUFA deficiencies in adults with 
ADHD may be weaker than that in children with ADHD (Hawkey & Nigg, 2014).   Furthermore the 
case/control sample included in the OCEAN study appears to be the largest sample to date to 
investigate n-3 PUFA differences in adults with ADHD. Therefore evidence from this thesis could 
suggest that there may not be n-3 PUFA differences in adults with ADHD compared to controls.  
This could question the proposed causal relationship between n-3 PUFA and symptoms of ADHD.  
For example it is suggested that n-3 PUFA may be linked to dopamine neurotransmission and in 
turn the symptoms of ADHD (see Section 1.2.5.3). Evidence from this thesis undermines this causal 
hypothesis. Instead it could be the case that n-3 PUFA deficiencies are one factor that contributes 
towards ADHD symptom severity in childhood. However given that some but not all (~60%) of 
ADHD cases persist into adulthood  (Faraone et al., 2006), n-3 PUFA deficiency may not be one of 
the factors that contributes to adult ADHD. A more controversial explanation is the recent 
suggestion that at least in some cases adult ADHD may be a different disorder from childhood-onset 
forms of the condition (Moffitt et al., 2015). Future work would be required to test these potential 
hypotheses. 
 
7.5.10 Treatment duration  
Treatment duration differed greatly between the two trials. The OCEAN study was a relatively long-
term study with follow-up at 6-months whilst the EMA-C study was a short-term study with follow-
up at 6 weeks. Although a long follow up was chosen for the OCEAN study, evidence from studies in 
children with ADHD suggests that treatment effects may be uninfluenced by study duration (Bloch 
& Qawasmi, 2011; Cooper et al., 2016; Cooper et al., 2015). In Chapters 2 (Cooper et al., 2015) and 3 
(Cooper et al., 2016) we found no relationship between length of supplementation with n-3 PUFA 
and treatment effects on EL and oppositional behaviour (in children with ADHD), and on cognitive 
performance (in children with ADHD and typically developing children and adults), in trials that 
ranged from 4-52 weeks.  This is in line with a meta-analysis which found no relationship between 
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trial duration and efficacy of n-3 PUFA in reducing ADHD symptoms in children (in trials that 
ranged from 4 weeks-4 months) (Bloch & Qawasmi, 2011).  Given the failure to find a relationship 
between length of trial and treatment efficacy, and the suggestion that the long length of the trial 
could have contributed towards the high drop-out rate (see Section 7.6.2), the design of the OCEAN 
study could have been improved by having a shorter follow-up period.  Although it is important to 
note that this recommendation is limited as it is based mainly on evidence from trials in children 
with ADHD, not adults.   Although future studies in adults should consider employing a shorter (~3-
4 month) follow-up period, more trials of varying length in adults with ADHD may be required to 
confirm whether efficacy (or lack of efficacy) of n-3 PUFA is uninfluenced by trial duration.   
 
In contrast the EMA-C study employed a short follow-up period (6 weeks). Given this was the first 
study to examine the effects of Sativex in adults with ADHD, the follow-up period was based on 
previous RCTs of Sativex in patients with multiple sclerosis, or who had neuropathic pain, which 
found efficacy of Sativex after 5-6 weeks (Collin, Davies, Mutiboko, & Ratcliffe, 2007; Nurmikko et 
al., 2007).  Although this short follow-up period may have contributed to the low drop-out rate, I 
think the trial could have benefitted from a longer follow-up period (~ 3 months).  This is because it 
would often take participants longer than the 2-week titration period to adjust to taking the Sativex 
and find an optimum dose of the medication. I feel that the trial was therefore not long enough for 
participants to stabilise on the medication which may have led to an underestimation of the 
treatment effect.   
 
7.5.11 Adverse events 
A potential limitation to the use of Sativex in adults with ADHD is the  number of minor (n=3) and 
major (n=1) adverse events that were experienced by participants in the active group. In 
comparison very few (n=3) minor adverse events were experienced by participants in the active, n-
3 PUFA group. Therefore n-3 PUFA supplementation was better tolerated than treatment with 
Sativex.  The number of adverse events experienced in the EMA-C study, particularly at higher 
doses, could potentially limit the use of Sativex as a treatment for adults with ADHD. As discussed 
above (Section 7.5.8) it was realised after the first 2-3 participants had begun the trial that the 
titration schedule provided by GW Pharma was too high.  Although participants were verbally 
informed to not increase the dose too quickly, a small number of particiants may have taken too 
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high a dose during the trial or 'double-dosed' which was not advised. This may have led to an 
overestimation of the adverse effects of Sativex. As discussed above, the development of a new 
titration schedule (which increases to a maxmum dose of 8-9 sprays) is important, in order to 
clarify the commonality of adverse effects of Sativex when it is taken at a lower dose.      
 
7.5.12 Strengths of the meta-analytic and RCT methods 
The meta-analyses conducted in this thesis offer the most precise estimate of the treatment effect of 
n-3 PUFA on cognitive performance and EL to date. The studies were conducted to recommended 
standards for systematic reviews and meta-analysis. We were careful to combine homogenous 
measures by, for example, separating parent and teacher ratings of EL in Chapter 3, including only 
omission errors as a cognitive measure of 'attention’ in Chapter 2, and conducting separate 
analyses in children and adults (in the TD group) in Chapter 2. The low levels of heterogeneity in 
both studies illustrates the similarity of the combined outcome measures; increasing the reliability 
of the reported findings.  
 
The strength of our placebo-controlled RCTs is that they are considered the 'gold standard' for the 
evaluation of treatment efficacy. Although we were limited in our conclusions due to lack of power, 
the overriding aim of this thesis was to attempt to improve treatments for adults with ADHD by 
investigating possible alternative treatments and highlighting the potential role of alternative 
mechanisms for further investigation. I feel this has been met, with cannabinoid medication in 
particular proving to be a worthwhile area for future research.  Furthermore these treatment trials 
received an extremely positive response from the patients themselves. For the n-3 PUFA research, 
patients were pleased to see an investigation of a non-pharmacological treatment. For the EMA-C 
study the response was extremely positive with patients feeling that the research was really 
engaging and listening to them. This was particularly true for those who had received consistent 
negative feedback in relation to their cannabis use. 





7.6  Observations and conclusions from running the OCEAN and EMA-C studies 
7.6.1 Clinical observations of the ADHD samples 
Observations from the screened ADHD samples are in line with previous research (Section 1.1.5). 
ADHD in adulthood is a severe and impairing disorder with significantly high rates of comorbid 
conditions including autism spectrum disorder (ASD), substance use disorder (SUD), depression, 
anxiety, bipolar disorder, obsessive compulsive disorder (OCD), and schizophrenia.  The most 
common comorbidity was ASD (either diagnosed or suspected). The co-occurrence of ASD and 
ADHD is well established. In children the prevalence of ADHD in ASD has been reported to be as 
high as 28-53% (Simonoff et al., 2008; Sinzig, Walter, & Doepfner, 2009) and 32-43% in adults 
(Anckarsater, Stahlberg, Larson, & Hakansson, 2006; Hofvander et al., 2009). Despite the high 
prevalence a concurrent ADHD and ASD diagnosis has only recently been acknowledged by the 
DSM-5 (American Psychiatric Association, 2013). It is important that clinicians bear in mind the 
high rates of overlap between ASD and ADHD. 
 
The second most common comorbidity in the OCEAN study were depression and anxiety disorders. 
Research has found risk of depression to be elevated in ADHD, with 35-50% of adults with ADHD 
experiencing one or more episode of depression during their lifetime, compared to a 15% risk in 
the general population (Sobanski, 2006). These high rates of comorbidities led to alteration of the 
exclusion criteria for the OCEAN study to allow participants on antidepressants (or in one case anti-
anxiety medication) to take part due to the very high numbers being treated with such medications.  
This led to 14 participants being recruited into the study who were taking either antidepressants 
only, or as a concomitant (with stimulants/non-stimulants) medication. It is important that 
clinicians bear in mind the high rates of overlap between ADHD and depression/anxiety. 
 
Substance abuse problems were also common in the samples screened for both studies. The most 
common drug of abuse was cannabis. These high rates of cannabis use in adults with ADHD 
contribute to the theory that individuals are self-medicating with this drug.  This observation 
during the OCEAN study contributed to the motivation to conduct the EMA-C study.  
 
A main reason for exclusion in the EMA-C study was that potential participants were unwilling to 
stop taking their usual ADHD (stimulant) medication (12.1%).  This highlights that, despite this 
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thesis examining 'alternative treatments', many adults with ADHD are happy with their current 
medication and gain significant benefit from it (Banaschewski et al., 2006; NICE, 2008). A number 
of individuals with ADHD told me that they ‘cannot function’ without their medication or that going 
on the medication ‘changed their lives’. Some individuals had been on medication since early 
childhood and therefore felt they depended on it to function.  
 
Finally a number of participants declined to take part in the EMA-C study because they did not wish 
to take a cannabinoid medication (5.1%). This is understandable given that cannabis is classified as 
a controlled (illegal) Class B drug. In line with this others did not wish to take part as they felt their 
work would not approve (4%). A potential concern is the link between cannabis use and psychosis 
(Henquet et al., 2005; Moore et al., 2007).  As discussed in Section 1.3.1, recent research has found 
sinsemilla (‘skunk’) (which has high Δ9-THC and low CBD) but not cannabis resin (‘hash’) (which 
contains relatively similar amounts of Δ9-THC to CBD) to be related to psychosis (Di Forti et al., 
2015). The properties of Sativex are more comparable with ‘hash’ (containing a 1:1 ratio of Δ9-
THC:CBD) and therefore it has a much better safety profile than black market cannabis, which is 
generally dominated by sinsimella, and has a high THC content. The distinction between Sativex 
and black market cannabis needs to be made clear if Sativex were to be prescribed to patients. 
There is also an understandable fear of taking any illegal or controlled drug, although ‘speed’ or 
street amphetamine is also an illegal Class B drug closely related to dexamphetamine, a commonly 
prescribed and effective treatment for ADHD (Faraone & Buitelaar, 2010; NICE, 2008). Therefore 
the use of medications derived from illegal drugs such as ‘cannabis’ should not be discounted. 
Patients should be informed of the distinction between these and 'black market' drugs. 
 
Despite the severity of the disorder, a prominent theme that came up during the recruitment 
process was the difficulty a large number of individuals had in obtaining a diagnosis. For example, 
23% of the EMA-C participants and 12% of the OCEAN participants obtained a 'research diagnosis' 
of ADHD by entering the study, whereas they were previously undiagnosed because of the 
significant difficulties that still remain in obtaining a diagnostic assessment for ADHD as an adult. In 
Section 1.1.11.1, I highlighted the factors thought to contribute to the difficulty in obtaining a 





1) There may be unease within some mental health professionals in the identification and treatment of 
ADHD  (Bolea et al., 2012; Singh, 2008). For example, some hold the erroneous view that ADHD is a 
construct manufactured by the pharmaceutical industry (Goldstein, 2006): 
 
Many people would research the diagnosis of ADHD before going to their GP and ask to be referred 
for an ADHD assessment. However there seemed to often be an unwillingness to make the referral. 
 
2) Lack of training and services  in ADHD: 
 
Misdiagnosis was common, as many patients were initially diagnosed with depression or anxiety 
disorders, but found treatment with antidepressant medication to be ineffective. There appear to be 
very few specialist Adult ADHD clinics in the UK. People would often not be referred because there 
was no clinic in the area that they could attend. Alternatively, patients were referred to clinics huge 
distances from where they lived and would have to incur the expense and time to travel there. Once 
referred the waiting lists were very long (6 months to 1 year). 
 
3) Clinicians may be reluctant to widen the already overstretched psychiatric services to include adults 
with ADHD  (Bolea et al., 2012): 
 
Very often the funding for the ADHD diagnostic assessment was declined. In the case of funding 
decline, patients were often unaware that this had occurred so would be left unsupported for 
months with no feedback.   
 
Due to these problems, a number of patients were diagnosed privately, at great expense. A number 
of participants also entered the study in order to obtain a research diagnosis from a recognised 
group with expertise in adult ADHD. There is therefore considerable room for improvement in the 
NHS in terms of the diagnosis (and subsequent treatment) of ADHD in adulthood. Improved 
training and increased funding to the service is required.  Improvements in training may also 




7.6.2 Research observations from running the studies 
Due to the nature of the condition, disorganisation, appointment cancellations, and no-shows were 
common, increasing the difficulty of the research process. It is estimated that around 30-40% of 
participants for the OCEAN study cancelled or re-arranged their appointments, often at short 
notice. Participants were also often very difficult to contact. This caused the most difficulty in the 
EMA-C study where it was of great importance that regular contact was maintained during the 
titration period, in order to monitor the participant’s response to the medication and obtain the 
optimum dosage.  Notably, once contact had been made there was no suggestion that participants 
were reluctant to take part or did not wish to continue in the study.  In future studies using Sativex 
the importance of the titration phone calls must be stressed.   
 
A small number of participants could not tolerate the cognitive testing sessions. One participant in 
the OCEAN study could not complete the EEG session and two participants in the EMA-C study 
could not complete the Qb Test as they found it too difficult to maintain their attention. It is 
possible that a number of the drop-outs from the OCEAN study may have been because the baseline 
testing sessions were long and cognitively demanding, which may have caused unwillingness for 
participants to return. This may have been compounded by the long follow-up period (6 months) 
during which time participants may have lost interest or found it too demanding to take the 
supplements every day. One reason for the lower drop-out rate in the EMA-C study may have been 
because the baseline testing sessions (~3 hours versus ~5 hours) and follow-up period (6 weeks 
versus 6 months) were significantly shorter and less cognitively demanding than the OCEAN study. 
In the OCEAN study participants were required to take four capsules a day of the placebo or active 
supplements. Some participants found it difficult to remember to take this many capsules which 
could have contributed to non-compliance and potentially the high drop-out rate (although this was 
not explicitly stated). For the EMA-C study some participants did not like the taste of the 
medication. This may have influenced the higher drop-out rate in the placebo group; those who did 
not like the taste and were not deriving benefits may have been more likely to drop-out (although 
again this was not explicitly stated).  Future longitudinal n-3 PUFA studies should employ a shorter 
follow-up period (~3-4 months) and testing sessions (~2-3 hours). The testing sessions should not 
be too cognitively demanding. Future studies of n-3 PUFA supplementation should consider the 
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dosage (perhaps using a higher concentration supplement and therefore fewer capsules) and of 
Sativex, the taste (try to mask an unpleasant taste) of the medication. 
 
A small number of people were excluded who were considered to be cannabis-dependent. This 
criteria was in place due to the potential for abuse of Sativex at high doses (Schoedel et al., 2011), 
and to avoid prior potential effects of cannabis on ADHD, which remain unknown. Furthermore, 
participants were asked to abstain from cannabis use for 30 days prior to study entry; those who 
were cannabis dependent or used cannabis on a regular basis might experience withdrawal during 
this period. However previous research has found heavy cannabis users to have a more positive 
response to cannabis than occasional users  (D’Souza et al., 2008; Ramaekers et al., 2009). It is 
therefore possible that those with ADHD who are heavy cannabis users may have an optimum 
response to Sativex. Although we included 'daily' users who used 4-5 days a week, this was only 4 
participants. A future trial could consider recruiting a larger sample of adults with ADHD with some 
who are also heavy cannabis users, to clarify whether effects may be stronger in this subgroup.  
 
7.7 Implications 
7.7.1 Clinical implications 
 Omega-3 PUFA supplementation as a treatment for children with ADHD (Chapters 2 
and 3):  
− Given the small effects of n-3 PUFA supplementation on ADHD symptoms and potentially 
EL, n-3 PUFA supplementation could be used as an adjunctive treatment in children with 
ADHD. It should be considered as a monotherapy only for those who do not wish to use 
pharmacological treatment. Patients should be advised that there is no evidence for effects 
on cognition.  
 Omega-3 PUFA supplementation as a treatment for adults with ADHD (Chapter 5):  
− The efficacy of n-3 PUFA supplementation on improving symptoms of ADHD, EL and 
cognitive impairments in adults with ADHD is currently unclear.  This is particularly the 
case given that we failed to find baseline differences in n-3 PUFA levels of adults with 
ADHD compared to controls. Omega-3 PUFA supplementation cannot currently be 
recommended as an evidence based-treatment for adults with ADHD.  
 Reward sensitivity in ADHD (Chapter 5): 
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− Results suggesting sensitivity to reward and fast presentation rate in adults with ADHD as 
well as children, emphasises the advantages of incorporating fast-paced activities and 
incentives into the environment of both children and adults with ADHD (such as 
competitive sports). Patients should be informed of this recommendation. 
 Sativex as a treatment for adults with ADHD (Chapter 6): 
− Although the EMA-C study has provided promising results for the effect of Sativex in the 
treatment of adult ADHD, a further, definitive trial is required in order to examine efficacy 
and the underlying mechanisms involved. We cannot advise the use of Sativex on the basis 
of this one small study. The use of medications derived from illegal drugs such as ‘cannabis’ 
should not be discounted. Patients should be informed of the distinction between these and 
'black market' drugs. 
 General observations regarding the treatment of ADHD in adulthood (Chapters 5 and 
6):  
− There is considerable room for improvement in the NHS in terms of the treatment of ADHD 
in adulthood. Improved training and increased funding to the service is required.  
Improvements in training may also reduce any potential unease that some doctors may 
have in diagnosing and treating the disorder.   
− It is important that clinicians bear in mind the high rates of overlap between ASD and 
ADHD, and also ADHD and depression/anxiety. 
7.7.2 Implications for the general population 
 Omega-3 PUFA supplementation and cognition (Chapter 2):  
− There is no evidence to suggest that n-3 PUFA supplementation improves cognitive 
performance in the general population. This should be taken into account by individuals 
who are considering whether to purchase these products, and regulators and producers 
when promoting these products. 
7.7.3 Future directions 
 Reward sensitivity in adults with ADHD (Chapter 5):  
− Results of reward/presentation rate sensitivity in adults with ADHD emphasises the 
need for further studies in order to rigorously evaluate the causal role of ‘state 
regulation’ factors in ADHD across the lifespan. The observation that children and 
adults with ADHD may function better in fast-paced/incentive driven environments 
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highlights the need for more research into the optimal environments for patients with 
ADHD. One way in which this has been done is in a qualitative study which I have been 
involved in, which interviewed patients with ADHD about 'the positive aspects of 
ADHD'. Analysis of this data will be starting soon and results could be used to advise 
patients on lifestyle interventions in order to improve function. 
 Emotional dysregulation in adults with ADHD (Chapter 5): 
− We propose the PASAT-C could be a suitable frustration task in adults with ADHD. 
Further research could take advantage of this experimental paradigm in the 
investigation of emotional dysregulation in adults with ADHD.  
 Omega-3 PUFA supplementation in adults with ADHD (Chapter 5): 
− Large cross-sectional studies examining differences in n-3 PUFA levels in adults with 
ADHD compared to controls are required to clarify whether this difference is also 
present in adults. Longitudinal studies which examine n-3 PUFA levels and ADHD 
symptoms from childhood to adulthood are then required to clarify whether there is a 
causal relationship between n-3 PUFA and ADHD symptoms. If deficiencies in n-3 
PUFA in adults are established along with evidence of a causal relationship, these 
studies should be used to establish suitable doses of n-3 PUFA to be used in treatment 
studies for adults with ADHD.   
− In the future we will combine our data on ADHD symptoms and EL with RCT data from 
60 adults with ADHD (conducted by Michael Rösler's group at Saarland University 
(Germany)). This will provide us with increased power to examine treatment effects 
on these measures.   
− In the future the EEG data which we have collected as part of this study will be 
analysed to examine any potential treatment effects, we expect EEG could be a more 
sensitive measure to treatment effects than cognitive performance. 
− A large RCT of n-3 PUFA supplementation in ~ 352 adults with ADHD is required to 
examine for small but significant effects, similar to those seen in children with ADHD. 
Such a study should employ a shorter follow-up period (~3-4 months) and testing 
sessions (~1-2 hours). The testing sessions should not be too cognitively demanding.  
If possible the study could use a higher concentration supplement so that participants 
would need to take fewer capsules per day (~2 instead of 4 capsules). Researchers 
240 
 
should consider over-recruiting or using a sequential trial design to ensure a fully 
powered trial is conducted. 
− It is important to note that although future studies in adults should consider employing 
a shorter (~3-4 month) follow-up period, more trials of varying length in adults with 
ADHD may be required to confirm whether efficacy (or lack of efficacy) of n-3 PUFA is 
uninfluenced by trial duration.   
 Sativex as a treatment for adults with ADHD (Chapter 6):  
− A large RCT examining the effect of Sativex compared to a stimulant medication in 
adults with ADHD is warranted. This should include 150-200 participants (in line with 
the sample size calculations estimated from the effects on cognition in the EMA-C 
study (Chapter 6, Section 6.6), have a longer follow-up period (~ 3 months),  and have 
the ADHD symptom of hyperactivity/impulsivity as the primary outcome. Recruitment 
of a higher number of participants into the placebo group should also be considered to 
limit any bias caused by non-random drop-out. Dosing guidelines for the medication 
should be altered based on the optimum dose found in the current trial: the schedule 
should increase to a maximum dose of ~8-9 sprays per day, but recommend an 
optimum dosage of ~3-5 sprays.  If possible any unpleasant flavour of the medication 
should be masked.   
− Given that the two cannabinoids in Sativex: delta-9-tetrahydrocannabinol (Δ9-THC) 
and cannabidiol (CBD) have been found to have differential, and even opposing, effects 
it is important that their effects in adults with ADHD are researched separately. 
 Mechanisms of Sativex and n-3 PUFA (Chapters 3, 5 and 6):  
− One of the proposed causal underpinnings of the effect of n-3 PUFA and Sativex on ADHD 
symptoms is through alterations in dopamine levels (Assisi et al., 2006; Haag, 2003; 
Hibbeln et al., 2006; Young & Conquer, 2005).  However this has yet to be formally tested.  
Future longitudinal studies could examine the relationship between changes in dopamine 





7.8 Concluding remarks 
Through the meta-analytic strategy of combining previous research and through two novel RCTs, 
this thesis has provided important insights into the effect of n-3 PUFA and the cannabinoid 
medication, Sativex, on cognitive performance, ADHD symptoms, and EL. This is in light of the 
evidence I have provided which shows adults with ADHD to be significantly impaired in these 
domains. I have found a generally null effect of n-3 PUFA on cognitive performance in both the 
general population, children with ADHD and related neurodevelopmental disorders, and in adults 
with ADHD. I have presented evidence to suggest there could be a small effect of n-3 PUFA 
supplementation in reducing EL in children and potentially adults with ADHD. I have also shown 
that n-3 PUFA could have a moderate effect on reducing symptoms of ADHD in adults which, 
combined with previous meta-analytic results, suggests that further investigation of n-3 PUFA as a 
treatment for adults with ADHD is warranted.  I have finally provided evidence to suggest that the 
cannabinoid medication, Sativex, has shown promise at reducing the symptoms and cognitive 
impairments in adults with ADHD, which points strongly to the need for a future, larger treatment 
trial.  The main aim of this thesis, to identify potential alternative treatments for adults with ADHD 
has therefore been met, with cannabinoid medication proving to be the most worthwhile area for 
future research. Omega-3 supplementation, whilst providing overall weaker evidence, has not yet 
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Appendix B. Chapter 3 Appendices  
Table AB-1 
Detailed breakdown of behavioural rating scales included in the meta-analysis per study by the six behavioural domains  
First author Domain(s) investigated Rating scale Measure included in meta-analysisa Numbers in Analysis 
   Active  Placebo 
ADHD+RND Group: ADHD only 
Gustafsson et al., (2010) Oppositional behaviour – parent 
rated 
CPRS Oppositionality 46 46 
 Oppositional behaviour – teacher 
rated 
CTRS Oppositionality 46 46 
Manor et al., (2012) Emotional lability – parent rated CRS-P Global emotional lability 94 41 
 Oppositional behaviour – parent 
rated 
CRS-P Oppositional 99 42 
 Emotional lability – teacher rated CRS-T Global emotional lability 93 41 
 Oppositional behaviour – teacher 
rated 
CRS-T Oppositionality 92 40 
Milte et al., (2012) 
 
Emotional lability – parent rated CPRS Emotional lability 41 23 
 Oppositional behaviour – parent 
rated 
CPRS Oppositionality 42 22 
Sinn and Bryan, (2007) 
 
Emotional lability – parent rated CPRS Global emotional lability 33 27 
 Oppositional behaviour – parent 
rated 
CPRS Oppositionality 33 27 
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First author Domain(s) investigated Rating scale Measure included in meta-analysisa Numbers in Analysis 
   Active  Placebo 
Stevens et al., (2003) 
 
Oppositional behaviour – teacher 
rated 
DBD Oppositionality 20 12 
 Oppositional behaviour – parent 
rated 
DBD Oppositionality 20 15 
 Conduct problems – parent rated DBD Conduct  18 14 
Widenhorn-Müller et al., 
(2014) 
Oppositional behaviour – parent 
rated 
CBCL Delinquent behaviour 45 47 
 Oppositional behaviour – teacher 
rated 
CBCL - TRF Delinquent behaviour 40 45 
 Aggression CBCL  Aggressive behaviour - parent rated 
 
45 47 
ADHD + RND Group: RND only 
Dean et al., (2014) Aggression CAS-parent  Total 12 7 
 Aggression MOAS-parent Total 12 8 




Oppositional behaviour – teacher 
rated 
CTRS Oppositional 50 52 
 Emotional lability –teacher rated CTRS Global emotional lability 50 52 
Richardson et al., (2012) Emotional lability – parent rated CPRS Emotional lability 180 182 
 Oppositional behaviour – parent 
rated 
CPRS Oppositionality 180 182 
 Emotional lability – teacher rated CTRS Emotional lability 180 182 
 Oppositional behaviour – teacher 
rated 
CTRS Oppositionality 180 182 
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First author Domain(s) investigated Rating scale Measure included in meta-analysisa Numbers in Analysis 
   Active  Placebo 
ADHD + RND Group: ADHD+RND 
Richardson and Puri, 
(2002) 
Emotional lability – parent rated CPRS Emotional lability 15 14 
 Oppositional behaviour – parent 
rated 
CPRS Oppositional 15 14 
Note. SDQ = Strengths and Difficulties Questionnaire(Goodman, 1997); CPRS = Conners’ Parent Rating Scales(Conners, 1990); CTRS = Conners’ Teacher Rating Scales 
(Conners, 1990); CRS-T = Conners’ Teacher Rating Scale Revised Long-Hebrew Version (Conners, 1998); CRS-P = Conners’ Parent Rating Scale Revised Long – Hebrew 
Version (CRS-P) (Conners, 1998); DBD = Disruptive Behaviour Disorders (DBD) Rating Scale (Pelham, Gnagy, Greenslade, & Milich, 1992); CBCL = Child Behaviour 
Checklist (Arbeitsgruppe Deutsche Child Behavior Checklist, 1993a); CBCL-TRF = Child Behaviour Checklist – Teacher Report Form (Arbeitsgruppe Deutsche Child 
Behavior Checklist, 1993b); CAS – parent = The Children’s Aggression Scale – Parent Version (Halperin et al., 2002); MOAS – parent = Modified Overt Aggression Scale – 
parent rated (Connor, 2002) 










Database Search Strategy  
Ovid Medline 
(1946 to September week 3 2014) 
Embase 
(1974 to 2014 September 29th) 
Psychinfo 
(1806 to September week 4 2014) 
Keyword search: (“attention deficit hyperactivity disorder” 
OR “ADHD” OR  “emotional lability” OR “aggression” OR 
“oppositional” OR “conduct”) AND (“fish oils” OR “fatty 
acids” OR “omega 3 fatty acids” OR “docosahexaenoic acid” 
OR “DHA” OR “eicosapentaenoic acid” OR “EPA”) AND 
(“randomised controlled trial” OR “randomized controlled 
trial” OR “RCT”) 
Clinicaltrials.gov (“attention deficit hyperactivity disorder” OR “ADHD” OR  
“emotional lability” OR “aggression” OR “oppositional” OR 
“conduct”) AND (“fish oils” OR “fatty acids” OR “omega 3 
fatty acids” OR “docosahexaenoic acid” OR “DHA” OR 
“eicosapentaenoic acid” OR “EPA”) AND (“randomised 
























Study quality appraisal (scored as low, high or unclear risk) 





















Other bias Overall risk Other 
limitations 
ADHD+RND Group: ADHD only 
Gustafsson et al., 
(2010) 
Low Low Low Low Unclear Unclear Low Unclear Yes 
Manor et al., (2012) Low Low Low Low Low Low Low Low Yes 
Milte et al., (2012) Low Low Unclear Low Low Low Low Unclear Yes 
Sinn and Bryan, 
(2007) 
Low Unclear Low Low Low Low Low Unclear Yes 
Stevens et al., (2003) Unclear Low Low Low Low Low Low Unclear Yes 
Widenhorn-Müller et 
al., (2014) 
Low Low Low Low Low Unclear  Low Unclear Yes 
ADHD+RND Group: RND only 
Dean et al., (2014) Low Low Low Low Low Low Unclear Unclear Yes 
Richardson and 
Montgomery, (2005) 
Low Low Low Low Low Low Low Low Yes 
Richardson et al., 
(2012) 
Low Low Low Low Low Low Low Low Yes 
ADHD+ RND Group: ADHD+RND 
Richardson and Puri, 
(2002) 
Low Low Low Low Low Low Low Low Yes 
Studies only in qualitative synthesis  
Bélanger et al., (2009) Unclear Unclear Low Low Low High Low High Yes 
310 
 





















Other bias Overall risk Other 
limitations 
Hirayama et al., (2004) Low Low Low Low Low High Low High Yes 




Study quality appraisal 
First Author Reason if not low risk? Other limitations 
 
ADHD+RND Group: ADHD only 
Gustafsson et al., (2010) Incomplete outcome data: 17 children 
dropped out because their parents 
wanted pharmacotherapy. It is unclear if 
this was equally distributed between 
placebo and active.  
Selective reporting bias: Results mainly 
reported for a subgroup of participants 
with a lower level of hyperactivity or 
higher level of oppositional behaviour. 
Data not shown for one cognitive task 
(QB test).  
No assessment of 
blinding 













Milte et al., (2012) 
 
Blinding of participants: Overall 51% 
correctly guessed which group they 
were in. However 70% in the active 2 
group correctly guessed - above what 
would be expected by chance 




Sinn and Bryan, (2007) 
 
Allocation concealment: Unspecified Supplements also 
contained evening 
primrose oil (600mg 
p/day) (as above) 
No assessment of 
blinding 
Stevens et al., (2003) 
 
Random sequence generation: 
procedure unspecified 
 
At baseline placebo 
and active groups 
differed significantly 
on reaction time in a 
cognitive task (CPT 









rating scale)).  
No assessment of 
blinding. Does not 
state that capsules 
were identically 
flavoured. 
Olive oil placebo 
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First Author Reason if not low risk? Other limitations 
 
may have active 
properties 
Widenhorn-Müller et al., 
(2014) 
Selective reporting bias: Mean and SD 
not reported for 2 of the 3 tested 
cognitive domains   
Olive oil placebo 
may have active 
properties 
ADHD + RND Group: RND only 
Dean et al., (2014) Other bias: Small sample size (N=21) Olive oil placebo 





NA Supplements also 
contained evening 
primrose oil (20%) 




No assessment of 
blinding 
Olive oil placebo 
may have active 
properties 
Richardson et al., (2012) NA Blinding assessment 
carried out although 
only parents and 
teachers of 
participants were 
asked to guess 
treatment allocation 
ADHD + RND Group: ADHD+RND 
Richardson and Puri, 
(2002) 




Olive oil placebo 
may have active 
properties 
Studies only in qualitative synthesis 
Bélanger et al., (2009) 
 
Random sequence generation/allocation 
concealment: Unspecified 
Selective reporting bias: Two outcome 
measures are unreported  




Hirayama et al., (2004) 
 
Selective reporting bias: Only medians 
reported.  
No assessment of 
blinding 
Olive oil placebo 










Studies excluded at full text stage with reasons (N=40) 
Reason for exclusion Studies 
Failure to report placebo group Fontani et al., (2005) 
Unsuitable supplementation Aman et al., (1987), Arnold et al., (1989), Raz et 
al., (2009), Dubnov-Raz et al., (2014) 
Unsuitable population Rogers et al., (2008), Hamazaki et al., (2008), 
Antypa et al., (2009), Benton et al., (2013), 
Hamazaki et al., (1998), Kirby et al., (2010), 
Long and Benton, (2013), Zaalberg et al., (2010), 
Itomura et al., (2005), Gesch et al., (2002), 
Unsuitable outcome measures Johnson et al., (2009), Kairaluoma et al., (2009),  
Perera et al., (2012),  Sinn et al., (2008), 
Vaisman et al., (2008), Voigt et al., (2001), 
Young et al., (2005)  
Unsuitable population and outcome measures Nilsson et al., (2012), Vakhapova et al., (2011), 
Baumgartner et al., (2012), Bradbury et al., 
(2004), Dalton et al., (2009),Hamazaki et al., 
(2002, 1999, 1996), Jackson et al., (2012), Karr 
et al., (2012), Kennedy et al., (2009), Mcnamara 
et al., (2010), Osendarp et al., (2007), Parletta et 
al., (2013), Portillo-Reyes et al., (2014), Ryan 
and Nelson, (2008), Sawazaki et al., (1999), 

































 Active 1 Active 2a Placebo    Active  Placebo 
ADHD+RND Group: ADHD only 




















and teacher rated) 
46 46 







80mg EPA  40mg 
DHA 
300mg PS 








lability (parent and 
teacher rated) 
99 60 
Milte et al., 
(2012) 
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10.8mg Vit E 





lability (both parent 
rated) 
45 38 








 80 mg EPA 
480 mg DHA 
40mg AA 
96mg GLA 
24mg vitamin E 






















15mg Vit E 






and teacher rated), 
Aggression 
46 49 
ADHD+RND Group: RND only 











l olive oil, 
10mg fish 
oil 







































9.6mg Vit E 





94% behaviour, emotional 
lability (both teacher 
rated)  




















lability (parent and 
teacher rated) 
180 182 










186 mg EPA, 
480mg DHA, 
960mg LA, Vit E, 
42 mg AA, 8mg 
thyme oil 






lability (both parent 
rated)  
22 19 
Studies only in qualitative synthesis 






500mg - 1000mg 
EPA (depending 




























 Active 1 Active 2a Placebo    Active  Placebo 
Quebec over) 












NA Olive oil 8 weeks Parallel 
100% 
 20 20 
a. Where active 2 is shown it was combined with active 1 for the purpose of analysis. NA = there was no active 2 group 
b.76% met criteria for ADHD 










Characteristics of studies included in qualitative synthesis 
Characteristic Frequencies 
N  (studies) 12 
N  (participants) 1181 
% Male1 68 
Completion rate 88% 
Medication Unmedicated: 9 
Medicated: 1 
Partially medicated: 1 
Unspecified: 1 
 Weighted mean 
Age (years) 9.1 
Trial duration (weeks) 14.7 
EPA (daily dose) 429.83mg 
DHA (daily dose) 341.46mg 
ALA (daily dose) 60mg2 
1. One study did not specify sex ratio’s and was therefore not included in this 
calculation(Gustafsson et al., 2010). 



















Detailed description of meta-analyses results 
 
Emotional lability  
 
Parent  rated    
Five trials in 650 ADHD+RND participants examined parent rated emotional lability (EL-P). There 
was no effect of n-3 PUFA on EL-P (SMD = 0.15; 95% CI: -0.07 to 0.36, z = 1.34, p = 0.18) with no 
heterogeneity (x 2 = 5.63, I2 = 29%, p = 0.23).  
 
Analysis using SD of the change 
In the two trials(Manor et al., 2012; Richardson et al., 2012)manor that provided change score data 
there was no effect (SMD = 0.08; 95% CI: -0.41 to 0.57, z = 0.33, p = 0.74) with significant 
heterogeneity (x 2 = 5.42, I2 =81.5%, p = 0.02).  
 
Teacher rated    
 
Three studies in 598 ADHD+RND participants examined teacher rated emotional lability (EL-T). 
There was no effect of n-3 PUFA on EL-T (SMD = 0.06; 95% CI: -0.19 to 0.31, z = 0.46, p = 0.65) with 
no evidence of heterogeneity (x 2 = 3.81, I2 = 47.5%, p = 0.15).  
 




Eight studies in 875 ADHD+RND participants investigated parent-rated oppositional behaviour (O-
P). There was no effect of n-3 PUFA on O-P (SMD = 0.13; 95% CI: -0.01 to 0.27, z =1.77, p = 0.08) 







Six studies in 805 ADHD+RND participants investigated teacher rated oppositional behaviour (O-
T). There was no effect of n-3 PUFA supplementation on O-T (SMD = 0.04; 95% CI:-0.10 to 0.18, z = 






Two studies in ADHD+RND participants (N=51) examined parent rated conduct problems (C-P).  
There was no effect of n-3 PUFA on C-P (SMD = -0.22; 95% CI: -1.22 to 0.79, z =0.43, p = 0.67) with 
no evidence of heterogeneity (x 2 =2.86, I2 =65.0%, p = 0.09).    
    
Aggression 
 
Two studies in 111 participants examined aggression. There was no effect of n-3 PUFA 
supplementation on aggression (SMD=-0.12; 95% CI: -0.47 to 0.22, z = 0.70, p = 0.48) and no 















Appendix C. Chapter 4 Appendices  
Table AC-1  
 
Adult Self Rating Scale for ADHD (ASRS)  (Ronald C Kessler, Adler, Ames, et al., 2005) 
Screening questionnaire 
Please answer the questions below, rating yourself on each of the criteria shown using the scale on 
the right side of the page. As you answer each question, place an X in the box that best describes 
how you have felt and conducted yourself over the past 6 months.  
 
  Never Rarely Sometimes Often Very 
often 
1 How often do you have trouble wrapping up 
the final details of a project, once the 
challenging parts have been done? 
     
2 How often do you have difficulty getting 
things in order when you have to do a task 
that requires organization? 
     
3 How often do you have problems 
remembering appointments or obligations? 
     
4 When you have a task that requires a lot of 
thought, how often do you avoid 
or delay getting started? 
     
5 How often do you fidget or squirm with your 
hands or feet when you have 
to sit down for a long time? 
     
6 How often do you feel overly active and 
compelled to do things, like you 
were driven by a motor? 
     
7 How often do you make careless mistakes 
when you have to work on a boring or 
difficult project? 
     
8 How often do you have difficulty keeping 
your attention when you are doing boring 
or repetitive work? 
     
9 How often do you have difficulty 
concentrating on what people say to you, 
even when they are speaking to you directly? 
     
10 How often do you misplace or have difficulty 
finding things at home or at work? 
     
11 How often are you distracted by activity or 
noise around you? 
     
12 How often do you leave your seat in 
meetings or other situations in which 
you are expected to remain seated? 
     
13 How often do you feel restless or fidgety?      
14 How often do you have difficulty unwinding 
and relaxing when you have time 
to yourself? 
     
15 How often do you find yourself talking too 
much when you are in social situations? 
     
16 When you’re in a conversation, how often do 
you find yourself finishing 
the sentences of the people you are talking 
to, before they can finish 
them themselves? 
     
17 How often do you have difficulty waiting 
your turn in situations when 
turn taking is required? 
     
18 How often do you interrupt others when 
they are busy? 







ADHD screening questionnaire: diagnostic criteria 
 
 
If four or more marks appear in the darkly shaded boxes then the patient has symptoms highly 
consistent with ADHD in adults and further investigation is warranted. 
 
  Never Rarely Sometimes Often Very often 
1 How often do you have 
trouble wrapping up the 
final details of a project, 
once the challenging 
parts have been done? 
     
2 How often do you have 
difficulty getting things in 
order when you have to 
do a task that requires 
organization? 
     




     
4 When you have a task 
that requires a lot of 
thought, how often do 
you avoid 
or delay getting started? 
     
5 How often do you fidget 
or squirm with your 
hands or feet when you 
have 
to sit down for a long 
time? 
     
6 How often do you feel 
overly active and 
compelled to do things, 
like you 
were driven by a motor? 















Barkley childhood behaviour scale 
Barkley Childhood Behaviour Scale –  Self Report 
Instructions 
Please circle the number next to each item that best describes your behaviour 
when you were a child. PLEASE RATE YOUR BEHAVIOUR BETWEEN 7 and 12 YEARS 
OF AGE  
 











1.  Failed to give close attention to details or 
made careless mistakes in my work 
 
0 1 2 3 
2.  Fidgeted with hands or feet or squirmed 
in seat 
 
0 1 2 3 
3.  Had difficulty sustaining my attention in 
tasks or fun activities 
 
0 1 2 3 
4.  Left my seat in classroom or other 
situations in which sitting was expected 
 
0 1 2 3 
5.  Didn’t listen when spoken to directly 
 
0 1 2 3 
6.  Restless in the “squirmy” sense 
 
0 1 2 3 
7.  Didn’t follow through on instructions and 
failed to finish work 
 
0 1 2 3 
8.  Had difficulty engaging in leisure 
activities or doing fun things quietly 
 
0 1 2 3 
9.  Had difficulty organising tasks and 
activities 
 
0 1 2 3 
10.  Felt “on the go” or acted as if “driven by a 
motor” 
 
0 1 2 3 
11.  Avoided, disliked, or was reluctant to 
engage in work that required sustained 
mental effort 
 
0 1 2 3 
12.  Talked excessively 
 
0 1 2 3 
13.  Lost things necessary for tasks or 
activities 
 
0 1 2 3 
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14.  Blurted out answers before questions had 
been completed 
 
0 1 2 3 
15.  Easily distracted 
 
0 1 2 3 
16.  Had difficulty awaiting turn 
 
0 1 2 3 
17.  Forgetful in daily activities 
 
0 1 2 3 
18.  Interrupted or intruded on others 
 
0 1 2 3 
 
To what extent did the problems you may have circled on the previous page interfere with your 
ability to function in each of these areas of life activities when you were a child between 7 and 12 
years of age? 
 
 
 Areas: Never or 
Rarely 
 
Sometimes Often Very 
Often 
1. In your home life with your immediate 
family 
 
0 1 2 3 
2. In your social interactions with other 
children 
 
0 1 2 3 
3. In your activities or dealings in the 
community 
 
0 1 2 3 
4. In school 
 
0 1 2 3 
5. In sports, clubs, or other organisations 
 
0 1 2 3 
6. In learning to take care of yourself 
 
0 1 2 3 
7. In your play, leisure or recreational 
activities 
 
0 1 2 3 
8. In your handling of your daily chores or 
other responsibilities 
 














Breakdown of exclusions OCEAN Study 
Reason  N %  
Excluded (total n = 916)  % of excluded 
Excluded due to mental health problems 370 40.4 
Depression/Anxiety/panic disorder 46 5.0 
Autism spectrum disorders (inc PDD) 211 23.0 
OCD 34 3.7 
Agoraphobia/Social phobia 6 0.7 
Eating disorder 3 0.3 
Psychosis/Schizophrenia 18 2.0 
High suicidality 1 0.1 
High risk: aggression/anger problems 5 0.5 
Complex comorbidities 17 1.9 
Bipolar  23 2.5 
Tourettes syndrome 5 0.5 
Chronic fatigue syndrome 1 0.1 
Excluded due to substance abuse/dependence 96 10.5 
Cannabis 52 5.7 
Alcohol 19 2.1 
Stimulants 1 0.1 
Opiates 2 0.2 
Complex/general substance abuse/dependence 22 2.4 
Current psychoactive medication 56 6.1 
Does not have ADHD on assessment/not enough symptoms 167 18.2 
Physical health problems 30 3.3 
Head injury/neurological problem/cognitive impairment (inc 
low IQ) 
107 11.7 
Other 90 9.8 
Unsuitable age 51 5.6 
Already taking Omega-3/6 6 0.7 
Live too far away 6 0.7 
In prison  5 0.5 
Pregnant 4 0.4 
Deceased 1 0.1 
English not first language 3 0.3 
Taking part in other research/treatment 14 1.5 
Could not take part for other reasons (total n=619)  % of could not 
take part for 
other reasons 
Declined 163 26.3 
Not responded 356 57.5 
Not enough information to screen 86 13.9 
Booked to start study then dropped out 14 2.3 
Note. PDD = Pervasive Developmental Disorder, OCD = Obsessive Compulsive Disorder, 
Participants  with overlapping mental health/substance abuse  exclusion categories: N=89. 






A comparison of ADHD symptom severity between those who were taking concomitant 
antidepressant medication and the remaining OCEAN sample (who were either unmedicated or 
medicated with stimulant or non-stimulant medication) 
 
 Unmedicated/ 




t  p 
CW Inattention 27.36 (5.74) 26.21 (7.91) 0.63 0.53 
CW Hyp/Imp 20.22 (6.11) 19.43 (4.07) 0.46 0.64 























Breakdown of exclusions EMA-C Study 
Reason  N % 
Excluded (total n = 99)  % of excluded 
sample 
Excluded due to mental health problems 15 15.2 
Depression/Anxiety/panic disorder 1 1.0 
Autism spectrum disorders  3 3.0 
OCD 2 2.0 
Psychosis/Schizophrenia 4 4.0 
Tourettes 1 1.0 
Complex comorbidities 1 1.0 
Bipolar  3 3.0 
Excluded due to substance abuse/dependence 9 9.1 
Cannabis 4 4.0 
Opiates 1 1.0 
Complex/general substance abuse/dependence (or 
history) 
4 4.0 
Did not want to come off medication 12 12.1 
Did not want to take cannabis 5 5.1 
Current psychoactive medication 11 11.1 
Does not have ADHD on assessment/not enough 
symptoms 
19 19.2 
Physical health problems 7 7.1 
Epilepsy/seizures 2 2.0 
Other 19 19.2 
Religious reasons 1 1.0 
Unsuitable age 3 3.0 
Lived too far away 4 4.0 
Work would not approve 4 4.0 
Pregnant/breastfeeding 1 1.0 
Could not take part as the study was fully recruited 1 1.0 
Taking part in other research/treatment 1 1.0 
Their psychiatrist did not approve them to take part 1 1.0 
First degree relative with Psychosis/schizophrenia 3 3.0 
Could not take part for other reasons (total n=104)  % of could not 
take part for 
other reasons 
Declined 18 17.3 
Not responded 56 53.8 
More info needed/awaiting assessment 25 24.0 
Booked to start study then dropped out 5 4.8 
Note. OCD = Obsessive Compulsive Disorder. 
Participants with overlapping mental health/substance abuse exclusion categories: N=13 







Telephone screening for OCEAN study 
 








1. Have you taken omega-3/6 supplements in the 
previous 6-months (exclude if they have taken 
regularly within past 3 months) (omega 3/6 = 
fish oils) 
  
2. Do you have any medical problems? (such as 
diabetes, thyroid problems or kidney disease)  
  
3. Do you have any known fish allergies?   
4. How much fish do you consume a week?   
5. Are you currently taking medication for your 
ADHD? (find out if it is slow release (they don’t 
need to come off these for testing) eg. 
Atomoxetine or strattera or ask how many they 
take a day) 
 What medication are you taking and how 
many mg a day? 
 How long have you been taking this? (are 
they stable?) 
  
2.  Have you EVER had any problems that have troubled 
you with regards to your mental health (apart from 
ADHD)? (this includes ASD and Aspergers?) 
  
3.  Are you currently being treated for any other mental 
health problems? 
Including CBT (how long are they having this for), if 
psychotherapy/psychodynamic/counselling – ask how 
long for 
Exclude if currently 





4.  Are you currently taking any medication for mental 
health problems other than ADHD? If so, which 
medications and for what? 
Exclude if on 
medication 
prescribed for a 
comorbid disorder 





5. Have you ever taken any medication for mental health 
problems other than your ADHD?  If so, when were you 
last taking this medication? 
Exclude if medicated 
within the 3 – 
months apart from if 
taking a low dose of 
antidepressant. 
 
6. Have you ever seen your own doctor about difficulties 
with nerves, tension, depression, anything related to your 
mental health (other than ADHD)? 
Did you get professional attention? 
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7. Have you ever had distinct episodes of depression or 
sadness different from what you’re normally like lasting a 
week or more?  If so, when was this? 
Yes? – Can you tell me about it? E.g symptoms, severity 
If no – go to Q 10 
Exclude if currently 
experiencing a 
distinct episode of 
major depression. ie. 







8. a) Have you had a period recently where you felt sad, 
miserable, depressed, empty or tearful most of the time? 
     If yes: 
 When did you first feel like this? 
 Are you still feeling like this? 
 Have you felt like this for at least two weeks 
when NEARLY EVERY DAY, you felt sad, 
depressed, empty or tearful most of the time? 
 
 
b) Have you recently had a period of at least TWO WEEKS 
when, NEARLY EVERY DAY, you lost all interest in things, 
or got no pleasure from things which would usually make 
you happy? 
     If yes: 
 When was this? 





If answer to a) is 






Exclude if currently 
experiencing a 
distinct episode of 
depression (yes to 
question b or severe 
enough on question 
a)  
 
If uncertain or yes to 
either/both 
questions follow up 
with more detailed 
questions.  
  
9. Have you had more than one spell like this in the last 2 
years?  I mean more than just one period when you have 
been seriously depressed or anxious 
Consider excluding 
if depression is 
recurrent 
 
10. Have you had periods of feeling far more happy or 
energetic than your usual self, lasting for a week or more? 
So that your friends told you were talking too fast or that 
you were too 'hyper, compared to usual? If so, when was 
this? 
Exclude if 




not rapid cycling 
 
11. Do you drink alcohol?   
12. Approximately how many units of alcohol do you 
drink per day? 
Recommended limit for women 2-3 Units, for men 3-4 
Units.   
To calculate: 
 Single shot is 1 unit 
 Alcopop is 2 Units 
 Can/pint of light beer is 1 unit. 
 Can/pint of lager is 2 Units 
 Can/pint of extra strong lager is 4 units 
 Party cocktail is 5 units 
Glass of wine (175ml) is 2 units 
Exclude women who 
drink more than 6 
units a day and men 
who drink more 
than 8 units. 
 
13.  Do you smoke Cigarettes or Cigars?   
14. How many cigarettes or cigars do you smoke a day on 
average? 
  
15.  Do you take any other drugs, legal or illegal?  Which 
ones do you take?  And how often do you take these? 
 
Exclude if illegal 
drugs taken more 
often than twice 
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Do you take any other medications? weekly – but not 
ecstasy/heroin 
16.  Have you ever been addicted or dependent on any 
drugs or alcohol?  If so, when was this? 
Exclude if major 
history of drug or 
alcohol addiction, 
exclude if current 




17.  Have you ever suffered any injury to your head? If 
yes have you recovered from this/has it affected you in 
the long-term?  
 
Have you suffered from any neurological disorder (e.g. 
epilepsy, stroke, dementia)? 
Exclude if they feel 
this has affected 
them in the long-
term (eg. if  
Symptoms began 
from the injury) 
 
 
Exclude if answer to 
this question is yes 
 
 
18.  Do you have any difficulty in reading? Are you 
dyslexic 
  
19. What is your first language? Consider excluding 
if not English and if 




so as to not 
confound results on 




Follow up questions from question 7  
ASK ONLY IF UNCERTAIN OR WANT TO GET BETTER PICTURE OF DEPRESSIVE STATE 
 
During this time when you had worst two weeks where you felt sad, miserable or depressed 
 
 
How was your appetite? (check for weight loss/gain)  
How was your sleep pattern? (check if slept too much or 
trouble falling asleep or erratic 
sleep pattern) 
 
Nearly every day, were you unable to make 
up your mind about things you ordinarily 
would have had no trouble deciding about? 
  
Did you lack in energy or feel much more 
tired than usual even if you had not been 
working very hard?  
  
Did you feel worthless nearly every day?   
Did you think a lot about your own death, or 








Telephone screening for EMA-C study 
 
Participant Checklist: Exclusion/Inclusion criteria to be checked over the telephone 
Question Guidance Answer 
(Y/N) 
and notes 
1. Do you have any physical health problems 
such as any problems with your liver, heart, 
kidneys  
  
2. Are you currently taking medication for 
your ADHD?  
 What medication are you taking and 
how many mg a day? 
 How long have you been taking this? 
(are they stable? ie. > 1 month) 








3. Do you take your medication every day? If 
not how many days a week do you take it? 
Consider excluding if 
participant takes 
medication every day  
 
4. This trial requires you to come off your 
medication for 7 weeks (1 week before and 
the six weeks during the trial) Will that be a 
problem for you? 
Only include if the 
patient (and 
psychiatrist) feels 
that coming off their 
medication will not 
represent a clinical 
problem in their 




5. Just to remind you this is a placebo 
controlled trial so there is a 50% chance 
that you may receive the placebo (dud 
medication that doesn’t do anything) or the 
cannabis treatment – will that be okay? 
Only include if patient 
feels comfortable with 
this 
 
6. Do you take cannabis currently? 
 
If so how often? 
 
Have you taken it in the past or are you 
planning on taking it in the next couple of 
months? 
 
Have you ever had any major problems 
after using cannabis? 
 
If yes, what problems have you had? 
 
Would you be able to come off cannabis for 
30 days prior to starting the study 
Exclude if currently 
cannabis dependent 
 
Consider excluding if 
previous adverse 
effects from cannabis 
(discuss with Philip) 
 
Exclude if unwilling to 
come off cannabis for 
30 days prior to study 
entry 
 
7. As part of our protocol we can’t give this 
medication to people who are pregnant or 
planning on becoming pregnant or 
currently breastfeeding. 
 
* Are you pregnant or breastfeeding or is 
your partner planning on becoming 
pregnant? 
 
Exclude if pregnant or 
breastfeeding or if 






Question Guidance Answer 
(Y/N) 
and notes 
5.  Have you EVER had any problems that have 
troubled you with regards to your mental health 
(apart from ADHD)? 
   
Any depression or anxiety? (also includes ASD and 
Aspergers) 
If yes for depression, 
move to questions 6, 
7, 8, 9 to get a better 
picture of the health 
problem.  
 
If no to depression 
move to question 9 
 
6.  Have you ever had distinct episodes of 
depression or sadness different from what you’re 




Yes? – Can you tell me about it? E.g symptoms, 
severity 
If no – go to Q 9 
Exclude if currently 
experiencing a 
distinct episode of 
major depression. ie. 
more severe than 
usual. 
 
7. a) Have you had a period recently where you felt 
sad, miserable, depressed, empty or tearful most of 
the time? 
     If yes: 
 When did you first feel like this? 
 Are you still feeling like this? 
 Have you felt like this for at least two 
weeks when NEARLY EVERY DAY, you felt 




b) Have you recently had a period of at least TWO 
WEEKS when, NEARLY EVERY DAY, you lost all 
interest in things, or got no pleasure from things 
which would usually make you happy? 
     If yes: 
 When was this? 
 Are you still feeling like this? 
 
 
If answer to a) is yes, 
try to gauge severity 




Exclude if currently 
experiencing a 
distinct episode of 
depression (yes to 
question b or severe 
enough on question a)  
 
If uncertain or yes to 
either/both questions 
follow up with more 
detailed questions.  
  
8. Have you had more than one spell like this in the 
last 2 years?  I mean more than just one period 
when you have been seriously depressed or anxious 




9. Have you had periods of feeling far more happy 
or energetic than your usual self, lasting for a week 
or more? So that your friends told you you were 
talking too fast or that you were too 'hyper, 
compared to usual? If so, when was this?  
 
Does it cause problems for you/was this impairing? 
Exclude if participant 
has  experienced 
distinct episodes of 
mania/elation but not 
rapid cycling 
 
10.  Are you currently being treated for any other 
mental health problems? 
 
 
Including CBT (how long are they having this for), if 
psychotherapy/psychodynamic/counseling – ask 
how long for 
Exclude if currently 




11. Are you currently taking any medication for 
mental health problems other than ADHD?  If so, 
which medications and for what? 
Exclude if on 
medication 
prescribed for a 
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Question Guidance Answer 
(Y/N) 
and notes 
comorbid disorder  
12. Have you ever taken any medication for mental 
health problems other than your ADHD?  If so, when 
were you last taking this medication? 
Exclude if medicated 
within the 3 – months  
 
 
13. Have you ever seen your own doctor about 
difficulties with nerves, tension, depression, any 
thing related to your mental health (other than 
ADHD)? 
 
Did you get professional attention? 
  
14. Do you drink alcohol?   
15. Approximately how many units of alcohol do 
you drink per day? 
Recommended limit for women 2-3 Units, for men 
3-4 Units.   
To calculate: 
 Single shot is 1 unit 
 Alcopop is 2 Units 
 Can/pint of light beer is 1 unit. 
 Can/pint of lager is 2 Units 
 Can/pint of extra strong lager is 4 units 
 Party cocktail is 5 units 
Glass of wine (175ml) is 2 units 
Exclude women who 
drink more than 6 
Units a day and men 
who drink more than 
8 Units. 
 
18. Do you take any other prescribed drugs? (as in 
for physical health problems) 
 
How often?  
Exclude if psychiatrist 
considers drugs to be 
unsuitable for the 
study 
 
18.  Do you take any other drugs legal or illegal?  
Which ones do you take?  And how often do you 
take these? 
 
If no – are you planning to in the next few months? 
If yes – are you willing to not take these drugs 





Exclude if unwilling to 
stop taking drugs 
during the study. 
Exclude  if taking 
drugs regularly 
 
18a. Have you ever been addicted or dependent on 
any drugs or alcohol?  If so, when was this? 
Exclude if major 
history of drug or 
alcohol addiction, 
exclude if current 
substance abuse or 
addiction and there is 
evidence of an 
ongoing problem 
 
19.  Have you ever suffered any injury to your head? 
If yes have you recovered from this/has it affected 
you in the long-term?  
 
Have you suffered from any neurological disorder 
(e.g. epilepsy, stroke, dementia)? 
Exclude if they feel 
this has affected them 
in the long-term (eg. if  
Symptoms began 
from the injury) 
 
Exclude if there were 
any serious brain 
problems as a result 
 
19. What is your first language? Consider excluding if 
not English and if you 
do not think they can 
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effectively enough to 
not confound results 
20. Do you have any relatives with a diagnosis of 
Schizophrenia? 
Exclude if parent, 
child or sibling has 
schizophrenia 
 
Follow up questions from question 5: 
 
ASK ONLY IF UNCERTAIN OR WANT TO GET BETTER PICTURE OF DEPRESSIVE STATE 
 













How was your appetite? (check for weight loss/gain)  
How was your sleep 
pattern? 
(check if slept too much or trouble 
falling asleep or erratic sleep pattern) 
 
Nearly every day, were 
you unable to make up 
your mind about things 
you ordinarily would have 
had no trouble deciding 
about? 
  
Did you lack in energy or 
feel much more tired than 
usual even if you had not 
been working very hard?  
  
Did you feel worthless 
nearly every day? 
  
Did you think a lot about 
your own death, or 
someone else’s death or 




CAARS-Observer-Report (18 item) and WRADDS 
 
Participant ID_________________________               Date_______________ 
 
‘Please describe how much or how frequently each item describes you recently when you have not 
been taking your medication’ 
 
Use the scale 0-3: 0 = Not at all, never; 1 = Just a little, once in a while; 2 = Pretty much, often; and 3 
= Very much, very frequently. 
 The following items will be read out loud to the participant and the participant will be asked to 
decide how much or how frequently each item describes them recently. Circle the number that 
corresponds to the participant’s choice. 
If more information is needed the following probes can be used: 
Has this occurred in the last week? 
Have others commented about this? 
What have they said? 
What difficulties or problems has this caused with other people or work?  
  















1 loses things necessary for tasks or activities 
(e.g. to-do lists, pencils, books, or tools). 
0 1 2 3 
2 talk too much. 0 1 2 3 
3 gets rowdy or boisterous during leisure activities. 0 1 2 3 
4 leaves seat when you are not supposed to. 0 1 2 3 
5 has trouble waiting in line or taking turns with 
others. 
0 1 2 3 
6 has trouble keeping attention focused when 
working or at leisure. 
0 1 2 3 
7 is forgetful in daily activities. 0 1 2 3 
8 has trouble listening to what other people are 
saying. 
0 1 2 3 
9 is always on the go. 0 1 2 3 
10 fidgets (with hands or feet) or squirms in seat. 0 1 2 3 
11 makes careless mistakes or has trouble paying close 
attention to details. 
0 1 2 3 
12 doesn't like academic studies/work projects where 
effort at thinking a lot is required. 
0 1 2 3 
13 is restless or overactive. 0 1 2 3 
14 gives answers to questions before the questions 
have been completed. 
0 1 2 3 
15 has trouble finishing job tasks. 0 1 2 3 
16 interrupts others when they are working or busy. 0 1 2 3 
17 appears distracted when things are going on around 
him/her. 
0 1 2 3 





Appendix D. Chapter 5 Appendices 
 
Table AD-1 
Pearson correlation coefficient between commission errors (CPT, SART) and CW 
hyperactivity/impulsivity and omission errors and CW inattention  in ADHD cases  






-0.01 (0.91) - 
SART Omission errors - 0.03 (0.81) 
CPT Commission errors 0.20 (0.10) - 
CPT Ommission errors - 0.03 (0.78) 
CW = CAARS/WRAADS investigator rating scale 
 
Table AD-2 
Pearson correlation coefficient between commission errors (CPT, SART) and CW 
hyperactivity/Impulsivity and omission errors and CW inattention in controls  






0.04 (0.82) - 
SART Omission errors - 0.27 (0.15) 
CPT Commission errors 0.19 (0.33) - 
CPT Ommission errors - -0.14 (0.45) 











Spearman correlation coefficient PASAT, CNS-LS, ALS and CAARS/WRAADS emotional lability in 
ADHD cases 






CNS LS 0.76 (<.0001) - - 
ALS 0.67 (<.0001) 0.69 (<.0001) - 
PASAT Irritability 
post-task 
0.29 (0.008) 0.17 (0.12) 0.08 (0.50) 
PASAT Frustration 
post-task 
0.45 (<.0001) 0.30 (0.006) 0.19 (0.10) 
 
Table AD-4 
Spearman correlation coefficient PASAT, CNS-LS, ALS and CAARS/WRAADS emotional lability in 
controls 






CNS LS 0.67 (<.0001) - - 
ALS 0.69 (<.0001) 0.53 (0.002) - 
PASAT Irritability 
post-task 
0.02 (0.91) 0.14 (0.47) -0.14 (0.46) 
PASAT Frustration 
post-task 



















Chi2 Chi2  (p) Fisher’s 
exact (p) 
Drop-out (total) 16 10 1.44 0.23  
Drop-out before T2 11 2 6.66 0.01**  
Drop out before T3 5 8 - - 0.76 
Drop-out reasons 
Lost to follow-up T2 7 2 - 0.31 1.00 
Discontinued intervention 
T2 
4 0 - 0.31 1.00 
Lost to follow-up T3 1 8 - - 0.007** 
Discontinued intervention 
T3 
4 0 - - 0.007** 
* Significant at p ≤ .05 
**Significant at p ≤ .01 
 
Table AD-6 







CW Inattention 26.31(6.96) 27.56(5.72) 0.86 0.39 
CW Hyp/Imp 19.42(6.46) 20.40(5.50) 0.71 0.48 













Breakdown of participant’s medication status by placebo/active group 
Medication Active (n) Placebo (n) 
No meds 14 12 
Stimulants 18 17 





































Breakdown of the comorbid conditions between the placebo and active groups (rated using The 
MINI 6.0 (Mini International Neuropsychiatric Interview) diagnostic interview (Lecrubier et al., 
1997) 




Major depressive episode current 1 0 
Major depressive episode past 20 15 
Major depressive episode current and past 1 1 
Major Depressive Episode Recurrent 11 8 
Major Depressive Episode with Melancholic Features Current 0 0 
Major Depressive Episode with Melancholic Features Past 10 8 
Dysthymia Current (Past 2 years) 6 5 
Suicidality Risk Current (Past month) 13 10 
Level of Suicide Risk: Low 10 7 
Level of Suicide Risk: Medium 1 2 
Level of Suicide Risk: High 2 1 
Hypomanic Episode (Current) 1 0 
Hypomanic Episode (Past) 6 5 
Manic Episode (Current) 1 0 
Manic Episode (Past) 4 5 
Panic Disorder (Lifetime) 8 3 
Panic Disorder (Limited Symptom Attacks Lifetime) 8 11 
Panic Disorder (Current) 3 0 
Agoraphobia Current 5 4 
Panic Disorder without Agoraphobia Current 1 1 
Panic Disorder with Agoraphobia Current 2 0 
Agoraphobia Current without History of Panic Disorder 1 2 
Agoraphobia Current with History of Panic Disorder 3 2 
Social Phobia Current (Past month) 6 3  
Obsessive-Compulsive Disorder Current (Past month) 1 0 
Post traumatic Stress Disorder Current (Past month) 2 0 
Alcohol Dependence Past 12 Months 3 2 
Alcohol Abuse Past 12 Months 0 3 
Substance Abuse (Non alcohol) Past 12 Months 1 0 
Substance Dependence (Non alcohol) Past 12 Months 2 2 
Mood Disorder with Psychotic Features (Lifetime) 0 0 
Mood Disorder with Psychotic Features (Current) 0 0 
Psychotic Disorders (Current) 0 0 
Psychotic Disorders (Lifetime) 0 0 
Anorexia Nervosa Current (Past 3 Months) 0 0 
Bulimia Nervosa Current (Past 3 Months) 1 0 
Anorexia Nervosa, Binge Eating/Purging Type Current 0 0 
Generalised Anxiety Disorder Current 11 5 
Antisocial Personality Disorder Lifetimea 4 0 








Sensitivity analysis: Intent-to-treat analysis with multiple imputation (arbitrary imputation) 
 Time x Treatment 
 Est SE P 95% CI  
Primary outcome     
SART Commission errors  3.14 9.73 0.75 -17.79 to 24.07 
SART Omission errors  3.15 9.49 0.74 -17.14 to 23.44  
SART RTV -12.51 44.97 0.79 -110.64 to 85.62 
SART CV 1.15 7.08 0.87 -13.57 to 15.87 
ADHD Symptoms     
CW Inattention 2.01 8.56 0.82 -15.86 to 19.88 
CW Hyp/Imp 2.69 8.14 0.74 -14.12 to 19.49 
CW EL -0.32 12.77 0.98 -27.98 to 27.35 
Cognition     
CPT Commission 4.65 13.26 0.73 -22.51 to 31.81 
CPT Omission 9.48 16.58 0.57 -25.31 to 44.28 
CPT RTV  9.15 14.85 0.54 -20.70 to 39.01 
CPT CV 6.59 11.29 0.56 -16.12 to 29.30 
Fast task MRT 24.21 36.75 0.52 -51.11 to 99.53 
Fast task RTV  17.50 19.77 0.38 -22.31 to 57.31 
Fast task reward MRT 3.47 19.40 0.86 -35.21 to 42.16 
Fast task reward RTV  7.04 14.34 0.63 -22.41 to 36.49 
Emotional lability     
CNS_LS 7.84 9.57 0.42 -11.74 to 27.42 
ALS 4.41 10.94 0.69 -18.71 to 27.52 
PASAT time to quit 0.22 16.86 0.99 -34.16 to 34.61 
PASAT frustration pre-task 3.18 7.81 0.69 -13.07 to 19.42 
PASAT frustration post-task 5.22 11.92 0.67 -20.28 to 30.73 
PASAT Irritability pre-task -0.88 7.17 0.90 -15.93 to 14.18 








Appendix E. Chapter 6 Appendices 
Supplement AE-1:  EMA-C Study:  Dosing instructions (the below was transferred to diary format 
for the study) 
First 14 days 
 For the first 14 days, you should gradually increase the dose by one spray per day  
 Please follow the dosing schedule according to the table below, up to a maximum 
of 14 sprays per day or until you find a dose that is effective 
 Do not exceed more than 14 sprays per day.  
 Please fill out Table 1 with the number of actual sprays you have used per day 
 You should leave at least a 15 minute gap between sprays.  
 Spray the dose under your tongue or onto the inside of your cheek. Change 
the area in your mouth where you spray each time to avoid soreness. 
The remainder of the study 
 After 14 days and for the remaining 28 days of the study please continue at the 
dose which you have found most effective.  
 Do not exceed more than 14 sprays per day.  
 Please spread the doses out throughout the day as best suits you  
 Please leave at least a 15 minute gap between doses  
 Spray the dose under your tongue or onto the inside of your cheek. Change 
the area in your mouth where you spray each time to avoid soreness. 
 Please record the number of doses you spray each day in the note books that we 
have given you.   








Please follow and fill out this table for the first 2 weeks (transferred to diary format for the study 
with one page representing one day) 
Day Number of 
sprays in the 
morning  
Number of 
sprays in the 
afternoon and 
evening  
Total number of 
sprays per day 
Actual number 
of sprays 
1 1 0 1  
2 1 1 2  
3 1 2 3  
4 2 2 4  
5 2 3 5  
6 2 4 6  
7 3 4 7  
8 3 5 8  
9 3 6 9  
10 4 6 10  
11 4 7 11  
12 4 8 12  
13 5 8 13  















Supplement AE-2: Safety monitoring and titration documents for the EMA-C study 
General questions 
1. Have you noticed any effects from the medication? 
 
2. If you have noticed an effect how long do you think that effect has last for? (if an hour they may 















Participant ID_______________________ Date_________________ 
Adverse Events Scale 
Please indicate below the frequency of any side effects experienced since the last medical 
appointment (mark with an X). Please contact your physician if side effects are significant. 
SIDE EFFECT FREQUENCY  











Headache       
Dryness of the skin       
Dryness of the eyes       
Dryness of the mouth       
Thirst       
Sore throat       
Dizziness       
Nausea       
Stomach aches       
Vomiting       
Sweating       
Appetite reduction       
Weight loss       
Weight gain       
Diarrhea       
Frequent urination       
Tics       
Sleep difficulties       
Mood instability       
Irritability       
Agitation/excitability       
Sadness       
Heart palpitations       
Increased blood pressure       
Sexual dysfunction       
Feeling worse or different when 
the medication wears off 
(rebound)  
     
Paranoia      




CAARS-Observer (18 item) 
 




Instructions: listed below are items concerning behaviours or problems experienced by adults. 
Read each item carefully and decide how much or how frequently each item describes this person 
in the last 7 days. Indicate your response for each item by circling the number that corresponds to 
your choice. Use the following scale: 0 = Not at all, never; 1 = Just a little, once in a while; 2 = Pretty 
much, often; and 3 = Very much, very frequently. 
 















1 loses things necessary for tasks or activities 
(e.g. to-do lists, pencils, books, or tools). 
    
2 talks too much.     
3 gets rowdy or boisterous during leisure 
activities. 
    
4 leaves seat when not supposed to.     
5 has trouble waiting in line or taking turns 
with others. 
    
6 has trouble keeping attention focused when 
working or at leisure. 
    
7 is forgetful in daily activities.     
8 has trouble listening to what other people 
are saying. 
    
9 is always on the go.     
10 fidgets (with hands or feet) or squirms in 
seat. 
    
11 makes careless mistakes or has trouble 
paying close attention to details. 
    
12 doesn't like academic studies/work projects 
where effort at thinking a lot is required. 
    
13 is restless or overactive.     
14 gives answers to questions before the 
questions have been completed. 
    
15 has trouble finishing job tasks.     
16 interrupts others when they are working or 
busy. 
    
17 appears distracted when things are going on 
around him/her. 
    
18 has problems organizing tasks and activities.     
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Table AE-1: Comparison of drop-outs between active and placebo group for the per-protocol 
analysis 
 




Fisher’s exact (p) 



























Table AE-2: Intent to treat analysis (monotone imputation (MAR assumption)) 
 
 Time x treatment 
 Est SE P 95% CI 
Primary outcome     
Qb -0.46 1.15 0.69 -2.76 to 1.84 
Post-hoc     
Qb Activity 0.07 1.17 0.95 -2.37 to 2.52 
Qb Inattention -0.33 1.20 0.79 -2.73 to 2.08 
Qb Impulsivity -0.14 1.59 0.93 -3.48 to 3.20 
Secondary outcomes 
ADHD Symptoms     
CW Innattention -2.72 1.56 0.08 -5.77 to 0.34 
CW Hyp/Imp -3.13 1.32 0.02 -5.74 to -0.51 
CW EL -0.18 1.38 0.90 -2.89 to 2.53 
Cognition     
SART Commission errors -2.13 2.55 0.40 -7.19 to 2.92 
SART Omission errors  -0.38 5.23 0.94 -10.63 to 9.87 
SART RTV -3.90 6.64 0.56 -16.92 to 9.11 
SART CV 0.81 3.18 0.80 -6.22 to 7.84 
Emotional lability     
CNS_LS -3.74 2.41 0.12 -8.47 to 0.98 
ALS -2.41 2.47 0.33 -7.28 to 2.46 
Functional impairment     














Table AE-3: Intent to treat analysis (arbitrary imputation (under MAR assumption)) 
 Time x Treatment 
 Est SE P 95% CI  
Primary outcome 
Qb Test 0.25 1.45 0.87 -2.62 to 3.12 
Post-hoc     
Qb Activity -0.02 1.38 0.99 -2.80 to 2.75 
Qb Inattention -0.37 1.51 0.81 -3.39 to 2.65 
Qb Impulsivity -0.25 1.81 0.89 -3.95 to 3.46 
Secondary outcomes 
ADHD Symptoms     
CW Innattention -3.06 1.68 0.07 -6.37 to 0.26 
CW Hyp/Imp -3.08 1.70 0.08 -6.50 to 0.34 
CW EL -0.82 1.59 0.61 -3.95 to 2.31 
Cognition     
SART Commission errors -1.32 2.36 0.58 -5.96 to 3.33 
SART Omission errors -0.94 5.14 0.85 -11.01 to 9.13 
SART RTV -2.51 6.61 0.70 -15.46 to 10.44 
SART CV -0.19 1.94 0.92 -4.29 to 3.92 
Emotional lability     
CNS-LS -4.01 2.37 0.09 -8.66 to 0.65 
ALS -2.40 2.36 0.31 -7.06 to 2.25 
Functional impairment     














Table AE-4: Intent-to-treat analysis (multiple imputation using the MNAR assumption) 
 Time x Treatment 
Primary Outcome Est SE P 95% CI  
Qb Test -0.72 0.99 0.47 -2.70 to 1.27 
Post-hoc     
Qb activity -0.11 1.28 0.93 -2.72 to 2.51 
Qb inattention -0.55 1.28 0.67 -3.14 to 2.04 
Qb impulsivity  0.13 1.43 0.93 -2.76 to 3.03 
Secondary outcomes     
ADHD Symptoms     
CW inattention -2.72 1.71 0.11 -6.11 to 0.66 
CW hyp/imp  -2.81 1.21 0.02 -5.19 to -0.44 
CW EL -0.67 1.53 0.66 -3.71 to 2.36 
Cognition     
SART Commission errors  -1.78 2.26 0.43 -6.23 to 2.68 
SART Omission errors  -0.58 5.23 0.91 -10.83 to 9.67 
SART RTV -2.71 6.71 0.69 -15.86 to 10.44 
SART CV -0.72 1.74 0.68 -4.47 to 3.02 
Emotional lability     
CNS-LS -3.48 2.27 0.13 -7.94 to 0.97 
ALS -2.88 2.28 0.21 -7.37 to 1.60 
Functional impairment     














Table AE-5: Feedback from participant's in the active group in response to the open question 'how has the medication made you feel overall' and why they guessed 
whether they were taking the placebo/active medication 
Feedback (Each row represents one participant) 
Tastes like cannabis, noticeable effects. Made them feel calm, clear and sometimes spacey, and more focussed when doing 
certain things. Quite liked it but would have liked to have more time to adjust to it or experimented more with doses 
Noticed a considerable difference when sprayed, felt calm, relaxed and energetic, was able to do things that needed a higher 
level of concentration. Would like to take again if available, although slows you down a bit though. 
Have felt effects, slightly stoned at times. Didn't help attention that much though. Slowed thoughts, sleeping better - would 
want to take it in the evening. 
Didn't feel anything, tasted disgusting 
Sustained periods of concentration which would have been difficult to achieve unmedicated. Effects were positive overall. 
Didn't like the taste, but no dry mouth or insomnia like she gets from usual ADHD meds. Slept well and woke rested - major 
benefit. Stayed on tasks for longer generally. Would prefer to take over ADHD meds. 
Sedating effects, calming effect and taste. Effected the depth of sleep. Thinks it works but individual does are too high, 
doesn't think it impairs. Mouth ulcers - aggressive oil. 
He just knows it was active. Felt better, calmer and happier. Felt relaxed, but that effects took longer to kick in than street 
cannabis. A bit sedative, would want higher THC. Possibly still street cannabis if given a choice 
Mainly the taste and when trying a higher dose, felt a bit odd. Definitely calmer and less anxiety/panicky feelings in 
situations where they might normally feel that way. Calmer at night, easier transition to wake in the morning. 
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Feedback (Each row represents one participant) 
Experienced strong effects similar to smoked cannabis. Flavour tasted of cannabis. Became more engaged in activities and 
work, felt relaxed and able to sustain interest. Steadied his thought processes. Would definitely take as a treatment. 
Although vulnerability to anxiety at times. 
Just feels like it had an effect on me. Everything becomes more focused, clearer, thoughts are clearer. Also lessens anxiety I 
have from time to time. Less of a come down that ritain and effects probably last for 1 to 2 hours. 
Feel calmer and more relaxed after spray. Partner also noticed improvements. Would definitely take as medication, would 
not need it all the time though he doesn't think 
Made me feel tired/sleep/lethargic/slowed me up. Pressure at the back of the head. Clarity of vision/focus of vision. Felt 
something going through me. Headaches initially. Slept the best in years, felt much calmer. Appetite increased. 
No improvement - maybe slightly improved productivity, felt a little calmer. Side effects - odd thoughts on 8+ sprays a day, 
feeling detached, couldn't be bothered, in my own world and sometimes forgetful 
When taking spray at highest doses I felt high 'ish'. I could watch boring movies and I loved them - wouldn't usually be able 
to do this. If the dose is too high became restless, talkative, confused, trapped in own head, saying wrong things 
 
 
